<SEC-DOCUMENT>0001193125-19-287262.txt : 20191107
<SEC-HEADER>0001193125-19-287262.hdr.sgml : 20191107
<ACCEPTANCE-DATETIME>20191107160254
ACCESSION NUMBER:		0001193125-19-287262
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		56
CONFORMED PERIOD OF REPORT:	20190930
FILED AS OF DATE:		20191107
DATE AS OF CHANGE:		20191107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MEI Pharma, Inc.
		CENTRAL INDEX KEY:			0001262104
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				510407811
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50484
		FILM NUMBER:		191200205

	BUSINESS ADDRESS:	
		STREET 1:		3611 VALLEY CENTER DRIVE
		STREET 2:		SUITE 500
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		858-792-6300

	MAIL ADDRESS:	
		STREET 1:		3611 VALLEY CENTER DRIVE
		STREET 2:		SUITE 500
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MARSHALL EDWARDS INC
		DATE OF NAME CHANGE:	20030902
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>d667344d10q.htm
<DESCRIPTION>10-Q
<TEXT>
<HTML><HEAD>
<TITLE>10-Q</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">10-Q</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B>&#9746;<B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
</B></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the quarterly period ended September&nbsp;30, 2019 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OR </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B>&#9744;<B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
</B></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the transition period from
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> to
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number: <FONT STYLE="white-space:nowrap">000-50484</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>MEI Pharma, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>DELAWARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">51-0407811</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>3611 Valley Centre Drive, San Diego, CA 92130 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices) (Zip Code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(858) <FONT STYLE="white-space:nowrap">369-7100</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Securities registered pursuant to Section&nbsp;12(b) of the Act: </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title&nbsp;of&nbsp;each&nbsp;class</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Trading</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Symbol</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name&nbsp;of&nbsp;each&nbsp;exchange</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>on&nbsp;which&nbsp;registered</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Common Stock, $0.00000002 par value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>MEIP</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>The NASDAQ&nbsp;Stock&nbsp;Market&nbsp;LLC</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d)
of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past 90
days.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant has
submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period
that the registrant was required to submit such files).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <FONT STYLE="white-space:nowrap">non-accelerated</FONT>
filer, a smaller reporting company, or an emerging growth company. See definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting company,&#148; and &#147;emerging growth company&#148; in Rule <FONT
STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-accelerated</FONT> filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Emerging&nbsp;growth&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a shell company (as defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange
Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of November&nbsp;4, 2019, the number of shares
outstanding of the issuer&#146;s common stock, $0.00000002 par value, was 73,654,927.<U></U><U></U><U></U><U></U> </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MEI PHARMA, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>Table of Contents </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>PART&nbsp;I</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#tx667344_1">FINANCIAL&nbsp;INFORMATION </A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;1:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx667344_2">Financial Statements (Unaudited)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx667344_3">Condensed Balance Sheets as of September&nbsp;30, 2019 and June&nbsp;
30, 2019</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx667344_4">Condensed Statements of Operations for the three months ended September&nbsp;
30, 2019 and 2018</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx667344_5">Condensed Statements of Stockholders&#146; Equity for the three months ended September&nbsp;30,
2019 and 2018</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx667344_6">Condensed Statements of Cash Flows for the three months ended September&nbsp;
30, 2019 and 2018</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx667344_7">Notes to Condensed Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;2:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx667344_8">Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;3:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx667344_9">Quantitative and Qualitative Disclosures about Market Risk</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;4:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx667344_10">Controls and Procedures</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>PART&nbsp;II</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#tx667344_11">OTHER INFORMATION </A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;1:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx667344_12">Legal Proceedings</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;1A:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx667344_13">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;2:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx667344_14">Unregistered Sales of Equity Securities and Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;3:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx667344_15">Defaults upon Senior Securities</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;4:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx667344_16">Mine Safety Disclosures</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;5:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx667344_17">Other Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;6:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx667344_18">Exhibits</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#tx667344_19">SIGNATURES </A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx667344_1"></A>PART I FINANCIAL INFORMATION </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx667344_2"></A>Item&nbsp;1:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Condensed Financial Statements &#150; Unaudited </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx667344_3"></A>MEI PHARMA, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDENSED BALANCE SHEETS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(In thousands, except per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">(unaudited)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="8" ALIGN="center"><B>ASSETS</B></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 5,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 9,590</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cash, cash equivalents and short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,916</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock proceeds receivable (Note 10)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68,051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 68,923</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 82,663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="8" ALIGN="center"><B>LIABILITIES AND STOCKHOLDERS&#146; EQUITY</B></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 3,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 4,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,955</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue, long-term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,819</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,643</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (Note 7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, $0.01 par value; 100 shares authorized; none outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.00000002 par value; 226,000 shares authorized; 73,655 and 73,545 shares issued
and outstanding at September&nbsp;30, 2019 and June&nbsp;30, 2019, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">paid-in-capital</FONT></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">281,492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">279,148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(234,212</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(231,218</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 68,923</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 82,663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>See accompanying notes to condensed financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx667344_4"></A>MEI PHARMA, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDENSED STATEMENTS OF OPERATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(In thousands, except per share amounts) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Unaudited) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">688</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">989</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,780</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,623</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,033</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,962</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest and dividend income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,994</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14,542</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,994</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14,542</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> (0.04</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> (0.21</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares used in computing net loss per share:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>See accompanying notes to condensed financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx667344_5"></A>MEI PHARMA, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDENSED STATEMENTS OF STOCKHOLDERS&#146; EQUITY </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(In thousands) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Unaudited) </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR>paid&nbsp;in<BR>Capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#146;<BR>Equity</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at June&nbsp;30, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">279,148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(231,218</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 47,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,994</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,994</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at September&nbsp;30, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">281,492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(234,212</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 47,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR>paid in<BR>Capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#146;<BR>Equity</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at June&nbsp;30, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">264,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(214,399</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 50,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,542</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,542</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of common stock for vested restricted stock units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(324</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(324</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at September&nbsp;30, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">268,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(228,941</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 39,759</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>See accompanying notes to condensed financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx667344_6"></A>MEI PHARMA, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDENSED STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(In thousands) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Unaudited) </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash&nbsp;flows&nbsp;from&nbsp;operating&nbsp;activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,994</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14,542</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,269</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,085</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,689</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,088</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,702</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(965</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(868</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,078</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,816</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from investing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,979</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,937</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from maturity of short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from exercise of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collection of common stock proceeds receivable </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,274 </TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment of RSU tax withholdings in exchange for common shares surrendered by RSU holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(324</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,505</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">837</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net decrease in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,606</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,191</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at beginning of the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,590</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at end of the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 5,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 6,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental cash flow information:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income taxes paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> (1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> (1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-cash</FONT> financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of warrants exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>See accompanying notes to condensed financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx667344_7"></A>MEI PHARMA, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONDENSED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Unaudited) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note
1.&nbsp;&nbsp;&nbsp;&nbsp;The Company and Summary of Significant Accounting Policies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We are a late-stage pharmaceutical company
focused on leveraging our extensive development and oncology expertise to identify and advance new therapies intended to meaningfully improve the treatment of cancer. Our portfolio of drug candidates contains four clinical-stage candidates,
including one candidate in an ongoing Phase 3 global registration trial and another candidate in an ongoing Phase 2 clinical trial that we intend to submit to the U.S. Food and Drug Administration (&#147;FDA&#148;) to support accelerated approval of
a marketing application. Our common stock is listed on the NASDAQ Capital Market under the symbol &#147;MEIP&#148;. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Clinical Development Programs
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Our approach to building our pipeline is to license promising cancer agents and build value in programs through development,
commercialization and strategic partnerships, as appropriate. Our drug candidate pipeline includes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">ME-401,</FONT> an oral phosphatidylinositol
<FONT STYLE="white-space:nowrap">3-kinase</FONT> delta (&#147;PI3K<I></I><FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT><I></I><I></I>&#148;) inhibitor; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Voruciclib, an oral cyclin-dependent kinase (&#147;CDK&#148;) inhibitor; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">ME-344,</FONT> a mitochondrial inhibitor targeting the oxidative phosphorylation
(&#147;OXPHOS&#148;) complex; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Pracinostat, an oral histone deacetylase (&#147;HDAC&#148;) inhibitor. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We have accumulated losses of
$234.2&nbsp;million since inception and expect to incur operating losses and generate negative cash flows from operations for the foreseeable future.&nbsp;As of September&nbsp;30, 2019, we had $65.9&nbsp;million in cash and cash equivalents,
short-term investments, and common stock proceeds receivable, which we believe will be sufficient to meet obligations and fund our liquidity and capital expenditure requirements for at least the next 12 months from the issuance of these financial
statements.&nbsp;Our current business operations are focused on continuing the clinical development of our drug candidates.&nbsp;Changes to our research and development plans or other changes affecting our operating expenses may affect actual future
use of existing cash resources.&nbsp;Our research and development expenses are expected to increase in the foreseeable future.&nbsp;We cannot determine with certainty costs associated with ongoing and future clinical trials or the regulatory
approval process. The duration, costs and timing associated with the development of our product candidates will depend on a variety of factors, including uncertainties associated with the results of our clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">To date, we have obtained cash and funded our operations primarily through equity financings and license agreements.&nbsp;In order to continue
the development of our drug candidates, we expect to pursue one or more capital transactions, whether through the sale of equity securities, debt financing, license agreements or entry into strategic partnerships. There can be no assurance that we
will be able to continue to raise additional capital in the future.</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis of Presentation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United
States (&#147;U.S. GAAP&#148;) for interim financial information and in accordance with the instructions to Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and Article 10 of Regulation <FONT STYLE="white-space:nowrap">S-X.</FONT> Accordingly, the
accompanying financial statements do not include all of the information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying financial statements reflect all adjustments (consisting of
normal recurring adjustments) that are necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. We have evaluated subsequent events through the date the financial statements were
issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The accompanying unaudited financial statements should be read in conjunction with the audited financial statements and notes
thereto as of and for the fiscal year ended June&nbsp;30, 2019, included in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> (&#147;2019 Annual Report&#148;) filed with the Securities and Exchange Commission (&#147;SEC&#148;)
on August&nbsp;28, 2019. Interim results are not necessarily indicative of results for a full year. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Use of Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. We use estimates that affect the reported amounts (including assets, liabilities, revenues and expenses) and related
disclosures. Actual results could materially differ from those estimates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Revenue Recognition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We recognize revenue when control of the promised goods or services is transferred to our customers, in an amount that reflects the
consideration we expect to be entitled to in exchange for those goods or services. To determine revenue recognition, we perform the following five steps: (i)&nbsp;identify the contract(s) with a customer; (ii)&nbsp;identify the performance
obligations in the contract; (iii)&nbsp;determine the transaction price; (iv)&nbsp;allocate the transaction price to the performance obligations in the contract; and (v)&nbsp;recognize revenue when (or as) the entity satisfies a performance
obligation. See Note 5 for further discussion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Cost of revenue primarily includes external costs paid to third-party contractors to
perform research, conduct clinical trials and develop and manufacture drug materials, and internal compensation and related personnel expenses to support our research and development performance obligations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Research and Development Costs </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Research
and development costs are expensed as incurred and include costs paid to third-party contractors to perform research, conduct clinical trials and develop and manufacture drug materials. Clinical trial costs, including costs associated with
third-party contractors, are a significant component of research and development expenses. We expense research and development costs based on work performed. In determining the amount to expense, management relies on estimates of total costs based
on contract components completed, the enrollment of subjects, the completion of trials, and other events. Costs incurred related to the purchase or licensing of <FONT STYLE="white-space:nowrap">in-process</FONT> research and development for
early-stage products or products that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Share-Based Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Share-based
compensation expense for employees and directors is recognized in the Condensed Statement of Operations based on estimated amounts, including the grant date fair value and the expected service period. For stock options, we estimate the grant date
fair value using a Black-Scholes valuation model, which requires the use of multiple subjective inputs including estimated future volatility, expected forfeitures and the expected term of the awards. We estimate the expected future volatility based
on the stock&#146;s historical price volatility. The stock&#146;s future volatility may differ from the estimated volatility at the grant date. For restricted stock unit (&#147;RSU&#148;) equity awards, we estimate the grant date fair value using
our closing stock price on the date of grant. We recognize the effect of forfeitures in compensation expense when the forfeitures occur. The estimated forfeiture rates may differ from actual forfeiture rates which would affect the amount of expense
recognized during the period. We recognize the value of the awards over the awards&#146; requisite service or performance periods. The requisite service period is generally the time over which our share-based awards vest. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Income Taxes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Our income tax expense
consists of current and deferred income tax expense or benefit. Current income tax expense or benefit is the amount of income taxes expected to be payable or refundable for the current year. A deferred income tax asset or liability is recognized for
the future tax consequences attributable to tax credits and loss carryforwards and to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets are reduced by
a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. As of September&nbsp;30, 2019 and June&nbsp;30, 2019, we have established a valuation
allowance to fully reserve our net deferred tax assets. Changes in our ownership may limit the amount of net operating loss carry-forwards that can be utilized in the future to offset taxable income. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Financial Accounting Standards Board (&#147;FASB&#148;) Topic on Income Taxes prescribes a recognition threshold and measurement attribute
criteria for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be <FONT STYLE="white-space:nowrap">more-likely-than-not</FONT>
to be sustained upon examination by taxing authorities. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. There were no unrecognized tax benefits as of September&nbsp;30, 2019 or
June&nbsp;30, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">There have been no material changes in our unrecognized tax benefits since June&nbsp;30, 2019, and, as such, the
disclosures included in our 2019 Annual Report continue to be relevant for the three month period ended September&nbsp;30, 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Accounting
Pronouncements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Adopted Accounting Standards </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In February 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-02,</FONT> Leases. The new standard establishes a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> (&#147;ROU&#148;) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months.
Leases are classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after July&nbsp;1, 2019, including interim
periods within those fiscal years. See Note 8 for further discussion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 2.&nbsp;&nbsp;&nbsp;&nbsp;Fair Value Measurements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the
principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize
the use of unobservable inputs. The fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value is as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="91%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Level&nbsp;1&nbsp;&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Observable inputs such as quoted prices in active markets for identical assets or liabilities.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Level&nbsp;2&nbsp;&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be
corroborated by observable market data for substantially the full term of the assets or liabilities.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Level&nbsp;3&nbsp;&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We measure the following financial instruments at fair value on a recurring basis. The fair values of
these financial instruments were as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,&nbsp;2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,&nbsp;2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,344</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,613</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,344</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,613</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The carrying amounts of financial instruments such as cash equivalents, short-term investments and accounts
payable approximate the related fair values due to the short-term maturities of these instruments. We invest our excess cash in financial instruments which are readily convertible into cash, such as money market funds and U.S. government securities.
Cash equivalents, where applicable, and short-term investments are classified as Level&nbsp;1 as defined by the fair value hierarchy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In
May 2018, we issued warrants in connection with our private placement of shares of common stock. Pursuant to the terms of the warrants, we could be required to settle the warrants in cash in the event of an acquisition of the Company and, as a
result, the warrants are required to be measured at fair value and reported as a liability in the Condensed Balance Sheet.&nbsp;We recorded the fair value of the warrants upon issuance using the Black-Scholes valuation model and are required to
revalue the warrants at each reporting date with any changes in fair value recorded on our Condensed Statement of Operations. The valuation of the warrants is considered under Level&nbsp;3 of the fair value hierarchy due to the need to use
assumptions in the valuation that are both significant to the fair value measurement and unobservable.&nbsp;Inputs used to determine estimated fair value of the warrant liabilities include the estimated fair value of the underlying stock at the
valuation date, the estimated term of the warrants, risk-free interest rates, expected dividends and the expected volatility of the underlying stock. The significant unobservable inputs used in the fair value measurement of the warrant liabilities
were the volatility rate and the estimated term of the warrants. Generally, increases (decreases) in the fair value of the underlying stock and estimated term would result in a directionally similar impact to the fair value measurement. The change
in the fair value of the&nbsp;Level 3 warrant liability is reflected in the Condensed Statement of Operations for the three months ended September&nbsp;30, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To calculate the fair value of the warrant liability, the following assumptions were used: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,</B><br><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,</B><br><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected life (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Black-Scholes Fair Value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The following table sets forth a summary of changes in the estimated fair value of our
Level&nbsp;3 warrant liability for the three months ended September&nbsp;30, 2019 and 2018 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;Value&nbsp;of&nbsp;Warrants&nbsp;Using&nbsp;Significant<BR>Unobservable&nbsp;Inputs&nbsp;(Level&nbsp;3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at July&nbsp;1,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">46,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reclassification of warrant liability to equity upon exercise of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,068</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in estimated fair value of liability classified warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,269</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at September&nbsp;30,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 8,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 3.&nbsp;&nbsp;&nbsp;&nbsp;License Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>KKC License Agreement </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In
October 2018, we entered into a license agreement with Kyowa Kirin Company (formerly &#147;Kyowa Hakko Kirin Co., Ltd.&#148;) (&#147;KKC&#148;), a Japanese life sciences company, for <FONT STYLE="white-space:nowrap">ME-401</FONT> (the &#147;KKC
License Agreement&#148;). Under the terms of the KKC License Agreement, KKC was granted the exclusive right to develop and commercialize <FONT STYLE="white-space:nowrap">ME-401</FONT> in Japan. We also granted KKC the right to purchase supply of <FONT
STYLE="white-space:nowrap">ME-401</FONT> for commercial requirements at cost plus a <FONT STYLE="white-space:nowrap">pre-negotiated</FONT> percentage, as well as manufacturing rights in Japan. In return, we received an upfront payment of
$10.0&nbsp;million and are also eligible to receive up to $87.5&nbsp;million in additional development and commercialization milestones, as well as royalties on net sales of <FONT STYLE="white-space:nowrap">ME-401</FONT> in Japan extending into the <FONT
STYLE="white-space:nowrap">mid-teens.</FONT> The KKC License Agreement expires at the end of the royalty term, that is, upon the last to occur of (a)&nbsp;expiration of our patents in Japan, (b)&nbsp;expiration of regulatory exclusivity for <FONT
STYLE="white-space:nowrap">ME-401</FONT> in Japan or (c) 10 years from the first commercial sale of <FONT STYLE="white-space:nowrap">ME-401</FONT> in Japan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We assessed the KKC License Agreement in accordance with ASC 606 and determined that our performance obligations comprise the license,
research and development obligations, and our obligation to provide clinical trial materials to KKC. We determined that the transaction price amounts to the upfront payment of $10.0&nbsp;million. Future milestone payments are fully contingent as the
risk of significant revenue reversal will only be resolved depending on future research and development and/or regulatory approval outcomes. We will <FONT STYLE="white-space:nowrap">re-evaluate</FONT> the likelihood of achieving future milestones at
the end of each reporting period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We determined that control of the license was transferred to KKC during the year ended June&nbsp;30,
2019. Revenue allocated to the research and development obligations is recognized based on the proportional performance of these research and development activities, which we expect to recognize through fiscal year 2022. Revenue allocated to
providing clinical trial materials is recognized upon delivery. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>Helsinn License Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In August 2016, we entered into an exclusive worldwide license, development, manufacturing and commercialization agreement with Helsinn
Healthcare SA, a Swiss pharmaceutical corporation (&#147;Helsinn&#148;) for pracinostat in acute myeloid leukemia (&#147;AML&#148;), myelodysplastic syndrome (&#147;MDS&#148;) and other potential indications (the &#147;Helsinn License
Agreement&#148;). Under the terms of the agreement, Helsinn was granted a worldwide exclusive license to develop, manufacture and commercialize pracinostat, and is primarily responsible for funding its global development and commercialization. As
compensation for such grant of rights, we received payments of $20.0&nbsp;million. In addition, we are eligible to receive up to $444&nbsp;million in potential regulatory and sales-based milestones, along with royalty payments on the net sales of
pracinostat, which, in the U.S., are tiered and begin in the <FONT STYLE="white-space:nowrap">mid-teens.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We determined that the
agreement contains multiple performance obligations for purposes of revenue recognition. Revenue related to the research and development elements of the arrangement is recognized based on the extent of progress toward completion of each performance
obligation. Revenue is recognized on a gross basis as we are the primary obligor and have discretion in supplier selection. During the three months ended September&nbsp;30, 2019, our only remaining performance obligation under the agreement is the
conduct of a Phase 2 dose-optimization study of pracinostat in combination with azacitidine in patients with high and very high risk MDS who are previously untreated with hypomethylating agents (the &#147;POC study&#148;), for which Helsinn has
agreed to share third-party expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>Presage License Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In September 2017, we entered into a license agreement with Presage Biosciences, Inc. (&#147;Presage&#148;). Under the terms of such license
agreement (the &#147;Presage License Agreement&#148;), Presage granted to us exclusive worldwide rights to develop, manufacture and commercialize voruciclib, a clinical-stage, oral and selective CDK inhibitor, and related compounds. In exchange, we
paid $2.9&nbsp;million. With respect to the first indication, an incremental $2.0&nbsp;million payment, due upon dosing of the first subject in the first registration trial, will be owed to Presage, for total payments of $4.9&nbsp;million prior to
receipt of marketing approval of the first indication in the U.S., E.U. or Japan. Additional potential payments of up to $179&nbsp;million will be due upon the achievement of certain </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
development, regulatory and commercial milestones. We will also pay <FONT STYLE="white-space:nowrap">mid-single-digit</FONT> tiered royalties on the net sales of any product successfully
developed. As an alternative to milestone and royalty payments related to countries in which we sublicense product rights, we will pay to Presage a tiered percent (which decreases as product development progresses) of amounts received from such
sublicensees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>CyDex License Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We are party to a license agreement with CyDex Pharmaceuticals, Inc. (&#147;CyDex&#148;). Under the license agreement, CyDex granted to us an
exclusive, nontransferable license to intellectual property rights relating to Captisol<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> for use with our isoflavone-based drug compounds (currently
<FONT STYLE="white-space:nowrap">ME-344).</FONT> We agreed to pay to CyDex a <FONT STYLE="white-space:nowrap">non-refundable</FONT> license issuance fee, future milestone payments, and royalties at a low, single-digit percentage rate on future sales
of our approved drugs utilizing Captisol. Contemporaneously with the license agreement, CyDex entered into a commercial supply agreement with us, pursuant to which we agreed to purchase 100% of our requirements for Captisol from CyDex. We may
terminate both the license agreement and the supply agreement at any time upon 90 days&#146; prior written notice. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note
4.&nbsp;&nbsp;&nbsp;&nbsp;BeiGene Collaboration </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In October 2018, we entered into a clinical collaboration with BeiGene, Ltd.
(&#147;BeiGene&#148;) to evaluate the safety and efficacy of <FONT STYLE="white-space:nowrap">ME-401</FONT> in combination with BeiGene&#146;s zanubrutinib, an investigational inhibitor of Bruton&#146;s tyrosine kinase (&#147;BTK&#148;), for the
treatment of patients with <FONT STYLE="white-space:nowrap">B-cell</FONT> malignancies. Under the terms of the clinical collaboration agreement, we amended our ongoing Phase 1b trial to include evaluation of
<FONT STYLE="white-space:nowrap">ME-401</FONT> in combination with zanubrutinib in patients with <FONT STYLE="white-space:nowrap">B-cell</FONT> malignancies. Study costs are being shared equally by the parties, and we agreed to supply <FONT
STYLE="white-space:nowrap">ME-401</FONT> and BeiGene agreed to supply zanubrutinib. We record the costs reimbursed by BeiGene as a reduction of our research and development expenses. We retained full commercial rights for <FONT
STYLE="white-space:nowrap">ME-401</FONT> and BeiGene retained full commercial rights for zanubrutinib. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 5.&nbsp;&nbsp;&nbsp;&nbsp;Revenue
Recognition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Payments received under commercial arrangements, such as licensing technology rights, may include <FONT
STYLE="white-space:nowrap">non-refundable</FONT> fees at the inception of the arrangements, milestone payments for specific achievements designated in the agreements, and royalties on the sale of products. At the inception of arrangements that
include milestone payments, we use judgment to evaluate whether the milestones are probable of being achieved and we estimate the amount to include in the transaction price using the most likely method. If it is probable that a significant revenue
reversal will not occur, the estimated amount is included in the transaction price. Milestone payments that are not within our or the licensee&#146;s control, such as regulatory approvals, are not included in the transaction price until those
approvals are received. At the end of each reporting period, we <FONT STYLE="white-space:nowrap">re-evaluate</FONT> the probability of achievement of development milestones and any related constraint and, as necessary, we adjust our estimate of the
overall transaction price. Any adjustments are recorded on a cumulative <FONT STYLE="white-space:nowrap">catch-up</FONT> basis, which would affect revenues and earnings in the period of adjustment. To date, we have not recognized any material
cumulative <FONT STYLE="white-space:nowrap">catch-up</FONT> adjustments from changes in our estimate of the transaction price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We develop
estimates of the stand-alone selling price for each distinct performance obligation and allocate the overall transaction price to each accounting unit based on a relative stand-alone selling price approach. We develop assumptions that require
judgment to determine the stand-alone selling price for license-related performance obligations, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical,
regulatory and commercial success. We estimate stand-alone selling price for research and development performance obligations by forecasting the expected costs of satisfying a performance obligation plus an appropriate margin. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In the case of a license that is a distinct performance obligation, we recognize revenue from
<FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">up-front</FONT> fees at the point in time when the license is transferred to the licensee and the licensee can use and benefit from the license. For licenses
that are bundled with other obligations, we use judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the
appropriate method of measuring progress for purposes of recognizing revenue. If the performance obligation is satisfied over time, we evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and
related revenue recognition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The selection of the method to measure progress towards completion requires judgment and is based on the
nature of the products or services to be provided. Revenue is recorded proportionally as costs are incurred. We generally use the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cost-to-cost</FONT></FONT> measure of progress
because it best depicts the transfer of control to the customer which occurs as we incur costs. Under the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cost-to-cost</FONT></FONT> measure of progress, the extent of progress
towards completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation (an &#147;input method&#148; under ASC 606). We use judgment to estimate the total cost expected to
complete the research and development performance obligations, which include subcontractors&#146; costs, labor, materials, other direct costs and an allocation of indirect costs. We evaluate these cost estimates and the progress each reporting
period and, as necessary, we adjust the measure of progress and related revenue recognition. To date, we have not recognized any material cumulative <FONT STYLE="white-space:nowrap">catch-up</FONT> adjustments from changes in our estimate of the
measure of progress. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">For arrangements that include sales-based or usage-based royalties, we recognize revenue at
the later of (i)&nbsp;when the related sales occur or (ii)&nbsp;when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, we have not recognized any sales-based royalty
revenue from license agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We recognized revenue associated with the following license agreements (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">KKC License Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">797</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Helsinn License Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Revenue for the three months ended September&nbsp;30, 2019 included revenue related to the KKC License
Agreement (Note 3). The KKC License Agreement included distinct performance obligations that will be satisfied over time, and accordingly we recognized $0.8&nbsp;million related to our progress toward satisfying those obligations during the three
months ended September&nbsp;30, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Revenue for the three months ended September&nbsp;30, 2019 and 2018 included revenue related to the
Helsinn License Agreement (Note 3). The Helsinn License Agreement included distinct performance obligations that will be satisfied over time, and accordingly we recognized $0.4&nbsp;million and $0.5&nbsp;million related to our progress toward
satisfying those obligations during the three months ended September&nbsp;30, 2019 and 2018, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2019,
we had $6.9&nbsp;million of deferred revenue associated with our remaining performance obligations under the KKC and Helsinn License Agreements. We expect to recognize approximately $3.7&nbsp;million of deferred revenue in the next 12 months, and an
additional $3.2&nbsp;million thereafter. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>Contract Balances </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The following table presents changes in contract assets and contract liabilities during the three months ended September&nbsp;30, 2019 (in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;June&nbsp;30,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Net&nbsp;Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;September&nbsp;30,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract Assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(217</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract Liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(868</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The timing of revenue recognition, invoicing and cash collections results in billed accounts receivable and
unbilled receivables (contract assets), which are classified as &#147;prepaid expenses and other current assets&#148; on our Condensed Balance Sheet, and deferred revenue (contract liabilities). We invoice our customers in accordance with
agreed-upon contractual terms, typically at periodic intervals or upon achievement of contractual milestones. Invoicing may occur subsequent to revenue recognition, resulting in contract assets. We may receive advance payments from our customers
before revenue is recognized, resulting in contract liabilities. The contract assets and liabilities reported on the Condensed Balance Sheet relate to the KKC and Helsinn License Agreements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 6.&nbsp;&nbsp;&nbsp;&nbsp;Net Loss Per Share </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share are computed using the weighted-average number of shares of common stock outstanding during the period,
less any shares subject to repurchase or forfeiture. There were no shares of common stock subject to repurchase or forfeiture for the three months ended September&nbsp;30, 2019 and 2018. Diluted net loss per share is computed based on the sum of the
weighted average number of common shares and potentially dilutive common shares outstanding during the period. Our potentially dilutive shares, which include outstanding stock options, restricted stock units, and warrants, are considered to be
common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The
following table presents weighted-average potentially dilutive shares (in thousands) that have been excluded from the calculation of net loss per share because of their anti-dilutive effect: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted stock units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,062</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total anti-dilutive shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 7.&nbsp;&nbsp;&nbsp;&nbsp;Commitments and Contingencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We have contracted with various consultants and third parties to assist us in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> research and
development and clinical trials work for our leading drug compounds. The contracts are terminable at any time, but obligate us to reimburse the providers for any time or costs incurred through the date of termination. We also have employment
agreements with certain of our current employees that provide for severance payments and accelerated vesting for share-based awards if their employment is terminated under specified circumstances. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>Presage License Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">As discussed in Note 3, we are party to a license agreement with Presage under which we may be required to make future payments upon the
achievement of certain development, regulatory and commercial milestones, as well as potential future royalties based upon net sales. As of September&nbsp;30, 2019, we have not accrued any amounts for potential future payments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>S*Bio Purchase Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We are party to a definitive asset purchase agreement with S*Bio, pursuant to which we acquired certain assets comprised of intellectual
property and technology including rights to pracinostat. We agreed to make certain milestone payments to S*Bio based on the achievement of certain clinical, regulatory and net sales-based milestones, as well as to make certain contingent earnout
payments to S*Bio. Milestone payments will be made to S*Bio up to an aggregate amount of $74.5&nbsp;million if certain U.S., E.U. and Japanese regulatory approvals are obtained and if certain net sales thresholds are met in North America, the E.U.
and Japan. As of September&nbsp;30, 2019, we have not accrued any amounts for potential future payments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>CyDex License Agreement
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">As discussed in Note 3, we are party to a license agreement with CyDex under which we may be required to make future payments upon the
achievement of certain milestones, as well as potential future royalties based upon net sales. Contemporaneously with the license agreement, CyDex entered into a commercial supply agreement with us, pursuant to which we agreed to purchase 100% of
our requirements for Captisol from CyDex. As of September&nbsp;30, 2019, we have not accrued any amounts for potential future payments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note
8.&nbsp;&nbsp;&nbsp;&nbsp;Leases </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">As of July&nbsp;1, 2019, we adopted ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-02,</FONT>
Leases, using a modified retrospective basis method under which prior comparative periods are not restated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The new standard establishes
an ROU model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern
of expense recognition in the income statement. In addition, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-10,</FONT> Codification Improvements to Topic&nbsp;842, ASU
<FONT STYLE="white-space:nowrap">No.&nbsp;2018-11,&nbsp;Targeted</FONT> Improvements,&nbsp;and ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-20,&nbsp;Narrow-Scope</FONT> Improvements for Lessors, to clarify and amend the guidance in ASU <FONT
STYLE="white-space:nowrap">No.&nbsp;2016-02.</FONT> We elected the following as practical expedients from within these ASUs: 1) an entity need not reassess whether any expired or existing contracts are or contain leases, 2) an entity need not
reassess the lease classification for any expired or existing leases, and 3) an entity need not reassess initial direct costs for any existing leases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">As of July&nbsp;1, 2019, we had an operating lease for our office located in San Diego, California. We have leased approximately 20,800 square
feet of office space under a lease which expires in May 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">As of July&nbsp;1, 2019, our remaining minimum lease payments were
approximately $0.7&nbsp;million. Using a discount rate of 8% and a remaining lease term of ten months, we determined the ROU asset and corresponding lease liability at the date of adoption was $0.7&nbsp;million. There was no cumulative adjustment to
our beginning accumulated deficit balance. As of September&nbsp;30, 2019, our remaining minimum lease payments were approximately $0.5&nbsp;million, our lease liability was $0.5&nbsp;million, classified as &#145;Accrued liabilities&#146; on our
Condensed Balance Sheet, and our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset was $0.4&nbsp;million, classified as &#145;Property and equipment, net&#146; on our Condensed Balance Sheet. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 9.&nbsp;&nbsp;&nbsp;&nbsp;Short-Term Investments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2019 and June&nbsp;30, 2019, our short-term investments consisted of $59.9&nbsp;million and $64.9&nbsp;million,
respectively, in U.S. government securities. The short-term investments held as of September&nbsp;30, 2019 and June&nbsp;30, 2019 had maturity dates of less than one year, are considered to be &#147;held to maturity&#148; and are carried at
amortized cost. As of September&nbsp;30, 2019 and June&nbsp;30, 2019, the gross holding gains and losses were immaterial. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 10.&nbsp;&nbsp;&nbsp;&nbsp; Stockholders&#146; Equity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Transactions &nbsp;&nbsp;&nbsp;&nbsp; </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>Warrants </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">As of
September&nbsp;30, 2019, we have outstanding warrants to purchase 16,061,602 shares of our common stock. The warrants are fully vested, exercisable at a price of $2.54 per share and expire in May 2023. In the event of a sale of the Company, the
terms of the warrants require us to use our best efforts to ensure the holders of such warrants will have a continuing right to purchase shares of the acquirer and, if our efforts are unsuccessful, to make a payment to such warrant holders based on
a Black-Scholes valuation (using variables as specified in the warrants). Therefore, we are required to account for the warrants as liabilities and record them at fair value. The warrants were revalued as of June&nbsp;30, 2019 at $17.6&nbsp;million
and as of September&nbsp;30, 2019 at $8.3&nbsp;million; the changes in fair value were recorded in our Condensed Statement of Operations. No warrants were exercised during the three months ended September&nbsp;30, 2019. During the three months ended
September&nbsp;30, 2018, warrants were exercised for 440,043 shares of common stock, and we received proceeds of $1.1&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>Shelf Registration Statement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We have a shelf registration statement that permits us to sell, from time to time, up to $150.0&nbsp;million of common stock, preferred stock
and warrants. In November 2017, we entered into an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">At-The-Market</FONT></FONT> Equity Offering Sales Agreement (the &#147;ATM Sales Agreement&#148;), pursuant to which we may sell an
aggregate of up to $30.0&nbsp;million of our common stock pursuant to the shelf registration statement. During the year ended June&nbsp;30, 2019, we sold 2,214,658 shares under the ATM Sales Agreement for $5.4&nbsp;million, after deducting offering
costs; $5.2&nbsp;million of these proceeds were received on July&nbsp;2, 2019 and were recorded as common stock proceeds receivable as of June&nbsp;30, 2019. During the three months ended September&nbsp;30, 2019, we sold 63,684 shares under the ATM
Sales Agreement for $0.2&nbsp;million, after deducting offering costs. As of September&nbsp;30, 2019, there is $144.3&nbsp;million aggregate value of securities available under the shelf registration statement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 11.&nbsp;&nbsp;&nbsp;&nbsp; Share-based Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We use equity-based compensation programs to provide long-term performance incentives for our employees. These incentives consist primarily of
stock options and RSUs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Our 2008 Stock Omnibus Equity Compensation Plan (the &#147;2008 Plan&#148;) provides for the grant of options
and/or other share-based or share-denominated awards to our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors, officers, employees and advisors. The 2008 Plan was initially adopted in 2008 and was amended and restated in 2011, 2013,
2014, 2015, 2016 and 2018. There are 19,089,794 shares of common stock authorized for issuance under the 2008 Plan. As of September&nbsp;30, 2019, there were 6,979,777 shares available for future grant under the 2008 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Total share-based compensation expense for all stock awards consists of the following, (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>Stock Options </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Stock option activity for the three months ended September&nbsp;30, 2019 was as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Exercise&nbsp;Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-Average<BR>Remaining&nbsp;Contractual</B><br><B>Term&nbsp;(in years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Intrinsic&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at June&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,356,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,083,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(46,667</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited / Cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(49,186</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(527,080</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at September&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,817,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">501,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested and exercisable at September&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,114,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">428,455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The fair value of each stock option granted during the three months ended September&nbsp;30,
2019 is estimated on the grant date under the fair value method using a Black-Scholes valuation model. Stock options granted to employees during the three months ended September&nbsp;30, 2019 vest 25% one year from the date of grant and ratably each
month thereafter for a period of 36 months and expire ten years from the date of grant. Stock options granted to directors during the three months ended September&nbsp;30, 2019 vest ratably each month for a period of 12 or 36 months from the date of
grant and expire ten years from the date of grant. The estimated fair values of the stock options, including the effect of estimated forfeitures, are expensed over the service period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The following weighted-average assumptions were used to determine the fair value of options granted during the period: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected life (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average grant date fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2019, there was $8.5&nbsp;million of unrecognized compensation expense related to the
unvested portion of stock options. Such compensation expense is expected to be recognized over a weighted-average period of 1.8 years. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock Units </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In June 2016, we granted 364,726 RSUs to employees. Each RSU represented the contingent right to receive one share of our common stock. The
RSUs vested in August 2018, and we released 332,193 RSU shares. We issued 245,782 shares of common stock to RSU holders; 86,411 shares were surrendered to us by RSU holders as payment for the employee portion of the required withholding of
associated payroll taxes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="tx667344_8"></A><A NAME="tx667344_8"></A>Item&nbsp;2:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> includes forward-looking statements
within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;) and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;). All statements other than
statements of historical facts contained in this Quarterly Report, including statements regarding the future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. The
words &#147;believe,&#148; &#147;may,&#148; &#147;will,&#148; &#147;estimate,&#148; &#147;continue,&#148; &#147;anticipate,&#148; &#147;intend,&#148; &#147;should,&#148; &#147;plan,&#148; &#147;expect,&#148; and similar expressions, as they relate
to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on current expectations and projections about future events and financial trends that we believe may affect our financial condition,
results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, without limitation, those described in &#147;Risk Factors&#148; in our 2019
Annual Report, and elsewhere in this report, including, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to obtain required additional financing or financing available to us on acceptable terms, or at
all, which may cause us to delay, scale-back or eliminate plans related to development of our drug candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">parties with which we have entered into collaboration, license, development and/or commercialization agreements
may not satisfy their obligations under the agreements which could impact future revenues; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our payment obligations under the Presage License Agreement and the S*Bio Purchase Agreement, which may reduce
our cash available for other development efforts, and other obligations and risks related to the Presage License Agreement and the S*Bio Purchase Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical studies by their nature typically have a high level of risk and may not produce successful results;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the results of <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and completed clinical trials are not
necessarily predictive of future results, and our current drug candidates may not have favorable results in later studies or trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to maintain or enter into, and the risks resulting from our dependence upon, contractual
arrangements necessary for the clinical development, manufacture, commercialization, marketing, sales and distribution of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs and delays in our clinical development programs and/or receipt of FDA or other required foreign and
domestic governmental or regulatory approvals, or the failure to obtain such approvals, for our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA&#146;s interpretation and our interpretation of data from preclinical and clinical studies may differ
significantly; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our failure to successfully commercialize our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pricing regulations, third-party reimbursement practices and healthcare reform initiatives;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the failure of any products to gain market acceptance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reliance on third parties to conduct our clinical trials and manufacture our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to control the costs of manufacturing our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reliance on acquisitions or licenses from third parties to expand our pipeline of drug candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competition and competitive factors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and
intellectual property to operate our business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to operate our business without infringing the patents and proprietary rights of others;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs stemming from our defense against third party intellectual property infringement claims;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our exposure to potential product liability claims and other claims, may exceed our insurance limits;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract and retain key employees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">technological changes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cybersecurity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general economic conditions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">government regulation generally; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in industry practice; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">one-time</FONT> events. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">These risks are not exhaustive. Other sections of this report and our other filings with the SEC include additional factors which could
adversely impact our business and financial performance. Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time and it is not possible for us to predict all risk factors, nor can we
assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">You should not rely upon forward-looking statements as predictions of future events. We cannot assure you that the events and circumstances
reflected in the forward-looking statements will be achieved or occur. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or
achievements. Past performance may not be an indicator of future results. The following discussion is qualified in its entirety by, and should be read in conjunction with, the more detailed information set forth in the financial statements and the
notes thereto appearing elsewhere in this Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and the audited financial statements and notes thereto included in our 2019 Annual Report, as filed with the SEC. Operating results are
not necessarily indicative of results that may occur in future periods. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview and Recent Developments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We are a late-stage pharmaceutical company focused on leveraging our extensive development and oncology expertise to identify and advance new
therapies intended to meaningfully improve the treatment of cancer. Our portfolio of drug candidates contains four clinical-stage candidates, including one candidate in an ongoing Phase 3 global registration trial and another candidate in an ongoing
Phase 2 clinical trial intended to support an accelerated approval of a marketing application with the FDA under 21 CFR Part 314.500. Our common stock is listed on the NASDAQ Capital Market under the symbol &#147;MEIP&#148;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Clinical Development Programs </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Our
approach to building our pipeline is to license promising cancer agents and build value in programs through development, commercialization and strategic partnerships, as appropriate. Our drug candidate pipeline includes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">ME-401,</FONT> an oral
PI3K<I></I><FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT><I></I><I></I> inhibitor; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Voruciclib, an oral CDK inhibitor; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">ME-344,</FONT> a mitochondrial inhibitor targeting the OXPHOS complex; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Pracinostat, an oral HDAC inhibitor. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g667344g59z57.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Phase 2 study intended to support an accelerated approval marketing application with FDA </P></TD></TR></TABLE>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Study arm initiated under clinical collaboration with BeiGene, Ltd. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Evaluation in combination with venetoclax is subject to FDA approval </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Investigator-initiated trial </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">ME-401:</FONT> PI3K</I><FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT><I></I><I> Inhibitor in a Phase 2 Trial Intended to
Support an Accelerated Approval in Relapsed or Refractory Follicular Lymphoma </I></P> <P STYLE="line-height:0.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:91%">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">ME-401</FONT> is an oral, once-daily, selective PI3K<FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT> inhibitor
in clinical development for the treatment of <FONT STYLE="white-space:nowrap">B-cell</FONT> malignancies. We maintain worldwide rights to <FONT STYLE="white-space:nowrap">ME-401</FONT> in all geographies except Japan, which we licensed to Kyowa
Kirin Company (&#147;KKC&#148;) in October 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We are conducting two ongoing studies evaluating
<FONT STYLE="white-space:nowrap">ME-401.</FONT> The first is a Phase 2 clinical trial evaluating <FONT STYLE="white-space:nowrap">ME-401</FONT> as a monotherapy for the treatment of adults with relapsed or refractory follicular lymphoma
(&#147;FL&#148;) after failure of at least two prior systemic therapies including chemotherapy and an anti-CD20 antibody. Subject to the results, upon completion of the Phase 2 clinical trial, we are planning a submission with the FDA to support an
accelerated approval of a marketing application under 21 CFR Part 314.500, Subpart H. The second is a <FONT STYLE="white-space:nowrap">multi-arm,</FONT> open-label, Phase 1b dose escalation and expansion trial evaluating <FONT
STYLE="white-space:nowrap">ME-401</FONT> as a monotherapy and in combination with other therapies or investigational agents in patients with relapsed or refractory <FONT STYLE="white-space:nowrap">B-cell</FONT> malignancies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">While PI3K<FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT> inhibitors as a group are a clinically validated class for the treatment of <FONT
STYLE="white-space:nowrap">B-cell</FONT> malignancies, the FDA approved orally administered products, idelalisib (marketed as Zydelig<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) and duvelisib (marketed as COPIKTRA<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>), and the intravenously administered PI3K<FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT>/&#945; inhibitor copanlisib (marketed as
Aliqopa<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>), are challenged by dose-limiting toxicities. We believe this provides an opportunity for the development of a next-generation candidate with pharmaceutical properties that may better
maximize the biological potential of PI3K<FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT> inhibition by limiting toxicities, which hinder clinical utility. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The molecular structure and pharmacodynamic characteristics of <FONT STYLE="white-space:nowrap">ME-401</FONT> are distinct from the FDA
approved PI3K<FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT> inhibitors. <FONT STYLE="white-space:nowrap">ME-401</FONT> is characterized by prolonged target binding, preferential cellular accumulation, high volume of distribution
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
throughout the body tissues, and an approximately <FONT STYLE="white-space:nowrap">28-hour</FONT> half-life suitable for once daily oral administration. These properties of <FONT
STYLE="white-space:nowrap">ME-401</FONT> allow exploration of flexible dosing regimens such as an intermittent dosing schedule, which has the potential to maintain clinical benefit while minimizing immune-related toxicities common to other PI3K<FONT
STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT> agents, either as a monotherapy or in combination with other therapies or investigational agents. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">ME-401</FONT> Scientific Overview: at the Crossroads of <FONT STYLE="white-space:nowrap">B-cell</FONT>
Signaling Pathways </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The PI3K/AKT/mTOR pathway is an important signaling pathway for many cellular functions such as cell survival, cell
cycle progression and cellular growth. PI3Ks are a family of enzymes within this pathway that have been shown to play a critical role in the proliferation and survival of certain cancer cells. Specifically, the
PI3K<FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT> isoform is at the crossroads of <FONT STYLE="white-space:nowrap">B-cell</FONT> receptor signaling pathways that are major drivers of survival and proliferation of many
<FONT STYLE="white-space:nowrap">B-cell</FONT> malignancies. Because the <FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT> isoform is largely restricted to leukocytes, it is an attractive target for selectively inhibiting the PI3K pathway in <FONT
STYLE="white-space:nowrap">B-cell</FONT> malignancies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>PI3K</I><FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT><I></I><I> Inhibitors and
<FONT STYLE="white-space:nowrap">B-Cell</FONT> Malignancies </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>Clinical Program </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We are conducting two ongoing studies: a Phase 2 trial evaluating patients with relapsed or refractory FL intended to support an accelerated
approval of a marketing application with the FDA under 21 CFR Part 314.500, Subpart H, and a <FONT STYLE="white-space:nowrap">multi-arm,</FONT> open-label, Phase 1b dose escalation and expansion trial as a monotherapy and in combination with other
therapies or investigational agents in patients with FL and other <FONT STYLE="white-space:nowrap">B-cell</FONT> malignancies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>Phase
1b <FONT STYLE="white-space:nowrap">Multi-arm</FONT> Trial </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In October 2019, we reported updated interim data from the ongoing Phase 1b
clinical trial evaluating <FONT STYLE="white-space:nowrap">ME-401</FONT> as a monotherapy and in combination with rituximab in patients with relapsed or refractory <FONT STYLE="white-space:nowrap">B-cell</FONT> malignancies. Over 95 patients were
enrolled at the time of the update, of which data on 73 patients were reported on for efficacy: 55 patients with relapsed or refractory FL and 18 with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma
(&#147;CLL/SLL&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">ME-401</FONT> is administered once daily at 60 mg for two <FONT
STYLE="white-space:nowrap">28-day</FONT> cycles and then on an intermittent schedule (i.e. IS) of once daily dosing for the first seven days of each subsequent <FONT STYLE="white-space:nowrap">28-day</FONT> cycle. A previous cohort of monotherapy
patients in the trial was treated with <FONT STYLE="white-space:nowrap">ME-401</FONT> at 60 to 180 mg administered continuously once daily (i.e. CS) or were switched to the IS in later cycles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The overall response rate was 81% among the 73 evaluable r/r FL and r/r CLL/SLL patients. The overall response rate was 78% and 89% in the 55
and 18 patients with FL or CLL/SLL, respectively. Responses appeared durable with a median observation time in excess of 10 months. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">FL</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">CLL/SLL</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number<BR>Evaluable</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Overall<BR>Response<BR>Rate</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number<BR>Evaluable</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Overall<BR>Response<BR>Rate</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All patients</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">55</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43&nbsp;(78%</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">18</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16&nbsp;(89%</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By regimen:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">ME-401</FONT> alone</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">39</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31&nbsp;(79%</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11&nbsp;(100%</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">ME-401</FONT> + rituximab</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">16</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12&nbsp;(75%</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5&nbsp;(71%</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By schedule:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">29</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23&nbsp;(79%</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6&nbsp;(75%</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">26</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20&nbsp;(70%</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10&nbsp;(100%</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">ME-401</FONT> was generally well-tolerated and no grade 4 or grade 5 adverse
events of special interest have been observed in the Phase 1b trial. Among drug related grade 3 adverse events of special interest, the most common was diarrhea/colitis at 5.0% (3/57) on IS dosing and 23% (9/39) on CS dosing. Grade 3 elevations in
ALT and AST were transient and in each case were associated with grade 3 diarrhea or rash. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Grade&nbsp;3&nbsp;Drug&nbsp;Related&nbsp;Adverse&nbsp;Events&nbsp;of&nbsp;Special&nbsp;
Interest</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>CS&nbsp;Group</B><br><B>(N&nbsp;=&nbsp;39)</B><br><B>n&nbsp;(%)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>IS&nbsp;Group</B><br><B>(N&nbsp;=&nbsp;57)</B><br><B>n&nbsp;(%)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diarrhea/Colitis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9&nbsp;(23%</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3&nbsp;(5%</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rash, all types</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3&nbsp;(8%</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ALT/AST increased</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3&nbsp;(8%</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1&nbsp;(2%</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mucositis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1&nbsp;(3%</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pneumonia/Pneumonitis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4&nbsp;(10%</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1&nbsp;(2%</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Phase 1b trial is additionally evaluating <FONT STYLE="white-space:nowrap">ME-401</FONT>
(60 mg) in combination with zanubrutinib, an investigational inhibitor of Bruton&#146;s tyrosine kinase (&#147;BTK&#148;) being developed by BeiGene, Ltd. (&#147;BeiGene&#148;). Pursuant to a collaboration initiated with BeiGene in October 2018, we
began evaluating the safety and efficacy of <FONT STYLE="white-space:nowrap">ME-401</FONT> in combination with zanubrutinib for the treatment of patients with various <FONT STYLE="white-space:nowrap">B-cell</FONT> malignancies. The cost of the
combination trial is being equally shared. Each company is supplying its own investigational agent. We retain all commercial rights to <FONT STYLE="white-space:nowrap">ME-401</FONT> and BeiGene retains all commercial rights to zanubrutinib. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>Phase 2 Trial Intended to Support an Accelerated Approval Marketing Application </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In July 2018, we discussed with the FDA an <FONT STYLE="white-space:nowrap">ME-401</FONT> monotherapy accelerated approval strategy in patients
with relapsed or refractory FL. The FDA communicated support for our proposed randomized Phase 2 trial. An accelerated approval of <FONT STYLE="white-space:nowrap">ME-401</FONT> will be subject to FDA review of the improvement provided by <FONT
STYLE="white-space:nowrap">ME-401</FONT> over other therapies available. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We are recruiting patients in the global randomized Phase 2 trial
evaluating the efficacy, safety, and tolerability of <FONT STYLE="white-space:nowrap">ME-401</FONT> in patients with FL after failure of at least two prior systemic therapies including chemotherapy and an anti-CD20 antibody.&nbsp;The study will
evaluate both the CS and IS dosing regimens; in one arm, <FONT STYLE="white-space:nowrap">ME-401</FONT> will be administered once daily continuously and in the other arm, <FONT STYLE="white-space:nowrap">ME-401</FONT> will be administered once daily
for two cycles (i.e., eight weeks) followed by an intermittent schedule whereby <FONT STYLE="white-space:nowrap">ME-401</FONT> will be administered once daily for the first seven days of a <FONT STYLE="white-space:nowrap">28-day</FONT> cycle
followed by 21 days of placebo. Approximately 166 patients will be randomized in the trial and the primary efficacy endpoint will be the rate of objective response to therapy and tolerability of <FONT STYLE="white-space:nowrap">ME-401.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Voruciclib: CDK Inhibitor with CDK9 Inhibition in Phase 1 Studies</U> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Voruciclib is an orally administered CDK inhibitor differentiated by its potent in vitro inhibition of CDK9 in addition to CDK6, 4 and 1.
Voruciclib is currently being evaluated in a Phase 1b dose ranging trial in patients with <FONT STYLE="white-space:nowrap">B-cell</FONT> malignancies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>Voruciclib Scientific Overview: Cell Cycle Signaling </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The CDK family of proteins are important cell cycle regulators. CDK9 is a transcriptional regulator of the myeloid leukemia cell
differentiation protein (&#147;MCL1&#148;), a member of the family of anti-apoptotic proteins which, when elevated, may prevent the cell from undergoing cell death. Inhibition of CDK9 blocks the production of MCL1, which is an established resistance
mechanism to the <FONT STYLE="white-space:nowrap">B-cell</FONT> lymphoma (&#147;BCL2&#148;) inhibitor venetoclax (marketed as Venclexta<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies voruciclib shows dose-dependent suppression of MCL1; in December 2017 a study
of voruciclib published in the journal <I>Nature Scientific Reports</I> reported that the combination of voruciclib plus the <FONT STYLE="white-space:nowrap">BCL-2</FONT> inhibitor venetoclax was capable of inhibiting two master regulators of cell
survival, <FONT STYLE="white-space:nowrap">MCL-1</FONT> and <FONT STYLE="white-space:nowrap">BCL-2,</FONT> and achieved synergistic antitumor efficacy in an aggressive subset of DLBCL <FONT STYLE="white-space:nowrap">pre-clinical</FONT> models.
(Scientific Reports. (2017) 7:18007. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">DOI:10.1038/s41598-017-18368-w).</FONT></FONT></FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Additionally, at the 2018 American Society of Hematology (&#147;ASH&#148;) annual meeting we presented results from <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> studies demonstrating that voruciclib synergizes with venetoclax to induce apoptosis in both venetoclax sensitive and resistant acute myeloid leukemia (&#147;AML&#148;) cells. The <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> data further demonstrated that voruciclib transiently downregulates MCL1 and that MCL1 downregulation is likely responsible for the bulk of the synergy between voruciclib and venetoclax. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">CDK9 is also a transcriptional regulator of MYC, a transcription factor regulating cell proliferation and growth which contributes to many
human cancers and is frequently associated with poor prognosis and unfavorable patient survival. Targeting MYC directly has historically been difficult, but CDK9 is a transcriptional regulator of MYC and is a promising approach to target this
oncogene. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>Clinical Program </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We are evaluating patients with hematological malignancies in a dose ranging Phase 1b clinical trial of voruciclib. The trial is initially
intended to evaluate voruciclib as a monotherapy in patients with relapsed and/or refractory <FONT STYLE="white-space:nowrap">B-cell</FONT> malignancies or AML after failure of prior standard therapies to determine the safety, preliminary efficacy
and maximum tolerated dose. In parallel, subject to FDA agreement, we also plan to evaluate voruciclib in combination with a BCL2 inhibitor such as venetoclax to assess synergies and the opportunity for combination treatments across multiple
indications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Voruciclib was previously evaluated in more than 70 patients in multiple Phase 1 studies with a tolerability profile
consistent with other drugs in its class. In <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies, voruciclib shows dose-dependent suppression of MCL1 at concentrations achievable with doses that appear to be generally well tolerated in
earlier Phase 1 studies. <FONT STYLE="white-space:nowrap">Pre-clinical</FONT> studies additionally show inhibition of MYC protein expression. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U><FONT
STYLE="white-space:nowrap">ME-344:</FONT> Mitochondrial Inhibitor with Combinatorial Potential</U> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">ME-344</FONT> is our novel and tumor selective, isoflavone-derived mitochondrial inhibitor drug candidate. It
directly targets the OXPHOS complex 1, a pathway involved in ATP production in the mitochondria. <FONT STYLE="white-space:nowrap">ME-344</FONT> was recently studied in an investigator-initiated, multi-center, randomized clinical trial in combination
with the vascular endothelial growth factor (&#147;VEGF&#148;) inhibitor bevacizumab (marketed as Avastin<SUP STYLE="font-size:85%; vertical-align:top"> </SUP><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) in a total of 42 patients with
HER2 negative breast cancer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">ME-344</FONT> Scientific Overview: Cancer Metabolism
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Tumor cells often display a high metabolic rate to support cell division and growth. This heightened metabolism requires a continual
supply of energy in the form of adenosine triphosphate (&#147;ATP&#148;). The two major sources of ATP are the specialized cellular organelles termed mitochondria and through the metabolism of carbohydrates, proteins and lipids. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">ME-344</FONT> was identified through a screen of more than 400 new chemical structures originally created
based on the central design of naturally occurring plant isoflavones. We believe that some of these synthetic compounds, including our drug candidate <FONT STYLE="white-space:nowrap">ME-344,</FONT> interact with specific mitochondrial enzyme
targets, resulting in the inhibition of ATP generation. When these compounds interact with their target, a rapid reduction in ATP occurs, which leads to a cascade of biochemical events within the cell and ultimately to cell death. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>Clinical Program </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">ME-344</FONT> demonstrated evidence of single agent activity against refractory solid tumors in a Phase 1 trial, and in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies tumor cells treated with <FONT
STYLE="white-space:nowrap">ME-344</FONT> resulted in a rapid loss of ATP and cancer cell death. In addition to single agent activity, <FONT STYLE="white-space:nowrap">ME-344</FONT> may also have significant potential in combination with
anti-angiogenic therapeutics. In <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies, it was shown that one outcome of anti-angiogenics was to reduce the rate of glycolysis in tumors as a mechanism to slow tumor growth. However, tumor
metabolism was able to shift to mitochondrial metabolism for energy production to support continued tumor proliferation. In such cases of tumor plasticity in the presence of treatment with anti-angiogenics, targeting the alternative metabolic source
with <FONT STYLE="white-space:nowrap">ME-344</FONT> may open an important therapeutic opportunity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Support for this combinatorial use of <FONT
STYLE="white-space:nowrap">ME-344</FONT> was first published in the June 2016 edition of <I>Cell Reports</I>; <FONT STYLE="white-space:nowrap">pre-clinical</FONT> data from a collaboration with the Spanish National Cancer Research Centre in Madrid
demonstrated mitochondria-specific effects of <FONT STYLE="white-space:nowrap">ME-344</FONT> in cancer cells, including substantially enhanced anti-tumor activity when combined with agents that inhibit the activity of VEGF. These data demonstrating
the potential anti-cancer effects of combining <FONT STYLE="white-space:nowrap">ME-344</FONT> with a VEGF inhibitor due to an inhibition of both mitochondrial and glycolytic metabolism provided a basis for commencement of an investigator-initiated
trial of <FONT STYLE="white-space:nowrap">ME-344</FONT> in combination with bevacizumab in HER2 negative breast cancer patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In June
2019, at the American Society of Clinical Oncology annual meeting, further support for the combinatorial use of <FONT STYLE="white-space:nowrap">ME-344</FONT> with anti-angiogenic therapeutics was presented from a multicenter,
investigator-initiated, randomized, open-label, clinical trial that evaluated the combination of <FONT STYLE="white-space:nowrap">ME-344</FONT> and bevacizumab in 42 patients with early HER2-negative breast cancer. Patients were randomized <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-to-one</FONT></FONT> to either <FONT STYLE="white-space:nowrap">ME-344</FONT> in combination with bevacizumab or saline in combination with bevacizumab. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The primary objective of the trial was to show proof of <FONT STYLE="white-space:nowrap">ME-344</FONT> biologic activity as measured by Ki67
reductions (a measure of cell proliferation that is highly correlated with tumor response) from day 0 to 28 compared to the control group who received bevacizumab alone. Secondary objectives included determining whether <FONT
STYLE="white-space:nowrap">ME-344</FONT> biologic activity correlates with vascular normalization. The data demonstrate significant biologic activity in the <FONT STYLE="white-space:nowrap">ME-344</FONT> treatment group: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In <FONT STYLE="white-space:nowrap">ME-344</FONT> treated patients, mean absolute Ki67 decreases were 13.3
compared to an increase of 1.1 in the bevacizumab monotherapy group (P=0.01). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In <FONT STYLE="white-space:nowrap">ME-344</FONT> treated patients, mean relative Ki67 decreases were 23%
compared to an increase of 186% in the bevacizumab monotherapy group (P &lt; 0.01). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The mean relative Ki67 reduction in patients experiencing vascular normalization in the <FONT
STYLE="white-space:nowrap">ME-344</FONT> treated patients was 33%, compared to an increase of 11.8% in normalized patients from the bevacizumab monotherapy group (P=0.09). Approximately <FONT STYLE="white-space:nowrap">one-third</FONT> of patients
in each arm had vascular normalization. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Treatment was generally well tolerated; two Grade 3 adverse events of high
blood pressure were reported, one in each arm. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Results from our earlier,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human,</FONT></FONT> single-agent Phase 1 clinical trial of <FONT STYLE="white-space:nowrap">ME-344</FONT> in patients with refractory solid tumors were published in the
April&nbsp;1, 2015 issue of<I> Cancer</I>. The results indicated that eight of 21 evaluable patients (38%) treated with <FONT STYLE="white-space:nowrap">ME-344</FONT> achieved stable disease or better, including five who experienced progression-free
survival that was at least twice the duration of their last prior treatment before entry into the trial. In addition, one of these patients, a heavily <FONT STYLE="white-space:nowrap">pre-treated</FONT> patient with small cell lung cancer, achieved
a confirmed partial response and remained on study for two years. <FONT STYLE="white-space:nowrap">ME-344</FONT> was generally well tolerated at doses equal to or less than 10 mg/kg delivered on a weekly schedule for extended durations.
Treatment-related adverse events included nausea, dizziness and fatigue. Dose-limiting toxicities were observed at both the 15 mg/kg and 20 mg/kg dose levels, consisting primarily of grade three peripheral neuropathy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Pracinostat: HDAC Inhibitor Candidate in a Phase 3 Global Registration Clinical Trial </U></I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Pracinostat is an&nbsp;oral HDAC inhibitor being evaluated in a pivotal Phase 3 global registration clinical trial for the treatment of adults
with newly diagnosed AML who are unfit to receive intensive chemotherapy. Pracinostat is also being evaluated in a Phase 2 trial in patients with high or very high-risk <I>myelodysplastic syndrome</I> (&#147;MDS&#148;). In August 2016, we entered
into an exclusive worldwide license, development, manufacturing and commercialization agreement with Helsinn Healthcare SA, a Swiss pharmaceutical corporation (&#147;Helsinn&#148;) for pracinostat in AML, MDS and other potential indications (the
&#147;Helsinn License Agreement&#148;). Under the agreement, Helsinn is primarily responsible for funding global development and commercialization costs for pracinostat. We are responsible for conducting the Phase 2 MDS trial, the cost of which is
being shared equally with Helsinn. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Breakthrough Therapy Designation for pracinostat was granted by the FDA in 2016, and in
January 2018 the European Medicines Agency granted Orphan Drug Designation to pracinostat for the treatment of AML. The designations in the US and European Union (&#147;EU&#148;) are supported by data from a Phase 2 trial of pracinostat plus
azacitidine (marketed as Vidaza<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) in elderly patients with newly diagnosed AML who are not candidates for induction chemotherapy. The trial showed a median overall survival of 19.1 months and
a complete remission (&#147;CR&#148;) rate of 42% (21 of 50 patients). These data compare favorably to an international Phase 3 trial of azacitidine <FONT STYLE="white-space:nowrap">(AZA-001;</FONT> Dombret et al. Blood. 2015 May 18), which showed a
median overall survival of 10.4 months with azacitidine alone and a CR rate of 19.5% in a similar patient population. The combination of pracinostat and azacitidine was generally well tolerated, with no unexpected toxicities. The most common grade
3/4 treatment-emergent adverse events included febrile neutropenia, thrombocytopenia, anemia and fatigue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>Pracinostat Scientific
Overview; Epigenetics </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">HDACs play a key role in epigenetic regulation of gene expression by regulating chromatin structure. Acetylation
of positively charged lysine residues present in histone proteins by the histone acetyltransferase (&#147;HATs&#148;) reduces the affinity between histones and negatively charged DNA, resulting in the opening of the chromatin structure. This makes
it easier for the transcriptional machinery to access the DNA, enhancing RNA transcription. Conversely, deacetylation by the HDACs closes the chromatin structure leading to a repression of gene transcription. In normal cells, HDACs and HATs together
control histone acetylation levels to maintain a balance. In diseases such as cancer, this regulation can be disturbed. HDAC inhibitors cause accumulation of acetylated histones, enhance transcription and result in changes to a variety of cellular
responses including differentiation, proliferation, migration, survival and response to metabolic and hypoxic stress. In general, tumor cells are more susceptible than normal cells to the anti-proliferative and
<FONT STYLE="white-space:nowrap">pro-apoptotic</FONT> effects of HDAC inhibitors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">There are currently three HDAC inhibitors, one oral and
two injectable, approved by the FDA for the treatment of <FONT STYLE="white-space:nowrap">T-cell</FONT> lymphoma and a fourth orally administered HDAC inhibitor approved for multiple myeloma. Other HDAC inhibitors are being evaluated in clinical
trials as monotherapies and in combination for the treatment of various hematologic diseases and solid tumors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Pracinostat is an orally
available, potent HDAC inhibitor with potentially improved physicochemical, pharmaceutical and pharmacokinetic properties when compared to other compounds of this class, including increased bioavailability and increased half-life. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>Clinical Program </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The
ongoing pivotal Phase 3 registration trial, which is being run by Helsinn and was initiated in June 2017, is a randomized, double-blind, placebo-controlled study that will enroll worldwide approximately 500 adults with newly diagnosed AML who are
unfit to receive intensive chemotherapy. Patients are randomized 1:1 to receive pracinostat or placebo with azacitidine as background therapy. The primary endpoint of the trial is overall survival. Secondary endpoints include morphologic CR rate,
event-free survival and duration of CR. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Additionally, pracinostat is being investigated in a Phase 2 dose optimization trial evaluating
patients with high and very high-risk MDS who are previously untreated with hypomethylating agents. This patient group represents the highest unmet need in MDS, with median survival estimates of 1.6 years and 0.8 years, respectively (Greenberg et
al, Blood 2012). The ongoing Phase 2 open-label trial is evaluating a 45 mg dose of pracinostat in combination with the standard dose of azacitidine. The trial is designed to evaluate tolerability of the combination, with the intent of maintaining
patient enrollment longer than in an earlier Phase 2 trial evaluating a 60 mg dose. A prolonged treatment may result in a systemic exposure to pracinostat and azacitidine sufficient to achieve the desired treatment effect; data from the earlier
Phase 2 trial suggested that insufficient exposure to treatment may have limited the treatment effect of the combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">A <FONT
STYLE="white-space:nowrap">pre-planned</FONT> interim analysis of the ongoing Phase 2 MDS trial demonstrated a 10% discontinuation rate among the first 20 evaluable patients treated, meeting the predefined threshold in the first 3 treatment cycles.
The 10% rate is consistent with the discontinuation rate for azacitidine given as a monotherapy in earlier studies with pracinostat. Having met this threshold, the trial expanded open-label enrollment to a total of 60 patients in the study. An
interim analysis presented at the 2018 ASH meeting demonstrated a discontinuation rate due to adverse events in the first 3 months of 4%, substantially lower than the rate of 26% reported in the Company&#146;s prior Phase 2 trial. The Phase 2 trial
has completed enrollment and patients will be followed for one year to evaluate safety and efficacy. The primary endpoints of the trial are 1) safety and tolerability and 2) overall response rate, defined as CR, partial remission (&#147;PR&#148;)
and marrow CR. Secondary endpoints include CR rate, overall hematologic improvement (&#147;HI&#148;) response rate, clinical benefit rate (defined as rate of CR + PR + HI + Marrow CR), rate of cytogenetic complete response/remission, duration of
response, rate of leukemic transformation, event-free survival, progression-free survival and overall survival. If the Phase 2 open-label trial is successful, Helsinn intends to initiate a global registration trial. All future development and
commercialization costs after the completion of the Phase 2 trial are the responsibility of Helsinn. Pracinostat has been previously investigated in more than 300 patients in multiple Phase 1 and Phase 2 clinical trials and found to be generally
well tolerated with manageable side effects often associated with drugs of this class, including fatigue, myelosuppression and gastrointestinal toxicity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Comparison of Three Months Ended September&nbsp;30, 2019 and 2018 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We had a loss from operations of $12.6&nbsp;million for the three months ended September&nbsp;30, 2019 compared to a loss from operations of
$10.0&nbsp;million for the three months ended September&nbsp;30, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue: </I></B>We recognized revenue of $1.2&nbsp;million for the three
months ended September&nbsp;30, 2019 compared to $0.5&nbsp;million for the three months ended September&nbsp;30, 2018. Revenue increased primarily due to our license agreement with KKC and resulted from the partial satisfaction of our research and
development obligations and providing clinical trial materials. Revenue related to the license agreement with KKC was $0.8&nbsp;million for the three months ended September&nbsp;30, 2019. There was no revenue related to the license agreement with
KKC for the three months ended September&nbsp;30, 2018. Revenue also includes recognition of amounts allocated to performance obligations in accordance with the Helsinn License Agreement. Revenue related the Helsinn License Agreement was
$0.4&nbsp;million for the three months ended September&nbsp;30, 2019 compared to $0.5&nbsp;million for the three months ended September&nbsp;30, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cost of Revenue:</I></B> We recognized cost of revenue of $0.7&nbsp;million for the three months ended September&nbsp;30, 2019 compared to
$1.0&nbsp;million for the three months ended September&nbsp;30, 2018. The cost of revenue includes external costs paid to third-party contractors to perform research, conduct clinical trials and develop and manufacture drug materials, and internal
compensation and related personnel expenses associated with pracinostat. Costs of revenue relate to expenses for pracinostat incurred in connection with our development activities in accordance with the Helsinn License Agreement, including both
Helsinn&#146;s share and our share of costs related to the POC study, which we are responsible for conducting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and
Development</I></B><B>:</B> The following is a summary of our research and development expenses to supplement the more detailed discussion below. The dollar values in the following table are in thousands. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Research&nbsp;and&nbsp;development&nbsp;expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">ME-401</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,505</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Voruciclib</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">ME-344</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Research and development expenses consist primarily of clinical trial costs (including payments to clinical
research organizations), <FONT STYLE="white-space:nowrap">pre-clinical</FONT> study costs, and costs to manufacture our drug candidates for <FONT STYLE="white-space:nowrap">non-clinical</FONT> and clinical studies. Other research and development
expenses consist primarily of salaries and personnel costs, share-based compensation, legal costs, and other costs not allocated to specific drug programs. Research and development expenses were $9.0&nbsp;million for the three months ended
September&nbsp;30, 2019 compared to $6.1&nbsp;million for the three months ended September&nbsp;30, 2018. Costs related to <FONT STYLE="white-space:nowrap">ME-401</FONT> were higher for the three months ended September&nbsp;30, 2019 due to
$2.4&nbsp;million of increased clinical trial costs as a result of starting the Phase 2 study. Costs related to voruciblib decreased due primarily to reduced costs for drug manufacturing. Costs related to
<FONT STYLE="white-space:nowrap">ME-344</FONT> decreased due to completion of the investigator-initiated clinical trial. Other research and development costs increased for the three months ended September&nbsp;30, 2019 due to increased headcount to
support our clinical activities, as well as to increased legal and consulting fees ($0.3 million). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General and Administrative</I></B><B>:
</B>General and administrative expenses increased by $0.7&nbsp;million to $4.1&nbsp;million for the three months ended September&nbsp;30, 2019 compared to $3.4&nbsp;million for the three months ended September&nbsp;30, 2018. The increase is
primarily due to increased headcount to support our activities, and $0.2&nbsp;million in increased professional services expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other income or
expense: </I></B>We recorded a <FONT STYLE="white-space:nowrap">non-cash</FONT> gain of $9.3&nbsp;million during the three months ended September&nbsp;30, 2019, compared to a <FONT STYLE="white-space:nowrap">non-cash</FONT> loss of $5.0&nbsp;million
during the three months ended September&nbsp;30, 2018, due to a change in the fair value of our warrant liability. The change in the warrant liability is primarily due to changes in our stock price. Additionally, we received interest and dividend
income of $0.4&nbsp;million for the three months ended September&nbsp;30, 2019 compared to $0.5&nbsp;million for the three months ended September&nbsp;30, 2018. The decrease was due to lower investment balances during the three months ended
September&nbsp;30, 2019 compared to the three months ended September&nbsp;30, 2018. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We have accumulated losses of $234.2&nbsp;million since inception and expect to incur operating losses and generate negative cash flows from
operations for the foreseeable future. As of September&nbsp;30, 2019, we had $65.9&nbsp;million in cash, cash equivalents and short-term investments, which we believe will be sufficient to fund our operations for at least the next 12 months from the
issuance of these financial statements. Our current business operations are focused on continuing the clinical development of our drug candidates. Changes to our research and development plans or other changes affecting our operating expenses may
affect actual future use of existing cash resources. To date, we have obtained cash and funded our operations primarily through equity financings and license payments. In order to continue the development of our drug candidates, we expect to pursue
one or more capital transactions, whether through the sale of equity securities, debt financing, license agreements or entry into strategic partnerships. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>Sources and Uses of Our Cash </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities for the three months ended September&nbsp;30, 2019 was $14.1&nbsp;million. This compares to
$12.8&nbsp;million used in operating activities for the three months ended September&nbsp;30, 2018. The increase in cash used in operating activities reflects increased costs in our clinical development programs, including <FONT
STYLE="white-space:nowrap">start-up</FONT> costs related to the <FONT STYLE="white-space:nowrap">ME-401</FONT> Phase 2 study. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Net cash
provided by investing activities for the three months ended September&nbsp;30, 2019 was $5.0&nbsp;million compared to net cash provided by investing activities of $4.8&nbsp;million in the three months ended September&nbsp;30, 2018. Cash provided by
investing activities represents maturities of investments in short-term U.S. government securities in excess of purchases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Net cash
provided by financing activities for the three months ended September&nbsp;30, 2019 was $5.5&nbsp;million compared to $0.8&nbsp;million for the three months ended September&nbsp;30, 2018. Cash provided during the three months ended
September&nbsp;30, 2019 primarily represents the collection of $5.3&nbsp;million of amounts receivable as of June&nbsp;30, 2019 from the issuance of common stock and exercise of stock options during the year ended June&nbsp;30, 2019, as well as
$0.2&nbsp;million of proceeds received from the issuance of common stock and exercise of stock options during the three months ended September&nbsp;30, 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We have
contracted with various consultants and third parties to assist us in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> research and development and clinical trials work for our leading drug compounds. The contracts are terminable at any time,
but obligate us to reimburse the providers for any time or costs incurred through the date of termination. Additionally, we have employment agreements with certain of our current employees that provide for severance payments and accelerated vesting
for share-based awards if their employment is terminated under specified circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We have leased approximately 20,800 square feet
of office space, located at 3611 Valley Centre Drive, San Diego, California. The location houses our executive and administrative offices. The lease commenced in July 2017 and expires in May 2020. The monthly rental rate is approximately $67,000 per
month over the remaining term of the lease, plus a pro rata share of certain building expenses. The remaining contractual obligations are approximately $0.5&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>Presage License Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In September 2017, we entered into the Presage License Agreement. Under the terms of the Presage License Agreement, Presage granted to us
exclusive worldwide rights to develop, manufacture and commercialize voruciclib, a clinical-stage, oral and selective CDK inhibitor, and related compounds. In exchange, we paid Presage $2.9&nbsp;million. With respect to the first indication, an
incremental $2.0&nbsp;million payment, due upon dosing the first subject in the first registration trial will be owed to Presage, for total payments of $4.9&nbsp;million prior to receipt of marketing approval of the first indication in the U.S.,
E.U. or Japan. Additional potential payments of up to $179&nbsp;million will be due upon the achievement of certain development, regulatory and commercial milestones. We will also pay <FONT STYLE="white-space:nowrap">mid-single-digit</FONT> tiered
royalties on the net sales of any product successfully developed. As an alternative to milestone and royalty payments related to countries in which we sublicense product rights, we will pay to Presage a tiered percent (which decreases as product
development progresses) of amounts received from such sublicensees. As of September&nbsp;30, 2019, we have not accrued any amounts for potential future payments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>S*Bio Purchase Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We are party to a definitive asset purchase agreement with S*Bio, pursuant to which we acquired certain assets comprised of intellectual
property and technology including rights to pracinostat. We agreed to make certain milestone payments to S*Bio based on the achievement of certain clinical, regulatory and net sales-based milestones, as well as to make certain contingent earnout
payments to S*Bio. Milestone payments will be made to S*Bio up to an aggregate amount of $74.5&nbsp;million if certain U.S., E.U. and Japanese regulatory approvals are obtained and if certain net sales thresholds are met in North America, the E.U.
and Japan. The first milestone payment of $200,000 plus 166,527 shares of our common stock having a value of $500,000 was paid in August 2017 upon the first dosing of a patient in a Phase 3 clinical trial. Subsequent milestone payments will be due
upon certain regulatory approvals and sales-based events. As of September&nbsp;30, 2019, we have not accrued any amounts for potential future payments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>CyDex License Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We are party to a license agreement with CyDex. Under the license agreement, CyDex granted to us an exclusive, nontransferable license to
intellectual property rights relating to Captisol<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> for use with our two isoflavone-based drug compounds (currently <FONT STYLE="white-space:nowrap">ME-344).</FONT> We agreed to pay to CyDex a <FONT
STYLE="white-space:nowrap">non-refundable</FONT> license issuance fee, future milestone payments, and royalties at a low, single-digit percentage rate on future sales of our approved drugs utilizing Captisol. Contemporaneously with the license
agreement, CyDex entered into a commercial supply agreement with us, pursuant to which we agreed to purchase 100% of our requirements for Captisol from CyDex. We may terminate both the license agreement and the supply agreement for convenience at
any time upon 90 days&#146; prior written notice. As of September&nbsp;30, 2019, we have not accrued any amounts for potential future payments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and Management Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We describe our significant accounting policies in Note 1, The Company and Summary of Significant Accounting Policies, of the notes to the
financial statements included in our 2019 Annual Report. We discuss our critical accounting estimates in Item 7, Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations, in our 2019 Annual Report. Except for the
adoption of ASC 842, there have been no changes in our significant accounting policies or critical accounting estimates since June&nbsp;30, 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Accounting Pronouncements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">See
Note 1 to the Financial Statements included in Item 1 of this Quarterly Report. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx667344_9"></A><A NAME="tx667344_9"></A><A NAME="tx667344_9"></A>Item&nbsp;3:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Quantitative and Qualitative Disclosures about Market Risk </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Our exposure to market interest rates relates primarily to the investment of cash balances and short-term
investments.&nbsp;&nbsp;&nbsp;&nbsp;We have cash reserves held in U.S. dollars and we place funds on deposit with financial institutions, which are readily available. Our short-term investments consist solely of U.S. government securities with a
maturity of three to twelve months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We place our cash deposits with high credit quality financial institutions and by policy limit the
amount of credit exposure to any one corporation or bank. These deposits are in excess of the FDIC insurance limits. We are adverse to principal loss and we ensure the safety and preservation of our invested funds by limiting default risk, market
risk and reinvestment risk. We seek to mitigate default risk by depositing funds with high credit quality financial institutions, by limiting the amount of credit exposure to any one corporation or bank, by purchasing short-term investments
consisting of U.S. government securities, and by positioning our portfolio to respond appropriately to a significant reduction in a credit rating of any such financial institution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We do not consider the effects of interest rate movements to be a material risk to our financial condition. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx667344_10"></A><A NAME="tx667344_10"></A><A NAME="tx667344_10"></A>Item&nbsp;4:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Controls and Procedures </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">At the end of the period covered by this Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> our management, with the
participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures. Disclosure controls and procedures include, without limitation, controls and procedures designed to
ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer&#146;s management, including its principal executive and principal financial
officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and
procedures were effective to ensure that the information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#146;s
rules and forms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">There were no changes in our internal control over financial reporting during the period covered by this Quarterly
Report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx667344_11">
</A><A NAME="tx667344_11"></A><A NAME="tx667344_11"></A>PART II OTHER INFORMATION </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx667344_12"></A><A NAME="tx667344_12"></A><A NAME="tx667344_12"></A>Item&nbsp;1:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Legal Proceedings </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">None. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="tx667344_13"></A><A NAME="tx667344_13"></A><A NAME="tx667344_13"></A>Item&nbsp;1A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Risk Factors </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">There have been no material changes in our risk factors from those included in our 2019 Annual Report. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx667344_14"></A><A NAME="tx667344_14"></A>Item&nbsp;2:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Unregistered Sales of Equity Securities and Use of Proceeds </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">None. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx667344_15"></A><A NAME="tx667344_15"></A>Item&nbsp;3:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Defaults upon Senior Securities </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">None. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx667344_16"></A>Item&nbsp;4:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Mine Safety Disclosures </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Not applicable. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx667344_17"></A>Item&nbsp;5:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Other Information </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">None. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx667344_18"></A>Item&nbsp;6:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exhibits </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit Index </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Exhibits </U></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;31.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d667344dex311.htm"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Rule&nbsp;13a-14(a)&nbsp;or&nbsp;Rule&nbsp;15d-14(a)&nbsp;Certification&nbsp;of&nbsp;Principal&nbsp;Executive&nbsp;Officer</FONT></FONT>
</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;31.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d667344dex312.htm">Rule <FONT STYLE="white-space:nowrap">13a-14(a)</FONT> or Rule <FONT STYLE="white-space:nowrap">15d-14(a)</FONT> Certification of Principal Financial Officer </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;32.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d667344dex321.htm">Certification of Principal Executive Officer and Principal Financial Officer required by Rule <FONT STYLE="white-space:nowrap">13a-14(b)</FONT> or Rule <FONT STYLE="white-space:nowrap">15d-14(b)</FONT> and Section&nbsp;1350
 of Chapter 63 of Title 18 of the United States Code (18 U.S.C 1350). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.INS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Instance Document.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.SCH</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Schema Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.CAL</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Calculation Linkbase Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.DEF</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Definition Linkbase Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.LAB</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">XBRL Taxonomy Extension Label Linkbase Document</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.PRE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Presentation Linkbase Document</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx667344_19"></A>SIGNATURES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Quarterly Report to be signed on its behalf by the
undersigned, thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">MEI Pharma, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Daniel P. Gold</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Daniel P. Gold</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: November&nbsp;7, 2019</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>d667344dex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Daniel P. Gold, certify
that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I have reviewed this Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> of MEI Pharma, Inc.;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, this Quarterly Report does not contain any untrue statement of a material fact or omit
to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Quarterly Report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, the financial statements, and other financial information included in this Quarterly
Report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this Quarterly Report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> and internal control over financial reporting (as defined in Exchange Act
Rules <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f))</FONT> for the registrant and have: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this Quarterly
Report is being prepared; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting
principles; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in the
Quarterly Report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this Quarterly Report based on such evaluation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">disclosed in this Quarterly Report any change in the registrant&#146;s internal control over financial
reporting that occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant&#146;s internal control over financial reporting. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any fraud, whether or not material, that involves management or other employees who have a significant role in
the registrant&#146;s internal control over financial reporting. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: November&nbsp;7, 2019</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Daniel P. Gold</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Daniel P. Gold</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Principal Executive Officer)</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>d667344dex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Brian G. Drazba,
certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I have reviewed this Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> of MEI Pharma, Inc.;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, this Quarterly Report does not contain any untrue statement of a material fact or omit
to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Quarterly Report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, the financial statements, and other financial information included in this Quarterly
Report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this Quarterly Report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> and internal control over financial reporting (as defined in Exchange Act
Rules <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f))</FONT> for the registrant and have: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this Quarterly
Report is being prepared; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting
principles; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in the
Quarterly Report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this Quarterly Report based on such evaluation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">disclosed in this Quarterly Report any change in the registrant&#146;s internal control over financial
reporting that occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant&#146;s internal control over financial reporting. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Our other certifying officer and I have disclosed, based on our most recent evaluation of internal control over
financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any fraud, whether or not material, that involves management or other employees who have a significant role in
the registrant&#146;s internal control over financial reporting. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: November&nbsp;7, 2019</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Brian G. Drazba</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Brian G. Drazba</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Principal Financial Officer)</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>d667344dex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 32.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the
requirement set forth in Rule <FONT STYLE="white-space:nowrap">13a-14(b)</FONT> or Rule <FONT STYLE="white-space:nowrap">15d-14(b)</FONT> of the Securities Exchange Act of 1934, as amended, and Section&nbsp;1350 of Chapter 63 of Title 18 of the
United States Code (18 U.S.C. &#167; 1350), Daniel P. Gold, the Chief Executive Officer of MEI Pharma, Inc. (the &#147;Registrant&#148;), and Brian G. Drazba, the Chief Financial Officer of the Registrant, each hereby certifies that, to his
knowledge: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Registrant&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the period
ended September&nbsp;30, 2019, (the &#147;Form <FONT STYLE="white-space:nowrap">10-Q&#148;)</FONT> to which this Certification is attached as Exhibit 32.1, fully complies with the requirements of Section&nbsp;13(a) or Section&nbsp;15(d) of the
Securities Exchange Act of 1934, as amended; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The information contained in the Form <FONT STYLE="white-space:nowrap">10-Q</FONT> fairly presents, in all
material respects, the financial condition of the Registrant at the end of the period covered by the Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and results of operations of the registrant for the period covered by the Form <FONT
STYLE="white-space:nowrap">10-Q.</FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These certifications accompanying the Form <FONT STYLE="white-space:nowrap">10-Q</FONT> to
which they relate, are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934,
as amended (whether made before or after the date of the Form <FONT STYLE="white-space:nowrap">10-Q),</FONT> irrespective of any general incorporation language contained in such filing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: November&nbsp;7, 2019 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Daniel P. Gold</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Brian G. Drazba</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Daniel P. Gold</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Brian G. Drazba</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Principal Executive
Officer)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Principal Financial
Officer)</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>5
<FILENAME>meip-20190930.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 07-November-2019 [03:35:54] {PM}-->
<xbrli:xbrl xmlns:meip="http://www.meipharma.com/20190930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2019-01-31">
<link:schemaRef xlink:type="simple" xlink:href="meip-20190930.xsd" />
<xbrli:context id="PAsOn09_30_2019">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2019">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To09_30_2019">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2019-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To12_31_2018">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2018">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn11_04_2019">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-11-04</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2018">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2019_TwoThousandAndEightOmnibusPlanMemberusgaapPlanNameAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">meip:TwoThousandAndEightOmnibusPlanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2019_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2019_SbioPurchaseAgreementMemberusgaapTypeOfArrangementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">meip:SbioPurchaseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2019_CydexLicenseAgreementMemberusgaapTypeOfArrangementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">meip:CydexLicenseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2019_PresageLicenseAgreementMemberusgaapTypeOfArrangementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">meip:PresageLicenseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2019_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">meip:EmployeesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2019_WarrantMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2019_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2019_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2019_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2019_MeasurementInputExpectedDividendRateMemberusgaapMeasurementInputTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2019_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2019_AccountingStandardsUpdate201602MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis_PropertyPlantAndEquipmentNetMemberusgaapBalanceSheetLocationAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">meip:PropertyPlantAndEquipmentNetMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2019_AccountingStandardsUpdate201602MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis_AccruedLiabilitiesMemberusgaapBalanceSheetLocationAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2019_AccountingStandardsUpdate201602MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2019_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2019_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2019_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2019_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2019_MeasurementInputExpectedDividendRateMemberusgaapMeasurementInputTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2019_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To09_30_2019_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2019-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To09_30_2019_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2019-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To09_30_2019_EmployeeStockOptionMemberusgaapAwardTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2019-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To09_30_2019_DirectorMembersrtTitleOfIndividualAxis_MinimumMembersrtRangeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2019-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To09_30_2019_DirectorMembersrtTitleOfIndividualAxis_MaximumMembersrtRangeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2019-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To09_30_2019_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2019-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To09_30_2019_AtTheMarketSaleAgreementMemberusgaapSubsidiarySaleOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">meip:AtTheMarketSaleAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2019-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To09_30_2019_KHKLicenseAgreementMemberusgaapTypeOfArrangementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">meip:KHKLicenseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2019-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To09_30_2019_HelsinnLicenseAgreementMemberusgaapTypeOfArrangementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">meip:HelsinnLicenseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2019-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To09_30_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2019-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To09_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2019-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To09_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2019-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To09_30_2019_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2019-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To09_30_2019_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2019-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To09_30_2019_MaximumMembersrtRangeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2019-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To09_30_2019_AccountingStandardsUpdate201602MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2019-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018_HelsinnLicenseAgreementMemberusgaapTypeOfArrangementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">meip:HelsinnLicenseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018_CommonStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P10_01_2018To10_31_2018_KyowaKirinCoMemberdeiLegalEntityAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">meip:KyowaKirinCoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-10-01</xbrli:startDate>
<xbrli:endDate>2018-10-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P10_01_2018To10_31_2018_KyowaKirinCoMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">meip:KyowaKirinCoMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-10-01</xbrli:startDate>
<xbrli:endDate>2018-10-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P08_30_2016To08_31_2016_HelsinnLicenseAgreementMemberusgaapTypeOfArrangementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">meip:HelsinnLicenseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2016-08-30</xbrli:startDate>
<xbrli:endDate>2016-08-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn08_31_2016_MaximumMembersrtRangeAxis_PotentialRegulatoryAndSalesbasedMilestonePaymentMemberusgaapRelatedPartyTransactionAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">meip:PotentialRegulatoryAndSalesbasedMilestonePaymentMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2016-08-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P09_01_2017To09_30_2017_PresageBiosciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_PresageLicenseAgreementMemberusgaapTypeOfArrangementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">meip:PresageLicenseAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">meip:PresageBiosciencesIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-09-01</xbrli:startDate>
<xbrli:endDate>2017-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2017_IncrementalPaymentMemberusgaapRelatedPartyTransactionAxis_PresageBiosciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_PresageLicenseAgreementMemberusgaapTypeOfArrangementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">meip:PresageLicenseAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">meip:PresageBiosciencesIncMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">meip:IncrementalPaymentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2017_PresageBiosciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_PresageLicenseAgreementMemberusgaapTypeOfArrangementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">meip:PresageBiosciencesIncMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">meip:PresageLicenseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2017_MaximumMembersrtRangeAxis_PotentialPaymentsOnAchievementOfDevelopmentRegulatoryAndCommercialMilestonesMemberusgaapRelatedPartyTransactionAxis_PresageBiosciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_PresageLicenseAgreementMemberusgaapTypeOfArrangementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">meip:PresageLicenseAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">meip:PresageBiosciencesIncMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">meip:PotentialPaymentsOnAchievementOfDevelopmentRegulatoryAndCommercialMilestonesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn11_30_2017_AtTheMarketSaleAgreementMemberusgaapSubsidiarySaleOfStockAxis_MaximumMembersrtRangeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">meip:AtTheMarketSaleAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-11-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To06_30_2019_AtTheMarketSaleAgreementMemberusgaapSubsidiarySaleOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">meip:AtTheMarketSaleAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2019-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P06_01_2016To06_30_2016_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">meip:EmployeesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2016-06-01</xbrli:startDate>
<xbrli:endDate>2016-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P08_01_2018To08_31_2018_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">meip:EmployeesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-08-01</xbrli:startDate>
<xbrli:endDate>2018-08-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn07_01_2019_AccountingStandardsUpdate201602MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis_MinimumMembersrtRangeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-07-01</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn07_01_2019_AccountingStandardsUpdate201602MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis_CentralAmericaMembersrtStatementGeographicalAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:CentralAmericaMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-07-01</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn07_01_2019_AccountingStandardsUpdate201602MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-07-01</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To07_01_2019_AccountingStandardsUpdate201602MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2019-07-01</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2018_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2018_CommonStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2018_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2018_CommonStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<us-gaap:FiniteLivedIntangibleAssetsNet id="Factid_7988348" contextRef="PAsOn09_30_2019" unitRef="Unit_USD" decimals="-3">253000</us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:FiniteLivedIntangibleAssetsNet id="Factid_7988349" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">261000</us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:Assets id="Factid_7988350" contextRef="PAsOn09_30_2019" unitRef="Unit_USD" decimals="-3">68923000</us-gaap:Assets>
<us-gaap:Assets id="Factid_7988351" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">82663000</us-gaap:Assets>
<us-gaap:PropertyPlantAndEquipmentNet id="Factid_7988352" contextRef="PAsOn09_30_2019" unitRef="Unit_USD" decimals="-3">619000</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:PropertyPlantAndEquipmentNet id="Factid_7988353" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">204000</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:CashCashEquivalentsAndShortTermInvestments id="Factid_7988356" contextRef="PAsOn09_30_2019" unitRef="Unit_USD" decimals="-3">65916000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
<us-gaap:CashCashEquivalentsAndShortTermInvestments id="Factid_7988357" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">74489000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="Factid_7988358" contextRef="PAsOn09_30_2019" unitRef="Unit_USD" decimals="-3">2135000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="Factid_7988359" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">2435000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:ShortTermInvestments id="Factid_7988360" contextRef="PAsOn09_30_2019" unitRef="Unit_USD" decimals="-3">59932000</us-gaap:ShortTermInvestments>
<us-gaap:ShortTermInvestments id="Factid_7988361" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">64899000</us-gaap:ShortTermInvestments>
<us-gaap:AccountsPayableCurrent id="Factid_7988362" contextRef="PAsOn09_30_2019" unitRef="Unit_USD" decimals="-3">3098000</us-gaap:AccountsPayableCurrent>
<us-gaap:AccountsPayableCurrent id="Factid_7988363" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">4787000</us-gaap:AccountsPayableCurrent>
<us-gaap:AccruedLiabilitiesCurrent id="Factid_7988364" contextRef="PAsOn09_30_2019" unitRef="Unit_USD" decimals="-3">3295000</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:AccruedLiabilitiesCurrent id="Factid_7988365" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">4559000</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:AssetsCurrent id="Factid_7988366" contextRef="PAsOn09_30_2019" unitRef="Unit_USD" decimals="-3">68051000</us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent id="Factid_7988367" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">82198000</us-gaap:AssetsCurrent>
<us-gaap:CommitmentsAndContingencies id="Factid_7988368" contextRef="PAsOn09_30_2019" unitRef="Unit_USD" xsi:nil="true" />
<us-gaap:CommitmentsAndContingencies id="Factid_7988369" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" xsi:nil="true" />
<us-gaap:DeferredRevenueCurrent id="Factid_7988370" contextRef="PAsOn09_30_2019" unitRef="Unit_USD" decimals="-3">3675000</us-gaap:DeferredRevenueCurrent>
<us-gaap:DeferredRevenueCurrent id="Factid_7988371" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">4955000</us-gaap:DeferredRevenueCurrent>
<us-gaap:Liabilities id="Factid_7988372" contextRef="PAsOn09_30_2019" unitRef="Unit_USD" decimals="-3">21643000</us-gaap:Liabilities>
<us-gaap:Liabilities id="Factid_7988373" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">34733000</us-gaap:Liabilities>
<us-gaap:LiabilitiesAndStockholdersEquity id="Factid_7988374" contextRef="PAsOn09_30_2019" unitRef="Unit_USD" decimals="-3">68923000</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity id="Factid_7988375" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">82663000</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:AdditionalPaidInCapitalCommonStock id="Factid_7988378" contextRef="PAsOn09_30_2019" unitRef="Unit_USD" decimals="-3">281492000</us-gaap:AdditionalPaidInCapitalCommonStock>
<us-gaap:AdditionalPaidInCapitalCommonStock id="Factid_7988379" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">279148000</us-gaap:AdditionalPaidInCapitalCommonStock>
<us-gaap:CommonStockValue id="Factid_7988380" contextRef="PAsOn09_30_2019" unitRef="Unit_USD" xsi:nil="true" />
<us-gaap:CommonStockValue id="Factid_7988381" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" xsi:nil="true" />
<us-gaap:LiabilitiesCurrent id="Factid_7988382" contextRef="PAsOn09_30_2019" unitRef="Unit_USD" decimals="-3">10068000</us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent id="Factid_7988383" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">14301000</us-gaap:LiabilitiesCurrent>
<us-gaap:PreferredStockValue id="Factid_7988384" contextRef="PAsOn09_30_2019" unitRef="Unit_USD" xsi:nil="true" />
<us-gaap:PreferredStockValue id="Factid_7988385" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" xsi:nil="true" />
<us-gaap:RetainedEarningsAccumulatedDeficit id="Factid_7988386" contextRef="PAsOn09_30_2019" unitRef="Unit_USD" decimals="-3">-234212000</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit id="Factid_7988387" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">-231218000</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:StockholdersEquity id="Factid_7988388" contextRef="PAsOn09_30_2019" unitRef="Unit_USD" decimals="-3">47280000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_7988389" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">47930000</us-gaap:StockholdersEquity>
<us-gaap:CostOfGoodsAndServicesSold id="Factid_7988390" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">688000</us-gaap:CostOfGoodsAndServicesSold>
<us-gaap:CostOfGoodsAndServicesSold id="Factid_7988391" contextRef="P07_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">989000</us-gaap:CostOfGoodsAndServicesSold>
<us-gaap:ResearchAndDevelopmentExpense id="Factid_7988392" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">8962000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense id="Factid_7988393" contextRef="P07_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">6131000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:GeneralAndAdministrativeExpense id="Factid_7988394" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">4130000</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense id="Factid_7988395" contextRef="P07_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">3401000</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:CostsAndExpenses id="Factid_7988396" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">13780000</us-gaap:CostsAndExpenses>
<us-gaap:CostsAndExpenses id="Factid_7988397" contextRef="P07_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">10521000</us-gaap:CostsAndExpenses>
<us-gaap:OperatingIncomeLoss id="Factid_7988401" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">-12623000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss id="Factid_7988402" contextRef="P07_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">-10033000</us-gaap:OperatingIncomeLoss>
<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss id="Factid_7988408" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">9269000</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss id="Factid_7988409" contextRef="P07_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">-4962000</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
<us-gaap:DepreciationDepletionAndAmortization id="Factid_7988412" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">31000</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:DepreciationDepletionAndAmortization id="Factid_7988413" contextRef="P07_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">13000</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="Factid_7988414" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">-300000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="Factid_7988415" contextRef="P07_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">2085000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInAccountsPayableTrade id="Factid_7988416" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">-1689000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
<us-gaap:IncreaseDecreaseInAccountsPayableTrade id="Factid_7988417" contextRef="P07_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">-2088000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
<us-gaap:IncreaseDecreaseInAccruedLiabilities id="Factid_7988418" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">-1702000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccruedLiabilities id="Factid_7988419" contextRef="P07_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">-965000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
<us-gaap:IncreaseDecreaseInContractWithCustomerLiability id="Factid_7988421" contextRef="P07_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">-48000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
<us-gaap:PaymentsToAcquireShortTermInvestments id="Factid_7988422" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">19979000</us-gaap:PaymentsToAcquireShortTermInvestments>
<us-gaap:ProceedsFromStockOptionsExercised id="Factid_7988423" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">72000</us-gaap:ProceedsFromStockOptionsExercised>
<us-gaap:ProceedsFromStockOptionsExercised id="Factid_7988424" contextRef="P07_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">43000</us-gaap:ProceedsFromStockOptionsExercised>
<us-gaap:NetCashProvidedByUsedInFinancingActivities id="Factid_7988427" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">5505000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities id="Factid_7988428" contextRef="P07_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">837000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation id="Factid_7988429" contextRef="P07_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">324000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
<us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments id="Factid_7988430" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">24946000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
<us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments id="Factid_7988431" contextRef="P07_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">9725000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
<us-gaap:NetCashProvidedByUsedInInvestingActivities id="Factid_7988432" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">4967000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:NetCashProvidedByUsedInInvestingActivities id="Factid_7988433" contextRef="P07_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">4788000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:ProfitLoss id="Factid_7988434" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">-2994000</us-gaap:ProfitLoss>
<us-gaap:ProfitLoss id="Factid_7988435" contextRef="P07_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">-14542000</us-gaap:ProfitLoss>
<us-gaap:NetCashProvidedByUsedInOperatingActivities id="Factid_7988436" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">-14078000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities id="Factid_7988437" contextRef="P07_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">-12816000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect id="Factid_7988438" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">-3606000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect id="Factid_7988439" contextRef="P07_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">-7191000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
<us-gaap:CashAndCashEquivalentsAtCarryingValue id="Factid_7988440" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">9590000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue id="Factid_7988441" contextRef="PAsOn06_30_2018" unitRef="Unit_USD" decimals="-3">13309000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue id="Factid_7988442" contextRef="PAsOn09_30_2019" unitRef="Unit_USD" decimals="-3">5984000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue id="Factid_7988443" contextRef="PAsOn09_30_2018" unitRef="Unit_USD" decimals="-3">6118000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<meip:LicenseAgreementExpiryPeriod id="Factid_7988444" contextRef="P10_01_2018To10_31_2018_KyowaKirinCoMemberdeiLegalEntityAxis">P10Y</meip:LicenseAgreementExpiryPeriod>
<meip:UpFrontPayment id="Factid_7988445" contextRef="P10_01_2018To10_31_2018_KyowaKirinCoMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5">10000000</meip:UpFrontPayment>
<meip:PaymentRelatedToDevelopmentAndCommercialMilestonePayments id="Factid_7988446" contextRef="P10_01_2018To10_31_2018_KyowaKirinCoMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="INF">87500000</meip:PaymentRelatedToDevelopmentAndCommercialMilestonePayments>
<meip:PotentialMilestonePaymentsReceivable id="Factid_7988447" contextRef="PAsOn08_31_2016_MaximumMembersrtRangeAxis_PotentialRegulatoryAndSalesbasedMilestonePaymentMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="INF">444000000</meip:PotentialMilestonePaymentsReceivable>
<us-gaap:DueToRelatedPartiesCurrentAndNoncurrent id="Factid_7988448" contextRef="PAsOn09_30_2017_IncrementalPaymentMemberusgaapRelatedPartyTransactionAxis_PresageBiosciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_PresageLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5">2000000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
<meip:PaymentForLicenseAgreement id="Factid_7988449" contextRef="P09_01_2017To09_30_2017_PresageBiosciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_PresageLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5">2900000</meip:PaymentForLicenseAgreement>
<us-gaap:DueToRelatedPartiesCurrentAndNoncurrent id="Factid_7988450" contextRef="PAsOn09_30_2017_PresageBiosciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_PresageLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5">4900000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
<meip:PotentialMilestonePaymentsPayable id="Factid_7988451" contextRef="PAsOn09_30_2017_MaximumMembersrtRangeAxis_PotentialPaymentsOnAchievementOfDevelopmentRegulatoryAndCommercialMilestonesMemberusgaapRelatedPartyTransactionAxis_PresageBiosciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_PresageLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="INF">179000000</meip:PotentialMilestonePaymentsPayable>
<meip:AgreementTerminationNoticePeriod id="Factid_7988452" contextRef="P07_01_2018To12_31_2018">P90D</meip:AgreementTerminationNoticePeriod>
<meip:PercentageOfPurchasesFromMajorSuppliers id="Factid_7988453" contextRef="P07_01_2018To12_31_2018" unitRef="Unit_pure" decimals="INF">1.00</meip:PercentageOfPurchasesFromMajorSuppliers>
<meip:AccountsReceivableNetBeginningBalance id="Factid_7988455" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">0</meip:AccountsReceivableNetBeginningBalance>
<us-gaap:IncreaseDecreaseInReceivables id="Factid_7988456" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">326000</us-gaap:IncreaseDecreaseInReceivables>
<meip:AccountsReceivableNetEndingBalance id="Factid_7988457" contextRef="PAsOn09_30_2019" unitRef="Unit_USD" decimals="-3">326000</meip:AccountsReceivableNetEndingBalance>
<us-gaap:ContractWithCustomerAssetNetCurrent id="Factid_7988458" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">686000</us-gaap:ContractWithCustomerAssetNetCurrent>
<us-gaap:IncreaseDecreaseInContractWithCustomerAsset id="Factid_7988459" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">-217000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
<us-gaap:ContractWithCustomerAssetNetCurrent id="Factid_7988460" contextRef="PAsOn09_30_2019" unitRef="Unit_USD" decimals="-3">469000</us-gaap:ContractWithCustomerAssetNetCurrent>
<us-gaap:ContractWithCustomerLiability id="Factid_7988461" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">7774000</us-gaap:ContractWithCustomerLiability>
<us-gaap:IncreaseDecreaseInContractWithCustomerLiability id="Factid_7988462" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">-868000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
<us-gaap:ContractWithCustomerLiability id="Factid_7988463" contextRef="PAsOn09_30_2019" unitRef="Unit_USD" decimals="-3">6906000</us-gaap:ContractWithCustomerLiability>
<us-gaap:WarrantsNotSettleableInCashFairValueDisclosure id="Factid_7988464" contextRef="PAsOn09_30_2019_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3">8344000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
<us-gaap:WarrantsNotSettleableInCashFairValueDisclosure id="Factid_7988465" contextRef="PAsOn06_30_2019_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3">17613000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
<us-gaap:LiabilitiesFairValueDisclosure id="Factid_7988466" contextRef="PAsOn09_30_2019_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3">8344000</us-gaap:LiabilitiesFairValueDisclosure>
<us-gaap:LiabilitiesFairValueDisclosure id="Factid_7988467" contextRef="PAsOn06_30_2019_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3">17613000</us-gaap:LiabilitiesFairValueDisclosure>
<us-gaap:WarrantsNotSettleableInCashFairValueDisclosure id="Factid_7988468" contextRef="PAsOn06_30_2019_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3">17613000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss id="Factid_7988470" contextRef="P07_01_2019To09_30_2019_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3">-9269000</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss id="Factid_7988471" contextRef="P07_01_2018To09_30_2018_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3">4962000</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
<us-gaap:WarrantsNotSettleableInCashFairValueDisclosure id="Factid_7988472" contextRef="PAsOn09_30_2019_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3">8344000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
<us-gaap:WarrantsNotSettleableInCashFairValueDisclosure id="Factid_7988473" contextRef="PAsOn09_30_2018_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3">50207000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
<us-gaap:StockholdersEquity id="Factid_7988476" contextRef="PAsOn06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">73545000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_7988477" contextRef="PAsOn06_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">279148000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_7988478" contextRef="PAsOn06_30_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-231218000</us-gaap:StockholdersEquity>
<us-gaap:NetIncomeLoss id="Factid_7988480" contextRef="P07_01_2019To09_30_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-2994000</us-gaap:NetIncomeLoss>
<us-gaap:StockIssuedDuringPeriodValueNewIssues id="Factid_7988482" contextRef="P07_01_2019To09_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">64000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues id="Factid_7988483" contextRef="P07_01_2019To09_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">159000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues id="Factid_7988484" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">159000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Factid_7988485" contextRef="P07_01_2019To09_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">46000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Factid_7988486" contextRef="P07_01_2019To09_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">72000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Factid_7988487" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">72000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Factid_7988488" contextRef="P07_01_2019To09_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">2113000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Factid_7988489" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">2113000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:StockholdersEquity id="Factid_7988490" contextRef="PAsOn09_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">73655000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_7988491" contextRef="PAsOn09_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">281492000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_7988492" contextRef="PAsOn09_30_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-234212000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_7988494" contextRef="PAsOn06_30_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">70406000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_7988495" contextRef="PAsOn06_30_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">264858000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_7988496" contextRef="PAsOn06_30_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-214399000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_7988497" contextRef="PAsOn06_30_2018" unitRef="Unit_USD" decimals="-3">50459000</us-gaap:StockholdersEquity>
<us-gaap:NetIncomeLoss id="Factid_7988498" contextRef="P07_01_2018To09_30_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-14542000</us-gaap:NetIncomeLoss>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures id="Factid_7988500" contextRef="P07_01_2018To09_30_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">246000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures id="Factid_7988501" contextRef="P07_01_2018To09_30_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-324000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures id="Factid_7988502" contextRef="P07_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">-324000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Factid_7988503" contextRef="P07_01_2018To09_30_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">23000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Factid_7988504" contextRef="P07_01_2018To09_30_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">43000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Factid_7988505" contextRef="P07_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">43000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Factid_7988506" contextRef="P07_01_2018To09_30_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">1937000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Factid_7988507" contextRef="P07_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">1937000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<meip:Stockissuedduringperiodvaluestockwarrantsexercised id="Factid_7988508" contextRef="P07_01_2018To09_30_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">440000</meip:Stockissuedduringperiodvaluestockwarrantsexercised>
<meip:Stockissuedduringperiodvaluestockwarrantsexercised id="Factid_7988509" contextRef="P07_01_2018To09_30_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">2186000</meip:Stockissuedduringperiodvaluestockwarrantsexercised>
<meip:Stockissuedduringperiodvaluestockwarrantsexercised id="Factid_7988510" contextRef="P07_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">2186000</meip:Stockissuedduringperiodvaluestockwarrantsexercised>
<us-gaap:StockholdersEquity id="Factid_7988511" contextRef="PAsOn09_30_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">71115000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_7988512" contextRef="PAsOn09_30_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">268700000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_7988513" contextRef="PAsOn09_30_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-228941000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_7988514" contextRef="PAsOn09_30_2018" unitRef="Unit_USD" decimals="-3">39759000</us-gaap:StockholdersEquity>
<us-gaap:IncomeTaxesPaidNet id="Factid_7988515" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">-1000</us-gaap:IncomeTaxesPaidNet>
<us-gaap:IncomeTaxesPaidNet id="Factid_7988516" contextRef="P07_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">-1000</us-gaap:IncomeTaxesPaidNet>
<meip:CashAndCashEquivalentsshortTermInvestmentsAndCommonStockProceedsReceivable id="Factid_7988519" contextRef="PAsOn09_30_2019" unitRef="Unit_USD" decimals="-5">65900000</meip:CashAndCashEquivalentsshortTermInvestmentsAndCommonStockProceedsReceivable>
<us-gaap:ProceedsFromLicenseFeesReceived id="Factid_7988520" contextRef="P08_30_2016To08_31_2016_HelsinnLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5">20000000</us-gaap:ProceedsFromLicenseFeesReceived>
<meip:MilestonePaymentsMaximumAmount id="Factid_7988521" contextRef="PAsOn09_30_2019" unitRef="Unit_USD" decimals="INF">74500000</meip:MilestonePaymentsMaximumAmount>
<meip:PercentageOfPurchasesFromMajorSuppliers id="Factid_7988522" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_pure" decimals="INF">1.00</meip:PercentageOfPurchasesFromMajorSuppliers>
<meip:SaleOfSharesAndWarrantsUnderAgreement id="Factid_7988523" contextRef="P07_01_2019To09_30_2019_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="INF">150000000</meip:SaleOfSharesAndWarrantsUnderAgreement>
<meip:NumberOfSharesAgreedToBeSoldUnderAgreement id="Factid_7988524" contextRef="PAsOn11_30_2017_AtTheMarketSaleAgreementMemberusgaapSubsidiarySaleOfStockAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="INF">30000000</meip:NumberOfSharesAgreedToBeSoldUnderAgreement>
<meip:ShelfRegistrationStatementValue id="Factid_7988525" contextRef="PAsOn09_30_2019" unitRef="Unit_USD" decimals="-5">144300000</meip:ShelfRegistrationStatementValue>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues id="Factid_7988526" contextRef="P07_01_2018To06_30_2019_AtTheMarketSaleAgreementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0">2214658</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues id="Factid_7988527" contextRef="P07_01_2018To06_30_2019_AtTheMarketSaleAgreementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5">5400000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="Factid_7988529" contextRef="PAsOn09_30_2019_TwoThousandAndEightOmnibusPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF">19089794</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant id="Factid_7988530" contextRef="PAsOn09_30_2019_TwoThousandAndEightOmnibusPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF">6979777</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod id="Factid_7988531" contextRef="P06_01_2016To06_30_2016_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF">364726</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod id="Factid_7988532" contextRef="P08_01_2018To08_31_2018_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF">332193</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="Factid_7988533" contextRef="P08_01_2018To08_31_2018_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="0">245782</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation id="Factid_7988534" contextRef="P08_01_2018To08_31_2018_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF">86411</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="Factid_7988535" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_pure" decimals="3">0.018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="Factid_7988536" contextRef="P07_01_2018To09_30_2018" unitRef="Unit_pure" decimals="3">0.028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="Factid_7988537" contextRef="P07_01_2019To09_30_2019">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="Factid_7988538" contextRef="P07_01_2018To09_30_2018">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="Factid_7988539" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_pure" decimals="3">0.736</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="Factid_7988540" contextRef="P07_01_2018To09_30_2018" unitRef="Unit_pure" decimals="3">0.860</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="Factid_7988541" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_pure" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="Factid_7988542" contextRef="P07_01_2018To09_30_2018" unitRef="Unit_pure" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="Factid_7988543" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD_per_Share" decimals="2">1.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="Factid_7988544" contextRef="P07_01_2018To09_30_2018" unitRef="Unit_USD_per_Share" decimals="2">3.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions id="Factid_7988545" contextRef="PAsOn09_30_2019" unitRef="Unit_USD" decimals="-5">8500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="Factid_7988546" contextRef="P07_01_2019To09_30_2019">P1Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="Factid_7988547" contextRef="PAsOn09_30_2019" unitRef="Unit_USD" decimals="0">501818</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="Factid_7988549" contextRef="PAsOn06_30_2019" unitRef="Unit_shares" decimals="INF">8356961</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="Factid_7988551" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_shares" decimals="INF">3083333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="Factid_7988552" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD_per_Share" decimals="2">2.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="Factid_7988553" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_shares" decimals="INF">46667</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="Factid_7988554" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD_per_Share" decimals="2">1.54</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod id="Factid_7988555" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_shares" decimals="INF">49186</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice id="Factid_7988556" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD_per_Share" decimals="2">1.81</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod id="Factid_7988557" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_shares" decimals="INF">527080</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice id="Factid_7988558" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD_per_Share" decimals="2">6.89</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="Factid_7988559" contextRef="PAsOn09_30_2019" unitRef="Unit_shares" decimals="INF">10817361</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="Factid_7988560" contextRef="PAsOn09_30_2019" unitRef="Unit_USD_per_Share" decimals="2">2.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="Factid_7988561" contextRef="P07_01_2019To09_30_2019">P8Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="Factid_7988562" contextRef="PAsOn09_30_2019" unitRef="Unit_shares" decimals="INF">4114253</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="Factid_7988563" contextRef="PAsOn09_30_2019" unitRef="Unit_USD_per_Share" decimals="2">2.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 id="Factid_7988564" contextRef="P07_01_2019To09_30_2019">P7Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
<us-gaap:ShareBasedCompensation id="Factid_7988565" contextRef="P07_01_2019To09_30_2019_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3">781000</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation id="Factid_7988566" contextRef="P07_01_2018To09_30_2018_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3">630000</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation id="Factid_7988567" contextRef="P07_01_2019To09_30_2019_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3">1332000</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation id="Factid_7988568" contextRef="P07_01_2018To09_30_2018_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3">1307000</us-gaap:ShareBasedCompensation>
<us-gaap:Revenues id="Factid_7988571" contextRef="P07_01_2019To09_30_2019_KHKLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-3">797000</us-gaap:Revenues>
<us-gaap:Revenues id="Factid_7988572" contextRef="P07_01_2019To09_30_2019_HelsinnLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-3">360000</us-gaap:Revenues>
<us-gaap:Revenues id="Factid_7988573" contextRef="P07_01_2018To09_30_2018_HelsinnLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-3">488000</us-gaap:Revenues>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Factid_7988579" contextRef="P07_01_2019To09_30_2019_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0">10930</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Factid_7988580" contextRef="P07_01_2018To09_30_2018_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0">7774</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Factid_7988582" contextRef="P07_01_2018To09_30_2018_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0">130</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Factid_7988583" contextRef="P07_01_2019To09_30_2019_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0">16062</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Factid_7988584" contextRef="P07_01_2018To09_30_2018_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0">16186</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Factid_7988585" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_shares" decimals="0">26992</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Factid_7988586" contextRef="P07_01_2018To09_30_2018" unitRef="Unit_shares" decimals="0">24090</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:WarrantsAndRightsOutstandingMeasurementInput id="Factid_7988587" contextRef="PAsOn09_30_2019_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_ClinicalTrials" decimals="1">1.6</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
<us-gaap:WarrantsAndRightsOutstandingMeasurementInput id="Factid_7988588" contextRef="PAsOn06_30_2019_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_ClinicalTrials" decimals="1">1.7</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
<us-gaap:WarrantsAndRightsOutstandingMeasurementInput id="Factid_7988589" contextRef="PAsOn09_30_2019_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_ClinicalTrials" decimals="1">3.6</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
<us-gaap:WarrantsAndRightsOutstandingMeasurementInput id="Factid_7988590" contextRef="PAsOn06_30_2019_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_ClinicalTrials" decimals="1">3.8</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
<us-gaap:WarrantsAndRightsOutstandingMeasurementInput id="Factid_7988591" contextRef="PAsOn09_30_2019_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_ClinicalTrials" decimals="1">56.9</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
<us-gaap:WarrantsAndRightsOutstandingMeasurementInput id="Factid_7988592" contextRef="PAsOn06_30_2019_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_ClinicalTrials" decimals="1">56.8</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
<us-gaap:WarrantsAndRightsOutstandingMeasurementInput id="Factid_7988593" contextRef="PAsOn09_30_2019_MeasurementInputExpectedDividendRateMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_ClinicalTrials" decimals="1">0.0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
<us-gaap:WarrantsAndRightsOutstandingMeasurementInput id="Factid_7988594" contextRef="PAsOn06_30_2019_MeasurementInputExpectedDividendRateMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_ClinicalTrials" decimals="1">0.0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
<us-gaap:WarrantsAndRightsOutstandingMeasurementInput id="Factid_7988595" contextRef="PAsOn09_30_2019_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_ClinicalTrials" decimals="2">0.52</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
<us-gaap:WarrantsAndRightsOutstandingMeasurementInput id="Factid_7988596" contextRef="PAsOn06_30_2019_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_ClinicalTrials" decimals="2">1.10</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
<dei:DocumentType id="Factid_7988599" contextRef="P07_01_2019To09_30_2019">10-Q</dei:DocumentType>
<dei:DocumentPeriodEndDate id="Factid_7988600" contextRef="P07_01_2019To09_30_2019">2019-09-30</dei:DocumentPeriodEndDate>
<dei:Security12bTitle id="Factid_7988601" contextRef="P07_01_2019To09_30_2019">Common Stock</dei:Security12bTitle>
<dei:TradingSymbol id="Factid_7988602" contextRef="P07_01_2019To09_30_2019">MEIP</dei:TradingSymbol>
<dei:EntityCommonStockSharesOutstanding id="Factid_7988603" contextRef="PAsOn11_04_2019" unitRef="Unit_shares" decimals="INF">73654927</dei:EntityCommonStockSharesOutstanding>
<dei:DocumentFiscalYearFocus id="Factid_7988604" contextRef="P07_01_2019To09_30_2019">2020</dei:DocumentFiscalYearFocus>
<dei:DocumentFiscalPeriodFocus id="Factid_7988605" contextRef="P07_01_2019To09_30_2019">Q1 </dei:DocumentFiscalPeriodFocus>
<dei:EntityRegistrantName id="Factid_7988606" contextRef="P07_01_2019To09_30_2019">MEI Pharma, Inc.</dei:EntityRegistrantName>
<dei:EntityCentralIndexKey id="Factid_7988607" contextRef="P07_01_2019To09_30_2019">0001262104</dei:EntityCentralIndexKey>
<dei:CurrentFiscalYearEndDate id="Factid_7988608" contextRef="P07_01_2019To09_30_2019">--06-30</dei:CurrentFiscalYearEndDate>
<dei:EntityCurrentReportingStatus id="Factid_7988609" contextRef="P07_01_2019To09_30_2019">Yes</dei:EntityCurrentReportingStatus>
<dei:EntityEmergingGrowthCompany id="Factid_7988610" contextRef="P07_01_2019To09_30_2019">false</dei:EntityEmergingGrowthCompany>
<dei:EntityShellCompany id="Factid_7988611" contextRef="P07_01_2019To09_30_2019">false</dei:EntityShellCompany>
<dei:EntitySmallBusiness id="Factid_7988612" contextRef="P07_01_2019To09_30_2019">true</dei:EntitySmallBusiness>
<dei:SecurityExchangeName id="Factid_7988613" contextRef="P07_01_2019To09_30_2019">NASDAQ</dei:SecurityExchangeName>
<dei:EntityAddressStateOrProvince id="Factid_7988614" contextRef="P07_01_2019To09_30_2019">CA</dei:EntityAddressStateOrProvince>
<us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable id="Factid_7988615" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">5274000</us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable>
<us-gaap:DeferredRevenueNoncurrent id="Factid_7988617" contextRef="PAsOn09_30_2019" unitRef="Unit_USD" decimals="-3">3231000</us-gaap:DeferredRevenueNoncurrent>
<us-gaap:DeferredRevenueNoncurrent id="Factid_7988618" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">2819000</us-gaap:DeferredRevenueNoncurrent>
<us-gaap:WarrantsNotSettleableInCashFairValueDisclosure id="Factid_7988619" contextRef="PAsOn09_30_2019" unitRef="Unit_USD" decimals="-3">8344000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
<us-gaap:WarrantsNotSettleableInCashFairValueDisclosure id="Factid_7988620" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">17613000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
<us-gaap:PreferredStockParOrStatedValuePerShare id="Factid_7988621" contextRef="PAsOn09_30_2019" unitRef="Unit_USD_per_Share" decimals="2">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockParOrStatedValuePerShare id="Factid_7988622" contextRef="PAsOn06_30_2019" unitRef="Unit_USD_per_Share" decimals="2">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockSharesAuthorized id="Factid_7988623" contextRef="PAsOn09_30_2019" unitRef="Unit_shares" decimals="0">100</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized id="Factid_7988624" contextRef="PAsOn06_30_2019" unitRef="Unit_shares" decimals="0">100</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesOutstanding id="Factid_7988625" contextRef="PAsOn09_30_2019" unitRef="Unit_shares" decimals="0">0</us-gaap:PreferredStockSharesOutstanding>
<us-gaap:PreferredStockSharesOutstanding id="Factid_7988626" contextRef="PAsOn06_30_2019" unitRef="Unit_shares" decimals="0">0</us-gaap:PreferredStockSharesOutstanding>
<us-gaap:CommonStockParOrStatedValuePerShare id="Factid_7988627" contextRef="PAsOn09_30_2019" unitRef="Unit_USD_per_Share" decimals="8">0.00000002</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare id="Factid_7988628" contextRef="PAsOn06_30_2019" unitRef="Unit_USD_per_Share" decimals="8">0.00000002</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized id="Factid_7988629" contextRef="PAsOn06_30_2019" unitRef="Unit_shares" decimals="0">226000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized id="Factid_7988630" contextRef="PAsOn09_30_2019" unitRef="Unit_shares" decimals="0">226000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:Revenues id="Factid_7988639" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">1157000</us-gaap:Revenues>
<us-gaap:Revenues id="Factid_7988640" contextRef="P07_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">488000</us-gaap:Revenues>
<meip:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted id="Factid_7988641" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">-2994000</meip:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted>
<meip:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted id="Factid_7988642" contextRef="P07_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">-14542000</meip:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted id="Factid_7988643" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD_per_Share" decimals="2">-0.04</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted id="Factid_7988644" contextRef="P07_01_2018To09_30_2018" unitRef="Unit_USD_per_Share" decimals="2">-0.21</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="Factid_7988645" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_shares" decimals="-3">73628000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="Factid_7988646" contextRef="P07_01_2018To09_30_2018" unitRef="Unit_shares" decimals="-3">70885000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss id="Factid_7988647" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">9269000</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss id="Factid_7988648" contextRef="P07_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">-4962000</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
<us-gaap:InvestmentIncomeInterestAndDividend id="Factid_7988649" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">374000</us-gaap:InvestmentIncomeInterestAndDividend>
<us-gaap:InvestmentIncomeInterestAndDividend id="Factid_7988650" contextRef="P07_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">454000</us-gaap:InvestmentIncomeInterestAndDividend>
<us-gaap:OtherNonoperatingExpense id="Factid_7988651" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">14000</us-gaap:OtherNonoperatingExpense>
<us-gaap:OtherNonoperatingExpense id="Factid_7988652" contextRef="P07_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">1000</us-gaap:OtherNonoperatingExpense>
<us-gaap:NetIncomeLoss id="Factid_7988653" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">-2994000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss id="Factid_7988654" contextRef="P07_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">-14542000</us-gaap:NetIncomeLoss>
<us-gaap:PaymentsToAcquireShortTermInvestments id="Factid_7988655" contextRef="P07_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">4937000</us-gaap:PaymentsToAcquireShortTermInvestments>
<us-gaap:ProceedsFromWarrantExercises id="Factid_7988656" contextRef="P07_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">1118000</us-gaap:ProceedsFromWarrantExercises>
<us-gaap:ProceedsFromIssuanceOfCommonStock id="Factid_7988657" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">159000</us-gaap:ProceedsFromIssuanceOfCommonStock>
<meip:ProceedsFromPreviouslyIssuedCommonStock id="Factid_7988658" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">5274000</meip:ProceedsFromPreviouslyIssuedCommonStock>
<meip:ChangeInFairValueOfWarrantsExercised id="Factid_7988659" contextRef="PAsOn09_30_2018" unitRef="Unit_USD" decimals="-3">1068000</meip:ChangeInFairValueOfWarrantsExercised>
<us-gaap:UnrecognizedTaxBenefits id="Factid_7988661" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="INF">0</us-gaap:UnrecognizedTaxBenefits>
<meip:NumberOfClinicalStageCandidates id="Factid_7988662" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_ClinicalTrials" decimals="INF">4</meip:NumberOfClinicalStageCandidates>
<meip:NumberOfCandidateInAnOngoingGlobalRegistrationTrial id="Factid_7988663" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_ClinicalTrials" decimals="INF">1</meip:NumberOfCandidateInAnOngoingGlobalRegistrationTrial>
<us-gaap:CollaborativeArrangementDisclosureTextBlock id="Factid_7988664" contextRef="P07_01_2019To09_30_2019">&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note 4.&amp;#160;&amp;#160;&amp;#160;&amp;#160;BeiGene Collaboration&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In October 2018, we entered into a clinical collaboration with BeiGene, Ltd. (&amp;#8220;BeiGene&amp;#8221;) to evaluate the safety and efficacy of &lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;ME-401&lt;/div&gt; in combination with BeiGene&amp;#8217;s zanubrutinib, an investigational inhibitor of Bruton&amp;#8217;s tyrosine kinase (&amp;#8220;BTK&amp;#8221;), for the treatment of patients with &lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-cell&lt;/div&gt; malignancies. Under the terms of the clinical collaboration agreement, we amended our ongoing Phase 1b trial to include evaluation of &lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;ME-401&lt;/div&gt; in combination with zanubrutinib in patients with &lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-cell&lt;/div&gt; malignancies. Study costs are being shared equally by the parties, and we agreed to supply &lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;ME-401&lt;/div&gt; and BeiGene agreed to supply zanubrutinib. We record the costs reimbursed by BeiGene as a reduction of our research and development expenses. We retained full commercial rights for &lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;ME-401&lt;/div&gt; and BeiGene retained full commercial rights for zanubrutinib.&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
<us-gaap:FairValueDisclosuresTextBlock id="Factid_7988665" contextRef="P07_01_2019To09_30_2019">&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt;.&lt;/div&gt;&lt;/div&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; line-height: 107%; font-family: calibri, sans-serif; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value is as follows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"&gt;&lt;div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; margin: 0in 0in 0in auto;;text-align:left;;width:91%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="padding: 0px; vertical-align: top;;width:9%;"&gt;&lt;/td&gt;&lt;td style="padding: 0px; vertical-align: top;;width:1%;"&gt;&lt;/td&gt;&lt;td style="padding: 0px; vertical-align: top;;width:90%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8226;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Level&amp;#160;1&amp;#160;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: top;"&gt;&lt;div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Observable inputs such as quoted prices in active markets for identical assets or liabilities.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1pt;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: top;;height:8;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: top;;height:8;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8226;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Level&amp;#160;2&amp;#160;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: top;"&gt;&lt;div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1pt;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: top;;height:8;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: top;;height:8;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8226;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Level&amp;#160;3&amp;#160;&amp;#8212;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: top;"&gt;&lt;div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;We measure the following financial instruments at fair value on a recurring basis. The fair values of these financial instruments were as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:100%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="padding: 0px; width: 65%;"&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 2%;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 2%;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 2%;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 2%;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 2%;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 2%;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="10" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&amp;#160;30, 2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30, 2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&amp;#160;1&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&amp;#160;2&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&amp;#160;3&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&amp;#160;1&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&amp;#160;2&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&amp;#160;3&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 65%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Warrant liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(8,344&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(17,613&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 65%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; width: 65%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;(8,344&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;(17,613&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 65%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The carrying amounts of financial instruments such as cash equivalents, short-term investments and accounts payable approximate the related fair values due to the short-term maturities of these instruments. We invest our excess cash in financial instruments which are readily convertible into cash, such as money market funds and U.S. government securities. Cash equivalents, where applicable, and short-term investments are classified as Level&amp;#160;1 as defined by the fair value hierarchy. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;In May 2018, we issued warrants in connection with our private placement of shares of common stock. Pursuant to the terms of the warrants, we could be required to settle the warrants in cash in the event of an acquisition of the Company and, as a result, the warrants are required to be measured at fair value and reported as a liability in the Condensed Balance Sheet.&amp;#160;We recorded the fair value of the warrants upon issuance using the Black-Scholes valuation model and are required to revalue the warrants at each reporting date with any changes in fair value recorded on our Condensed Statement of Operations. The valuation of the warrants is considered under Level&amp;#160;3 of the fair value hierarchy due to the need to use assumptions in the valuation that are both significant to the fair value measurement and unobservable.&amp;#160;Inputs used to determine estimated fair value of the warrant liabilities include the estimated fair value of the underlying stock at the valuation date, the estimated term of the warrants, risk-free interest rates, expected dividends and the expected volatility of the underlying stock. The significant unobservable inputs used in the fair value measurement of the warrant liabilities were the volatility rate and the estimated term of the warrants. Generally, increases (decreases) in the fair value of the underlying stock and estimated term would result in a directionally similar impact to the fair value measurement. The change in the fair value of the&amp;#160;Level 3 warrant liability is reflected in the Condensed Statement of Operations for the three months ended September&amp;#160;30, 2019. &lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;To calculate the fair value of the warrant liability, the following assumptions were used: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="padding: 0px; width: 77%;"&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 9%;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 8%;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&amp;#160;30,&lt;br/&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&lt;br/&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 77%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 9%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1.6&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 8%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1.7&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; width: 77%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected life (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 9%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;3.6&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 8%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;3.8&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 77%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Expected volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 9%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;56.9&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 8%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;56.8&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; width: 77%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dividend yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 9%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;0.0&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 8%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;0.0&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 77%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Black-Scholes Fair Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 9%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;0.52&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 8%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1.10&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table sets forth a summary of changes in the estimated fair value of our Level&amp;#160;3 warrant liability for the three months ended September&amp;#160;30, 2019 and 2018 (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="padding: 0px; width: 73%;"&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 7%;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 6%;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&amp;#160;Value&amp;#160;of&amp;#160;Warrants&amp;#160;Using&amp;#160;Significant&lt;br/&gt;Unobservable Inputs (Level 3)&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 73%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance at July&amp;#160;1,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 7%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;17,613&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;46,313&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; width: 73%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Reclassification of &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;warrant&lt;/div&gt;&amp;#160;liability to equity upon exercise of warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 7%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 6%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;(1,068&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 73%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Change in estimated fair value of liability classified warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 7%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(9,269&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;4,962&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 73%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 7%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 6%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; width: 73%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance at September&amp;#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 7%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;8,344&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 6%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;50,207&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 73%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 7%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 6%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>
<meip:FairValueOfWarrantLiabilityAssumptionsTableTextBlock id="Factid_7988667" contextRef="P07_01_2019To09_30_2019">&lt;div style="text-indent: 4%; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;To calculate the fair value of the warrant liability, the following assumptions were used: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="padding: 0px; width: 77%;"&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 9%;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 8%;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&amp;#160;30,&lt;br/&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&lt;br/&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 77%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 9%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1.6&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 8%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1.7&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; width: 77%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected life (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 9%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;3.6&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 8%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;3.8&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 77%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Expected volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 9%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;56.9&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 8%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;56.8&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; width: 77%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dividend yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 9%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;0.0&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 8%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;0.0&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 77%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Black-Scholes Fair Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 9%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;0.52&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 8%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1.10&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</meip:FairValueOfWarrantLiabilityAssumptionsTableTextBlock>
<meip:ScheduleOfChangesInFairValueOfWarrantLiabilityTableTextBlock id="Factid_7988668" contextRef="P07_01_2019To09_30_2019">&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table sets forth a summary of changes in the estimated fair value of our Level&amp;#160;3 warrant liability for the three months ended September&amp;#160;30, 2019 and 2018 (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="padding: 0px; width: 73%;"&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 7%;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 6%;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&amp;#160;Value&amp;#160;of&amp;#160;Warrants&amp;#160;Using&amp;#160;Significant&lt;br/&gt;Unobservable Inputs (Level 3)&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 73%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance at July&amp;#160;1,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 7%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;17,613&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;46,313&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; width: 73%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Reclassification of &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;warrant&lt;/div&gt;&amp;#160;liability to equity upon exercise of warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 7%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 6%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;(1,068&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 73%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Change in estimated fair value of liability classified warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 7%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(9,269&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;4,962&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 73%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 7%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 6%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; width: 73%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance at September&amp;#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 7%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;8,344&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 6%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;50,207&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 73%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 7%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 6%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</meip:ScheduleOfChangesInFairValueOfWarrantLiabilityTableTextBlock>
<us-gaap:WarrantsNotSettleableInCashFairValueDisclosure id="Factid_7988669" contextRef="PAsOn06_30_2018_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3">46313000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements id="Factid_7988670" contextRef="P07_01_2018To09_30_2018_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3">1068000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
<us-gaap:RevenueFromContractWithCustomerTextBlock id="Factid_7988672" contextRef="P07_01_2019To09_30_2019">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&lt;/div&gt;.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; line-height: 107%; font-family: &amp;quot;times new roman&amp;quot;, serif; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Revenue Recognition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Payments received under commercial arrangements, such as licensing technology rights, may include &lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-refundable&lt;/div&gt; fees at the inception of the arrangements, milestone payments for specific achievements designated in the agreements, and royalties on the sale of products. At the inception of arrangements that include milestone payments, we use judgment to evaluate whether the milestones are probable of being achieved and we estimate the amount to include in the transaction price using the most likely method. If it is probable that a significant revenue reversal will not occur, the estimated amount is included in the transaction price. Milestone payments that are not within our or the licensee&amp;#8217;s control, such as regulatory approvals, are not included in the transaction price until those approvals are received. At the end of each reporting period, we &lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-evaluate&lt;/div&gt; the probability of achievement of development milestones and any related constraint and, as necessary, we adjust our estimate of the overall transaction price. Any adjustments are recorded on a cumulative &lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;catch-up&lt;/div&gt; basis, which would affect revenues and earnings in the period of adjustment. To date, we have not recognized any material cumulative &lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;catch-up&lt;/div&gt; adjustments from changes in our estimate of the transaction price.&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;We develop estimates of the stand-alone selling price for each distinct performance obligation and allocate the overall transaction price to each accounting unit based on a relative stand-alone selling price approach. We develop assumptions that require judgment to determine the stand-alone selling price for license-related performance obligations, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical, regulatory and commercial success. We estimate stand-alone selling price for research and development performance obligations by forecasting the expected costs of satisfying a performance obligation plus an appropriate margin. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In the case of a license that is a distinct performance obligation, we recognize revenue from &lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-refundable,&lt;/div&gt; &lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;up-front&lt;/div&gt; fees at the point in time when the license is transferred to the licensee and the licensee can use and benefit from the license. For licenses that are bundled with other obligations, we use judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. If the performance obligation is satisfied over time, we evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The selection of the method to measure progress towards completion requires judgment and is based on the nature of the products or services to be provided. Revenue is recorded proportionally as costs are incurred. We generally use the &lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;cost-to-cost&lt;/div&gt;&lt;/div&gt; measure of progress because it best depicts the transfer of control to the customer which occurs as we incur costs. Under the &lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;cost-to-cost&lt;/div&gt;&lt;/div&gt; measure of progress, the extent of progress towards completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation (an &amp;#8220;input method&amp;#8221; under ASC 606). We use judgment to estimate the total cost expected to complete the research and development performance obligations, which include subcontractors&amp;#8217; costs, labor, materials, other direct costs and an allocation of indirect costs. We evaluate these cost estimates and the progress each reporting period and, as necessary, we adjust the measure of progress and related revenue recognition. To date, we have not recognized any material cumulative &lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;catch-up&lt;/div&gt; adjustments from changes in our estimate of the measure of progress.&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;For arrangements that include sales-based or usage-based royalties, we recognize revenue at the later of (i)&amp;#160;when the related sales occur or (ii)&amp;#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, we have not recognized any sales-based royalty revenue from license agreements. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;We recognized revenue associated with the following license agreements (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="padding: 0px; width: 84%;"&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 4%;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 4%;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&amp;#160;Months&amp;#160;Ended&lt;br/&gt;September&amp;#160;30,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 84%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;KKC License Agreement&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;797&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; width: 84%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Helsinn License Agreement&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 4%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;360&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 4%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;488&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 84%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 4%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 4%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 84%;;vertical-align:top;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1,157&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;488&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 84%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 4%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 4%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue for the three months ended September&amp;#160;30, 2019 included revenue related to the KKC License Agreement (Note &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3&lt;/div&gt;). The KKC License Agreement included distinct performance obligations that will be satisfied over time, and accordingly we recognized $0.8&amp;#160;million related to our progress toward satisfying those obligations during the three months ended September&amp;#160;30, 2019. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue for the three months ended September&amp;#160;30, 2019 and 2018 included revenue related to the Helsinn License Agreement (Note &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3&lt;/div&gt;). The Helsinn License Agreement included distinct performance obligations that will be satisfied over time, and accordingly we recognized $0.4&amp;#160;million and $0.5&amp;#160;million related to our progress toward satisfying those obligations during the three months ended September&amp;#160;30, 2019 and 2018, respectively. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of September&amp;#160;30, 2019, we had $6.9&amp;#160;million of deferred revenue associated with our remaining performance obligations under the KKC and Helsinn License Agreements. We expect to recognize approximately $3.7&amp;#160;million of deferred revenue in the next 12 months, and an additional $3.2&amp;#160;million thereafter. &lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 9%; line-height: 12pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Contract Balances &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents changes in contract assets and contract liabilities during the three months ended September&amp;#160;30, 2019 (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:84%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="padding: 0px; width: 60%;"&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 9%;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 9%;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 9%;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&amp;#160;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&amp;#160;of&amp;#160;June&amp;#160;30,&lt;br/&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net&amp;#160;Change&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&amp;#160;of&amp;#160;September&amp;#160;30,&lt;br/&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 60%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Receivables&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 9%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 9%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;326&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 9%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;326&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; width: 60%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contract Assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 9%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;686&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 9%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;(217&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 9%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;469&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 60%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Contract Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 9%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;7,774&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 9%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(868&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 9%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;6,906&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The timing of revenue recognition, invoicing and cash collections results in billed accounts receivable and unbilled receivables (contract assets), which are classified as &amp;#8220;prepaid expenses and other current assets&amp;#8221; on our Condensed Balance Sheet, and deferred revenue (contract liabilities). We invoice our customers in accordance with agreed-upon contractual terms, typically at periodic intervals or upon achievement of contractual milestones. Invoicing may occur subsequent to revenue recognition, resulting in contract assets. We may receive advance payments from our customers before revenue is recognized, resulting in contract liabilities. The contract assets and liabilities reported on the Condensed Balance Sheet relate to the KKC and Helsinn License Agreements. &lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
<meip:ScheduleOfRevenueAssociatedWithLicenseAgreementTableTextBlock id="Factid_7988673" contextRef="P07_01_2019To09_30_2019">&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;We recognized revenue associated with the following license agreements (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="padding: 0px; width: 84%;"&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 4%;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 4%;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&amp;#160;Months&amp;#160;Ended&lt;br/&gt;September&amp;#160;30,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 84%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;KKC License Agreement&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;797&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; width: 84%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Helsinn License Agreement&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 4%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;360&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 4%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;488&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 84%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 4%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 4%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 84%;;vertical-align:top;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1,157&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;488&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 84%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 4%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 4%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</meip:ScheduleOfRevenueAssociatedWithLicenseAgreementTableTextBlock>
<us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock id="Factid_7988674" contextRef="P07_01_2019To09_30_2019">&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents changes in contract assets and contract liabilities during the three months ended September&amp;#160;30, 2019 (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:84%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="padding: 0px; width: 60%;"&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 9%;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 9%;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 9%;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&amp;#160;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&amp;#160;of&amp;#160;June&amp;#160;30,&lt;br/&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net&amp;#160;Change&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&amp;#160;of&amp;#160;September&amp;#160;30,&lt;br/&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 60%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Receivables&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 9%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 9%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;326&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 9%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;326&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; width: 60%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contract Assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 9%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;686&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 9%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;(217&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 9%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;469&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 60%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Contract Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 9%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;7,774&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 9%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(868&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 9%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;6,906&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
<meip:RevenuePerformanceObligationAmount id="Factid_7988675" contextRef="P07_01_2019To09_30_2019_KHKLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5">800000</meip:RevenuePerformanceObligationAmount>
<meip:RevenuePerformanceObligationAmount id="Factid_7988676" contextRef="P07_01_2019To09_30_2019_HelsinnLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5">400000</meip:RevenuePerformanceObligationAmount>
<meip:RevenuePerformanceObligationAmount id="Factid_7988677" contextRef="P07_01_2018To09_30_2018_HelsinnLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5">500000</meip:RevenuePerformanceObligationAmount>
<us-gaap:RevenueRemainingPerformanceObligation id="Factid_7988678" contextRef="PAsOn09_30_2019" unitRef="Unit_USD" decimals="-5">6900000</us-gaap:RevenueRemainingPerformanceObligation>
<us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod id="Factid_7988679" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-5">3700000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
<meip:AdditionalRecognitionOfDeferredRevenue id="Factid_7988680" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-5">3200000</meip:AdditionalRecognitionOfDeferredRevenue>
<us-gaap:RelatedPartyTransactionsDisclosureTextBlock id="Factid_7988681" contextRef="P07_01_2019To09_30_2019">&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note &lt;div style="display:inline;"&gt;3&lt;/div&gt;.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; line-height: 107%; font-family: &amp;quot;times new roman&amp;quot;, serif; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;License Agreements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;KKC License Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In October 2018, we entered into a license agreement with Kyowa Kirin Company (formerly &amp;#8220;Kyowa Hakko Kirin Co., Ltd.&amp;#8221;) (&amp;#8220;KKC&amp;#8221;), a Japanese life sciences company, for &lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;ME-401&lt;/div&gt; (the &amp;#8220;KKC License Agreement&amp;#8221;). Under the terms of the KKC License Agreement, KKC was granted the exclusive right to develop and commercialize &lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;ME-401&lt;/div&gt; in Japan. We also granted KKC the right to purchase supply of &lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;ME-401&lt;/div&gt; for commercial requirements at cost plus a &lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-negotiated&lt;/div&gt; percentage, as well as manufacturing rights in Japan. In return, we received an upfront payment of $10.0&amp;#160;million and are also eligible to receive up to $87.5&amp;#160;million in additional development and commercialization milestones, as well as royalties on net sales of &lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;ME-401&lt;/div&gt; in Japan extending into the &lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;mid-teens.&lt;/div&gt; The KKC License Agreement expires at the end of the royalty term, that is, upon the last to occur of (a)&amp;#160;expiration of our patents in Japan, (b)&amp;#160;expiration of regulatory exclusivity for &lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;ME-401&lt;/div&gt; in Japan or (c) 10 years from the first commercial sale of &lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;ME-401&lt;/div&gt; in Japan.&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;We assessed the KKC License Agreement in accordance with ASC 606 and determined that our performance obligations comprise the license, research and development obligations, and our obligation to provide clinical trial materials to KKC. We determined that the transaction price amounts to the upfront payment of $10.0&amp;#160;million. Future milestone payments are fully contingent as the risk of significant revenue reversal will only be resolved depending on future research and development and/or regulatory approval outcomes. We will &lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-evaluate&lt;/div&gt; the likelihood of achieving future milestones at the end of each reporting period.&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;We determined that control of the license was transferred to KKC during the year ended June&amp;#160;30, 2019. Revenue allocated to the research and development obligations is recognized based on the proportional performance of these research and development activities, which we expect to recognize through fiscal year 2022. Revenue allocated to providing clinical trial materials is recognized upon delivery.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Helsinn License Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In August 2016, we entered into an exclusive worldwide license, development, manufacturing and commercialization agreement with Helsinn Healthcare SA, a Swiss pharmaceutical corporation (&amp;#8220;Helsinn&amp;#8221;) for pracinostat in acute myeloid leukemia (&amp;#8220;AML&amp;#8221;), myelodysplastic syndrome (&amp;#8220;MDS&amp;#8221;) and other potential indications (the &amp;#8220;Helsinn License Agreement&amp;#8221;). Under the terms of the agreement, Helsinn was granted a worldwide exclusive license to develop, manufacture and commercialize pracinostat, and is primarily responsible for funding its global development and commercialization. As compensation for such grant of rights, we received payments of $20.0&amp;#160;million. In addition, we are eligible to receive up to $444&amp;#160;million in potential regulatory and sales-based milestones, along with royalty payments on the net sales of pracinostat, which, in the U.S., are tiered and begin in the &lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;mid-teens.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;We determined that the agreement contains multiple performance obligations for purposes of revenue recognition. Revenue related to the research and development elements of the arrangement is recognized based on the extent of progress toward completion of each performance obligation. Revenue is recognized on a gross basis as we are the primary obligor and have discretion in supplier selection. During the three months ended September&amp;#160;30, 2019, our only remaining performance obligation under the agreement is the conduct of a Phase 2 dose-optimization study of pracinostat in combination with azacitidine in patients with high and very high risk MDS who are previously untreated with hypomethylating agents (the &amp;#8220;POC study&amp;#8221;), for which Helsinn has agreed to share third-party expenses. &lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 9%; line-height: 12pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Presage License Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In September 2017, we entered into a license agreement with Presage Biosciences, Inc. (&amp;#8220;Presage&amp;#8221;). Under the terms of such license agreement (the &amp;#8220;Presage License Agreement&amp;#8221;), Presage granted to us exclusive worldwide rights to develop, manufacture and commercialize voruciclib, a clinical-stage, oral and selective CDK inhibitor, and related compounds. In exchange, we paid $2.9&amp;#160;million. With respect to the first indication, an incremental $2.0&amp;#160;million payment, due upon dosing of the first subject in the first registration trial, will be owed to Presage, for total payments of $4.9&amp;#160;million prior to receipt of marketing approval of the first indication in the U.S., E.U. or Japan. Additional potential payments of up to $179&amp;#160;million will be due upon the achievement of certain development, regulatory and commercial milestones. We will also pay &lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;mid-single-digit&lt;/div&gt; tiered royalties on the net sales of any product successfully developed. As an alternative to milestone and royalty payments related to countries in which we sublicense product rights, we will pay to Presage a tiered percent (which decreases as product development progresses) of amounts received from such sublicensees.&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 9%;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;CyDex License Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;We are party to a license agreement with CyDex Pharmaceuticals, Inc. (&amp;#8220;CyDex&amp;#8221;). Under the license agreement, CyDex granted to us an exclusive, nontransferable license to intellectual property rights relating to Captisol&lt;div style="font-size: 7.4pt; vertical-align: top;;vertical-align: super;font-size: smaller;display:inline;"&gt;&amp;#174;&lt;/div&gt; for use with our isoflavone-based drug compounds (currently &lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;ME-344).&lt;/div&gt; We agreed to pay to CyDex a &lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-refundable&lt;/div&gt; license issuance fee, future milestone payments, and royalties at a low, single-digit percentage rate on future sales of our approved drugs utilizing Captisol. Contemporaneously with the license agreement, CyDex entered into a commercial supply agreement with us, pursuant to which we agreed to purchase 100% of our requirements for Captisol from CyDex. We may terminate both the license agreement and the supply agreement at any time upon 90 days&amp;#8217; prior written notice.&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
<us-gaap:EarningsPerShareTextBlock id="Factid_7988682" contextRef="P07_01_2019To09_30_2019">&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note 6.&amp;#160;&amp;#160;&amp;#160;&amp;#160;Net Loss Per Share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted net loss per share are computed using the weighted-average number of shares of common stock outstanding during the period, less any shares subject to repurchase or forfeiture. There were no shares of common stock subject to repurchase or forfeiture for the three months ended September&amp;#160;30, 2019 and 2018. Diluted net loss per share is computed based on the sum of the weighted average number of common shares and potentially dilutive common shares outstanding during the period. Our potentially dilutive shares, which include outstanding stock options, restricted stock units, and warrants, are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents weighted-average potentially dilutive shares (in thousands) that have been excluded from the calculation of net loss per share because of their anti-dilutive effect: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="padding: 0px; width: 82%;"&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 2%;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 2%;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&amp;#160;Months&amp;#160;Ended&lt;br/&gt;September&amp;#160;30,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 82%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Stock &lt;div style="display:inline;"&gt;o&lt;/div&gt;ptions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;10,930&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;7,774&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; width: 82%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted stock units&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;130&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 82%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;16,062&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;16,186&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 82%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; width: 82%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total anti-dilutive shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;26,992&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;24,090&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 82%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
<us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock id="Factid_7988683" contextRef="P07_01_2019To09_30_2019">&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents weighted-average potentially dilutive shares (in thousands) that have been excluded from the calculation of net loss per share because of their anti-dilutive effect: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="padding: 0px; width: 82%;"&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 2%;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 2%;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&amp;#160;Months&amp;#160;Ended&lt;br/&gt;September&amp;#160;30,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 82%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Stock &lt;div style="display:inline;"&gt;o&lt;/div&gt;ptions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;10,930&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;7,774&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; width: 82%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted stock units&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;130&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 82%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;16,062&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;16,186&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 82%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; width: 82%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total anti-dilutive shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;26,992&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;24,090&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 82%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
<us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation id="Factid_7988684" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_shares" decimals="0">0</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
<us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation id="Factid_7988685" contextRef="P07_01_2018To09_30_2018" unitRef="Unit_shares" decimals="0">0</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock id="Factid_7988686" contextRef="P07_01_2019To09_30_2019">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note 7.&lt;/div&gt;&lt;/div&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; line-height: 107%; font-family: calibri, sans-serif; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Commitments and Contingencies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;We have contracted with various consultants and third parties to assist us in &lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-clinical&lt;/div&gt; research and development and clinical trials work for our leading drug compounds. The contracts are terminable at any time, but obligate us to reimburse the providers for any time or costs incurred through the date of termination. We also have employment agreements with certain of our current employees that provide for severance payments and accelerated vesting for share-based awards if their employment is terminated under specified circumstances.&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 9%;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Presage License Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;As discussed in Note &lt;div style="display:inline;"&gt;3&lt;/div&gt;, we are party to a license agreement with Presage under which we may be required to make future payments upon the achievement of certain development, regulatory and commercial milestones, as well as potential future royalties based upon net sales. As of September&amp;#160;30, 2019, we have not accrued any amounts for potential future payments. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 9%;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;S*Bio Purchase Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;We are party to a definitive asset purchase agreement with S*Bio, pursuant to which we acquired certain assets comprised of intellectual property and technology including rights to pracinostat. We agreed to make certain milestone payments to S*Bio based on the achievement of certain clinical, regulatory and net sales-based milestones, as well as to make certain contingent earnout payments to S*Bio. Milestone payments will be made to S*Bio up to an aggregate amount of $74.5&amp;#160;million if certain U.S., E.U. and Japanese regulatory approvals are obtained and if certain net sales thresholds are met in North America, the E.U. and Japan. As of September&amp;#160;30, 2019, we have not accrued any amounts for potential future payments. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 9%;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;CyDex License Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;As discussed in Note &lt;div style="display:inline;"&gt;3&lt;/div&gt;, we are party to a license agreement with CyDex under which we may be required to make future payments upon the achievement of certain milestones, as well as potential future royalties based upon net sales. Contemporaneously with the license agreement, CyDex entered into a commercial supply agreement with us, pursuant to which we agreed to purchase 100% of our requirements for Captisol from CyDex. As of September&amp;#160;30, 2019, we have not accrued any amounts for potential future payments. &lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
<meip:AccruedMilestonePayments id="Factid_7988687" contextRef="PAsOn09_30_2019_SbioPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="INF">0</meip:AccruedMilestonePayments>
<meip:AccruedMilestonePayments id="Factid_7988688" contextRef="PAsOn09_30_2019_CydexLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="INF">0</meip:AccruedMilestonePayments>
<meip:AccruedMilestonePayments id="Factid_7988689" contextRef="PAsOn09_30_2019_PresageLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="INF">0</meip:AccruedMilestonePayments>
<us-gaap:LesseeOperatingLeasesTextBlock id="Factid_7988690" contextRef="P07_01_2019To09_30_2019">&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note 8.&amp;#160;&amp;#160;&amp;#160;&amp;#160;Leases&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;As of July&amp;#160;1, 2019, &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;we&amp;#160;&lt;/div&gt;adopted ASU &lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&amp;#160;2016-02,&lt;/div&gt; Leases, using a modified retrospective basis method under which prior comparative periods are not restated.&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The new standard establishes an ROU model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. In addition, the FASB issued ASU &lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&amp;#160;2018-10,&lt;/div&gt; Codification Improvements to Topic&amp;#160;842, ASU &lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&amp;#160;2018-11,&amp;#160;Targeted&lt;/div&gt; Improvements,&amp;#160;and ASU &lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&amp;#160;2018-20,&amp;#160;Narrow-Scope&lt;/div&gt; Improvements for Lessors, to clarify and amend the guidance in ASU &lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&amp;#160;2016-02.&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;We&lt;/div&gt;&amp;#160;elected the following as practical expedients from within these ASUs: 1) an entity need not reassess whether any expired or existing contracts are or contain leases, 2) an entity need not reassess the lease classification for any expired or existing leases, and 3) an entity need not reassess initial direct costs for any existing leases.&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of July&amp;#160;1, 2019, &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;we&lt;/div&gt;&amp;#160;had an operating lease for our office located in San Diego, California. We have leased approximately 20,800 square feet of office space under a lease which expires in May 2020. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;As of July&amp;#160;1, 2019, &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;our&lt;/div&gt;&amp;#160;remaining minimum lease payments were approximately $0.7&amp;#160;million. Using a discount rate of 8% and a remaining lease term of &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;ten&lt;/div&gt; months, &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;we&lt;/div&gt;&amp;#160;determined the ROU asset and corresponding lease liability at the date of adoption was $0.7&amp;#160;million. There was no cumulative adjustment to our beginning accumulated deficit balance. As of September&amp;#160;30, 2019, &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;our&lt;/div&gt;&amp;#160;remaining minimum lease payments were approximately $0.5&amp;#160;million, our lease liability was $0.5&amp;#160;million, classified as &amp;#8216;Accrued liabilities&amp;#8217; on our &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Condensed&amp;#160;B&lt;/div&gt;alance &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;S&lt;/div&gt;heet, and our &lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset was $0.4&amp;#160;million, &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;classified as &amp;#8216;Property and equipment, net&amp;#8217; on our Condensed Balance Sheet.&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
<us-gaap:LesseeOperatingLeaseTermOfContract id="Factid_7988691" contextRef="PAsOn07_01_2019_AccountingStandardsUpdate201602MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis_MinimumMembersrtRangeAxis">P0M</us-gaap:LesseeOperatingLeaseTermOfContract>
<us-gaap:LandSubjectToGroundLeases id="Factid_7988692" contextRef="PAsOn07_01_2019_AccountingStandardsUpdate201602MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis_CentralAmericaMembersrtStatementGeographicalAxis" unitRef="Unit_sqft" decimals="0">20800</us-gaap:LandSubjectToGroundLeases>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent id="Factid_7988693" contextRef="PAsOn07_01_2019_AccountingStandardsUpdate201602MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" unitRef="Unit_USD" decimals="-5">700000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
<us-gaap:LesseeOperatingLeaseDiscountRate id="Factid_7988694" contextRef="PAsOn07_01_2019_AccountingStandardsUpdate201602MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" unitRef="Unit_pure" decimals="2">0.08</us-gaap:LesseeOperatingLeaseDiscountRate>
<us-gaap:OperatingLeaseRightOfUseAsset id="Factid_7988695" contextRef="PAsOn07_01_2019_AccountingStandardsUpdate201602MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" unitRef="Unit_USD" decimals="-5">700000</us-gaap:OperatingLeaseRightOfUseAsset>
<us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear id="Factid_7988696" contextRef="PAsOn09_30_2019_AccountingStandardsUpdate201602MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" unitRef="Unit_USD" decimals="-5">500000</us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear>
<us-gaap:OperatingLeaseLiability id="Factid_7988697" contextRef="PAsOn09_30_2019_AccountingStandardsUpdate201602MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis_AccruedLiabilitiesMemberusgaapBalanceSheetLocationAxis" unitRef="Unit_USD" decimals="-5">500000</us-gaap:OperatingLeaseLiability>
<us-gaap:OperatingLeaseRightOfUseAsset id="Factid_7988698" contextRef="PAsOn09_30_2019_AccountingStandardsUpdate201602MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis_PropertyPlantAndEquipmentNetMemberusgaapBalanceSheetLocationAxis" unitRef="Unit_USD" decimals="-5">400000</us-gaap:OperatingLeaseRightOfUseAsset>
<us-gaap:CumulativeEffectOnRetainedEarningsNetOfTax1 id="Factid_7988699" contextRef="P07_01_2019To09_30_2019_AccountingStandardsUpdate201602MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" unitRef="Unit_USD" decimals="0">0</us-gaap:CumulativeEffectOnRetainedEarningsNetOfTax1>
<us-gaap:OperatingLeaseLiability id="Factid_7988700" contextRef="PAsOn07_01_2019_AccountingStandardsUpdate201602MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" unitRef="Unit_USD" decimals="-5">700000</us-gaap:OperatingLeaseLiability>
<meip:LesseeOperatingLeaseRemainingLeaseTerm id="Factid_7988701" contextRef="P07_01_2019To07_01_2019_AccountingStandardsUpdate201602MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis">P10M</meip:LesseeOperatingLeaseRemainingLeaseTerm>
<us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock id="Factid_7988702" contextRef="P07_01_2019To09_30_2019">&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note 9.&amp;#160;&amp;#160;&amp;#160;&amp;#160;Short-Term Investments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of September&amp;#160;30, 2019 and June&amp;#160;30, 2019, our short-term investments consisted of $59.9&amp;#160;million and $64.9&amp;#160;million, respectively, in U.S. government securities. The short-term investments held as of September&amp;#160;30, 2019 and June&amp;#160;30, 2019 had maturity dates of less than one year, are considered to be &amp;#8220;held to maturity&amp;#8221; and are carried at amortized cost. As of September&amp;#160;30, 2019 and June&amp;#160;30, 2019, the gross holding gains and losses were immaterial. &lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
<us-gaap:StockholdersEquityNoteDisclosureTextBlock id="Factid_7988705" contextRef="P07_01_2019To09_30_2019">&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Equity Transactions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Warrants &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of September&amp;#160;30, 2019, we have outstanding warrants to purchase 16,061,602 shares of our common stock. The warrants are fully vested, exercisable at a price of $2.54 per share and expire in May 2023. In the event of a sale of the Company, the terms of the warrants require us to use our best efforts to ensure the holders of such warrants will have a continuing right to purchase shares of the acquirer and, if our efforts are unsuccessful, to make a payment to such warrant holders based on a Black-Scholes valuation (using variables as specified in the warrants). Therefore, we are required to account for the warrants as liabilities and record them at fair value. The warrants were revalued as of June&amp;#160;30, 2019 at $17.6&amp;#160;million and as of September&amp;#160;30, 2019 at $8.3&amp;#160;million; the changes in fair value were recorded in our &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Condensed&amp;#160;&lt;/div&gt;Statement of Operations. No warrants were exercised during the three months ended September&amp;#160;30, 2019. During the three months ended September&amp;#160;30, 2018, warrants were exercised for 440,043 shares of common stock, and we received proceeds of $1.1&amp;#160;million. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 9%;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Shelf Registration Statement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 12pt; line-height: 12pt;"&gt;We have a shelf registration statement that permits us to sell, from time to time, up to $150.0&amp;#160;million of common stock, preferred stock and warrants. In November 2017, we entered into an &lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;At-The-Market&lt;/div&gt;&lt;/div&gt; Equity Offering Sales Agreement (the &amp;#8220;ATM Sales Agreement&amp;#8221;), pursuant to which we may sell an aggregate of up to $30.0&amp;#160;million of our common stock pursuant to the shelf registration statement. During the year ended June&amp;#160;30, 2019, we sold 2,214,658 shares under the ATM Sales Agreement for $5.4&amp;#160;million, after deducting offering costs; $5.2&amp;#160;million of these proceeds were received on July&amp;#160;2, 2019 and were recorded as common stock proceeds receivable as of June&amp;#160;30, 2019. During the three months ended September&amp;#160;30, 2019, we sold 63,684 shares under the ATM Sales Agreement for $0.2&amp;#160;million, after deducting offering costs. As of September&amp;#160;30, 2019, there is $144.3&amp;#160;million aggregate value of securities available under the shelf registration statement.&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="Factid_7988706" contextRef="PAsOn09_30_2019_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD_per_Share" decimals="2">2.54</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<meip:ExerciseOfWarrantsForCommonStock id="Factid_7988709" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="0">440043</meip:ExerciseOfWarrantsForCommonStock>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues id="Factid_7988711" contextRef="P07_01_2019To09_30_2019_AtTheMarketSaleAgreementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0">63684</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues id="Factid_7988712" contextRef="P07_01_2019To09_30_2019_AtTheMarketSaleAgreementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5">200000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="Factid_7988714" contextRef="PAsOn09_30_2019_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0">16061602</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock id="Factid_7988715" contextRef="P07_01_2019To09_30_2019">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note 11. Share-based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;We use equity-based compensation programs to provide long-term performance incentives for our employees. These incentives consist primarily of stock options and RSUs. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Our 2008 Stock Omnibus Equity Compensation Plan (the &amp;#8220;2008 Plan&amp;#8221;) provides for the grant of options and/or other share-based or share-denominated awards to our &lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; directors, officers, employees and advisors. The 2008 Plan was initially adopted in 2008 and was amended and restated in 2011, 2013, 2014, 2015, 2016 and 2018. There are 19,089,794 shares of common stock authorized for issuance under the 2008 Plan. As of September&amp;#160;30, 2019, there were 6,979,777 shares available for future grant under the 2008 Plan.&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total share-based compensation expense for all stock awards consists of the following, (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="padding: 0px;;width:82%;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;;vertical-align:bottom;;width:3%;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;;vertical-align:bottom;;width:3%;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&amp;#160;Months&amp;#160;Ended&lt;br/&gt;September&amp;#160;30,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Research and development&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;781&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;630&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;General and administrative&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;1,332&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;1,307&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Total share-based compensation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#160;2,113&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#160;1,937&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Stock Options &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock option activity for the three months ended September&amp;#160;30, 2019 was as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="padding: 0px;;width:47%;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;;vertical-align:bottom;;width:8%;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;;vertical-align:bottom;;width:7%;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;;vertical-align:bottom;;width:8%;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;;vertical-align:bottom;;width:8%;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&amp;#160;of&lt;br/&gt;Options&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&amp;#160;Price&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted-Average&lt;/div&gt;&lt;br/&gt;Remaining&amp;#160;Contractual&lt;br/&gt;Term&amp;#160;(in years)&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;br/&gt;Intrinsic&amp;#160;Value&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Outstanding at June&amp;#160;30, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;8,356,961&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#160;3.20&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;3,083,333&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;2.50&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(46,667&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1.54&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited / Cancelled&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;(49,186&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;1.81&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Expired&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(527,080&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;6.89&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding at September&amp;#160;30, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;10,817,361&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;2.83&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;8.5&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;501,818&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Vested and exercisable at September&amp;#160;30, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;4,114,253&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;2.52&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;7.3&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#160;428,455&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="font-size: 1px; margin-top: 12px; margin-bottom: 0px; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of each stock option granted during the three months ended September&amp;#160;30, 2019 is estimated on the grant date under the fair value method using a Black-Scholes valuation model. Stock options granted to employees during the three months ended September&amp;#160;30, 2019 vest 25% one year from the date of grant and ratably each month thereafter for a period of 36 months and expire ten years from the date of grant. Stock options granted to directors during the three months ended September&amp;#160;30, 2019 vest ratably each month for a period of 12 or 36 months from the date of grant and expire ten years from the date of grant. The estimated fair values of the stock options, including the effect of estimated forfeitures, are expensed over the service period. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following weighted-average assumptions were used to determine the fair value of options granted during the period: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="padding: 0px;;width:85%;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;;vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;;vertical-align:bottom;;width:4%;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&amp;#160;Months&amp;#160;Ended&lt;br/&gt;September&amp;#160;30,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1.8&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;2.8&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected life (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;6.0&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;6.0&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Expected volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;73.6&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;86.0&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dividend yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;0.0&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;0.0&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Weighted-average grant date fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1.63&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;3.11&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of September&amp;#160;30, 2019, there was $8.5&amp;#160;million of unrecognized compensation expense related to the unvested portion of stock options. Such compensation expense is expected to be recognized over a weighted-average period of 1.8 years. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Restricted Stock Units &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;In June 2016, we granted 364,726 RSUs to employees. Each RSU represented the contingent right to receive one share of our common stock. The RSUs vested in August 2018, and we released 332,193 RSU shares. We issued 245,782 shares of common stock to RSU holders; 86,411 shares were surrendered to us by RSU holders as payment for the employee portion of the required withholding of associated payroll taxes. &lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
<us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock id="Factid_7988716" contextRef="P07_01_2019To09_30_2019">&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total share-based compensation expense for all stock awards consists of the following, (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="padding: 0px;;width:82%;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;;vertical-align:bottom;;width:3%;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;;vertical-align:bottom;;width:3%;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&amp;#160;Months&amp;#160;Ended&lt;br/&gt;September&amp;#160;30,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Research and development&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;781&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;630&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;General and administrative&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;1,332&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;1,307&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Total share-based compensation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#160;2,113&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#160;1,937&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
<us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock id="Factid_7988717" contextRef="P07_01_2019To09_30_2019">&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock option activity for the three months ended September&amp;#160;30, 2019 was as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="padding: 0px;;width:47%;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;;vertical-align:bottom;;width:8%;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;;vertical-align:bottom;;width:7%;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;;vertical-align:bottom;;width:8%;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;;vertical-align:bottom;;width:8%;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&amp;#160;of&lt;br/&gt;Options&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&amp;#160;Price&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted-Average&lt;/div&gt;&lt;br/&gt;Remaining&amp;#160;Contractual&lt;br/&gt;Term&amp;#160;(in years)&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;br/&gt;Intrinsic&amp;#160;Value&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Outstanding at June&amp;#160;30, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;8,356,961&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#160;3.20&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;3,083,333&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;2.50&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(46,667&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1.54&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited / Cancelled&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;(49,186&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;1.81&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Expired&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(527,080&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;6.89&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding at September&amp;#160;30, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;10,817,361&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;2.83&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;8.5&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;501,818&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Vested and exercisable at September&amp;#160;30, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;4,114,253&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;2.52&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;7.3&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#160;428,455&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock id="Factid_7988718" contextRef="P07_01_2019To09_30_2019">&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following weighted-average assumptions were used to determine the fair value of options granted during the period: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="padding: 0px;;width:85%;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;;vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;;vertical-align:bottom;;width:4%;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&amp;#160;Months&amp;#160;Ended&lt;br/&gt;September&amp;#160;30,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1.8&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;2.8&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected life (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;6.0&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;6.0&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Expected volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;73.6&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;86.0&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dividend yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;0.0&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;0.0&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Weighted-average grant date fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1.63&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;3.11&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage id="Factid_7988719" contextRef="P07_01_2019To09_30_2019_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="2">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="Factid_7988720" contextRef="P07_01_2019To09_30_2019_EmployeeStockOptionMemberusgaapAwardTypeAxis">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="Factid_7988721" contextRef="P07_01_2019To09_30_2019_DirectorMembersrtTitleOfIndividualAxis_MinimumMembersrtRangeAxis">P12M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="Factid_7988722" contextRef="P07_01_2019To09_30_2019_DirectorMembersrtTitleOfIndividualAxis_MaximumMembersrtRangeAxis">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<meip:NumberOfSharesToBeReceived id="Factid_7988723" contextRef="PAsOn09_30_2019_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0">1</meip:NumberOfSharesToBeReceived>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod id="Factid_7988724" contextRef="P07_01_2019To09_30_2019_EmployeeStockOptionMemberusgaapAwardTypeAxis">P10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
<us-gaap:BasisOfAccountingPolicyPolicyTextBlock id="Factid_7988726" contextRef="P07_01_2019To09_30_2019">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&amp;#8220;U.S. GAAP&amp;#8221;) for interim financial information and in accordance with the instructions to Form &lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-Q&lt;/div&gt; and Article 10 of Regulation &lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-X.&lt;/div&gt; Accordingly, the accompanying financial statements do not include all of the information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying financial statements reflect all adjustments (consisting of normal recurring adjustments) that are necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. We have evaluated subsequent events through the date the financial statements were issued.&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The accompanying unaudited financial statements should be read in conjunction with the audited financial statements and notes thereto as of and for the fiscal year ended June&amp;#160;30, 2019, included in our Annual Report on Form &lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-K&lt;/div&gt; (&amp;#8220;2019 Annual Report&amp;#8221;) filed with the Securities and Exchange Commission (&amp;#8220;SEC&amp;#8221;) on August&amp;#160;28, 2019. Interim results are not necessarily indicative of results for a full year.&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
<us-gaap:UseOfEstimates id="Factid_7988728" contextRef="P07_01_2019To09_30_2019">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. We use estimates that affect the reported amounts (including assets, liabilities, revenues and expenses) and related disclosures. Actual results could materially differ from those estimates. &lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:UseOfEstimates>
<us-gaap:RevenueRecognitionPolicyTextBlock id="Factid_7988729" contextRef="P07_01_2019To09_30_2019">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Revenue Recognition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;We recognize revenue when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. To determine revenue recognition, we perform the following five steps: (i)&amp;#160;identify the contract(s) with a customer; (ii)&amp;#160;identify the performance obligations in the contract; (iii)&amp;#160;determine the transaction price; (iv)&amp;#160;allocate the transaction price to the performance obligations in the contract; and (v)&amp;#160;recognize revenue when (or as) the entity satisfies a performance obligation. See Note &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&lt;/div&gt; for further discussion. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cost of revenue primarily includes external costs paid to third-party contractors to perform research, conduct clinical trials and develop and manufacture drug materials, and internal compensation and related personnel expenses to support our research and development performance obligations. &lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
<us-gaap:ResearchAndDevelopmentExpensePolicy id="Factid_7988730" contextRef="P07_01_2019To09_30_2019">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Research and Development Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Research and development costs are expensed as incurred and include costs paid to third-party contractors to perform research, conduct clinical trials and develop and manufacture drug materials. Clinical trial costs, including costs associated with third-party contractors, are a significant component of research and development expenses. We expense research and development costs based on work performed. In determining the amount to expense, management relies on estimates of total costs based on contract components completed, the enrollment of subjects, the completion of trials, and other events. Costs incurred related to the purchase or licensing of &lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development for early-stage products or products that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred.&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
<us-gaap:CompensationRelatedCostsPolicyTextBlock id="Factid_7988731" contextRef="P07_01_2019To09_30_2019">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Share-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based compensation expense for employees and directors is recognized in the Condensed Statement of Operations based on estimated amounts, including the grant date fair value and the expected service period. For stock options, we estimate the grant date fair value using a Black-Scholes valuation model, which requires the use of multiple subjective inputs including estimated future volatility, expected forfeitures and the expected term of the awards. We estimate the expected future volatility based on the stock&amp;#8217;s historical price volatility. The stock&amp;#8217;s future volatility may differ from the estimated volatility at the grant date. For restricted stock unit (&amp;#8220;RSU&amp;#8221;) equity awards, we estimate the grant date fair value using our closing stock price on the date of grant. We recognize the effect of forfeitures in compensation expense when the forfeitures occur. The estimated forfeiture rates may differ from actual forfeiture rates which would affect the amount of expense recognized during the period. We recognize the value of the awards over the awards&amp;#8217; requisite service or performance periods. The requisite service period is generally the time over which our share-based awards vest. &lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
<us-gaap:IncomeTaxPolicyTextBlock id="Factid_7988732" contextRef="P07_01_2019To09_30_2019">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Our income tax expense consists of current and deferred income tax expense or benefit. Current income tax expense or benefit is the amount of income taxes expected to be payable or refundable for the current year. A deferred income tax asset or liability is recognized for the future tax consequences attributable to tax credits and loss carryforwards and to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. As of September&amp;#160;30, 2019 and June&amp;#160;30, 2019, we have established a valuation allowance to fully reserve our net deferred tax assets. Changes in our ownership may limit the amount of net operating loss carry-forwards that can be utilized in the future to offset taxable income. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) Topic on Income Taxes prescribes a recognition threshold and measurement attribute criteria for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be &lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;more-likely-than-not&lt;/div&gt; to be sustained upon examination by taxing authorities. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. There were no unrecognized tax benefits as of September&amp;#160;30, 2019 or June&amp;#160;30, 2019.&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;There have been no material changes in our unrecognized tax benefits since June&amp;#160;30, 2019, and, as such, the disclosures included in our 2019 Annual Report continue to be relevant for the three month period ended September&amp;#160;30, 2019. &lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:IncomeTaxPolicyTextBlock>
<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock id="Factid_7988733" contextRef="P07_01_2019To09_30_2019">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Recent Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Adopted Accounting Standards &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In February 2016, the FASB issued ASU &lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&amp;#160;2016-02,&lt;/div&gt; Leases. The new standard establishes a &lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; (&amp;#8220;ROU&amp;#8221;) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases are classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after July&amp;#160;1, 2019, including interim periods within those fiscal years. See Note 8 for further discussion.&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
<dei:AmendmentFlag id="Factid_7988734" contextRef="P07_01_2019To09_30_2019">false</dei:AmendmentFlag>
<dei:EntityInteractiveDataCurrent id="Factid_7988735" contextRef="P07_01_2019To09_30_2019">Yes</dei:EntityInteractiveDataCurrent>
<us-gaap:ShareBasedCompensation id="Factid_7988738" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">2113000</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation id="Factid_7988739" contextRef="P07_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">1937000</us-gaap:ShareBasedCompensation>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 id="Factid_7988740" contextRef="PAsOn09_30_2019" unitRef="Unit_USD" decimals="0">428455</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="Factid_7988741" contextRef="PAsOn06_30_2019" unitRef="Unit_USD_per_Share" decimals="2">3.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:CommonStockSharesIssued id="Factid_7988742" contextRef="PAsOn09_30_2019" unitRef="Unit_shares" decimals="0">73655</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding id="Factid_7988743" contextRef="PAsOn09_30_2019" unitRef="Unit_shares" decimals="0">73655</us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesIssued id="Factid_7988744" contextRef="PAsOn06_30_2019" unitRef="Unit_shares" decimals="0">73545</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding id="Factid_7988745" contextRef="PAsOn06_30_2019" unitRef="Unit_shares" decimals="0">73545</us-gaap:CommonStockSharesOutstanding>
<dei:EntityFilerCategory id="Factid_7988746" contextRef="P07_01_2019To09_30_2019">Accelerated Filer</dei:EntityFilerCategory>
<us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock id="Factid_8181077" contextRef="P07_01_2019To09_30_2019">&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;We measure the following financial instruments at fair value on a recurring basis. The fair values of these financial instruments were as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:100%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="padding: 0px; width: 65%;"&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 2%;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 2%;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 2%;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 2%;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 2%;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 2%;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;td style="padding: 0px;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="10" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&amp;#160;30, 2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30, 2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&amp;#160;1&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&amp;#160;2&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&amp;#160;3&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&amp;#160;1&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&amp;#160;2&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&amp;#160;3&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 65%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Warrant liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(8,344&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(17,613&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 65%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="padding-top: 0px; padding-bottom: 0px; width: 65%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;(8,344&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"&gt;(17,613&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 65%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
<meip:ClinicalDevelopmentProgramsPolicyTextBlock id="Factid_8182879" contextRef="P07_01_2019To09_30_2019">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Clinical Development Programs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Our approach to building our pipeline is to license promising cancer agents and build value in programs through development, commercialization and strategic partnerships, as appropriate. Our drug candidate pipeline includes: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"&gt;&lt;div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:13%;"&gt;&lt;div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:left;;vertical-align:top;;width:4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8226;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:top;;width:2%;"&gt;&lt;div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;ME-401,&lt;/div&gt; an oral phosphatidylinositol &lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-kinase&lt;/div&gt; delta (&amp;#8220;PI3K&lt;div style="font-family: symbol; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;d&lt;/div&gt;&amp;#8221;) inhibitor; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"&gt;&lt;div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:13%;"&gt;&lt;div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:left;;vertical-align:top;;width:4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8226;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:top;;width:2%;"&gt;&lt;div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Voruciclib, an oral cyclin-dependent kinase (&amp;#8220;CDK&amp;#8221;) inhibitor; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"&gt;&lt;div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:13%;"&gt;&lt;div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:left;;vertical-align:top;;width:4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8226;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:top;;width:2%;"&gt;&lt;div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;ME-344,&lt;/div&gt; a mitochondrial inhibitor targeting the oxidative phosphorylation (&amp;#8220;OXPHOS&amp;#8221;) complex; and &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"&gt;&lt;div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:13%;"&gt;&lt;div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:left;;vertical-align:top;;width:4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8226;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:top;;width:2%;"&gt;&lt;div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pracinostat, an oral histone deacetylase (&amp;#8220;HDAC&amp;#8221;) inhibitor. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</meip:ClinicalDevelopmentProgramsPolicyTextBlock>
<meip:LiquidityPolicyTextBlock id="Factid_8182881" contextRef="P07_01_2019To09_30_2019">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Liquidity &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;We have accumulated losses of $234.2&amp;#160;million since inception and expect to incur operating losses and generate negative cash flows from operations for the foreseeable future.&amp;#160;As of September&amp;#160;30, 2019, we had $65.9&amp;#160;million in cash and cash equivalents, short-term investments, and common stock proceeds receivable, which we believe will be sufficient to meet obligations and fund our liquidity and capital expenditure requirements for at least the next 12 months from the issuance of these financial statements.&amp;#160;Our current business operations are focused on continuing the clinical development of our drug candidates.&amp;#160;Changes to our research and development plans or other changes affecting our operating expenses may affect actual future use of existing cash resources.&amp;#160;Our research and development expenses are expected to increase in the foreseeable future.&amp;#160;We cannot determine with certainty costs associated with ongoing and future clinical trials or the regulatory approval process. The duration, costs and timing associated with the development of our product candidates will depend on a variety of factors, including uncertainties associated with the results of our clinical trials. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0);font-family: &amp;quot;times new roman&amp;quot;;font-size: 13.3333px;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: 0px;orphans: 2;text-align: start;text-indent: 9%;text-transform: none;white-space: normal;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;text-decoration-style: initial;text-decoration-color: initial;float: none;display: inline !important;top: 0px;;display:inline;"&gt;To date, we have obtained cash and funded our operations primarily through equity financings and license agreements.&amp;#160;In order to continue the development of our drug candidates, we expect to pursue one or more capital transactions, whether through the sale of equity securities, debt financing, license agreements or entry into strategic partnerships. There can be no assurance that we will be able to continue to raise additional capital in the future.&lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</meip:LiquidityPolicyTextBlock>
<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock id="Factid_8193093" contextRef="P07_01_2019To09_30_2019">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note 1.&lt;/div&gt;&lt;/div&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; line-height: 107%; font-family: calibri, sans-serif; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;The Company and Summary of Significant Accounting Policies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;We are a late-stage pharmaceutical company focused on leveraging our extensive development and oncology expertise to identify and advance new therapies intended to meaningfully improve the treatment of cancer. Our portfolio of drug candidates contains four clinical-stage candidates, including one candidate in an ongoing Phase 3 global registration trial and another candidate in an ongoing Phase 2 clinical trial that we intend to submit to the U.S. Food and Drug Administration (&amp;#8220;FDA&amp;#8221;) to support accelerated approval of a marketing application. Our common stock is listed on the NASDAQ Capital Market under the symbol &amp;#8220;MEIP&amp;#8221;. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Clinical Development Programs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Our approach to building our pipeline is to license promising cancer agents and build value in programs through development, commercialization and strategic partnerships, as appropriate. Our drug candidate pipeline includes: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"&gt;&lt;div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:13%;"&gt;&lt;div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:left;;vertical-align:top;;width:4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8226;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:top;;width:2%;"&gt;&lt;div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;ME-401,&lt;/div&gt; an oral phosphatidylinositol &lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-kinase&lt;/div&gt; delta (&amp;#8220;PI3K&lt;div style="font-family: symbol; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;d&lt;/div&gt;&amp;#8221;) inhibitor; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"&gt;&lt;div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:13%;"&gt;&lt;div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:left;;vertical-align:top;;width:4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8226;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:top;;width:2%;"&gt;&lt;div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Voruciclib, an oral cyclin-dependent kinase (&amp;#8220;CDK&amp;#8221;) inhibitor; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"&gt;&lt;div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:13%;"&gt;&lt;div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:left;;vertical-align:top;;width:4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8226;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:top;;width:2%;"&gt;&lt;div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;ME-344,&lt;/div&gt; a mitochondrial inhibitor targeting the oxidative phosphorylation (&amp;#8220;OXPHOS&amp;#8221;) complex; and &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"&gt;&lt;div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:13%;"&gt;&lt;div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:left;;vertical-align:top;;width:4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#8226;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:top;;width:2%;"&gt;&lt;div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pracinostat, an oral histone deacetylase (&amp;#8220;HDAC&amp;#8221;) inhibitor. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Liquidity &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;We have accumulated losses of $234.2&amp;#160;million since inception and expect to incur operating losses and generate negative cash flows from operations for the foreseeable future.&amp;#160;As of September&amp;#160;30, 2019, we had $65.9&amp;#160;million in cash and cash equivalents, short-term investments, and common stock proceeds receivable, which we believe will be sufficient to meet obligations and fund our liquidity and capital expenditure requirements for at least the next 12 months from the issuance of these financial statements.&amp;#160;Our current business operations are focused on continuing the clinical development of our drug candidates.&amp;#160;Changes to our research and development plans or other changes affecting our operating expenses may affect actual future use of existing cash resources.&amp;#160;Our research and development expenses are expected to increase in the foreseeable future.&amp;#160;We cannot determine with certainty costs associated with ongoing and future clinical trials or the regulatory approval process. The duration, costs and timing associated with the development of our product candidates will depend on a variety of factors, including uncertainties associated with the results of our clinical trials. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0);font-family: &amp;quot;times new roman&amp;quot;;font-size: 13.3333px;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: 0px;orphans: 2;text-align: start;text-indent: 9%;text-transform: none;white-space: normal;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;text-decoration-style: initial;text-decoration-color: initial;float: none;display: inline !important;top: 0px;;display:inline;"&gt;To date, we have obtained cash and funded our operations primarily through equity financings and license agreements.&amp;#160;In order to continue the development of our drug candidates, we expect to pursue one or more capital transactions, whether through the sale of equity securities, debt financing, license agreements or entry into strategic partnerships. There can be no assurance that we will be able to continue to raise additional capital in the future.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&amp;#8220;U.S. GAAP&amp;#8221;) for interim financial information and in accordance with the instructions to Form &lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-Q&lt;/div&gt; and Article 10 of Regulation &lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-X.&lt;/div&gt; Accordingly, the accompanying financial statements do not include all of the information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying financial statements reflect all adjustments (consisting of normal recurring adjustments) that are necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. We have evaluated subsequent events through the date the financial statements were issued.&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The accompanying unaudited financial statements should be read in conjunction with the audited financial statements and notes thereto as of and for the fiscal year ended June&amp;#160;30, 2019, included in our Annual Report on Form &lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-K&lt;/div&gt; (&amp;#8220;2019 Annual Report&amp;#8221;) filed with the Securities and Exchange Commission (&amp;#8220;SEC&amp;#8221;) on August&amp;#160;28, 2019. Interim results are not necessarily indicative of results for a full year.&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. We use estimates that affect the reported amounts (including assets, liabilities, revenues and expenses) and related disclosures. Actual results could materially differ from those estimates. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 1px; margin-top: 18px; margin-bottom: 0px; background: none;"&gt;&lt;div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Revenue Recognition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;We recognize revenue when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. To determine revenue recognition, we perform the following five steps: (i)&amp;#160;identify the contract(s) with a customer; (ii)&amp;#160;identify the performance obligations in the contract; (iii)&amp;#160;determine the transaction price; (iv)&amp;#160;allocate the transaction price to the performance obligations in the contract; and (v)&amp;#160;recognize revenue when (or as) the entity satisfies a performance obligation. See Note &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&lt;/div&gt; for further discussion. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cost of revenue primarily includes external costs paid to third-party contractors to perform research, conduct clinical trials and develop and manufacture drug materials, and internal compensation and related personnel expenses to support our research and development performance obligations. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Research and Development Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Research and development costs are expensed as incurred and include costs paid to third-party contractors to perform research, conduct clinical trials and develop and manufacture drug materials. Clinical trial costs, including costs associated with third-party contractors, are a significant component of research and development expenses. We expense research and development costs based on work performed. In determining the amount to expense, management relies on estimates of total costs based on contract components completed, the enrollment of subjects, the completion of trials, and other events. Costs incurred related to the purchase or licensing of &lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development for early-stage products or products that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred.&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Share-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based compensation expense for employees and directors is recognized in the Condensed Statement of Operations based on estimated amounts, including the grant date fair value and the expected service period. For stock options, we estimate the grant date fair value using a Black-Scholes valuation model, which requires the use of multiple subjective inputs including estimated future volatility, expected forfeitures and the expected term of the awards. We estimate the expected future volatility based on the stock&amp;#8217;s historical price volatility. The stock&amp;#8217;s future volatility may differ from the estimated volatility at the grant date. For restricted stock unit (&amp;#8220;RSU&amp;#8221;) equity awards, we estimate the grant date fair value using our closing stock price on the date of grant. We recognize the effect of forfeitures in compensation expense when the forfeitures occur. The estimated forfeiture rates may differ from actual forfeiture rates which would affect the amount of expense recognized during the period. We recognize the value of the awards over the awards&amp;#8217; requisite service or performance periods. The requisite service period is generally the time over which our share-based awards vest. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Our income tax expense consists of current and deferred income tax expense or benefit. Current income tax expense or benefit is the amount of income taxes expected to be payable or refundable for the current year. A deferred income tax asset or liability is recognized for the future tax consequences attributable to tax credits and loss carryforwards and to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. As of September&amp;#160;30, 2019 and June&amp;#160;30, 2019, we have established a valuation allowance to fully reserve our net deferred tax assets. Changes in our ownership may limit the amount of net operating loss carry-forwards that can be utilized in the future to offset taxable income. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) Topic on Income Taxes prescribes a recognition threshold and measurement attribute criteria for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be &lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;more-likely-than-not&lt;/div&gt; to be sustained upon examination by taxing authorities. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. There were no unrecognized tax benefits as of September&amp;#160;30, 2019 or June&amp;#160;30, 2019.&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;There have been no material changes in our unrecognized tax benefits since June&amp;#160;30, 2019, and, as such, the disclosures included in our 2019 Annual Report continue to be relevant for the three month period ended September&amp;#160;30, 2019. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Recent Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Adopted Accounting Standards &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In February 2016, the FASB issued ASU &lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&amp;#160;2016-02,&lt;/div&gt; Leases. The new standard establishes a &lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; (&amp;#8220;ROU&amp;#8221;) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases are classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after July&amp;#160;1, 2019, including interim periods within those fiscal years. See Note 8 for further discussion.&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
<xbrli:unit id="Unit_USD">
<xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit>
<xbrli:unit id="Unit_pure">
<xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit>
<xbrli:unit id="Unit_shares">
<xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit>
<xbrli:unit id="Unit_sqft">
<xbrli:measure>utr:sqft</xbrli:measure>
</xbrli:unit>
<xbrli:unit id="Unit_USD_per_Share">
<xbrli:divide>
<xbrli:unitNumerator>
<xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unitNumerator>
<xbrli:unitDenominator>
<xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unitDenominator>
</xbrli:divide>
</xbrli:unit>
<xbrli:unit id="Unit_ClinicalTrials">
<xbrli:measure>meip:ClinicalTrials</xbrli:measure>
</xbrli:unit>
<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended" />
</xbrli:xbrl>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>meip-20190930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 07-November-2019 [03:35:54] {PM}-->
<schema targetNamespace="http://www.meipharma.com/20190930" elementFormDefault="qualified" xmlns:meip="http://www.meipharma.com/20190930" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31">
<annotation>
<appinfo>
<link:roleType roleURI="http://www.meipharma.com/role/CoverPage" id="CoverPage">
<link:definition>1001 - Document - Cover Page</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/CondensedBalanceSheets" id="CondensedBalanceSheets">
<link:definition>1002 - Statement - CONDENSED BALANCE SHEETS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/CondensedBalanceSheetsParenthetical" id="CondensedBalanceSheetsParenthetical">
<link:definition>1003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/CondensedStatementsOfOperations" id="CondensedStatementsOfOperations">
<link:definition>1004 - Statement - CONDENSED STATEMENTS OF OPERATIONS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/CondensedStatementsOfStockholdersEquity" id="CondensedStatementsOfStockholdersEquity">
<link:definition>1005 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/CondensedStatementsOfCashFlows" id="CondensedStatementsOfCashFlows">
<link:definition>1006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/TheCompanyAndSummaryOfSignificantAccountingPolicies" id="TheCompanyAndSummaryOfSignificantAccountingPolicies">
<link:definition>1007 - Disclosure - The Company and Summary of Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/FairValueMeasurements" id="FairValueMeasurements">
<link:definition>1008 - Disclosure - Fair Value Measurements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/LicenseAgreements" id="LicenseAgreements">
<link:definition>1009 - Disclosure - License Agreements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/BeigeneCollaboration" id="BeigeneCollaboration">
<link:definition>1010 - Disclosure - BeiGene Collaboration</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/RevenueRecognition" id="RevenueRecognition">
<link:definition>1011 - Disclosure - Revenue Recognition</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/NetLossPerShare" id="NetLossPerShare">
<link:definition>1012 - Disclosure - Net Loss Per Share</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
<link:definition>1013 - Disclosure - Commitments and Contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/Leases" id="Leases">
<link:definition>1014 - Disclosure - Leases</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/ShortTermInvestments" id="ShortTermInvestments">
<link:definition>1015 - Disclosure - Short-Term Investments</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/StockholdersEquity" id="StockholdersEquity">
<link:definition>1016 - Disclosure - Stockholders' Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/ShareBasedCompensation" id="ShareBasedCompensation">
<link:definition>1017 - Disclosure - Share-based Compensation</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/TheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies" id="TheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies">
<link:definition>1018 - Disclosure - The Company and Summary of Significant Accounting Policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
<link:definition>1019 - Disclosure - Fair Value Measurements (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/RevenueRecognitionTables" id="RevenueRecognitionTables">
<link:definition>1020 - Disclosure - Revenue Recognition (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/NetLossPerShareTables" id="NetLossPerShareTables">
<link:definition>1021 - Disclosure - Net Loss Per Share (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/ShareBasedCompensationTables" id="ShareBasedCompensationTables">
<link:definition>1022 - Disclosure - Share-based Compensation (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/TheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" id="TheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
<link:definition>1023 - Disclosure - The Company and Summary of Significant Accounting Policies  - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/ScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetail" id="ScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetail">
<link:definition>1024 - Disclosure - Schedule of Financial Instruments Measured at Fair Value on Recurring Basis (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/ScheduleOfAssumptionsUsedToCalculateFairValueOfWarrantLiabilityDetail" id="ScheduleOfAssumptionsUsedToCalculateFairValueOfWarrantLiabilityDetail">
<link:definition>1025 - Disclosure - Schedule of Assumptions Used to Calculate Fair Value of Warrant Liability (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/ScheduleOfChangesInEstimatedFairValueOfWarrantLiabilityDetail" id="ScheduleOfChangesInEstimatedFairValueOfWarrantLiabilityDetail">
<link:definition>1026 - Disclosure - Schedule of Changes in Estimated Fair Value of Warrant Liability (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/LicenseAgreementsAdditionalInformationDetail" id="LicenseAgreementsAdditionalInformationDetail">
<link:definition>1027 - Disclosure - License Agreements - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/RevenueRecognitionAdditionalInformationDetail" id="RevenueRecognitionAdditionalInformationDetail">
<link:definition>1028 - Disclosure - Revenue Recognition - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/RevenueRecognitionRevenueAssociatedWithTheFollowingLicenseAgreementsDetail" id="RevenueRecognitionRevenueAssociatedWithTheFollowingLicenseAgreementsDetail">
<link:definition>1029 - Disclosure - Revenue Recognition - Revenue Associated With The Following license agreements (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/RevenueRecognitionScheduleOfChangesInContractAssetsAndContractLiabilitiesDetail" id="RevenueRecognitionScheduleOfChangesInContractAssetsAndContractLiabilitiesDetail">
<link:definition>1030 - Disclosure - Revenue Recognition - Schedule of Changes in Contract Assets and Contract Liabilities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/NetLossPerShareAdditionalInformationDetail" id="NetLossPerShareAdditionalInformationDetail">
<link:definition>1031 - Disclosure - Net Loss Per Share - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/AntidilutiveSecuritiesDetail" id="AntidilutiveSecuritiesDetail">
<link:definition>1032 - Disclosure - Antidilutive Securities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" id="CommitmentsAndContingenciesAdditionalInformationDetail">
<link:definition>1033 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/LeasesAdditionalInformationDetail" id="LeasesAdditionalInformationDetail">
<link:definition>1034 - Disclosure - Leases - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/ShortTermInvestmentsAdditionalInformationDetail" id="ShortTermInvestmentsAdditionalInformationDetail">
<link:definition>1035 - Disclosure - Short-Term Investments - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/StockholdersEquityAdditionalInformationDetail" id="StockholdersEquityAdditionalInformationDetail">
<link:definition>1036 - Disclosure - Stockholders' Equity - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/ShareBasedCompensationAdditionalInformationDetail" id="ShareBasedCompensationAdditionalInformationDetail">
<link:definition>1037 - Disclosure - Share-based Compensation - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/ShareBasedCompensationExpenseForStockAwardsDetail" id="ShareBasedCompensationExpenseForStockAwardsDetail">
<link:definition>1038 - Disclosure - Share-Based Compensation Expense for Stock Awards (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/SummaryOfStockOptionActivityDetail" id="SummaryOfStockOptionActivityDetail">
<link:definition>1039 - Disclosure - Summary of Stock Option Activity (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.meipharma.com/role/FairValueOfStockOptionsWeightedAverageAssumptionsUsedDetail" id="FairValueOfStockOptionsWeightedAverageAssumptionsUsedDetail">
<link:definition>1040 - Disclosure - Fair Value of Stock Options Weighted-Average Assumptions Used (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="meip-20190930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="meip-20190930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="meip-20190930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="meip-20190930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
<import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/currency/2019-01-31" schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/exch/2019-01-31" schemaLocation="https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
<import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" />
<import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
<import namespace="http://fasb.org/srt-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" />
<element name="NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="meip_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="Stockissuedduringperiodvaluestockwarrantsexercised" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="meip_Stockissuedduringperiodvaluestockwarrantsexercised" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ProceedsFromPreviouslyIssuedCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="meip_ProceedsFromPreviouslyIssuedCommonStock" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ChangeInFairValueOfWarrantsExercised" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="meip_ChangeInFairValueOfWarrantsExercised" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ClinicalDevelopmentProgramsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="meip_ClinicalDevelopmentProgramsPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="LiquidityPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="meip_LiquidityPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="FairValueOfWarrantLiabilityAssumptionsTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="meip_FairValueOfWarrantLiabilityAssumptionsTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfChangesInFairValueOfWarrantLiabilityTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="meip_ScheduleOfChangesInFairValueOfWarrantLiabilityTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfRevenueAssociatedWithLicenseAgreementTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="meip_ScheduleOfRevenueAssociatedWithLicenseAgreementTableTextBlock" substitutionGroup="xbrli:item" />
<element name="AssetsAndLiabilitiesEliminatedUponConsolidationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_AssetsAndLiabilitiesEliminatedUponConsolidationAbstract" substitutionGroup="xbrli:item" />
<element name="NumberOfCandidateInAnOngoingGlobalRegistrationTrial" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="meip_NumberOfCandidateInAnOngoingGlobalRegistrationTrial" substitutionGroup="xbrli:item" />
<element name="NumberOfClinicalStageCandidates" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="meip_NumberOfClinicalStageCandidates" substitutionGroup="xbrli:item" />
<element name="CashAndCashEquivalentsshortTermInvestmentsAndCommonStockProceedsReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="meip_CashAndCashEquivalentsshortTermInvestmentsAndCommonStockProceedsReceivable" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="FairValueMeasurementsSignificantUnobservableInputsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_FairValueMeasurementsSignificantUnobservableInputsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="FairValueMeasurementsSignificantUnobservableInputsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_FairValueMeasurementsSignificantUnobservableInputsLineItems" substitutionGroup="xbrli:item" />
<element name="KyowaKirinCoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_KyowaKirinCoMember" substitutionGroup="xbrli:item" />
<element name="IncrementalPaymentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_IncrementalPaymentMember" substitutionGroup="xbrli:item" />
<element name="PotentialPaymentsOnAchievementOfDevelopmentRegulatoryAndCommercialMilestonesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_PotentialPaymentsOnAchievementOfDevelopmentRegulatoryAndCommercialMilestonesMember" substitutionGroup="xbrli:item" />
<element name="PotentialRegulatoryAndSalesbasedMilestonePaymentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_PotentialRegulatoryAndSalesbasedMilestonePaymentMember" substitutionGroup="xbrli:item" />
<element name="AgreementTerminationNoticePeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="meip_AgreementTerminationNoticePeriod" substitutionGroup="xbrli:item" />
<element name="LicenseAgreementExpiryPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="meip_LicenseAgreementExpiryPeriod" substitutionGroup="xbrli:item" />
<element name="PaymentForLicenseAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="meip_PaymentForLicenseAgreement" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PaymentRelatedToDevelopmentAndCommercialMilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="meip_PaymentRelatedToDevelopmentAndCommercialMilestonePayments" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PercentageOfPurchasesFromMajorSuppliers" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="meip_PercentageOfPurchasesFromMajorSuppliers" substitutionGroup="xbrli:item" />
<element name="PotentialMilestonePaymentsPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="meip_PotentialMilestonePaymentsPayable" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PotentialMilestonePaymentsReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="meip_PotentialMilestonePaymentsReceivable" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="UpFrontPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="meip_UpFrontPayment" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PresageBiosciencesIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_PresageBiosciencesIncMember" substitutionGroup="xbrli:item" />
<element name="HelsinnLicenseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_HelsinnLicenseAgreementMember" substitutionGroup="xbrli:item" />
<element name="PresageLicenseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_PresageLicenseAgreementMember" substitutionGroup="xbrli:item" />
<element name="RevenuePerformanceObligationAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="meip_RevenuePerformanceObligationAmount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AdditionalRecognitionOfDeferredRevenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="meip_AdditionalRecognitionOfDeferredRevenue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="KHKLicenseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_KHKLicenseAgreementMember" substitutionGroup="xbrli:item" />
<element name="RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsAbstract" substitutionGroup="xbrli:item" />
<element name="RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsLineItems" substitutionGroup="xbrli:item" />
<element name="ContractWithCustomerAssetAndLiabilityTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_ContractWithCustomerAssetAndLiabilityTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="ContractWithCustomerAssetAndLiabilityLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_ContractWithCustomerAssetAndLiabilityLineItems" substitutionGroup="xbrli:item" />
<element name="AccountsReceivableNetBeginningBalance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="meip_AccountsReceivableNetBeginningBalance" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AccountsReceivableNetEndingBalance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="meip_AccountsReceivableNetEndingBalance" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PotentiallyDilutiveSecuritiesOutstandingLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_PotentiallyDilutiveSecuritiesOutstandingLineItems" substitutionGroup="xbrli:item" />
<element name="AccruedMilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="meip_AccruedMilestonePayments" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="MilestonePaymentsMaximumAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="meip_MilestonePaymentsMaximumAmount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CydexLicenseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_CydexLicenseAgreementMember" substitutionGroup="xbrli:item" />
<element name="SbioPurchaseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_SbioPurchaseAgreementMember" substitutionGroup="xbrli:item" />
<element name="LesseeOperatingLeaseRemainingLeaseTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="meip_LesseeOperatingLeaseRemainingLeaseTerm" substitutionGroup="xbrli:item" />
<element name="PropertyPlantAndEquipmentNetMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_PropertyPlantAndEquipmentNetMember" substitutionGroup="xbrli:item" />
<element name="ExerciseOfWarrantsForCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="meip_ExerciseOfWarrantsForCommonStock" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="NumberOfSharesAgreedToBeSoldUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="meip_NumberOfSharesAgreedToBeSoldUnderAgreement" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="SaleOfSharesAndWarrantsUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="meip_SaleOfSharesAndWarrantsUnderAgreement" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ShelfRegistrationStatementValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="meip_ShelfRegistrationStatementValue" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AtTheMarketSaleAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_AtTheMarketSaleAgreementMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandAndEightOmnibusPlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_TwoThousandAndEightOmnibusPlanMember" substitutionGroup="xbrli:item" />
<element name="NumberOfSharesToBeReceived" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="meip_NumberOfSharesToBeReceived" substitutionGroup="xbrli:item" />
<element name="EmployeesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_EmployeesMember" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="meip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>meip-20190930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 07-November-2019 [03:35:53] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#CondensedBalanceSheets" roleURI="http://www.meipharma.com/role/CondensedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#CondensedStatementsOfOperations" roleURI="http://www.meipharma.com/role/CondensedStatementsOfOperations" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#CondensedStatementsOfCashFlows" roleURI="http://www.meipharma.com/role/CondensedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#ScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetail" roleURI="http://www.meipharma.com/role/ScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetail" />
<calculationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/CondensedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_PreferredStockValue" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableCurrent" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_DeferredRevenueCurrent" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" use="optional" order="12" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/CondensedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="loc_us-gaap_ShortTermInvestments" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:label="loc_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" use="optional" order="20" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/CondensedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_CostsAndExpenses" use="optional" order="2" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_Revenues" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_InvestmentIncomeInterestAndDividend" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaap_OtherNonoperatingExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_OtherNonoperatingExpense" use="optional" order="9" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/CondensedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ProfitLoss" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" use="optional" order="3" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" use="optional" order="6" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments" use="optional" order="11" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" use="optional" order="16" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_ProceedsFromPreviouslyIssuedCommonStock" xlink:label="loc_MEIP_ProceedsFromPreviouslyIssuedCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_MEIP_ProceedsFromPreviouslyIssuedCommonStock" use="optional" order="18" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/ScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" use="optional" order="1" weight="1" />
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>meip-20190930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 07-November-2019 [03:35:54] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#CondensedBalanceSheets" roleURI="http://www.meipharma.com/role/CondensedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#CondensedBalanceSheetsParenthetical" roleURI="http://www.meipharma.com/role/CondensedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#CondensedStatementsOfOperations" roleURI="http://www.meipharma.com/role/CondensedStatementsOfOperations" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#CondensedStatementsOfStockholdersEquity" roleURI="http://www.meipharma.com/role/CondensedStatementsOfStockholdersEquity" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#CondensedStatementsOfCashFlows" roleURI="http://www.meipharma.com/role/CondensedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#TheCompanyAndSummaryOfSignificantAccountingPolicies" roleURI="http://www.meipharma.com/role/TheCompanyAndSummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#FairValueMeasurements" roleURI="http://www.meipharma.com/role/FairValueMeasurements" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#LicenseAgreements" roleURI="http://www.meipharma.com/role/LicenseAgreements" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#BeigeneCollaboration" roleURI="http://www.meipharma.com/role/BeigeneCollaboration" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#RevenueRecognition" roleURI="http://www.meipharma.com/role/RevenueRecognition" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#NetLossPerShare" roleURI="http://www.meipharma.com/role/NetLossPerShare" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#CommitmentsAndContingencies" roleURI="http://www.meipharma.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#Leases" roleURI="http://www.meipharma.com/role/Leases" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#ShortTermInvestments" roleURI="http://www.meipharma.com/role/ShortTermInvestments" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#StockholdersEquity" roleURI="http://www.meipharma.com/role/StockholdersEquity" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#ShareBasedCompensation" roleURI="http://www.meipharma.com/role/ShareBasedCompensation" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#TheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.meipharma.com/role/TheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#FairValueMeasurementsTables" roleURI="http://www.meipharma.com/role/FairValueMeasurementsTables" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#RevenueRecognitionTables" roleURI="http://www.meipharma.com/role/RevenueRecognitionTables" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#NetLossPerShareTables" roleURI="http://www.meipharma.com/role/NetLossPerShareTables" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#ShareBasedCompensationTables" roleURI="http://www.meipharma.com/role/ShareBasedCompensationTables" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#TheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.meipharma.com/role/TheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#ScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetail" roleURI="http://www.meipharma.com/role/ScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#ScheduleOfAssumptionsUsedToCalculateFairValueOfWarrantLiabilityDetail" roleURI="http://www.meipharma.com/role/ScheduleOfAssumptionsUsedToCalculateFairValueOfWarrantLiabilityDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#ScheduleOfChangesInEstimatedFairValueOfWarrantLiabilityDetail" roleURI="http://www.meipharma.com/role/ScheduleOfChangesInEstimatedFairValueOfWarrantLiabilityDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#LicenseAgreementsAdditionalInformationDetail" roleURI="http://www.meipharma.com/role/LicenseAgreementsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#RevenueRecognitionAdditionalInformationDetail" roleURI="http://www.meipharma.com/role/RevenueRecognitionAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#RevenueRecognitionRevenueAssociatedWithTheFollowingLicenseAgreementsDetail" roleURI="http://www.meipharma.com/role/RevenueRecognitionRevenueAssociatedWithTheFollowingLicenseAgreementsDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#RevenueRecognitionScheduleOfChangesInContractAssetsAndContractLiabilitiesDetail" roleURI="http://www.meipharma.com/role/RevenueRecognitionScheduleOfChangesInContractAssetsAndContractLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#NetLossPerShareAdditionalInformationDetail" roleURI="http://www.meipharma.com/role/NetLossPerShareAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#AntidilutiveSecuritiesDetail" roleURI="http://www.meipharma.com/role/AntidilutiveSecuritiesDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#CommitmentsAndContingenciesAdditionalInformationDetail" roleURI="http://www.meipharma.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#LeasesAdditionalInformationDetail" roleURI="http://www.meipharma.com/role/LeasesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#ShortTermInvestmentsAdditionalInformationDetail" roleURI="http://www.meipharma.com/role/ShortTermInvestmentsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#StockholdersEquityAdditionalInformationDetail" roleURI="http://www.meipharma.com/role/StockholdersEquityAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#ShareBasedCompensationAdditionalInformationDetail" roleURI="http://www.meipharma.com/role/ShareBasedCompensationAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#ShareBasedCompensationExpenseForStockAwardsDetail" roleURI="http://www.meipharma.com/role/ShareBasedCompensationExpenseForStockAwardsDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#SummaryOfStockOptionActivityDetail" roleURI="http://www.meipharma.com/role/SummaryOfStockOptionActivityDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#FairValueOfStockOptionsWeightedAverageAssumptionsUsedDetail" roleURI="http://www.meipharma.com/role/FairValueOfStockOptionsWeightedAverageAssumptionsUsedDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#CoverPage" roleURI="http://www.meipharma.com/role/CoverPage" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/CondensedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_22" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_27" xlink:to="loc_us-gaap_AssetsAbstract_22" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_32" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_22" xlink:to="loc_us-gaap_Assets_32" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_23" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_22" xlink:to="loc_us-gaap_AssetsCurrentAbstract_23" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_37" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_23" xlink:to="loc_us-gaap_AssetsCurrent_37" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_33" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_23" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_33" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_35" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_23" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_35" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_36" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_23" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_36" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_34" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_23" xlink:to="loc_us-gaap_ShortTermInvestments_34" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:label="loc_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_478145" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_23" xlink:to="loc_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_478145" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_30" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_22" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_30" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_31" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_22" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_31" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_27" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_41" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25" xlink:to="loc_us-gaap_CommitmentsAndContingencies_41" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_40" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25" xlink:to="loc_us-gaap_Liabilities_40" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_42" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_42" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_26" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_26" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_43" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_26" xlink:to="loc_us-gaap_AccountsPayableCurrent_43" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_44" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_26" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_44" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_45" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_26" xlink:to="loc_us-gaap_DeferredRevenueCurrent_45" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_46" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_26" xlink:to="loc_us-gaap_LiabilitiesCurrent_46" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_29" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25" xlink:to="loc_us-gaap_StockholdersEquityAbstract_29" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_49" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_49" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_48" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29" xlink:to="loc_us-gaap_CommonStockValue_48" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_47" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29" xlink:to="loc_us-gaap_PreferredStockValue_47" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_50" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_50" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_51" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29" xlink:to="loc_us-gaap_StockholdersEquity_51" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_39" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_39" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_311823" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_311823" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_28" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_27" xlink:to="loc_us-gaap_StatementTable_28" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_24" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_28" xlink:to="loc_dei_LegalEntityAxis_24" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_38" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_24" xlink:to="loc_dei_EntityDomain_38" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_38_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_24" xlink:to="loc_dei_EntityDomain_38_default" use="optional" order="32" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/CondensedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_55" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_61" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_55" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_61" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_62" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_55" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_62" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_63" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_55" xlink:to="loc_us-gaap_CommonStockSharesIssued_63" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_64" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_55" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_64" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_58" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_55" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_58" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_59" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_55" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_59" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_60" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_55" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_60" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_56" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_55" xlink:to="loc_us-gaap_StatementTable_56" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_54" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_56" xlink:to="loc_dei_LegalEntityAxis_54" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_57" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_54" xlink:to="loc_dei_EntityDomain_57" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_57_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_54" xlink:to="loc_dei_EntityDomain_57_default" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/CondensedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_72" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_67" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_72" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_67" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_75" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_67" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_75" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_78" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_67" xlink:to="loc_us-gaap_CostsAndExpenses_78" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_77" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_67" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_77" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_76" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_67" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_76" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_89" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_72" xlink:to="loc_us-gaap_EarningsPerShareAbstract_89" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_503779" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_89" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_503779" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_69" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_72" xlink:to="loc_us-gaap_NetIncomeLossAbstract_69" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xlink:label="loc_meip_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_503753" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_69" xlink:to="loc_meip_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_503753" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_70" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_72" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_70" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_82" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_70" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_82" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_83" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_70" xlink:to="loc_us-gaap_InvestmentIncomeInterestAndDividend_83" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_85" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_70" xlink:to="loc_us-gaap_NetIncomeLoss_85" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaap_OtherNonoperatingExpense_503736" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_70" xlink:to="loc_us-gaap_OtherNonoperatingExpense_503736" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_88" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_72" xlink:to="loc_us-gaap_OperatingIncomeLoss_88" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_86" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_72" xlink:to="loc_us-gaap_Revenues_86" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_73" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_72" xlink:to="loc_us-gaap_StatementTable_73" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_68" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_73" xlink:to="loc_dei_LegalEntityAxis_68" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_79" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_68" xlink:to="loc_dei_EntityDomain_79" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_79_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_68" xlink:to="loc_dei_EntityDomain_79_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_74" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_72" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_74" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_503781" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_74" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_503781" use="optional" order="22" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/CondensedStatementsOfStockholdersEquity">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_409054" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_409046" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_409054" xlink:to="loc_us-gaap_StatementTable_409046" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_409047" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_409046" xlink:to="loc_dei_LegalEntityAxis_409047" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_409048" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_409047" xlink:to="loc_dei_EntityDomain_409048" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_409048_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_409047" xlink:to="loc_dei_EntityDomain_409048_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_409049" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_409046" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_409049" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_409050" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_409049" xlink:to="loc_us-gaap_EquityComponentDomain_409050" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_409050_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_409049" xlink:to="loc_us-gaap_EquityComponentDomain_409050_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_409051" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_409050" xlink:to="loc_us-gaap_CommonStockMember_409051" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_409052" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_409050" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_409052" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_409053" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_409050" xlink:to="loc_us-gaap_RetainedEarningsMember_409053" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_478153" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_409046" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_478153" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_478154" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_478153" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_478154" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_478154_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_478153" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_478154_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_478156" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_409046" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_478156" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_478157" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_478156" xlink:to="loc_us-gaap_LossContingencyNatureDomain_478157" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_478157_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_478156" xlink:to="loc_us-gaap_LossContingencyNatureDomain_478157_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_409058" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_409054" xlink:to="loc_us-gaap_StockholdersEquity_409058" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_409059" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_409054" xlink:to="loc_us-gaap_NetIncomeLoss_409059" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_409062" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_409054" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_409062" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_409064" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_409054" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_409064" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_409068" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_409054" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_409068" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_Stockissuedduringperiodvaluestockwarrantsexercised" xlink:label="loc_meip_Stockissuedduringperiodvaluestockwarrantsexercised_409187" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_409054" xlink:to="loc_meip_Stockissuedduringperiodvaluestockwarrantsexercised_409187" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_409219" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_409054" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_409219" use="optional" order="23" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/CondensedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_102" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_123" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_102" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_123" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_122" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_102" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_122" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_99" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_102" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_99" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_115" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_99" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_115" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_114" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_99" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_114" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_112" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_99" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_112" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_113" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_99" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_113" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_503822" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_99" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_503822" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_ProceedsFromPreviouslyIssuedCommonStock" xlink:label="loc_meip_ProceedsFromPreviouslyIssuedCommonStock_503826" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_99" xlink:to="loc_meip_ProceedsFromPreviouslyIssuedCommonStock_503826" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_100" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_102" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_100" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_119" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_100" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_119" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_117" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_100" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_117" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_118" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_100" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_118" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_101" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_102" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_101" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_96" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_101" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_96" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_106" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_96" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_106" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_96" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_104" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_105" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_96" xlink:to="loc_us-gaap_ShareBasedCompensation_105" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_97" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_101" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_97" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_108" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_97" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_108" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_109" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_97" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_109" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_110" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_97" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_110" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_107" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_97" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_107" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_121" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_101" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_121" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_120" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_101" xlink:to="loc_us-gaap_ProfitLoss_120" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_103" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_102" xlink:to="loc_us-gaap_StatementTable_103" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_98" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_103" xlink:to="loc_dei_LegalEntityAxis_98" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_111" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_98" xlink:to="loc_dei_EntityDomain_111" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_111_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_98" xlink:to="loc_dei_EntityDomain_111_default" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_478166" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_102" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_478166" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_478167" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_478166" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_478167" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_481017" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_102" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_481017" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_ChangeInFairValueOfWarrantsExercised" xlink:label="loc_meip_ChangeInFairValueOfWarrantsExercised_481052" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_481017" xlink:to="loc_meip_ChangeInFairValueOfWarrantsExercised_481052" use="optional" order="33" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/TheCompanyAndSummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_402" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_405" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_402" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_405" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_403" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_402" xlink:to="loc_us-gaap_StatementTable_403" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_401" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_403" xlink:to="loc_dei_LegalEntityAxis_401" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_404" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_401" xlink:to="loc_dei_EntityDomain_404" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_404_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_401" xlink:to="loc_dei_EntityDomain_404_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/FairValueMeasurements">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_430" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_433" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_430" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_433" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_431" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_430" xlink:to="loc_us-gaap_StatementTable_431" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_429" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_431" xlink:to="loc_dei_LegalEntityAxis_429" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_432" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_429" xlink:to="loc_dei_EntityDomain_432" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_432_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_429" xlink:to="loc_dei_EntityDomain_432_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/LicenseAgreements">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_446" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_449" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_446" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_449" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_447" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_446" xlink:to="loc_us-gaap_StatementTable_447" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_445" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_447" xlink:to="loc_dei_LegalEntityAxis_445" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_448" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_445" xlink:to="loc_dei_EntityDomain_448" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_448_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_445" xlink:to="loc_dei_EntityDomain_448_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/BeigeneCollaboration">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_453" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_456" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_453" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_456" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_454" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_453" xlink:to="loc_us-gaap_StatementTable_454" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_452" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_454" xlink:to="loc_dei_LegalEntityAxis_452" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_455" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_452" xlink:to="loc_dei_EntityDomain_455" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_455_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_452" xlink:to="loc_dei_EntityDomain_455_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/RevenueRecognition">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_505812" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_503973" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_505812" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_503973" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_505809" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_505812" xlink:to="loc_us-gaap_StatementTable_505809" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_505810" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_505809" xlink:to="loc_us-gaap_StatementClassOfStockAxis_505810" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_505811" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_505810" xlink:to="loc_us-gaap_ClassOfStockDomain_505811" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_505811_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_505810" xlink:to="loc_us-gaap_ClassOfStockDomain_505811_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/NetLossPerShare">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_460" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_463" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_460" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_463" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_461" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_460" xlink:to="loc_us-gaap_StatementTable_461" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_459" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_461" xlink:to="loc_dei_LegalEntityAxis_459" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_462" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_459" xlink:to="loc_dei_EntityDomain_462" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_462_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_459" xlink:to="loc_dei_EntityDomain_462_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_475" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_478" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_475" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_478" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_476" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_475" xlink:to="loc_us-gaap_StatementTable_476" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_474" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_476" xlink:to="loc_dei_LegalEntityAxis_474" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_477" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_474" xlink:to="loc_dei_EntityDomain_477" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_477_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_474" xlink:to="loc_dei_EntityDomain_477_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/Leases">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_505817" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_504090" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_505817" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_504090" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_505814" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_505817" xlink:to="loc_us-gaap_StatementTable_505814" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_505815" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_505814" xlink:to="loc_us-gaap_StatementClassOfStockAxis_505815" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_505816" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_505815" xlink:to="loc_us-gaap_ClassOfStockDomain_505816" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_505816_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_505815" xlink:to="loc_us-gaap_ClassOfStockDomain_505816_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/ShortTermInvestments">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_482" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_485" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_482" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_485" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_483" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_482" xlink:to="loc_us-gaap_StatementTable_483" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_481" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_483" xlink:to="loc_dei_LegalEntityAxis_481" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_484" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_481" xlink:to="loc_dei_EntityDomain_484" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_484_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_481" xlink:to="loc_dei_EntityDomain_484_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/StockholdersEquity">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_489" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_490" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_489" xlink:to="loc_us-gaap_StatementTable_490" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_488" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_490" xlink:to="loc_dei_LegalEntityAxis_488" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_491" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_488" xlink:to="loc_dei_EntityDomain_491" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_491_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_488" xlink:to="loc_dei_EntityDomain_491_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_492" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_489" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_492" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/ShareBasedCompensation">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_496" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_499" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_496" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_499" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_497" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_496" xlink:to="loc_us-gaap_StatementTable_497" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_495" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_497" xlink:to="loc_dei_LegalEntityAxis_495" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_498" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_495" xlink:to="loc_dei_EntityDomain_498" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_498_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_495" xlink:to="loc_dei_EntityDomain_498_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/TheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_409" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_413" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_409" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_413" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_ClinicalDevelopmentProgramsPolicyTextBlock" xlink:label="loc_meip_ClinicalDevelopmentProgramsPolicyTextBlock_412" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_409" xlink:to="loc_meip_ClinicalDevelopmentProgramsPolicyTextBlock_412" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_417" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_409" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_417" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_418" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_409" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_418" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_419" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_409" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_419" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_416" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_409" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_416" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_415" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_409" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_415" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_410" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_409" xlink:to="loc_us-gaap_StatementTable_410" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_408" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_410" xlink:to="loc_dei_LegalEntityAxis_408" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_411" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_408" xlink:to="loc_dei_EntityDomain_411" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_411_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_408" xlink:to="loc_dei_EntityDomain_411_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_414" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_409" xlink:to="loc_us-gaap_UseOfEstimates_414" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_LiquidityPolicyTextBlock" xlink:label="loc_meip_LiquidityPolicyTextBlock_481048" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_409" xlink:to="loc_meip_LiquidityPolicyTextBlock_481048" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/FairValueMeasurementsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_437" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_FairValueOfWarrantLiabilityAssumptionsTableTextBlock" xlink:label="loc_meip_FairValueOfWarrantLiabilityAssumptionsTableTextBlock_441" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_437" xlink:to="loc_meip_FairValueOfWarrantLiabilityAssumptionsTableTextBlock_441" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_ScheduleOfChangesInFairValueOfWarrantLiabilityTableTextBlock" xlink:label="loc_meip_ScheduleOfChangesInFairValueOfWarrantLiabilityTableTextBlock_442" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_437" xlink:to="loc_meip_ScheduleOfChangesInFairValueOfWarrantLiabilityTableTextBlock_442" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_440" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_437" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_440" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_438" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_437" xlink:to="loc_us-gaap_StatementTable_438" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_436" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_438" xlink:to="loc_dei_LegalEntityAxis_436" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_439" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_436" xlink:to="loc_dei_EntityDomain_439" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_439_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_436" xlink:to="loc_dei_EntityDomain_439_default" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/RevenueRecognitionTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_505826" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_ScheduleOfRevenueAssociatedWithLicenseAgreementTableTextBlock" xlink:label="loc_meip_ScheduleOfRevenueAssociatedWithLicenseAgreementTableTextBlock_503983" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_505826" xlink:to="loc_meip_ScheduleOfRevenueAssociatedWithLicenseAgreementTableTextBlock_503983" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_503985" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_505826" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_503985" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_505822" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_505826" xlink:to="loc_us-gaap_StatementTable_505822" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_505824" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_505822" xlink:to="loc_dei_LegalEntityAxis_505824" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_505825" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_505824" xlink:to="loc_dei_EntityDomain_505825" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_505825_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_505824" xlink:to="loc_dei_EntityDomain_505825_default" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/NetLossPerShareTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_467" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_468" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_467" xlink:to="loc_us-gaap_StatementTable_468" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_466" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_468" xlink:to="loc_dei_LegalEntityAxis_466" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_469" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_466" xlink:to="loc_dei_EntityDomain_469" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_469_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_466" xlink:to="loc_dei_EntityDomain_469_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_504057" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_467" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_504057" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/ShareBasedCompensationTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_503" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_507" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_503" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_507" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_506" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_503" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_506" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_508" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_503" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_508" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_504" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_503" xlink:to="loc_us-gaap_StatementTable_504" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_502" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_504" xlink:to="loc_dei_LegalEntityAxis_502" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_505" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_502" xlink:to="loc_dei_EntityDomain_505" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_505_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_502" xlink:to="loc_dei_EntityDomain_505_default" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/TheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TargetedOrTrackingStockStockLineItems" xlink:label="loc_us-gaap_TargetedOrTrackingStockStockLineItems_128" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_NumberOfCandidateInAnOngoingGlobalRegistrationTrial" xlink:label="loc_meip_NumberOfCandidateInAnOngoingGlobalRegistrationTrial_132" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockLineItems_128" xlink:to="loc_meip_NumberOfCandidateInAnOngoingGlobalRegistrationTrial_132" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_NumberOfClinicalStageCandidates" xlink:label="loc_meip_NumberOfClinicalStageCandidates_131" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockLineItems_128" xlink:to="loc_meip_NumberOfClinicalStageCandidates_131" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TargetedOrTrackingStockStockTable" xlink:label="loc_us-gaap_TargetedOrTrackingStockStockTable_129" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockLineItems_128" xlink:to="loc_us-gaap_TargetedOrTrackingStockStockTable_129" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_127" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockTable_129" xlink:to="loc_dei_LegalEntityAxis_127" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_130" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_127" xlink:to="loc_dei_EntityDomain_130" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_130_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_127" xlink:to="loc_dei_EntityDomain_130_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_311913" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockTable_129" xlink:to="loc_us-gaap_TypeOfArrangementAxis_311913" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_311916" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_311913" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_311916" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_311916_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_311913" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_311916_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_478189" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockTable_129" xlink:to="loc_srt_RangeAxis_478189" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_478190" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_478189" xlink:to="loc_srt_RangeMember_478190" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_478190_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_478189" xlink:to="loc_srt_RangeMember_478190_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_478193" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockTable_129" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_478193" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_478194" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_478193" xlink:to="loc_us-gaap_TypeOfAdoptionMember_478194" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_478194_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_478193" xlink:to="loc_us-gaap_TypeOfAdoptionMember_478194_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_136" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockLineItems_128" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_136" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_481044" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockLineItems_128" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_481044" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_CashAndCashEquivalentsshortTermInvestmentsAndCommonStockProceedsReceivable" xlink:label="loc_meip_CashAndCashEquivalentsshortTermInvestmentsAndCommonStockProceedsReceivable_481046" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockLineItems_128" xlink:to="loc_meip_CashAndCashEquivalentsshortTermInvestmentsAndCommonStockProceedsReceivable_481046" use="optional" order="18" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/ScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_154" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_155" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_154" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_155" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_156" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_155" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_156" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_159" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_156" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_159" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_159_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_156" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_159_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_168" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_159" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_168" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_157" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_155" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_157" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_158" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_157" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_158" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_158_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_157" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_158_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_166" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_158" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_166" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_160" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_155" xlink:to="loc_dei_LegalEntityAxis_160" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_169" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_160" xlink:to="loc_dei_EntityDomain_169" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_169_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_160" xlink:to="loc_dei_EntityDomain_169_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_165" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_154" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_165" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_164" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_154" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_164" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/ScheduleOfAssumptionsUsedToCalculateFairValueOfWarrantLiabilityDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_172" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_173" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_172" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_173" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_174" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_173" xlink:to="loc_dei_LegalEntityAxis_174" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_180" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_174" xlink:to="loc_dei_EntityDomain_180" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_180_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_174" xlink:to="loc_dei_EntityDomain_180_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_175" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_173" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_175" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_176" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_175" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_176" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_176_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_175" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_176_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_184" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_176" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_184" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_182" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_176" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_182" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_183" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_176" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_183" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_181" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_176" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_181" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="loc_us-gaap_MeasurementInputExercisePriceMember_478745" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_176" xlink:to="loc_us-gaap_MeasurementInputExercisePriceMember_478745" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_478746" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_172" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_478746" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/ScheduleOfChangesInEstimatedFairValueOfWarrantLiabilityDetail">
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_FairValueMeasurementsSignificantUnobservableInputsLineItems" xlink:label="loc_meip_FairValueMeasurementsSignificantUnobservableInputsLineItems_191" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_198" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meip_FairValueMeasurementsSignificantUnobservableInputsLineItems_191" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_198" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_FairValueMeasurementsSignificantUnobservableInputsTable" xlink:label="loc_meip_FairValueMeasurementsSignificantUnobservableInputsTable_192" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_meip_FairValueMeasurementsSignificantUnobservableInputsLineItems_191" xlink:to="loc_meip_FairValueMeasurementsSignificantUnobservableInputsTable_192" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_187" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_meip_FairValueMeasurementsSignificantUnobservableInputsTable_192" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_187" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_190" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_187" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_190" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_190_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_187" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_190_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_195" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_190" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_195" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_188" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_meip_FairValueMeasurementsSignificantUnobservableInputsTable_192" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_188" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_189" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_188" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_189" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_189_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_188" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_189_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_194" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_189" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_194" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_193" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_meip_FairValueMeasurementsSignificantUnobservableInputsTable_192" xlink:to="loc_dei_LegalEntityAxis_193" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_200" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_193" xlink:to="loc_dei_EntityDomain_200" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_200_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_193" xlink:to="loc_dei_EntityDomain_200_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_197" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meip_FairValueMeasurementsSignificantUnobservableInputsLineItems_191" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_197" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_196" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meip_FairValueMeasurementsSignificantUnobservableInputsLineItems_191" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_196" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/LicenseAgreementsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_211" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_AgreementTerminationNoticePeriod" xlink:label="loc_meip_AgreementTerminationNoticePeriod_236" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_meip_AgreementTerminationNoticePeriod_236" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_232" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_232" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_LicenseAgreementExpiryPeriod" xlink:label="loc_meip_LicenseAgreementExpiryPeriod_230" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_meip_LicenseAgreementExpiryPeriod_230" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_PaymentForLicenseAgreement" xlink:label="loc_meip_PaymentForLicenseAgreement_234" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_meip_PaymentForLicenseAgreement_234" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_PaymentRelatedToDevelopmentAndCommercialMilestonePayments" xlink:label="loc_meip_PaymentRelatedToDevelopmentAndCommercialMilestonePayments_229" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_meip_PaymentRelatedToDevelopmentAndCommercialMilestonePayments_229" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_PercentageOfPurchasesFromMajorSuppliers" xlink:label="loc_meip_PercentageOfPurchasesFromMajorSuppliers_235" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_meip_PercentageOfPurchasesFromMajorSuppliers_235" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_PotentialMilestonePaymentsPayable" xlink:label="loc_meip_PotentialMilestonePaymentsPayable_233" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_meip_PotentialMilestonePaymentsPayable_233" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_PotentialMilestonePaymentsReceivable" xlink:label="loc_meip_PotentialMilestonePaymentsReceivable_226" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_meip_PotentialMilestonePaymentsReceivable_226" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="loc_us-gaap_ProceedsFromLicenseFeesReceived_311871" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_us-gaap_ProceedsFromLicenseFeesReceived_311871" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_213" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_213" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_205" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_213" xlink:to="loc_dei_LegalEntityAxis_205" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_204" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_205" xlink:to="loc_dei_EntityDomain_204" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_204_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_205" xlink:to="loc_dei_EntityDomain_204_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_KyowaKirinCoMember" xlink:label="loc_meip_KyowaKirinCoMember_218" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_204" xlink:to="loc_meip_KyowaKirinCoMember_218" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_206" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_213" xlink:to="loc_srt_RangeAxis_206" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_207" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_206" xlink:to="loc_srt_RangeMember_207" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_207_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_206" xlink:to="loc_srt_RangeMember_207_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_219" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_207" xlink:to="loc_srt_MaximumMember_219" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_209" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_213" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_209" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_210" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_209" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_210" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_210_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_209" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_210_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_IncrementalPaymentMember" xlink:label="loc_meip_IncrementalPaymentMember_223" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_210" xlink:to="loc_meip_IncrementalPaymentMember_223" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_PotentialPaymentsOnAchievementOfDevelopmentRegulatoryAndCommercialMilestonesMember" xlink:label="loc_meip_PotentialPaymentsOnAchievementOfDevelopmentRegulatoryAndCommercialMilestonesMember_224" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_210" xlink:to="loc_meip_PotentialPaymentsOnAchievementOfDevelopmentRegulatoryAndCommercialMilestonesMember_224" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_PotentialRegulatoryAndSalesbasedMilestonePaymentMember" xlink:label="loc_meip_PotentialRegulatoryAndSalesbasedMilestonePaymentMember_222" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_210" xlink:to="loc_meip_PotentialRegulatoryAndSalesbasedMilestonePaymentMember_222" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_212" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_213" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_212" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_208" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_212" xlink:to="loc_us-gaap_RelatedPartyDomain_208" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_208_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_212" xlink:to="loc_us-gaap_RelatedPartyDomain_208_default" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_PresageBiosciencesIncMember" xlink:label="loc_meip_PresageBiosciencesIncMember_221" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_208" xlink:to="loc_meip_PresageBiosciencesIncMember_221" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_214" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_213" xlink:to="loc_us-gaap_TypeOfArrangementAxis_214" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_203" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_214" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_203" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_203_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_214" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_203_default" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_HelsinnLicenseAgreementMember" xlink:label="loc_meip_HelsinnLicenseAgreementMember_215" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_203" xlink:to="loc_meip_HelsinnLicenseAgreementMember_215" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_PresageLicenseAgreementMember" xlink:label="loc_meip_PresageLicenseAgreementMember_216" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_203" xlink:to="loc_meip_PresageLicenseAgreementMember_216" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_UpFrontPayment" xlink:label="loc_meip_UpFrontPayment_228" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_meip_UpFrontPayment_228" use="optional" order="34" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/RevenueRecognitionAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_503993" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_503990" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_503993" xlink:to="loc_us-gaap_StatementTable_503990" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_503991" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_503990" xlink:to="loc_us-gaap_StatementClassOfStockAxis_503991" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_503992" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_503991" xlink:to="loc_us-gaap_ClassOfStockDomain_503992" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_503992_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_503991" xlink:to="loc_us-gaap_ClassOfStockDomain_503992_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_503995" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_503990" xlink:to="loc_us-gaap_TypeOfArrangementAxis_503995" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_503996" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_503995" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_503996" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_503996_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_503995" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_503996_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_KHKLicenseAgreementMember" xlink:label="loc_meip_KHKLicenseAgreementMember_503997" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_503996" xlink:to="loc_meip_KHKLicenseAgreementMember_503997" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_HelsinnLicenseAgreementMember" xlink:label="loc_meip_HelsinnLicenseAgreementMember_503999" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_503996" xlink:to="loc_meip_HelsinnLicenseAgreementMember_503999" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_RevenuePerformanceObligationAmount" xlink:label="loc_meip_RevenuePerformanceObligationAmount_503998" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_503993" xlink:to="loc_meip_RevenuePerformanceObligationAmount_503998" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_504004" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_503993" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_504004" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_504010" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_503993" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_504010" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_AdditionalRecognitionOfDeferredRevenue" xlink:label="loc_meip_AdditionalRecognitionOfDeferredRevenue_504012" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_503993" xlink:to="loc_meip_AdditionalRecognitionOfDeferredRevenue_504012" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/RevenueRecognitionRevenueAssociatedWithTheFollowingLicenseAgreementsDetail">
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsLineItems" xlink:label="loc_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsLineItems_311880" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsTable" xlink:label="loc_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsTable_311877" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsLineItems_311880" xlink:to="loc_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsTable_311877" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_311881" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsTable_311877" xlink:to="loc_us-gaap_TypeOfArrangementAxis_311881" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_311882" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_311881" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_311882" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_311882_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_311881" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_311882_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_KHKLicenseAgreementMember" xlink:label="loc_meip_KHKLicenseAgreementMember_311883" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_311882" xlink:to="loc_meip_KHKLicenseAgreementMember_311883" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_HelsinnLicenseAgreementMember" xlink:label="loc_meip_HelsinnLicenseAgreementMember_311892" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_311882" xlink:to="loc_meip_HelsinnLicenseAgreementMember_311892" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_481081" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsTable_311877" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_481081" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_481082" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_481081" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_481082" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_481082_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_481081" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_481082_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_311885" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsLineItems_311880" xlink:to="loc_us-gaap_Revenues_311885" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/RevenueRecognitionScheduleOfChangesInContractAssetsAndContractLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_ContractWithCustomerAssetAndLiabilityLineItems" xlink:label="loc_meip_ContractWithCustomerAssetAndLiabilityLineItems_139" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_AccountsReceivableNetBeginningBalance" xlink:label="loc_meip_AccountsReceivableNetBeginningBalance_142" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meip_ContractWithCustomerAssetAndLiabilityLineItems_139" xlink:to="loc_meip_AccountsReceivableNetBeginningBalance_142" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_AccountsReceivableNetEndingBalance" xlink:label="loc_meip_AccountsReceivableNetEndingBalance_144" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meip_ContractWithCustomerAssetAndLiabilityLineItems_139" xlink:to="loc_meip_AccountsReceivableNetEndingBalance_144" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_ContractWithCustomerAssetAndLiabilityTable" xlink:label="loc_meip_ContractWithCustomerAssetAndLiabilityTable_140" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_meip_ContractWithCustomerAssetAndLiabilityLineItems_139" xlink:to="loc_meip_ContractWithCustomerAssetAndLiabilityTable_140" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_141" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_meip_ContractWithCustomerAssetAndLiabilityTable_140" xlink:to="loc_dei_LegalEntityAxis_141" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_151" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_141" xlink:to="loc_dei_EntityDomain_151" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_151_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_141" xlink:to="loc_dei_EntityDomain_151_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_145" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meip_ContractWithCustomerAssetAndLiabilityLineItems_139" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_145" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_148" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meip_ContractWithCustomerAssetAndLiabilityLineItems_139" xlink:to="loc_us-gaap_ContractWithCustomerLiability_148" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_146" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meip_ContractWithCustomerAssetAndLiabilityLineItems_139" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_146" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_149" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meip_ContractWithCustomerAssetAndLiabilityLineItems_139" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_149" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_143" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meip_ContractWithCustomerAssetAndLiabilityLineItems_139" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_143" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/NetLossPerShareAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_PotentiallyDilutiveSecuritiesOutstandingLineItems" xlink:label="loc_meip_PotentiallyDilutiveSecuritiesOutstandingLineItems_240" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_241" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_meip_PotentiallyDilutiveSecuritiesOutstandingLineItems_240" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_241" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_239" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_241" xlink:to="loc_dei_LegalEntityAxis_239" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_242" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_239" xlink:to="loc_dei_EntityDomain_242" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_242_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_239" xlink:to="loc_dei_EntityDomain_242_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_243" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meip_PotentiallyDilutiveSecuritiesOutstandingLineItems_240" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_243" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/AntidilutiveSecuritiesDetail">
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_PotentiallyDilutiveSecuritiesOutstandingLineItems" xlink:label="loc_meip_PotentiallyDilutiveSecuritiesOutstandingLineItems_478237" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_478229" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_meip_PotentiallyDilutiveSecuritiesOutstandingLineItems_478237" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_478229" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_478230" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_478229" xlink:to="loc_dei_LegalEntityAxis_478230" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_478231" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_478230" xlink:to="loc_dei_EntityDomain_478231" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_478231_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_478230" xlink:to="loc_dei_EntityDomain_478231_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_478232" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_478229" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_478232" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_478233" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_478232" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_478233" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_478233_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_478232" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_478233_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_478234" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_478233" xlink:to="loc_us-gaap_EmployeeStockOptionMember_478234" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_478235" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_478233" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_478235" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_478236" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_478233" xlink:to="loc_us-gaap_WarrantMember_478236" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_478238" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meip_PotentiallyDilutiveSecuritiesOutstandingLineItems_478237" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_478238" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/CommitmentsAndContingenciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_271" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_AccruedMilestonePayments" xlink:label="loc_meip_AccruedMilestonePayments_284" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_271" xlink:to="loc_meip_AccruedMilestonePayments_284" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_MilestonePaymentsMaximumAmount" xlink:label="loc_meip_MilestonePaymentsMaximumAmount_285" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_271" xlink:to="loc_meip_MilestonePaymentsMaximumAmount_285" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_PercentageOfPurchasesFromMajorSuppliers" xlink:label="loc_meip_PercentageOfPurchasesFromMajorSuppliers_286" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_271" xlink:to="loc_meip_PercentageOfPurchasesFromMajorSuppliers_286" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_272" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_271" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_272" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_268" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_272" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_268" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_269" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_268" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_269" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_269_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_268" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_269_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_273" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_272" xlink:to="loc_us-gaap_TypeOfArrangementAxis_273" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_267" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_273" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_267" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_267_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_273" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_267_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_CydexLicenseAgreementMember" xlink:label="loc_meip_CydexLicenseAgreementMember_276" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_267" xlink:to="loc_meip_CydexLicenseAgreementMember_276" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_PresageLicenseAgreementMember" xlink:label="loc_meip_PresageLicenseAgreementMember_274" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_267" xlink:to="loc_meip_PresageLicenseAgreementMember_274" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_SbioPurchaseAgreementMember" xlink:label="loc_meip_SbioPurchaseAgreementMember_275" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_267" xlink:to="loc_meip_SbioPurchaseAgreementMember_275" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaap_OtherCommitmentsAxis_478582" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_272" xlink:to="loc_us-gaap_OtherCommitmentsAxis_478582" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaap_OtherCommitmentsDomain_478583" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherCommitmentsAxis_478582" xlink:to="loc_us-gaap_OtherCommitmentsDomain_478583" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaap_OtherCommitmentsDomain_478583_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherCommitmentsAxis_478582" xlink:to="loc_us-gaap_OtherCommitmentsDomain_478583_default" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/LeasesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_504099" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_504096" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_504099" xlink:to="loc_us-gaap_StatementTable_504096" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_504097" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_504096" xlink:to="loc_us-gaap_StatementClassOfStockAxis_504097" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_504098" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_504097" xlink:to="loc_us-gaap_ClassOfStockDomain_504098" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_504098_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_504097" xlink:to="loc_us-gaap_ClassOfStockDomain_504098_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_504111" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_504096" xlink:to="loc_srt_RangeAxis_504111" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_504112" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_504111" xlink:to="loc_srt_RangeMember_504112" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_504112_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_504111" xlink:to="loc_srt_RangeMember_504112_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_504113" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_504112" xlink:to="loc_srt_MinimumMember_504113" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_504114" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_504096" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_504114" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_504115" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_504114" xlink:to="loc_us-gaap_TypeOfAdoptionMember_504115" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_504115_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_504114" xlink:to="loc_us-gaap_TypeOfAdoptionMember_504115_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_504116" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_504115" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_504116" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_504117" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_504096" xlink:to="loc_srt_StatementGeographicalAxis_504117" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_504119" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_504117" xlink:to="loc_srt_SegmentGeographicalDomain_504119" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_504119_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_504117" xlink:to="loc_srt_SegmentGeographicalDomain_504119_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CentralAmericaMember" xlink:label="loc_srt_CentralAmericaMember_504123" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_504119" xlink:to="loc_srt_CentralAmericaMember_504123" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_504127" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_504096" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_504127" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_504129" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_504127" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_504129" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_504129_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_504127" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_504129_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_504140" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_504129" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_504140" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_PropertyPlantAndEquipmentNetMember" xlink:label="loc_meip_PropertyPlantAndEquipmentNetMember_515916" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_504129" xlink:to="loc_meip_PropertyPlantAndEquipmentNetMember_515916" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_504100" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_504099" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_504100" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LandSubjectToGroundLeases" xlink:label="loc_us-gaap_LandSubjectToGroundLeases_504101" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_504099" xlink:to="loc_us-gaap_LandSubjectToGroundLeases_504101" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_504102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_504099" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_504102" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_504103" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_504099" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_504103" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_meip_LesseeOperatingLeaseRemainingLeaseTerm_504104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_504099" xlink:to="loc_meip_LesseeOperatingLeaseRemainingLeaseTerm_504104" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_504106" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_504099" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_504106" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_504107" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_504099" xlink:to="loc_us-gaap_OperatingLeaseLiability_504107" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1" xlink:label="loc_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_504108" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_504099" xlink:to="loc_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_504108" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_504109" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_504099" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_504109" use="optional" order="30" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/ShortTermInvestmentsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_290" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_291" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_290" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_291" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_289" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_291" xlink:to="loc_dei_LegalEntityAxis_289" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_292" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_289" xlink:to="loc_dei_EntityDomain_292" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_292_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_289" xlink:to="loc_dei_EntityDomain_292_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_293" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_290" xlink:to="loc_us-gaap_ShortTermInvestments_293" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/StockholdersEquityAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_296" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_307" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_296" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_307" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_306" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_296" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_306" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_ExerciseOfWarrantsForCommonStock" xlink:label="loc_meip_ExerciseOfWarrantsForCommonStock_310" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_296" xlink:to="loc_meip_ExerciseOfWarrantsForCommonStock_310" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_NumberOfSharesAgreedToBeSoldUnderAgreement" xlink:label="loc_meip_NumberOfSharesAgreedToBeSoldUnderAgreement_314" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_296" xlink:to="loc_meip_NumberOfSharesAgreedToBeSoldUnderAgreement_314" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_311" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_296" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_311" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_SaleOfSharesAndWarrantsUnderAgreement" xlink:label="loc_meip_SaleOfSharesAndWarrantsUnderAgreement_313" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_296" xlink:to="loc_meip_SaleOfSharesAndWarrantsUnderAgreement_313" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_301" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_296" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_301" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_297" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_301" xlink:to="loc_dei_LegalEntityAxis_297" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_316" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_297" xlink:to="loc_dei_EntityDomain_316" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_316_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_297" xlink:to="loc_dei_EntityDomain_316_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_298" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_301" xlink:to="loc_srt_RangeAxis_298" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_299" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_298" xlink:to="loc_srt_RangeMember_299" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_299_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_298" xlink:to="loc_srt_RangeMember_299_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_317" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_299" xlink:to="loc_srt_MaximumMember_317" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_302" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_301" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_302" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_300" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_302" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_300" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_300_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_302" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_300_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_AtTheMarketSaleAgreementMember" xlink:label="loc_meip_AtTheMarketSaleAgreementMember_318" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_300" xlink:to="loc_meip_AtTheMarketSaleAgreementMember_318" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_478572" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_301" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_478572" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_478573" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_478572" xlink:to="loc_us-gaap_RelatedPartyDomain_478573" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_478573_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_478572" xlink:to="loc_us-gaap_RelatedPartyDomain_478573_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_478574" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_301" xlink:to="loc_us-gaap_TypeOfArrangementAxis_478574" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_478576" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_478574" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_478576" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_478576_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_478574" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_478576_default" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_504167" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_301" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_504167" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_504168" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_504167" xlink:to="loc_us-gaap_EquityComponentDomain_504168" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_504168_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_504167" xlink:to="loc_us-gaap_EquityComponentDomain_504168_default" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_504169" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_504168" xlink:to="loc_us-gaap_WarrantMember_504169" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_ShelfRegistrationStatementValue" xlink:label="loc_meip_ShelfRegistrationStatementValue_315" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_296" xlink:to="loc_meip_ShelfRegistrationStatementValue_315" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_304" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_296" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_304" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_309" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_296" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_309" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_478548" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_296" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_478548" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:label="loc_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_478553" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_296" xlink:to="loc_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_478553" use="optional" order="33" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/ShareBasedCompensationAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_339" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_339" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_338" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_338" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_NumberOfSharesToBeReceived" xlink:label="loc_meip_NumberOfSharesToBeReceived_341" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" xlink:to="loc_meip_NumberOfSharesToBeReceived_341" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_326" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_326" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_322" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_326" xlink:to="loc_us-gaap_AwardTypeAxis_322" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_328" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_322" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_328" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_328_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_322" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_328_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_345" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_328" xlink:to="loc_us-gaap_EmployeeStockOptionMember_345" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_346" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_328" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_346" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_323" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_326" xlink:to="loc_srt_RangeAxis_323" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_478618" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_323" xlink:to="loc_srt_RangeMember_478618" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_478618_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_323" xlink:to="loc_srt_RangeMember_478618_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_478619" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_478618" xlink:to="loc_srt_MaximumMember_478619" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_478620" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_478618" xlink:to="loc_srt_MinimumMember_478620" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_324" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_326" xlink:to="loc_us-gaap_PlanNameAxis_324" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_325" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_324" xlink:to="loc_us-gaap_PlanNameDomain_325" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_325_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_324" xlink:to="loc_us-gaap_PlanNameDomain_325_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_TwoThousandAndEightOmnibusPlanMember" xlink:label="loc_meip_TwoThousandAndEightOmnibusPlanMember_332" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_325" xlink:to="loc_meip_TwoThousandAndEightOmnibusPlanMember_332" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_329" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_326" xlink:to="loc_srt_TitleOfIndividualAxis_329" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_330" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_329" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_330" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_330_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_329" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_330_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_347" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_330" xlink:to="loc_srt_DirectorMember_347" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_EmployeesMember" xlink:label="loc_meip_EmployeesMember_348" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_330" xlink:to="loc_meip_EmployeesMember_348" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_336" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_336" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_335" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_335" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_340" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_340" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_342" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_342" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_337" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_337" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_333" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_333" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_334" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_334" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_344" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_344" use="optional" order="31" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/ShareBasedCompensationExpenseForStockAwardsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_351" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_355" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_351" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_355" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_352" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_355" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_352" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_353" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_352" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_353" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_353_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_352" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_353_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_358" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_353" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_358" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_357" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_353" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_357" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_354" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_355" xlink:to="loc_dei_LegalEntityAxis_354" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_359" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_354" xlink:to="loc_dei_EntityDomain_359" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_359_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_354" xlink:to="loc_dei_EntityDomain_359_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_356" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_351" xlink:to="loc_us-gaap_ShareBasedCompensation_356" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/SummaryOfStockOptionActivityDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_365" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_363" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_365" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_363" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_362" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_363" xlink:to="loc_dei_LegalEntityAxis_362" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_369" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_362" xlink:to="loc_dei_EntityDomain_369" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_369_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_362" xlink:to="loc_dei_EntityDomain_369_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_364" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_365" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_364" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_371" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_364" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_371" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_370" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_364" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_370" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_372" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_365" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_372" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_366" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_365" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_366" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_377" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_366" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_377" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_376" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_366" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_376" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_374" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_366" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_374" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_373" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_366" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_373" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_375" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_366" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_375" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_367" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_365" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_367" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_385" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_367" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_385" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_379" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_367" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_379" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_381" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_367" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_381" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_383" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_367" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_383" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_382" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_367" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_382" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_380" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_367" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_380" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="loc_meip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_368" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_365" xlink:to="loc_meip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_368" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_387" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_368" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_387" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_386" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_368" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_386" use="optional" order="24" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/FairValueOfStockOptionsWeightedAverageAssumptionsUsedDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_392" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_391" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_392" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_391" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_390" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_391" xlink:to="loc_dei_LegalEntityAxis_390" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_393" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_390" xlink:to="loc_dei_EntityDomain_393" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_393_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_390" xlink:to="loc_dei_EntityDomain_393_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_311943" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_391" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_311943" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_311944" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_311943" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_311944" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_311944_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_311943" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_311944_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_397" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_392" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_397" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_395" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_392" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_395" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_396" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_392" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_396" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_394" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_392" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_394" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_398" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_392" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_398" use="optional" order="12" />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>meip-20190930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 07-November-2019 [03:35:54] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract" xml:lang="en-US">Cover [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressStateOrProvince" xml:lang="en-US">Entity Address, State or Province</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCurrentReportingStatus" xml:lang="en-US">Entity Current Reporting Status</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityShellCompany" xml:lang="en-US">Entity Shell Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_Security12bTitle" xml:lang="en-US">Title of 12(b) Security</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_SecurityExchangeName" xml:lang="en-US">Security Exchange Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityInteractiveDataCurrent" xml:lang="en-US">Entity Interactive Data Current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">ASSETS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents at beginning of the period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents at end of the period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xml:lang="en-US">Total cash, cash equivalents and short-term investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid expenses and other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermInvestments" xml:lang="en-US">Short-term Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShortTermInvestments" xml:lang="en-US">Short-term investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:label="loc_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xml:lang="en-US">Common Stock, Share Subscribed but Unissued, Subscriptions Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xml:lang="en-US">Common stock proceeds receivable (Note 10)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:to="lab_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Intangible assets, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and contingencies (Note 7)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities and stockholders' equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xml:lang="en-US">Deferred Revenue, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xml:lang="en-US">Deferred revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent" xlink:to="lab_us-gaap_DeferredRevenueCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' equity:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional paid-in-capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, $0.00000002 par value; 226,000 shares authorized; 73,655 and 73,545 shares issued and outstanding at September 30, 2019 and June 30, 2019, respectively</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred stock, $0.01 par value; 100 shares authorized; none outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated Losses Since Inception</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total stockholders' equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xml:lang="en-US">Warrants Not Settleable in Cash, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xml:lang="en-US">Warrant liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xml:lang="en-US">Warrant liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xml:lang="en-US">Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xml:lang="en-US">Ending balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xml:lang="en-US">Fair value of warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:to="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent" xml:lang="en-US">Deferred Revenue, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent" xml:lang="en-US">Deferred revenue, long-term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueNoncurrent" xlink:to="lab_us-gaap_DeferredRevenueNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xml:lang="en-US">Costs and Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xml:lang="en-US">Operating expenses:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xml:lang="en-US">Cost of Goods and Services Sold</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xml:lang="en-US">Cost of revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostsAndExpenses" xml:lang="en-US">Costs and Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CostsAndExpenses" xml:lang="en-US">Total operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Earnings Per Share [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Net loss per share:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Basic and diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xml:lang="en-US">Net loss:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xlink:label="loc_meip_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_meip_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xml:lang="en-US">Net Income Loss Available To Common Stockholders Basic And Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_meip_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xml:lang="en-US">Basic and diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xlink:to="lab_meip_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_meip_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xml:lang="en-US">Net income loss available to common stockholders basic and diluted.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other income (expense):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Change in Unrealized Gain (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xml:lang="en-US">Change in fair value of warrant liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xml:lang="en-US">Change in fair value of warrant liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xml:lang="en-US">Change in estimated fair value of liability classified warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentIncomeInterestAndDividend" xml:lang="en-US">Investment Income, Interest and Dividend</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentIncomeInterestAndDividend" xml:lang="en-US">Interest and dividend income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterestAndDividend" xlink:to="lab_us-gaap_InvestmentIncomeInterestAndDividend" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaap_OtherNonoperatingExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNonoperatingExpense" xml:lang="en-US">Other Nonoperating Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OtherNonoperatingExpense" xml:lang="en-US">Other expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingExpense" xlink:to="lab_us-gaap_OtherNonoperatingExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Revenues" xml:lang="en-US">Revenues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Revenues" xml:lang="en-US">Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_Revenues" xml:lang="en-US">Revenues</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xml:lang="en-US">Shares used in computing net loss per share:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Basic and diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional paid in Capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Accumulated Deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Issuance of common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Common stock Value Issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Exercise of stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Share-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_Stockissuedduringperiodvaluestockwarrantsexercised" xlink:label="loc_meip_Stockissuedduringperiodvaluestockwarrantsexercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_meip_Stockissuedduringperiodvaluestockwarrantsexercised" xml:lang="en-US">StockIssuedDuringPeriodValueStockWarrantsExercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_meip_Stockissuedduringperiodvaluestockwarrantsexercised" xml:lang="en-US">Exercise of warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_Stockissuedduringperiodvaluestockwarrantsexercised" xlink:to="lab_meip_Stockissuedduringperiodvaluestockwarrantsexercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_meip_Stockissuedduringperiodvaluestockwarrantsexercised" xml:lang="en-US">Value of stock issued as a result of the exercise of stock warrants.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xml:lang="en-US">Issuance of common stock for vested restricted stock units</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xml:lang="en-US">Loss Contingency Nature [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xml:lang="en-US">Loss Contingency, Nature [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xml:lang="en-US">Net decrease in cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Cash flows from financing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash provided by financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xml:lang="en-US">Payments Related to Tax Withholding for Share-based Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xml:lang="en-US">Payment of RSU tax withholdings in exchange for common shares surrendered by RSU holders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US">Proceeds from exercise of stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xml:lang="en-US">Proceeds from Warrant Exercises</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xml:lang="en-US">Proceeds from exercise of warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xml:lang="en-US">Proceeds from warrant exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from issuance of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_ProceedsFromPreviouslyIssuedCommonStock" xlink:label="loc_meip_ProceedsFromPreviouslyIssuedCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_meip_ProceedsFromPreviouslyIssuedCommonStock" xml:lang="en-US">Proceeds From Previously Issued Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_meip_ProceedsFromPreviouslyIssuedCommonStock" xml:lang="en-US">Collection of common stock proceeds receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_ProceedsFromPreviouslyIssuedCommonStock" xlink:to="lab_meip_ProceedsFromPreviouslyIssuedCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_meip_ProceedsFromPreviouslyIssuedCommonStock" xml:lang="en-US">Proceeds From Previously Issued Common Stock.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Cash flows from investing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash provided by investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xml:lang="en-US">Payments to Acquire Short-term Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xml:lang="en-US">Purchases of short-term investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Short-term Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xml:lang="en-US">Proceeds from maturity of short-term investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Cash flows from operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation and amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in operating assets and liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Accrued liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xml:lang="en-US">Deferred revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xml:lang="en-US">Net Change</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Prepaid expenses and other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental cash flow information:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xml:lang="en-US">Income Taxes Paid, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xml:lang="en-US">Income taxes paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Non-cash financing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_ChangeInFairValueOfWarrantsExercised" xlink:label="loc_meip_ChangeInFairValueOfWarrantsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_meip_ChangeInFairValueOfWarrantsExercised" xml:lang="en-US">Change in fair value of warrants exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_meip_ChangeInFairValueOfWarrantsExercised" xml:lang="en-US">Change in fair value of warrants exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_ChangeInFairValueOfWarrantsExercised" xlink:to="lab_meip_ChangeInFairValueOfWarrantsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_meip_ChangeInFairValueOfWarrantsExercised" xml:lang="en-US">Represents Change in fair value of warrants exercised.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US">The Company and Summary of Significant Accounting Policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value Measurements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">License Agreements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xml:lang="en-US">BeiGene Collaboration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xml:lang="en-US">Revenue Recognition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Earnings Per Share [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Net Loss Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeasesAbstract" xml:lang="en-US">Leases [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xml:lang="en-US">Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xml:lang="en-US">Short-Term Investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FederalHomeLoanBanksAbstract" xlink:label="loc_us-gaap_FederalHomeLoanBanksAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FederalHomeLoanBanksAbstract" xml:lang="en-US">Federal Home Loan Banks [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalHomeLoanBanksAbstract" xlink:to="lab_us-gaap_FederalHomeLoanBanksAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Share-based Compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Presentation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_ClinicalDevelopmentProgramsPolicyTextBlock" xlink:label="loc_meip_ClinicalDevelopmentProgramsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_meip_ClinicalDevelopmentProgramsPolicyTextBlock" xml:lang="en-US">Clinical Development Programs [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_meip_ClinicalDevelopmentProgramsPolicyTextBlock" xml:lang="en-US">Clinical Development Programs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_ClinicalDevelopmentProgramsPolicyTextBlock" xlink:to="lab_meip_ClinicalDevelopmentProgramsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_meip_ClinicalDevelopmentProgramsPolicyTextBlock" xml:lang="en-US">Clinical development programs.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xml:lang="en-US">Share-based Compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Recent Accounting Pronouncements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue Recognition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_LiquidityPolicyTextBlock" xlink:label="loc_meip_LiquidityPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_meip_LiquidityPolicyTextBlock" xml:lang="en-US">Liquidity [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_meip_LiquidityPolicyTextBlock" xml:lang="en-US">Liquidity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_LiquidityPolicyTextBlock" xlink:to="lab_meip_LiquidityPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_meip_LiquidityPolicyTextBlock" xml:lang="en-US">The Disclosure In Its Entirety Pertaining to the Accounting Policy In Respect Of Liquid Resources Held By The Entity.</label>
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_FairValueOfWarrantLiabilityAssumptionsTableTextBlock" xlink:label="loc_meip_FairValueOfWarrantLiabilityAssumptionsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_meip_FairValueOfWarrantLiabilityAssumptionsTableTextBlock" xml:lang="en-US">Fair Value of Warrant Liability Assumptions [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_meip_FairValueOfWarrantLiabilityAssumptionsTableTextBlock" xml:lang="en-US">Schedule of Assumptions Used to Calculate Fair Value of Warrant Liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_FairValueOfWarrantLiabilityAssumptionsTableTextBlock" xlink:to="lab_meip_FairValueOfWarrantLiabilityAssumptionsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_meip_FairValueOfWarrantLiabilityAssumptionsTableTextBlock" xml:lang="en-US">Fair Value of Warrant Liability Assumptions [Table Text Block]</label>
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_ScheduleOfChangesInFairValueOfWarrantLiabilityTableTextBlock" xlink:label="loc_meip_ScheduleOfChangesInFairValueOfWarrantLiabilityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_meip_ScheduleOfChangesInFairValueOfWarrantLiabilityTableTextBlock" xml:lang="en-US">Schedule Of Changes In Fair Value Of Warrant Liability [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_meip_ScheduleOfChangesInFairValueOfWarrantLiabilityTableTextBlock" xml:lang="en-US">Schedule of Changes in Estimated Fair Value of Warrant Liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_ScheduleOfChangesInFairValueOfWarrantLiabilityTableTextBlock" xlink:to="lab_meip_ScheduleOfChangesInFairValueOfWarrantLiabilityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_meip_ScheduleOfChangesInFairValueOfWarrantLiabilityTableTextBlock" xml:lang="en-US">Schedule Of Changes In Fair Value Of Warrant Liability [Table Text Block]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xml:lang="en-US">Schedule of Financial Instruments Measured at Fair Value on Recurring Basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_ScheduleOfRevenueAssociatedWithLicenseAgreementTableTextBlock" xlink:label="loc_meip_ScheduleOfRevenueAssociatedWithLicenseAgreementTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_meip_ScheduleOfRevenueAssociatedWithLicenseAgreementTableTextBlock" xml:lang="en-US">Schedule Of Revenue Associated With License Agreement [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_meip_ScheduleOfRevenueAssociatedWithLicenseAgreementTableTextBlock" xml:lang="en-US">Schedule Of Revenue Associated With License Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_ScheduleOfRevenueAssociatedWithLicenseAgreementTableTextBlock" xlink:to="lab_meip_ScheduleOfRevenueAssociatedWithLicenseAgreementTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_meip_ScheduleOfRevenueAssociatedWithLicenseAgreementTableTextBlock" xml:lang="en-US">Schedule Of Revenue Associated With License Agreement</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xml:lang="en-US">Contract with Customer, Asset and Liability [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xml:lang="en-US">Schedule of Changes in Contract Assets and Contract Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Antidilutive Securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xml:lang="en-US">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xml:lang="en-US">Summary of Stock Option Activity and Related Data</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xml:lang="en-US">Share-Based Compensation Expense for Stock Awards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Fair Value of Stock Options Weighted-Average Assumptions Used</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_AssetsAndLiabilitiesEliminatedUponConsolidationAbstract" xlink:label="loc_meip_AssetsAndLiabilitiesEliminatedUponConsolidationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_meip_AssetsAndLiabilitiesEliminatedUponConsolidationAbstract" xml:lang="en-US">Assets and Liabilities Eliminated upon Consolidation [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_AssetsAndLiabilitiesEliminatedUponConsolidationAbstract" xlink:to="lab_meip_AssetsAndLiabilitiesEliminatedUponConsolidationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_meip_AssetsAndLiabilitiesEliminatedUponConsolidationAbstract" xml:lang="en-US">Assets and Liabilities Eliminated upon Consolidation [Abstract]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TargetedOrTrackingStockStockTable" xlink:label="loc_us-gaap_TargetedOrTrackingStockStockTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TargetedOrTrackingStockStockTable" xml:lang="en-US">Targeted or Tracking Stock, Stock [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TargetedOrTrackingStockStockTable" xml:lang="en-US">Targeted or Tracking Stock, Stock [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockTable" xlink:to="lab_us-gaap_TargetedOrTrackingStockStockTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TargetedOrTrackingStockStockLineItems" xlink:label="loc_us-gaap_TargetedOrTrackingStockStockLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TargetedOrTrackingStockStockLineItems" xml:lang="en-US">Targeted or Tracking Stock, Stock [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TargetedOrTrackingStockStockLineItems" xml:lang="en-US">Targeted or Tracking Stock, Stock [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockLineItems" xlink:to="lab_us-gaap_TargetedOrTrackingStockStockLineItems" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_NumberOfCandidateInAnOngoingGlobalRegistrationTrial" xlink:label="loc_meip_NumberOfCandidateInAnOngoingGlobalRegistrationTrial" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_meip_NumberOfCandidateInAnOngoingGlobalRegistrationTrial" xml:lang="en-US">Number of Candidate in an Ongoing Global Registration Trial</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_meip_NumberOfCandidateInAnOngoingGlobalRegistrationTrial" xml:lang="en-US">Number of candidate in an ongoing global registration trial</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_NumberOfCandidateInAnOngoingGlobalRegistrationTrial" xlink:to="lab_meip_NumberOfCandidateInAnOngoingGlobalRegistrationTrial" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_meip_NumberOfCandidateInAnOngoingGlobalRegistrationTrial" xml:lang="en-US">Number of candidate in an ongoing global registration trial.</label>
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_NumberOfClinicalStageCandidates" xlink:label="loc_meip_NumberOfClinicalStageCandidates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_meip_NumberOfClinicalStageCandidates" xml:lang="en-US">Number of Clinical Stage Candidates</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_meip_NumberOfClinicalStageCandidates" xml:lang="en-US">Number of clinical stage candidates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_NumberOfClinicalStageCandidates" xlink:to="lab_meip_NumberOfClinicalStageCandidates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_meip_NumberOfClinicalStageCandidates" xml:lang="en-US">Number of clinical stage candidates.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Unrecognized Tax Benefits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Unrecognized tax benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_CashAndCashEquivalentsshortTermInvestmentsAndCommonStockProceedsReceivable" xlink:label="loc_meip_CashAndCashEquivalentsshortTermInvestmentsAndCommonStockProceedsReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_meip_CashAndCashEquivalentsshortTermInvestmentsAndCommonStockProceedsReceivable" xml:lang="en-US">Cash And Cash EquivalentsShort Term Investments And Common Stock Proceeds Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_meip_CashAndCashEquivalentsshortTermInvestmentsAndCommonStockProceedsReceivable" xml:lang="en-US">Cash And Cash Equivalents,Short Term Investments And Common Stock Proceeds Receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_CashAndCashEquivalentsshortTermInvestmentsAndCommonStockProceedsReceivable" xlink:to="lab_meip_CashAndCashEquivalentsshortTermInvestmentsAndCommonStockProceedsReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_meip_CashAndCashEquivalentsshortTermInvestmentsAndCommonStockProceedsReceivable" xml:lang="en-US">Represents Cash And Cash Equivalents,Short Term Investments And Proceeds Receivable From The Sale Of Common Stock</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Range [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Range</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Range [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Range [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xml:lang="en-US">Type of Adoption [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xml:lang="en-US">Total liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Level 3</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xml:lang="en-US">Measurement Frequency [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xml:lang="en-US">Measurement Frequency [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xml:lang="en-US">Measurement Input Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xml:lang="en-US">Measurement Input Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xml:lang="en-US">Measurement Input Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xml:lang="en-US">Measurement Input Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xml:lang="en-US">Dividend Yield</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xml:lang="en-US">Measurement Input, Expected Term [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xml:lang="en-US">Expected life years</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xml:lang="en-US">Measurement Input, Price Volatility [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xml:lang="en-US">Expected volatility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xml:lang="en-US">Risk Free Interest Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="loc_us-gaap_MeasurementInputExercisePriceMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputExercisePriceMember" xml:lang="en-US">Measurement Input, Exercise Price [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputExercisePriceMember" xml:lang="en-US">Black-Scholes Fair Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExercisePriceMember" xlink:to="lab_us-gaap_MeasurementInputExercisePriceMember" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_FairValueMeasurementsSignificantUnobservableInputsTable" xlink:label="loc_meip_FairValueMeasurementsSignificantUnobservableInputsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_meip_FairValueMeasurementsSignificantUnobservableInputsTable" xml:lang="en-US">Fair Value Measurements, Significant Unobservable Inputs [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_meip_FairValueMeasurementsSignificantUnobservableInputsTable" xml:lang="en-US">Fair value measurements Significant unobservable inputs [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_FairValueMeasurementsSignificantUnobservableInputsTable" xlink:to="lab_meip_FairValueMeasurementsSignificantUnobservableInputsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_meip_FairValueMeasurementsSignificantUnobservableInputsTable" xml:lang="en-US">Schedule of fair value measurements significant unobservable inputs.</label>
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_FairValueMeasurementsSignificantUnobservableInputsLineItems" xlink:label="loc_meip_FairValueMeasurementsSignificantUnobservableInputsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_meip_FairValueMeasurementsSignificantUnobservableInputsLineItems" xml:lang="en-US">Fair Value Measurements, Significant Unobservable Inputs [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_meip_FairValueMeasurementsSignificantUnobservableInputsLineItems" xml:lang="en-US">Fair value measurements Significant unobservable inputs [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_FairValueMeasurementsSignificantUnobservableInputsLineItems" xlink:to="lab_meip_FairValueMeasurementsSignificantUnobservableInputsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_meip_FairValueMeasurementsSignificantUnobservableInputsLineItems" xml:lang="en-US">Fair Value Measurements, Significant Unobservable Inputs [Line Items]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xml:lang="en-US">Reclassification of warrant liability to equity upon exercise of warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_KyowaKirinCoMember" xlink:label="loc_meip_KyowaKirinCoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_meip_KyowaKirinCoMember" xml:lang="en-US">Kyowa Kirin Co [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_meip_KyowaKirinCoMember" xml:lang="en-US">Kyowa Kirin Co</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_KyowaKirinCoMember" xlink:to="lab_meip_KyowaKirinCoMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xml:lang="en-US">Related Party Transaction [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xml:lang="en-US">Related Party Transactions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xml:lang="en-US">Related Party Transaction [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xml:lang="en-US">Related Party Transaction [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_IncrementalPaymentMember" xlink:label="loc_meip_IncrementalPaymentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_meip_IncrementalPaymentMember" xml:lang="en-US">Incremental Payment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_meip_IncrementalPaymentMember" xml:lang="en-US">Incremental Payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_IncrementalPaymentMember" xlink:to="lab_meip_IncrementalPaymentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_meip_IncrementalPaymentMember" xml:lang="en-US">Incremental Payment.</label>
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_PotentialPaymentsOnAchievementOfDevelopmentRegulatoryAndCommercialMilestonesMember" xlink:label="loc_meip_PotentialPaymentsOnAchievementOfDevelopmentRegulatoryAndCommercialMilestonesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_meip_PotentialPaymentsOnAchievementOfDevelopmentRegulatoryAndCommercialMilestonesMember" xml:lang="en-US">Potential Payments on Achievement of Development Regulatory and Commercial Milestones [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_meip_PotentialPaymentsOnAchievementOfDevelopmentRegulatoryAndCommercialMilestonesMember" xml:lang="en-US">Potential Payments on Achievement of Development Regulatory and Commercial Milestones</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_PotentialPaymentsOnAchievementOfDevelopmentRegulatoryAndCommercialMilestonesMember" xlink:to="lab_meip_PotentialPaymentsOnAchievementOfDevelopmentRegulatoryAndCommercialMilestonesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_meip_PotentialPaymentsOnAchievementOfDevelopmentRegulatoryAndCommercialMilestonesMember" xml:lang="en-US">Potential payments on achievement of development regulatory and commercial milestones.</label>
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_PotentialRegulatoryAndSalesbasedMilestonePaymentMember" xlink:label="loc_meip_PotentialRegulatoryAndSalesbasedMilestonePaymentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_meip_PotentialRegulatoryAndSalesbasedMilestonePaymentMember" xml:lang="en-US">Potential Regulatory and Sales-Based Milestone Payment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_meip_PotentialRegulatoryAndSalesbasedMilestonePaymentMember" xml:lang="en-US">Potential Regulatory and Sales-Based Milestone Payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_PotentialRegulatoryAndSalesbasedMilestonePaymentMember" xlink:to="lab_meip_PotentialRegulatoryAndSalesbasedMilestonePaymentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_meip_PotentialRegulatoryAndSalesbasedMilestonePaymentMember" xml:lang="en-US">Potential regulatory and sales-based milestone payment.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xml:lang="en-US">Related Party Transaction [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xml:lang="en-US">Related Party Transaction [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_AgreementTerminationNoticePeriod" xlink:label="loc_meip_AgreementTerminationNoticePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_meip_AgreementTerminationNoticePeriod" xml:lang="en-US">Agreement Termination Notice Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_meip_AgreementTerminationNoticePeriod" xml:lang="en-US">License and supply agreement notice period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_AgreementTerminationNoticePeriod" xlink:to="lab_meip_AgreementTerminationNoticePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_meip_AgreementTerminationNoticePeriod" xml:lang="en-US">Agreement termination notice period.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xml:lang="en-US">Due to Related Parties</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xml:lang="en-US">Compensation payable for grant of rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_LicenseAgreementExpiryPeriod" xlink:label="loc_meip_LicenseAgreementExpiryPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_meip_LicenseAgreementExpiryPeriod" xml:lang="en-US">License Agreement Expiry Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_meip_LicenseAgreementExpiryPeriod" xml:lang="en-US">License agreement expiry period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_LicenseAgreementExpiryPeriod" xlink:to="lab_meip_LicenseAgreementExpiryPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_meip_LicenseAgreementExpiryPeriod" xml:lang="en-US">License agreement expiry period.</label>
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_PaymentForLicenseAgreement" xlink:label="loc_meip_PaymentForLicenseAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_meip_PaymentForLicenseAgreement" xml:lang="en-US">Payment For License Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_meip_PaymentForLicenseAgreement" xml:lang="en-US">Payment for license</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_PaymentForLicenseAgreement" xlink:to="lab_meip_PaymentForLicenseAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_meip_PaymentForLicenseAgreement" xml:lang="en-US">Payment for license agreement.</label>
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_PaymentRelatedToDevelopmentAndCommercialMilestonePayments" xlink:label="loc_meip_PaymentRelatedToDevelopmentAndCommercialMilestonePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_meip_PaymentRelatedToDevelopmentAndCommercialMilestonePayments" xml:lang="en-US">Payment Related to Development and Commercial Milestone Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_meip_PaymentRelatedToDevelopmentAndCommercialMilestonePayments" xml:lang="en-US">Development and commercialization milestones payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_PaymentRelatedToDevelopmentAndCommercialMilestonePayments" xlink:to="lab_meip_PaymentRelatedToDevelopmentAndCommercialMilestonePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_meip_PaymentRelatedToDevelopmentAndCommercialMilestonePayments" xml:lang="en-US">Payment Related to Development and Commercial Milestone Payments</label>
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_PercentageOfPurchasesFromMajorSuppliers" xlink:label="loc_meip_PercentageOfPurchasesFromMajorSuppliers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_meip_PercentageOfPurchasesFromMajorSuppliers" xml:lang="en-US">Percentage of Purchases from Major Suppliers</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_meip_PercentageOfPurchasesFromMajorSuppliers" xml:lang="en-US">Percentage of Purchase Requirement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_PercentageOfPurchasesFromMajorSuppliers" xlink:to="lab_meip_PercentageOfPurchasesFromMajorSuppliers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_meip_PercentageOfPurchasesFromMajorSuppliers" xml:lang="en-US">Percentage of purchases from major suppliers.</label>
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_PotentialMilestonePaymentsPayable" xlink:label="loc_meip_PotentialMilestonePaymentsPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_meip_PotentialMilestonePaymentsPayable" xml:lang="en-US">Potential Milestone Payments Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_meip_PotentialMilestonePaymentsPayable" xml:lang="en-US">Milestone payments payable amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_PotentialMilestonePaymentsPayable" xlink:to="lab_meip_PotentialMilestonePaymentsPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_meip_PotentialMilestonePaymentsPayable" xml:lang="en-US">Potential milestone payments payable.</label>
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_PotentialMilestonePaymentsReceivable" xlink:label="loc_meip_PotentialMilestonePaymentsReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_meip_PotentialMilestonePaymentsReceivable" xml:lang="en-US">Potential Milestone Payments Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_meip_PotentialMilestonePaymentsReceivable" xml:lang="en-US">Milestone payment receivable amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_PotentialMilestonePaymentsReceivable" xlink:to="lab_meip_PotentialMilestonePaymentsReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_meip_PotentialMilestonePaymentsReceivable" xml:lang="en-US">Potential milestone payments receivable.</label>
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_UpFrontPayment" xlink:label="loc_meip_UpFrontPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_meip_UpFrontPayment" xml:lang="en-US">Up Front Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_meip_UpFrontPayment" xml:lang="en-US">Upfront payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_UpFrontPayment" xlink:to="lab_meip_UpFrontPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_meip_UpFrontPayment" xml:lang="en-US">Up Front Payment</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="loc_us-gaap_ProceedsFromLicenseFeesReceived" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromLicenseFeesReceived" xml:lang="en-US">Proceeds from License Fees Received</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromLicenseFeesReceived" xml:lang="en-US">Compensation Receivable For Grant Of Rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLicenseFeesReceived" xlink:to="lab_us-gaap_ProceedsFromLicenseFeesReceived" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_PresageBiosciencesIncMember" xlink:label="loc_meip_PresageBiosciencesIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_meip_PresageBiosciencesIncMember" xml:lang="en-US">Presage Biosciences Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_meip_PresageBiosciencesIncMember" xml:lang="en-US">Presage Biosciences, Inc.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_PresageBiosciencesIncMember" xlink:to="lab_meip_PresageBiosciencesIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_meip_PresageBiosciencesIncMember" xml:lang="en-US">Presage Biosciences Inc.</label>
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_HelsinnLicenseAgreementMember" xlink:label="loc_meip_HelsinnLicenseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_meip_HelsinnLicenseAgreementMember" xml:lang="en-US">Helsinn License Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_meip_HelsinnLicenseAgreementMember" xml:lang="en-US">Helsinn License Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_meip_HelsinnLicenseAgreementMember" xml:lang="en-US">Helsinn License Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_HelsinnLicenseAgreementMember" xlink:to="lab_meip_HelsinnLicenseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_meip_HelsinnLicenseAgreementMember" xml:lang="en-US">Helsinn license agreement.</label>
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_PresageLicenseAgreementMember" xlink:label="loc_meip_PresageLicenseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_meip_PresageLicenseAgreementMember" xml:lang="en-US">Presage License Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_meip_PresageLicenseAgreementMember" xml:lang="en-US">Presage License Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_PresageLicenseAgreementMember" xlink:to="lab_meip_PresageLicenseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_meip_PresageLicenseAgreementMember" xml:lang="en-US">Presage License Agreement.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisaggregationOfRevenueAbstract" xml:lang="en-US">Disaggregation of Revenue [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract" xlink:to="lab_us-gaap_DisaggregationOfRevenueAbstract" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_RevenuePerformanceObligationAmount" xlink:label="loc_meip_RevenuePerformanceObligationAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_meip_RevenuePerformanceObligationAmount" xml:lang="en-US">Revenue Performance Obligation Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_meip_RevenuePerformanceObligationAmount" xml:lang="en-US">Revenue Recognised With Performance Obligation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_RevenuePerformanceObligationAmount" xlink:to="lab_meip_RevenuePerformanceObligationAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_meip_RevenuePerformanceObligationAmount" xml:lang="en-US">Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xml:lang="en-US">Deferred Revenue Associated With Remaining Performance Obligation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xml:lang="en-US">Recognition Of Deferred Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:to="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_AdditionalRecognitionOfDeferredRevenue" xlink:label="loc_meip_AdditionalRecognitionOfDeferredRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_meip_AdditionalRecognitionOfDeferredRevenue" xml:lang="en-US">Additional Recognition Of Deferred Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_meip_AdditionalRecognitionOfDeferredRevenue" xml:lang="en-US">Additional Recognition Of Deferred Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_AdditionalRecognitionOfDeferredRevenue" xlink:to="lab_meip_AdditionalRecognitionOfDeferredRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_meip_AdditionalRecognitionOfDeferredRevenue" xml:lang="en-US">The amount of additionally reported deferred or unearned revenue that was recognized as revenue during the period.</label>
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_KHKLicenseAgreementMember" xlink:label="loc_meip_KHKLicenseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_meip_KHKLicenseAgreementMember" xml:lang="en-US">KHK License Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_meip_KHKLicenseAgreementMember" xml:lang="en-US">KHK License Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_meip_KHKLicenseAgreementMember" xml:lang="en-US">KKC License Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_KHKLicenseAgreementMember" xlink:to="lab_meip_KHKLicenseAgreementMember" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsAbstract" xlink:label="loc_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsAbstract" xml:lang="en-US">Recognized Revenue Associated with The Following License Agreements [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsAbstract" xlink:to="lab_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsAbstract" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsTable" xlink:label="loc_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsTable" xml:lang="en-US">Recognized Revenue Associated with The Following License Agreements [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsTable" xlink:to="lab_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsTable" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsLineItems" xlink:label="loc_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsLineItems" xml:lang="en-US">Recognized Revenue Associated with The Following License Agreements [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsLineItems" xlink:to="lab_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xml:lang="en-US">Timing of Transfer of Good or Service [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:to="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xml:lang="en-US">Timing of Transfer of Good or Service [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:to="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityAbstract" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityAbstract" xml:lang="en-US">Contract with Customer, Asset and Liability [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityAbstract" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityAbstract" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_ContractWithCustomerAssetAndLiabilityTable" xlink:label="loc_meip_ContractWithCustomerAssetAndLiabilityTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_meip_ContractWithCustomerAssetAndLiabilityTable" xml:lang="en-US">Contract with Customer Asset and Liability [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_meip_ContractWithCustomerAssetAndLiabilityTable" xml:lang="en-US">Contract with Customer Asset and Liability [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_ContractWithCustomerAssetAndLiabilityTable" xlink:to="lab_meip_ContractWithCustomerAssetAndLiabilityTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_meip_ContractWithCustomerAssetAndLiabilityTable" xml:lang="en-US">Contract with customer asset and liability.</label>
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_ContractWithCustomerAssetAndLiabilityLineItems" xlink:label="loc_meip_ContractWithCustomerAssetAndLiabilityLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_meip_ContractWithCustomerAssetAndLiabilityLineItems" xml:lang="en-US">Contract with Customer Asset and Liability [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_meip_ContractWithCustomerAssetAndLiabilityLineItems" xml:lang="en-US">Contract with Customer Asset and Liability [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_ContractWithCustomerAssetAndLiabilityLineItems" xlink:to="lab_meip_ContractWithCustomerAssetAndLiabilityLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_meip_ContractWithCustomerAssetAndLiabilityLineItems" xml:lang="en-US">Contract with customer asset and liability Line items.</label>
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_AccountsReceivableNetBeginningBalance" xlink:label="loc_meip_AccountsReceivableNetBeginningBalance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_meip_AccountsReceivableNetBeginningBalance" xml:lang="en-US">Accounts Receivable Net Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_meip_AccountsReceivableNetBeginningBalance" xml:lang="en-US">Receivables Beginning Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_AccountsReceivableNetBeginningBalance" xlink:to="lab_meip_AccountsReceivableNetBeginningBalance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_meip_AccountsReceivableNetBeginningBalance" xml:lang="en-US">Accounts receivable net beginning balance.</label>
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_AccountsReceivableNetEndingBalance" xlink:label="loc_meip_AccountsReceivableNetEndingBalance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_meip_AccountsReceivableNetEndingBalance" xml:lang="en-US">Accounts Receivable Net Ending Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_meip_AccountsReceivableNetEndingBalance" xml:lang="en-US">Receivables Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_AccountsReceivableNetEndingBalance" xlink:to="lab_meip_AccountsReceivableNetEndingBalance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_meip_AccountsReceivableNetEndingBalance" xml:lang="en-US">Accounts receivable net ending balance.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xml:lang="en-US">Contract with Customer, Asset, Net, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xml:lang="en-US">Contract Assets Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xml:lang="en-US">Contract Assets Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xml:lang="en-US">Contract with Customer, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xml:lang="en-US">Contract Liabilities Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xml:lang="en-US">Contract Liabilities Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xml:lang="en-US">Net Change</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xml:lang="en-US">Increase (Decrease) in Receivables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xml:lang="en-US">Net Change</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInReceivables" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_PotentiallyDilutiveSecuritiesOutstandingLineItems" xlink:label="loc_meip_PotentiallyDilutiveSecuritiesOutstandingLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_meip_PotentiallyDilutiveSecuritiesOutstandingLineItems" xml:lang="en-US">Potentially Dilutive Securities Outstanding [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_meip_PotentiallyDilutiveSecuritiesOutstandingLineItems" xml:lang="en-US">Potentially Dilutive Securities Outstanding [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_PotentiallyDilutiveSecuritiesOutstandingLineItems" xlink:to="lab_meip_PotentiallyDilutiveSecuritiesOutstandingLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_meip_PotentiallyDilutiveSecuritiesOutstandingLineItems" xml:lang="en-US">Potentially Dilutive Securities Outstanding [Line Items]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xml:lang="en-US">Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xml:lang="en-US">Common stock subject to repurchase or forfeiture</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Employee Stock Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Employee Stock option</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Employee Stock Option</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xml:lang="en-US">Restricted Stock Units (RSUs)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantMember" xml:lang="en-US">Warrant [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WarrantMember" xml:lang="en-US">Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Total anti-dilutive shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" xlink:to="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseArrangementTypeAxis" xml:lang="en-US">Lease Arrangement, Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseArrangementTypeAxis" xml:lang="en-US">Lease Arrangement, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis" xlink:to="lab_us-gaap_LeaseArrangementTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseArrangementTypeDomain" xml:lang="en-US">Lease Arrangement, Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseArrangementTypeDomain" xml:lang="en-US">Lease Arrangement, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain" xlink:to="lab_us-gaap_LeaseArrangementTypeDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" xlink:to="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_AccruedMilestonePayments" xlink:label="loc_meip_AccruedMilestonePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_meip_AccruedMilestonePayments" xml:lang="en-US">Accrued Milestone Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_meip_AccruedMilestonePayments" xml:lang="en-US">Accrued payment for potential future payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_AccruedMilestonePayments" xlink:to="lab_meip_AccruedMilestonePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_meip_AccruedMilestonePayments" xml:lang="en-US">Accrued milestone payments.</label>
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_MilestonePaymentsMaximumAmount" xlink:label="loc_meip_MilestonePaymentsMaximumAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_meip_MilestonePaymentsMaximumAmount" xml:lang="en-US">Milestone Payments, Maximum Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_meip_MilestonePaymentsMaximumAmount" xml:lang="en-US">Future aggregate milestone payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_MilestonePaymentsMaximumAmount" xlink:to="lab_meip_MilestonePaymentsMaximumAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_meip_MilestonePaymentsMaximumAmount" xml:lang="en-US">Milestone payments, maximum amount.</label>
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_CydexLicenseAgreementMember" xlink:label="loc_meip_CydexLicenseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_meip_CydexLicenseAgreementMember" xml:lang="en-US">CyDex License Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_meip_CydexLicenseAgreementMember" xml:lang="en-US">CyDex License Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_CydexLicenseAgreementMember" xlink:to="lab_meip_CydexLicenseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_meip_CydexLicenseAgreementMember" xml:lang="en-US">CyDex License Agreement.</label>
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_SbioPurchaseAgreementMember" xlink:label="loc_meip_SbioPurchaseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_meip_SbioPurchaseAgreementMember" xml:lang="en-US">SBio Purchase Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_meip_SbioPurchaseAgreementMember" xml:lang="en-US">S*Bio Purchase Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_SbioPurchaseAgreementMember" xlink:to="lab_meip_SbioPurchaseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_meip_SbioPurchaseAgreementMember" xml:lang="en-US">S Bio Purchase Agreement.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaap_OtherCommitmentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xml:lang="en-US">Other Commitments [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsAxis" xlink:to="lab_us-gaap_OtherCommitmentsAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaap_OtherCommitmentsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xml:lang="en-US">Other Commitments [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsDomain" xlink:to="lab_us-gaap_OtherCommitmentsDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xml:lang="en-US">Lease Term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LandSubjectToGroundLeases" xlink:label="loc_us-gaap_LandSubjectToGroundLeases" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LandSubjectToGroundLeases" xml:lang="en-US">Land Subject to Ground Leases</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LandSubjectToGroundLeases" xml:lang="en-US">Area Of Land Subject To Lease</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandSubjectToGroundLeases" xlink:to="lab_us-gaap_LandSubjectToGroundLeases" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xml:lang="en-US">Operating Lease Remaining minimum Lease Payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xml:lang="en-US">Operating Lease Discount Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="lab_us-gaap_LesseeOperatingLeaseDiscountRate" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_meip_LesseeOperatingLeaseRemainingLeaseTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_meip_LesseeOperatingLeaseRemainingLeaseTerm" xml:lang="en-US">Lessee Operating Lease Remaining Lease Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_meip_LesseeOperatingLeaseRemainingLeaseTerm" xml:lang="en-US">Operating Lease Remaining Lease Term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_meip_LesseeOperatingLeaseRemainingLeaseTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_meip_LesseeOperatingLeaseRemainingLeaseTerm" xml:lang="en-US">Lessee Operating Lease Remaining Lease Term</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Right Of Use Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Operating Lease, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Lease Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1" xlink:label="loc_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1" xml:lang="en-US">Cumulative Effect on Retained Earnings, Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1" xml:lang="en-US">Cumulative Adjustment To Retained Earnings</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1" xlink:to="lab_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xml:lang="en-US">Operating Leases, Future Minimum Payments, Remainder of Fiscal Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xml:lang="en-US">Operating lease Minimum Lease Payments Remaining</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementGeographicalAxis" xml:lang="en-US">Geographical [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_SegmentGeographicalDomain" xml:lang="en-US">Geographical [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CentralAmericaMember" xlink:label="loc_srt_CentralAmericaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_CentralAmericaMember" xml:lang="en-US">Central America [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_CentralAmericaMember" xml:lang="en-US">CA</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CentralAmericaMember" xlink:to="lab_srt_CentralAmericaMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xml:lang="en-US">Balance Sheet Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xml:lang="en-US">Balance Sheet Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xml:lang="en-US">Accrued Liabilities [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesMember" xlink:to="lab_us-gaap_AccruedLiabilitiesMember" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_PropertyPlantAndEquipmentNetMember" xlink:label="loc_meip_PropertyPlantAndEquipmentNetMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_meip_PropertyPlantAndEquipmentNetMember" xml:lang="en-US">Property Plant and Equipment Net [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_PropertyPlantAndEquipmentNetMember" xlink:to="lab_meip_PropertyPlantAndEquipmentNetMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_meip_PropertyPlantAndEquipmentNetMember" xml:lang="en-US">Property, plant and equipment, net [member]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xml:lang="en-US">Schedule of Equity Method Investments [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xml:lang="en-US">Schedule of Equity Method Investments [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityAbstract" xml:lang="en-US">Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US">Schedule of Stock by Class [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US">Schedule of Stock by Class [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockLineItems" xml:lang="en-US">Class of Stock [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfStockLineItems" xml:lang="en-US">Class of Stock [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Exercise price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Warrants outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_ExerciseOfWarrantsForCommonStock" xlink:label="loc_meip_ExerciseOfWarrantsForCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_meip_ExerciseOfWarrantsForCommonStock" xml:lang="en-US">Exercise Of Warrants For Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_meip_ExerciseOfWarrantsForCommonStock" xml:lang="en-US">Warrants exercised for common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_ExerciseOfWarrantsForCommonStock" xlink:to="lab_meip_ExerciseOfWarrantsForCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_meip_ExerciseOfWarrantsForCommonStock" xml:lang="en-US">Exercise Of Warrants For Common Stock</label>
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_NumberOfSharesAgreedToBeSoldUnderAgreement" xlink:label="loc_meip_NumberOfSharesAgreedToBeSoldUnderAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_meip_NumberOfSharesAgreedToBeSoldUnderAgreement" xml:lang="en-US">Number of Shares Agreed to be Sold Under Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_meip_NumberOfSharesAgreedToBeSoldUnderAgreement" xml:lang="en-US">Sale of shares under agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_NumberOfSharesAgreedToBeSoldUnderAgreement" xlink:to="lab_meip_NumberOfSharesAgreedToBeSoldUnderAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_meip_NumberOfSharesAgreedToBeSoldUnderAgreement" xml:lang="en-US">Number of Shares Agreed to be Sold Under Agreement</label>
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_SaleOfSharesAndWarrantsUnderAgreement" xlink:label="loc_meip_SaleOfSharesAndWarrantsUnderAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_meip_SaleOfSharesAndWarrantsUnderAgreement" xml:lang="en-US">Sale Of Shares And Warrants Under Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_meip_SaleOfSharesAndWarrantsUnderAgreement" xml:lang="en-US">Sale of shares and warrants under agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_SaleOfSharesAndWarrantsUnderAgreement" xlink:to="lab_meip_SaleOfSharesAndWarrantsUnderAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_meip_SaleOfSharesAndWarrantsUnderAgreement" xml:lang="en-US">Sale of shares and warrants under agreement.</label>
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_ShelfRegistrationStatementValue" xlink:label="loc_meip_ShelfRegistrationStatementValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_meip_ShelfRegistrationStatementValue" xml:lang="en-US">Shelf Registration Statement Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_meip_ShelfRegistrationStatementValue" xml:lang="en-US">Aggregate value of securities available under shelf registration statement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_ShelfRegistrationStatementValue" xlink:to="lab_meip_ShelfRegistrationStatementValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_meip_ShelfRegistrationStatementValue" xml:lang="en-US">Represents Shelf registration statement value.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Common stock share issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_AtTheMarketSaleAgreementMember" xlink:label="loc_meip_AtTheMarketSaleAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_meip_AtTheMarketSaleAgreementMember" xml:lang="en-US">At The Market Sale Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_meip_AtTheMarketSaleAgreementMember" xml:lang="en-US">ATM Sales Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_AtTheMarketSaleAgreementMember" xlink:to="lab_meip_AtTheMarketSaleAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_meip_AtTheMarketSaleAgreementMember" xml:lang="en-US">At-the-market equity offering sales agreement.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Equity Award [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Equity Award [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_TwoThousandAndEightOmnibusPlanMember" xlink:label="loc_meip_TwoThousandAndEightOmnibusPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_meip_TwoThousandAndEightOmnibusPlanMember" xml:lang="en-US">Two Thousand And Eight Omnibus Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_meip_TwoThousandAndEightOmnibusPlanMember" xml:lang="en-US">2008 Omnibus Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_TwoThousandAndEightOmnibusPlanMember" xlink:to="lab_meip_TwoThousandAndEightOmnibusPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_meip_TwoThousandAndEightOmnibusPlanMember" xml:lang="en-US">Two thousand and eight omnibus plan.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Expected weighted average period for recognition of compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US">Unrecognized compensation expense related to unvested stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_NumberOfSharesToBeReceived" xlink:label="loc_meip_NumberOfSharesToBeReceived" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_meip_NumberOfSharesToBeReceived" xml:lang="en-US">Number of Shares to be Received</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_meip_NumberOfSharesToBeReceived" xml:lang="en-US">Number of common stock to be received for each RSUs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_NumberOfSharesToBeReceived" xlink:to="lab_meip_NumberOfSharesToBeReceived" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_meip_NumberOfSharesToBeReceived" xml:lang="en-US">Number of shares to be received.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, award vesting period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xml:lang="en-US">Stock option vested percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">RSUs granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">RSUs grant date fair value per unit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, expiration period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xml:lang="en-US">Common stock authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US">Shares available for future grant</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xml:lang="en-US">Shares Paid for Tax Withholding for Share Based Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xml:lang="en-US">Shares withheld to satisfy tax withholding obligations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Title of Individual [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Relationship to Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_DirectorMember" xml:lang="en-US">Director [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_DirectorMember" xml:lang="en-US">Directors</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_EmployeesMember" xlink:label="loc_meip_EmployeesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_meip_EmployeesMember" xml:lang="en-US">Employees [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_meip_EmployeesMember" xml:lang="en-US">Employees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_EmployeesMember" xlink:to="lab_meip_EmployeesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_meip_EmployeesMember" xml:lang="en-US">Employees.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and Administrative Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xml:lang="en-US">Aggregate Intrinsic Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Vested and exercisable at end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Outstanding at end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Vested and exercisable at end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Number of Options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xml:lang="en-US">Expired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Forfeited / Cancelled</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xml:lang="en-US">Weighted- Average Exercise Price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Vested and exercisable at end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Expired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Forfeited / Cancelled</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="loc_meip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_meip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_meip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="lab_meip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_meip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, options, weighted average remaining contractual term.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Vested and exercisable at end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Outstanding at end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Dividend yield</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected life (years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Expected volatility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk-free interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted-average grant date fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
</labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>meip-20190930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 07-November-2019 [03:35:54] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#CoverPage" roleURI="http://www.meipharma.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#CondensedBalanceSheets" roleURI="http://www.meipharma.com/role/CondensedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#CondensedBalanceSheetsParenthetical" roleURI="http://www.meipharma.com/role/CondensedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#CondensedStatementsOfOperations" roleURI="http://www.meipharma.com/role/CondensedStatementsOfOperations" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#CondensedStatementsOfStockholdersEquity" roleURI="http://www.meipharma.com/role/CondensedStatementsOfStockholdersEquity" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#CondensedStatementsOfCashFlows" roleURI="http://www.meipharma.com/role/CondensedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#TheCompanyAndSummaryOfSignificantAccountingPolicies" roleURI="http://www.meipharma.com/role/TheCompanyAndSummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#FairValueMeasurements" roleURI="http://www.meipharma.com/role/FairValueMeasurements" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#LicenseAgreements" roleURI="http://www.meipharma.com/role/LicenseAgreements" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#BeigeneCollaboration" roleURI="http://www.meipharma.com/role/BeigeneCollaboration" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#RevenueRecognition" roleURI="http://www.meipharma.com/role/RevenueRecognition" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#NetLossPerShare" roleURI="http://www.meipharma.com/role/NetLossPerShare" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#CommitmentsAndContingencies" roleURI="http://www.meipharma.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#Leases" roleURI="http://www.meipharma.com/role/Leases" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#ShortTermInvestments" roleURI="http://www.meipharma.com/role/ShortTermInvestments" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#StockholdersEquity" roleURI="http://www.meipharma.com/role/StockholdersEquity" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#ShareBasedCompensation" roleURI="http://www.meipharma.com/role/ShareBasedCompensation" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#TheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.meipharma.com/role/TheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#FairValueMeasurementsTables" roleURI="http://www.meipharma.com/role/FairValueMeasurementsTables" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#RevenueRecognitionTables" roleURI="http://www.meipharma.com/role/RevenueRecognitionTables" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#NetLossPerShareTables" roleURI="http://www.meipharma.com/role/NetLossPerShareTables" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#ShareBasedCompensationTables" roleURI="http://www.meipharma.com/role/ShareBasedCompensationTables" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#TheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.meipharma.com/role/TheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#ScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetail" roleURI="http://www.meipharma.com/role/ScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#ScheduleOfAssumptionsUsedToCalculateFairValueOfWarrantLiabilityDetail" roleURI="http://www.meipharma.com/role/ScheduleOfAssumptionsUsedToCalculateFairValueOfWarrantLiabilityDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#ScheduleOfChangesInEstimatedFairValueOfWarrantLiabilityDetail" roleURI="http://www.meipharma.com/role/ScheduleOfChangesInEstimatedFairValueOfWarrantLiabilityDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#LicenseAgreementsAdditionalInformationDetail" roleURI="http://www.meipharma.com/role/LicenseAgreementsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#RevenueRecognitionAdditionalInformationDetail" roleURI="http://www.meipharma.com/role/RevenueRecognitionAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#RevenueRecognitionRevenueAssociatedWithTheFollowingLicenseAgreementsDetail" roleURI="http://www.meipharma.com/role/RevenueRecognitionRevenueAssociatedWithTheFollowingLicenseAgreementsDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#RevenueRecognitionScheduleOfChangesInContractAssetsAndContractLiabilitiesDetail" roleURI="http://www.meipharma.com/role/RevenueRecognitionScheduleOfChangesInContractAssetsAndContractLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#NetLossPerShareAdditionalInformationDetail" roleURI="http://www.meipharma.com/role/NetLossPerShareAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#AntidilutiveSecuritiesDetail" roleURI="http://www.meipharma.com/role/AntidilutiveSecuritiesDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#CommitmentsAndContingenciesAdditionalInformationDetail" roleURI="http://www.meipharma.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#LeasesAdditionalInformationDetail" roleURI="http://www.meipharma.com/role/LeasesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#ShortTermInvestmentsAdditionalInformationDetail" roleURI="http://www.meipharma.com/role/ShortTermInvestmentsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#StockholdersEquityAdditionalInformationDetail" roleURI="http://www.meipharma.com/role/StockholdersEquityAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#ShareBasedCompensationAdditionalInformationDetail" roleURI="http://www.meipharma.com/role/ShareBasedCompensationAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#ShareBasedCompensationExpenseForStockAwardsDetail" roleURI="http://www.meipharma.com/role/ShareBasedCompensationExpenseForStockAwardsDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#SummaryOfStockOptionActivityDetail" roleURI="http://www.meipharma.com/role/SummaryOfStockOptionActivityDetail" />
<roleRef xlink:type="simple" xlink:href="meip-20190930.xsd#FairValueOfStockOptionsWeightedAverageAssumptionsUsedDetail" roleURI="http://www.meipharma.com/role/FairValueOfStockOptionsWeightedAverageAssumptionsUsedDetail" />
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_187927" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_503677" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_DocumentType_503677" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_503678" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_AmendmentFlag_503678" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_503679" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_DocumentPeriodEndDate_503679" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_503680" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_DocumentFiscalYearFocus_503680" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_503681" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_DocumentFiscalPeriodFocus_503681" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_478689" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_TradingSymbol_478689" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_503682" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityRegistrantName_503682" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_503684" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityCentralIndexKey_503684" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_503685" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_CurrentFiscalYearEndDate_503685" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_503690" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityFilerCategory_503690" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_503688" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityCurrentReportingStatus_503688" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_503692" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityEmergingGrowthCompany_503692" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_503689" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityShellCompany_503689" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_503691" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntitySmallBusiness_503691" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_503694" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_Security12bTitle_503694" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_503697" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_SecurityExchangeName_503697" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_478691" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityAddressStateOrProvince_478691" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_478660" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_478660" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_504244" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityInteractiveDataCurrent_504244" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/CondensedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_21" xlink:to="loc_us-gaap_StatementTable_28" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_28" xlink:to="loc_dei_LegalEntityAxis_24" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_38" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_24" xlink:to="loc_dei_EntityDomain_38" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_28" xlink:to="loc_us-gaap_StatementLineItems_27" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_27" xlink:to="loc_us-gaap_AssetsAbstract_22" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_22" xlink:to="loc_us-gaap_AssetsCurrentAbstract_23" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_23" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_33" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_23" xlink:to="loc_us-gaap_ShortTermInvestments_34" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_23" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_35" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:label="loc_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_478145" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_23" xlink:to="loc_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_478145" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_23" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_36" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_37" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_23" xlink:to="loc_us-gaap_AssetsCurrent_37" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_22" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_30" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_22" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_31" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_22" xlink:to="loc_us-gaap_Assets_32" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_27" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_26" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_43" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_26" xlink:to="loc_us-gaap_AccountsPayableCurrent_43" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_44" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_26" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_44" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_45" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_26" xlink:to="loc_us-gaap_DeferredRevenueCurrent_45" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_46" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_26" xlink:to="loc_us-gaap_LiabilitiesCurrent_46" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_311823" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_311823" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_39" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_39" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_40" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25" xlink:to="loc_us-gaap_Liabilities_40" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_41" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25" xlink:to="loc_us-gaap_CommitmentsAndContingencies_41" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25" xlink:to="loc_us-gaap_StockholdersEquityAbstract_29" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_47" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29" xlink:to="loc_us-gaap_PreferredStockValue_47" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_48" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29" xlink:to="loc_us-gaap_CommonStockValue_48" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_49" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_49" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_50" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_50" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_51" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29" xlink:to="loc_us-gaap_StockholdersEquity_51" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_42" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_42" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/CondensedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_53" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_56" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_53" xlink:to="loc_us-gaap_StatementTable_56" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_54" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_56" xlink:to="loc_dei_LegalEntityAxis_54" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_57" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_54" xlink:to="loc_dei_EntityDomain_57" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_55" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_56" xlink:to="loc_us-gaap_StatementLineItems_55" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_58" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_55" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_58" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_59" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_55" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_59" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_60" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_55" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_60" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_61" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_55" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_61" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_62" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_55" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_62" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_63" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_55" xlink:to="loc_us-gaap_CommonStockSharesIssued_63" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_64" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_55" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_64" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/CondensedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_66" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_73" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_66" xlink:to="loc_us-gaap_StatementTable_73" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_68" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_73" xlink:to="loc_dei_LegalEntityAxis_68" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_79" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_68" xlink:to="loc_dei_EntityDomain_79" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_72" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_73" xlink:to="loc_us-gaap_StatementLineItems_72" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_86" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_72" xlink:to="loc_us-gaap_Revenues_86" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_67" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_72" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_67" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_75" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_67" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_75" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_76" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_67" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_76" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_77" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_67" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_77" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_78" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_67" xlink:to="loc_us-gaap_CostsAndExpenses_78" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_88" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_72" xlink:to="loc_us-gaap_OperatingIncomeLoss_88" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_70" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_72" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_70" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_82" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_70" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_82" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_83" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_70" xlink:to="loc_us-gaap_InvestmentIncomeInterestAndDividend_83" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaap_OtherNonoperatingExpense_503736" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_70" xlink:to="loc_us-gaap_OtherNonoperatingExpense_503736" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_85" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_70" xlink:to="loc_us-gaap_NetIncomeLoss_85" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_69" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_72" xlink:to="loc_us-gaap_NetIncomeLossAbstract_69" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xlink:label="loc_meip_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_503753" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_69" xlink:to="loc_meip_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_503753" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_89" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_72" xlink:to="loc_us-gaap_EarningsPerShareAbstract_89" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_503779" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_89" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_503779" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_74" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_72" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_74" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_503781" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_74" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_503781" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/CondensedStatementsOfStockholdersEquity">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_409045" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_409046" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_409045" xlink:to="loc_us-gaap_StatementTable_409046" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_409047" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_409046" xlink:to="loc_dei_LegalEntityAxis_409047" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_409048" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_409047" xlink:to="loc_dei_EntityDomain_409048" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_409049" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_409046" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_409049" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_409050" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_409049" xlink:to="loc_us-gaap_EquityComponentDomain_409050" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_409051" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_409050" xlink:to="loc_us-gaap_CommonStockMember_409051" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_409052" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_409050" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_409052" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_409053" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_409050" xlink:to="loc_us-gaap_RetainedEarningsMember_409053" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_478153" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_409046" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_478153" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_478154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_478153" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_478154" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_478156" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_409046" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_478156" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_478157" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_478156" xlink:to="loc_us-gaap_LossContingencyNatureDomain_478157" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_409054" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_409046" xlink:to="loc_us-gaap_StatementLineItems_409054" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_409058" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_409054" xlink:to="loc_us-gaap_StockholdersEquity_409058" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_409059" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_409054" xlink:to="loc_us-gaap_NetIncomeLoss_409059" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_409062" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_409054" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_409062" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_409219" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_409054" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_409219" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_Stockissuedduringperiodvaluestockwarrantsexercised" xlink:label="loc_meip_Stockissuedduringperiodvaluestockwarrantsexercised_409187" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_409054" xlink:to="loc_meip_Stockissuedduringperiodvaluestockwarrantsexercised_409187" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_409064" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_409054" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_409064" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_409068" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_409054" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_409068" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_409071" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_409054" xlink:to="loc_us-gaap_StockholdersEquity_409071" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/CondensedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_95" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_95" xlink:to="loc_us-gaap_StatementTable_103" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_98" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_103" xlink:to="loc_dei_LegalEntityAxis_98" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_111" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_98" xlink:to="loc_dei_EntityDomain_111" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_103" xlink:to="loc_us-gaap_StatementLineItems_102" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_102" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_101" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_120" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_101" xlink:to="loc_us-gaap_ProfitLoss_120" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_96" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_101" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_96" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_96" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_104" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_105" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_96" xlink:to="loc_us-gaap_ShareBasedCompensation_105" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_106" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_96" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_106" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_97" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_101" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_97" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_107" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_97" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_107" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_97" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_108" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_97" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_109" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_97" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_110" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_121" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_101" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_121" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_100" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_102" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_100" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_117" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_100" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_117" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_118" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_100" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_118" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_100" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_119" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_99" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_102" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_99" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_99" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_112" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_99" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_113" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_503822" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_99" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_503822" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_ProceedsFromPreviouslyIssuedCommonStock" xlink:label="loc_meip_ProceedsFromPreviouslyIssuedCommonStock_503826" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_99" xlink:to="loc_meip_ProceedsFromPreviouslyIssuedCommonStock_503826" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_99" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_114" use="optional" order="26" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_99" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_115" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_122" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_102" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_122" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_123" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_102" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_123" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_124" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_102" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_124" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_478166" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_102" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_478166" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_478167" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_478166" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_478167" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_481017" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_102" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_481017" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_ChangeInFairValueOfWarrantsExercised" xlink:label="loc_meip_ChangeInFairValueOfWarrantsExercised_481052" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_481017" xlink:to="loc_meip_ChangeInFairValueOfWarrantsExercised_481052" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/TheCompanyAndSummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_400" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_403" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_400" xlink:to="loc_us-gaap_StatementTable_403" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_401" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_403" xlink:to="loc_dei_LegalEntityAxis_401" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_404" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_401" xlink:to="loc_dei_EntityDomain_404" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_402" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_403" xlink:to="loc_us-gaap_StatementLineItems_402" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_405" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_402" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_405" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/FairValueMeasurements">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_428" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_431" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_428" xlink:to="loc_us-gaap_StatementTable_431" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_429" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_431" xlink:to="loc_dei_LegalEntityAxis_429" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_432" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_429" xlink:to="loc_dei_EntityDomain_432" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_430" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_431" xlink:to="loc_us-gaap_StatementLineItems_430" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_433" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_430" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_433" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/LicenseAgreements">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_444" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_447" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_444" xlink:to="loc_us-gaap_StatementTable_447" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_445" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_447" xlink:to="loc_dei_LegalEntityAxis_445" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_448" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_445" xlink:to="loc_dei_EntityDomain_448" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_446" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_447" xlink:to="loc_us-gaap_StatementLineItems_446" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_449" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_446" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_449" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/BeigeneCollaboration">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_451" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_454" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_451" xlink:to="loc_us-gaap_StatementTable_454" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_452" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_454" xlink:to="loc_dei_LegalEntityAxis_452" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_455" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_452" xlink:to="loc_dei_EntityDomain_455" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_453" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_454" xlink:to="loc_us-gaap_StatementLineItems_453" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_456" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_453" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_456" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/RevenueRecognition">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_503972" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_505809" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_503972" xlink:to="loc_us-gaap_StatementTable_505809" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_505810" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_505809" xlink:to="loc_us-gaap_StatementClassOfStockAxis_505810" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_505811" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_505810" xlink:to="loc_us-gaap_ClassOfStockDomain_505811" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_505812" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_505809" xlink:to="loc_us-gaap_StatementLineItems_505812" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_503973" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_505812" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_503973" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/NetLossPerShare">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_458" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_461" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_458" xlink:to="loc_us-gaap_StatementTable_461" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_459" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_461" xlink:to="loc_dei_LegalEntityAxis_459" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_462" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_459" xlink:to="loc_dei_EntityDomain_462" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_460" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_461" xlink:to="loc_us-gaap_StatementLineItems_460" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_463" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_460" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_463" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_473" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_476" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_473" xlink:to="loc_us-gaap_StatementTable_476" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_474" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_476" xlink:to="loc_dei_LegalEntityAxis_474" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_477" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_474" xlink:to="loc_dei_EntityDomain_477" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_475" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_476" xlink:to="loc_us-gaap_StatementLineItems_475" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_478" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_475" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_478" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/Leases">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_504088" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_505814" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_504088" xlink:to="loc_us-gaap_StatementTable_505814" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_505815" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_505814" xlink:to="loc_us-gaap_StatementClassOfStockAxis_505815" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_505816" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_505815" xlink:to="loc_us-gaap_ClassOfStockDomain_505816" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_505817" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_505814" xlink:to="loc_us-gaap_StatementLineItems_505817" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_504090" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_505817" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_504090" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/ShortTermInvestments">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_480" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_483" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_480" xlink:to="loc_us-gaap_StatementTable_483" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_481" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_483" xlink:to="loc_dei_LegalEntityAxis_481" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_484" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_481" xlink:to="loc_dei_EntityDomain_484" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_482" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_483" xlink:to="loc_us-gaap_StatementLineItems_482" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_485" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_482" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_485" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/StockholdersEquity">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FederalHomeLoanBanksAbstract" xlink:label="loc_us-gaap_FederalHomeLoanBanksAbstract_487" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_490" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FederalHomeLoanBanksAbstract_487" xlink:to="loc_us-gaap_StatementTable_490" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_488" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_490" xlink:to="loc_dei_LegalEntityAxis_488" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_491" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_488" xlink:to="loc_dei_EntityDomain_491" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_489" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_490" xlink:to="loc_us-gaap_StatementLineItems_489" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_492" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_489" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_492" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/ShareBasedCompensation">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_494" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_497" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_494" xlink:to="loc_us-gaap_StatementTable_497" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_495" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_497" xlink:to="loc_dei_LegalEntityAxis_495" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_498" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_495" xlink:to="loc_dei_EntityDomain_498" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_496" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_497" xlink:to="loc_us-gaap_StatementLineItems_496" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_499" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_496" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_499" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/TheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_407" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_410" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_407" xlink:to="loc_us-gaap_StatementTable_410" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_408" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_410" xlink:to="loc_dei_LegalEntityAxis_408" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_411" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_408" xlink:to="loc_dei_EntityDomain_411" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_409" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_410" xlink:to="loc_us-gaap_StatementLineItems_409" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_ClinicalDevelopmentProgramsPolicyTextBlock" xlink:label="loc_meip_ClinicalDevelopmentProgramsPolicyTextBlock_412" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_409" xlink:to="loc_meip_ClinicalDevelopmentProgramsPolicyTextBlock_412" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_LiquidityPolicyTextBlock" xlink:label="loc_meip_LiquidityPolicyTextBlock_481048" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_409" xlink:to="loc_meip_LiquidityPolicyTextBlock_481048" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_413" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_409" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_413" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_414" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_409" xlink:to="loc_us-gaap_UseOfEstimates_414" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_415" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_409" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_415" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_416" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_409" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_416" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_417" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_409" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_417" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_418" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_409" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_418" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_419" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_409" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_419" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/FairValueMeasurementsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_435" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_438" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_435" xlink:to="loc_us-gaap_StatementTable_438" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_436" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_438" xlink:to="loc_dei_LegalEntityAxis_436" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_439" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_436" xlink:to="loc_dei_EntityDomain_439" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_437" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_438" xlink:to="loc_us-gaap_StatementLineItems_437" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_440" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_437" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_440" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_FairValueOfWarrantLiabilityAssumptionsTableTextBlock" xlink:label="loc_meip_FairValueOfWarrantLiabilityAssumptionsTableTextBlock_441" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_437" xlink:to="loc_meip_FairValueOfWarrantLiabilityAssumptionsTableTextBlock_441" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_ScheduleOfChangesInFairValueOfWarrantLiabilityTableTextBlock" xlink:label="loc_meip_ScheduleOfChangesInFairValueOfWarrantLiabilityTableTextBlock_442" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_437" xlink:to="loc_meip_ScheduleOfChangesInFairValueOfWarrantLiabilityTableTextBlock_442" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/RevenueRecognitionTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_503982" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_505822" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_503982" xlink:to="loc_us-gaap_StatementTable_505822" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_505824" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_505822" xlink:to="loc_dei_LegalEntityAxis_505824" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_505825" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_505824" xlink:to="loc_dei_EntityDomain_505825" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_505826" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_505822" xlink:to="loc_us-gaap_StatementLineItems_505826" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_ScheduleOfRevenueAssociatedWithLicenseAgreementTableTextBlock" xlink:label="loc_meip_ScheduleOfRevenueAssociatedWithLicenseAgreementTableTextBlock_503983" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_505826" xlink:to="loc_meip_ScheduleOfRevenueAssociatedWithLicenseAgreementTableTextBlock_503983" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_503985" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_505826" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_503985" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/NetLossPerShareTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_465" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_468" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_465" xlink:to="loc_us-gaap_StatementTable_468" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_466" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_468" xlink:to="loc_dei_LegalEntityAxis_466" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_469" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_466" xlink:to="loc_dei_EntityDomain_469" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_467" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_468" xlink:to="loc_us-gaap_StatementLineItems_467" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_504057" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_467" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_504057" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/ShareBasedCompensationTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_501" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_504" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_501" xlink:to="loc_us-gaap_StatementTable_504" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_502" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_504" xlink:to="loc_dei_LegalEntityAxis_502" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_505" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_502" xlink:to="loc_dei_EntityDomain_505" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_503" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_504" xlink:to="loc_us-gaap_StatementLineItems_503" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_506" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_503" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_506" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_507" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_503" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_507" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_508" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_503" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_508" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/TheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_AssetsAndLiabilitiesEliminatedUponConsolidationAbstract" xlink:label="loc_meip_AssetsAndLiabilitiesEliminatedUponConsolidationAbstract_126" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TargetedOrTrackingStockStockTable" xlink:label="loc_us-gaap_TargetedOrTrackingStockStockTable_129" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_AssetsAndLiabilitiesEliminatedUponConsolidationAbstract_126" xlink:to="loc_us-gaap_TargetedOrTrackingStockStockTable_129" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockTable_129" xlink:to="loc_dei_LegalEntityAxis_127" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_127" xlink:to="loc_dei_EntityDomain_130" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_311913" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockTable_129" xlink:to="loc_us-gaap_TypeOfArrangementAxis_311913" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_311916" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_311913" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_311916" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_478189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockTable_129" xlink:to="loc_srt_RangeAxis_478189" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_478190" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_478189" xlink:to="loc_srt_RangeMember_478190" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_478193" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockTable_129" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_478193" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_478194" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_478193" xlink:to="loc_us-gaap_TypeOfAdoptionMember_478194" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TargetedOrTrackingStockStockLineItems" xlink:label="loc_us-gaap_TargetedOrTrackingStockStockLineItems_128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockTable_129" xlink:to="loc_us-gaap_TargetedOrTrackingStockStockLineItems_128" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_NumberOfClinicalStageCandidates" xlink:label="loc_meip_NumberOfClinicalStageCandidates_131" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockLineItems_128" xlink:to="loc_meip_NumberOfClinicalStageCandidates_131" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_NumberOfCandidateInAnOngoingGlobalRegistrationTrial" xlink:label="loc_meip_NumberOfCandidateInAnOngoingGlobalRegistrationTrial_132" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockLineItems_128" xlink:to="loc_meip_NumberOfCandidateInAnOngoingGlobalRegistrationTrial_132" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockLineItems_128" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_136" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_481044" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockLineItems_128" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_481044" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_CashAndCashEquivalentsshortTermInvestmentsAndCommonStockProceedsReceivable" xlink:label="loc_meip_CashAndCashEquivalentsshortTermInvestmentsAndCommonStockProceedsReceivable_481046" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TargetedOrTrackingStockStockLineItems_128" xlink:to="loc_meip_CashAndCashEquivalentsshortTermInvestmentsAndCommonStockProceedsReceivable_481046" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/ScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_153" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_153" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_155" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_160" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_155" xlink:to="loc_dei_LegalEntityAxis_160" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_160" xlink:to="loc_dei_EntityDomain_169" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_156" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_155" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_156" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_159" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_156" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_159" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_159" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_168" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_157" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_155" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_157" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_157" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_158" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_166" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_158" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_166" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_155" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_154" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_164" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_154" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_164" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_154" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_165" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/ScheduleOfAssumptionsUsedToCalculateFairValueOfWarrantLiabilityDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_171" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_173" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_171" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_173" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_173" xlink:to="loc_dei_LegalEntityAxis_174" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_180" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_174" xlink:to="loc_dei_EntityDomain_180" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_175" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_173" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_175" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_176" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_175" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_176" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_181" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_176" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_181" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_182" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_176" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_182" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_183" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_176" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_183" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_184" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_176" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_184" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="loc_us-gaap_MeasurementInputExercisePriceMember_478745" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_176" xlink:to="loc_us-gaap_MeasurementInputExercisePriceMember_478745" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_172" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_173" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_172" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_478746" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_172" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_478746" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/ScheduleOfChangesInEstimatedFairValueOfWarrantLiabilityDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_186" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_FairValueMeasurementsSignificantUnobservableInputsTable" xlink:label="loc_meip_FairValueMeasurementsSignificantUnobservableInputsTable_192" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_186" xlink:to="loc_meip_FairValueMeasurementsSignificantUnobservableInputsTable_192" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_193" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_FairValueMeasurementsSignificantUnobservableInputsTable_192" xlink:to="loc_dei_LegalEntityAxis_193" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_200" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_193" xlink:to="loc_dei_EntityDomain_200" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_188" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_FairValueMeasurementsSignificantUnobservableInputsTable_192" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_188" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_188" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_189" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_194" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_189" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_194" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_187" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_FairValueMeasurementsSignificantUnobservableInputsTable_192" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_187" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_190" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_187" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_190" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_195" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_190" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_195" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_FairValueMeasurementsSignificantUnobservableInputsLineItems" xlink:label="loc_meip_FairValueMeasurementsSignificantUnobservableInputsLineItems_191" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_FairValueMeasurementsSignificantUnobservableInputsTable_192" xlink:to="loc_meip_FairValueMeasurementsSignificantUnobservableInputsLineItems_191" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_196" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_FairValueMeasurementsSignificantUnobservableInputsLineItems_191" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_196" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_197" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_FairValueMeasurementsSignificantUnobservableInputsLineItems_191" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_197" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_198" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_FairValueMeasurementsSignificantUnobservableInputsLineItems_191" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_198" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_199" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_FairValueMeasurementsSignificantUnobservableInputsLineItems_191" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_199" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/LicenseAgreementsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_202" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_213" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_202" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_213" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_213" xlink:to="loc_us-gaap_TypeOfArrangementAxis_214" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_203" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_214" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_203" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_HelsinnLicenseAgreementMember" xlink:label="loc_meip_HelsinnLicenseAgreementMember_215" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_203" xlink:to="loc_meip_HelsinnLicenseAgreementMember_215" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_PresageLicenseAgreementMember" xlink:label="loc_meip_PresageLicenseAgreementMember_216" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_203" xlink:to="loc_meip_PresageLicenseAgreementMember_216" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_212" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_213" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_212" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_208" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_212" xlink:to="loc_us-gaap_RelatedPartyDomain_208" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_PresageBiosciencesIncMember" xlink:label="loc_meip_PresageBiosciencesIncMember_221" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_208" xlink:to="loc_meip_PresageBiosciencesIncMember_221" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_205" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_213" xlink:to="loc_dei_LegalEntityAxis_205" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_204" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_205" xlink:to="loc_dei_EntityDomain_204" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_KyowaKirinCoMember" xlink:label="loc_meip_KyowaKirinCoMember_218" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_204" xlink:to="loc_meip_KyowaKirinCoMember_218" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_209" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_213" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_209" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_210" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_209" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_210" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_PotentialRegulatoryAndSalesbasedMilestonePaymentMember" xlink:label="loc_meip_PotentialRegulatoryAndSalesbasedMilestonePaymentMember_222" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_210" xlink:to="loc_meip_PotentialRegulatoryAndSalesbasedMilestonePaymentMember_222" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_IncrementalPaymentMember" xlink:label="loc_meip_IncrementalPaymentMember_223" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_210" xlink:to="loc_meip_IncrementalPaymentMember_223" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_PotentialPaymentsOnAchievementOfDevelopmentRegulatoryAndCommercialMilestonesMember" xlink:label="loc_meip_PotentialPaymentsOnAchievementOfDevelopmentRegulatoryAndCommercialMilestonesMember_224" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_210" xlink:to="loc_meip_PotentialPaymentsOnAchievementOfDevelopmentRegulatoryAndCommercialMilestonesMember_224" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_206" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_213" xlink:to="loc_srt_RangeAxis_206" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_207" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_206" xlink:to="loc_srt_RangeMember_207" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_219" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_207" xlink:to="loc_srt_MaximumMember_219" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_213" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_211" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_PotentialMilestonePaymentsReceivable" xlink:label="loc_meip_PotentialMilestonePaymentsReceivable_226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_meip_PotentialMilestonePaymentsReceivable_226" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_UpFrontPayment" xlink:label="loc_meip_UpFrontPayment_228" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_meip_UpFrontPayment_228" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_PaymentRelatedToDevelopmentAndCommercialMilestonePayments" xlink:label="loc_meip_PaymentRelatedToDevelopmentAndCommercialMilestonePayments_229" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_meip_PaymentRelatedToDevelopmentAndCommercialMilestonePayments_229" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_LicenseAgreementExpiryPeriod" xlink:label="loc_meip_LicenseAgreementExpiryPeriod_230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_meip_LicenseAgreementExpiryPeriod_230" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_232" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_232" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_PotentialMilestonePaymentsPayable" xlink:label="loc_meip_PotentialMilestonePaymentsPayable_233" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_meip_PotentialMilestonePaymentsPayable_233" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_PaymentForLicenseAgreement" xlink:label="loc_meip_PaymentForLicenseAgreement_234" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_meip_PaymentForLicenseAgreement_234" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_PercentageOfPurchasesFromMajorSuppliers" xlink:label="loc_meip_PercentageOfPurchasesFromMajorSuppliers_235" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_meip_PercentageOfPurchasesFromMajorSuppliers_235" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_AgreementTerminationNoticePeriod" xlink:label="loc_meip_AgreementTerminationNoticePeriod_236" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_meip_AgreementTerminationNoticePeriod_236" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="loc_us-gaap_ProceedsFromLicenseFeesReceived_311871" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_211" xlink:to="loc_us-gaap_ProceedsFromLicenseFeesReceived_311871" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/RevenueRecognitionAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract_503988" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_503990" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract_503988" xlink:to="loc_us-gaap_StatementTable_503990" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_503991" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_503990" xlink:to="loc_us-gaap_StatementClassOfStockAxis_503991" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_503992" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_503991" xlink:to="loc_us-gaap_ClassOfStockDomain_503992" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_503995" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_503990" xlink:to="loc_us-gaap_TypeOfArrangementAxis_503995" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_503996" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_503995" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_503996" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_KHKLicenseAgreementMember" xlink:label="loc_meip_KHKLicenseAgreementMember_503997" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_503996" xlink:to="loc_meip_KHKLicenseAgreementMember_503997" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_HelsinnLicenseAgreementMember" xlink:label="loc_meip_HelsinnLicenseAgreementMember_503999" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_503996" xlink:to="loc_meip_HelsinnLicenseAgreementMember_503999" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_503993" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_503990" xlink:to="loc_us-gaap_StatementLineItems_503993" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_RevenuePerformanceObligationAmount" xlink:label="loc_meip_RevenuePerformanceObligationAmount_503998" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_503993" xlink:to="loc_meip_RevenuePerformanceObligationAmount_503998" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_504004" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_503993" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_504004" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_504010" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_503993" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_504010" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_AdditionalRecognitionOfDeferredRevenue" xlink:label="loc_meip_AdditionalRecognitionOfDeferredRevenue_504012" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_503993" xlink:to="loc_meip_AdditionalRecognitionOfDeferredRevenue_504012" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/RevenueRecognitionRevenueAssociatedWithTheFollowingLicenseAgreementsDetail">
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsAbstract" xlink:label="loc_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsAbstract_311876" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsTable" xlink:label="loc_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsTable_311877" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsAbstract_311876" xlink:to="loc_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsTable_311877" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_481081" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsTable_311877" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_481081" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_481082" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_481081" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_481082" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_311881" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsTable_311877" xlink:to="loc_us-gaap_TypeOfArrangementAxis_311881" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_311882" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_311881" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_311882" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_KHKLicenseAgreementMember" xlink:label="loc_meip_KHKLicenseAgreementMember_311883" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_311882" xlink:to="loc_meip_KHKLicenseAgreementMember_311883" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_HelsinnLicenseAgreementMember" xlink:label="loc_meip_HelsinnLicenseAgreementMember_311892" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_311882" xlink:to="loc_meip_HelsinnLicenseAgreementMember_311892" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsLineItems" xlink:label="loc_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsLineItems_311880" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsTable_311877" xlink:to="loc_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsLineItems_311880" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_311885" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsLineItems_311880" xlink:to="loc_us-gaap_Revenues_311885" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/RevenueRecognitionScheduleOfChangesInContractAssetsAndContractLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityAbstract" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityAbstract_138" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_ContractWithCustomerAssetAndLiabilityTable" xlink:label="loc_meip_ContractWithCustomerAssetAndLiabilityTable_140" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityAbstract_138" xlink:to="loc_meip_ContractWithCustomerAssetAndLiabilityTable_140" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_ContractWithCustomerAssetAndLiabilityTable_140" xlink:to="loc_dei_LegalEntityAxis_141" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_151" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_141" xlink:to="loc_dei_EntityDomain_151" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_ContractWithCustomerAssetAndLiabilityLineItems" xlink:label="loc_meip_ContractWithCustomerAssetAndLiabilityLineItems_139" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_ContractWithCustomerAssetAndLiabilityTable_140" xlink:to="loc_meip_ContractWithCustomerAssetAndLiabilityLineItems_139" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_AccountsReceivableNetBeginningBalance" xlink:label="loc_meip_AccountsReceivableNetBeginningBalance_142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_ContractWithCustomerAssetAndLiabilityLineItems_139" xlink:to="loc_meip_AccountsReceivableNetBeginningBalance_142" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_143" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_ContractWithCustomerAssetAndLiabilityLineItems_139" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_143" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_AccountsReceivableNetEndingBalance" xlink:label="loc_meip_AccountsReceivableNetEndingBalance_144" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_ContractWithCustomerAssetAndLiabilityLineItems_139" xlink:to="loc_meip_AccountsReceivableNetEndingBalance_144" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_145" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_ContractWithCustomerAssetAndLiabilityLineItems_139" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_145" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_ContractWithCustomerAssetAndLiabilityLineItems_139" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_146" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_ContractWithCustomerAssetAndLiabilityLineItems_139" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_147" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_ContractWithCustomerAssetAndLiabilityLineItems_139" xlink:to="loc_us-gaap_ContractWithCustomerLiability_148" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_ContractWithCustomerAssetAndLiabilityLineItems_139" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_149" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_ContractWithCustomerAssetAndLiabilityLineItems_139" xlink:to="loc_us-gaap_ContractWithCustomerLiability_150" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/NetLossPerShareAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_238" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_241" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_238" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_241" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_239" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_241" xlink:to="loc_dei_LegalEntityAxis_239" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_242" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_239" xlink:to="loc_dei_EntityDomain_242" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_PotentiallyDilutiveSecuritiesOutstandingLineItems" xlink:label="loc_meip_PotentiallyDilutiveSecuritiesOutstandingLineItems_240" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_241" xlink:to="loc_meip_PotentiallyDilutiveSecuritiesOutstandingLineItems_240" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_243" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_PotentiallyDilutiveSecuritiesOutstandingLineItems_240" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_243" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/AntidilutiveSecuritiesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityAbstract" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityAbstract_478228" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_478229" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityAbstract_478228" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_478229" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_478230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_478229" xlink:to="loc_dei_LegalEntityAxis_478230" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_478231" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_478230" xlink:to="loc_dei_EntityDomain_478231" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_478232" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_478229" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_478232" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_478233" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_478232" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_478233" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_478234" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_478233" xlink:to="loc_us-gaap_EmployeeStockOptionMember_478234" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_478235" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_478233" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_478235" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_478236" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_478233" xlink:to="loc_us-gaap_WarrantMember_478236" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_PotentiallyDilutiveSecuritiesOutstandingLineItems" xlink:label="loc_meip_PotentiallyDilutiveSecuritiesOutstandingLineItems_478237" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_478229" xlink:to="loc_meip_PotentiallyDilutiveSecuritiesOutstandingLineItems_478237" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_478238" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_PotentiallyDilutiveSecuritiesOutstandingLineItems_478237" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_478238" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/CommitmentsAndContingenciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_266" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_272" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_266" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_272" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_268" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_272" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_268" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_269" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_268" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_269" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_273" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_272" xlink:to="loc_us-gaap_TypeOfArrangementAxis_273" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_267" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_273" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_267" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_SbioPurchaseAgreementMember" xlink:label="loc_meip_SbioPurchaseAgreementMember_275" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_267" xlink:to="loc_meip_SbioPurchaseAgreementMember_275" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_CydexLicenseAgreementMember" xlink:label="loc_meip_CydexLicenseAgreementMember_276" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_267" xlink:to="loc_meip_CydexLicenseAgreementMember_276" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_PresageLicenseAgreementMember" xlink:label="loc_meip_PresageLicenseAgreementMember_274" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_267" xlink:to="loc_meip_PresageLicenseAgreementMember_274" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaap_OtherCommitmentsAxis_478582" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_272" xlink:to="loc_us-gaap_OtherCommitmentsAxis_478582" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaap_OtherCommitmentsDomain_478583" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAxis_478582" xlink:to="loc_us-gaap_OtherCommitmentsDomain_478583" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_272" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_271" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_AccruedMilestonePayments" xlink:label="loc_meip_AccruedMilestonePayments_284" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_271" xlink:to="loc_meip_AccruedMilestonePayments_284" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_MilestonePaymentsMaximumAmount" xlink:label="loc_meip_MilestonePaymentsMaximumAmount_285" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_271" xlink:to="loc_meip_MilestonePaymentsMaximumAmount_285" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_PercentageOfPurchasesFromMajorSuppliers" xlink:label="loc_meip_PercentageOfPurchasesFromMajorSuppliers_286" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_271" xlink:to="loc_meip_PercentageOfPurchasesFromMajorSuppliers_286" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/LeasesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_504093" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_504096" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_504093" xlink:to="loc_us-gaap_StatementTable_504096" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_504097" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_504096" xlink:to="loc_us-gaap_StatementClassOfStockAxis_504097" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_504098" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_504097" xlink:to="loc_us-gaap_ClassOfStockDomain_504098" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_504111" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_504096" xlink:to="loc_srt_RangeAxis_504111" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_504112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_504111" xlink:to="loc_srt_RangeMember_504112" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_504113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_504112" xlink:to="loc_srt_MinimumMember_504113" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_504114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_504096" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_504114" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_504115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_504114" xlink:to="loc_us-gaap_TypeOfAdoptionMember_504115" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_504116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_504115" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_504116" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_504117" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_504096" xlink:to="loc_srt_StatementGeographicalAxis_504117" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_504119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_504117" xlink:to="loc_srt_SegmentGeographicalDomain_504119" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CentralAmericaMember" xlink:label="loc_srt_CentralAmericaMember_504123" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_504119" xlink:to="loc_srt_CentralAmericaMember_504123" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_504127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_504096" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_504127" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_504129" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_504127" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_504129" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_504140" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_504129" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_504140" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_PropertyPlantAndEquipmentNetMember" xlink:label="loc_meip_PropertyPlantAndEquipmentNetMember_515916" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_504129" xlink:to="loc_meip_PropertyPlantAndEquipmentNetMember_515916" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_504099" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_504096" xlink:to="loc_us-gaap_StatementLineItems_504099" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_504100" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_504099" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_504100" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LandSubjectToGroundLeases" xlink:label="loc_us-gaap_LandSubjectToGroundLeases_504101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_504099" xlink:to="loc_us-gaap_LandSubjectToGroundLeases_504101" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_504102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_504099" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_504102" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_504103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_504099" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_504103" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_meip_LesseeOperatingLeaseRemainingLeaseTerm_504104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_504099" xlink:to="loc_meip_LesseeOperatingLeaseRemainingLeaseTerm_504104" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_504106" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_504099" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_504106" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_504107" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_504099" xlink:to="loc_us-gaap_OperatingLeaseLiability_504107" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1" xlink:label="loc_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_504108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_504099" xlink:to="loc_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_504108" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_504109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_504099" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_504109" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/ShortTermInvestmentsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_288" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_291" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_288" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_291" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_289" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_291" xlink:to="loc_dei_LegalEntityAxis_289" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_292" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_289" xlink:to="loc_dei_EntityDomain_292" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_290" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_291" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_290" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_293" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_290" xlink:to="loc_us-gaap_ShortTermInvestments_293" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/StockholdersEquityAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_295" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_301" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_295" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_301" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_297" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_301" xlink:to="loc_dei_LegalEntityAxis_297" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_316" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_297" xlink:to="loc_dei_EntityDomain_316" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_298" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_301" xlink:to="loc_srt_RangeAxis_298" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_299" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_298" xlink:to="loc_srt_RangeMember_299" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_317" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_299" xlink:to="loc_srt_MaximumMember_317" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_302" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_301" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_302" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_300" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_302" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_300" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_AtTheMarketSaleAgreementMember" xlink:label="loc_meip_AtTheMarketSaleAgreementMember_318" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_300" xlink:to="loc_meip_AtTheMarketSaleAgreementMember_318" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_478572" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_301" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_478572" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_478573" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_478572" xlink:to="loc_us-gaap_RelatedPartyDomain_478573" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_478574" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_301" xlink:to="loc_us-gaap_TypeOfArrangementAxis_478574" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_478576" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_478574" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_478576" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_504167" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_301" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_504167" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_504168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_504167" xlink:to="loc_us-gaap_EquityComponentDomain_504168" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_504169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_504168" xlink:to="loc_us-gaap_WarrantMember_504169" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_296" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_301" xlink:to="loc_us-gaap_ClassOfStockLineItems_296" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_309" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_296" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_309" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_ShelfRegistrationStatementValue" xlink:label="loc_meip_ShelfRegistrationStatementValue_315" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_296" xlink:to="loc_meip_ShelfRegistrationStatementValue_315" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_304" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_296" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_304" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_306" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_296" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_306" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_307" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_296" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_307" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_SaleOfSharesAndWarrantsUnderAgreement" xlink:label="loc_meip_SaleOfSharesAndWarrantsUnderAgreement_313" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_296" xlink:to="loc_meip_SaleOfSharesAndWarrantsUnderAgreement_313" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_NumberOfSharesAgreedToBeSoldUnderAgreement" xlink:label="loc_meip_NumberOfSharesAgreedToBeSoldUnderAgreement_314" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_296" xlink:to="loc_meip_NumberOfSharesAgreedToBeSoldUnderAgreement_314" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_ExerciseOfWarrantsForCommonStock" xlink:label="loc_meip_ExerciseOfWarrantsForCommonStock_310" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_296" xlink:to="loc_meip_ExerciseOfWarrantsForCommonStock_310" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_311" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_296" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_311" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_478548" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_296" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_478548" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:label="loc_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_478553" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_296" xlink:to="loc_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_478553" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/ShareBasedCompensationAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_321" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_326" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_321" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_326" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_326" xlink:to="loc_srt_RangeAxis_323" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_478618" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_323" xlink:to="loc_srt_RangeMember_478618" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_478619" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_478618" xlink:to="loc_srt_MaximumMember_478619" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_478620" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_478618" xlink:to="loc_srt_MinimumMember_478620" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_324" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_326" xlink:to="loc_us-gaap_PlanNameAxis_324" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_325" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_324" xlink:to="loc_us-gaap_PlanNameDomain_325" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_TwoThousandAndEightOmnibusPlanMember" xlink:label="loc_meip_TwoThousandAndEightOmnibusPlanMember_332" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_325" xlink:to="loc_meip_TwoThousandAndEightOmnibusPlanMember_332" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_322" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_326" xlink:to="loc_us-gaap_AwardTypeAxis_322" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_328" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_322" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_328" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_345" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_328" xlink:to="loc_us-gaap_EmployeeStockOptionMember_345" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_346" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_328" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_346" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_329" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_326" xlink:to="loc_srt_TitleOfIndividualAxis_329" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_330" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_329" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_330" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_330" xlink:to="loc_srt_DirectorMember_347" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_EmployeesMember" xlink:label="loc_meip_EmployeesMember_348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_330" xlink:to="loc_meip_EmployeesMember_348" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_326" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_333" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_333" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_334" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_334" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_335" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_335" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_336" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_336" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_337" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_337" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_338" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_338" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_339" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_339" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_340" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_340" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_NumberOfSharesToBeReceived" xlink:label="loc_meip_NumberOfSharesToBeReceived_341" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" xlink:to="loc_meip_NumberOfSharesToBeReceived_341" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_342" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_342" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_344" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_327" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_344" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/ShareBasedCompensationExpenseForStockAwardsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_350" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_355" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_350" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_355" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_354" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_355" xlink:to="loc_dei_LegalEntityAxis_354" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_359" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_354" xlink:to="loc_dei_EntityDomain_359" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_352" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_355" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_352" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_353" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_352" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_353" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_357" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_353" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_357" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_358" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_353" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_358" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_351" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_355" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_351" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_356" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_351" xlink:to="loc_us-gaap_ShareBasedCompensation_356" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/SummaryOfStockOptionActivityDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_361" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_363" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_361" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_363" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_362" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_363" xlink:to="loc_dei_LegalEntityAxis_362" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_369" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_362" xlink:to="loc_dei_EntityDomain_369" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_365" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_363" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_365" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_365" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_366" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_373" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_366" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_373" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_374" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_366" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_374" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_375" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_366" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_375" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_376" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_366" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_376" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_377" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_366" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_377" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_378" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_366" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_378" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_372" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_365" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_372" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_367" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_365" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_367" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_379" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_367" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_379" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_380" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_367" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_380" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_381" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_367" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_381" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_382" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_367" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_382" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_383" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_367" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_383" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_384" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_367" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_384" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_385" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_367" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_385" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="meip-20190930.xsd#meip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="loc_meip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_368" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_365" xlink:to="loc_meip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_368" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_386" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_368" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_386" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_387" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_368" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_387" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_364" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_365" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_364" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_370" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_364" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_370" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_371" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_364" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_371" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com/role/FairValueOfStockOptionsWeightedAverageAssumptionsUsedDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_389" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_391" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_389" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_391" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_390" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_391" xlink:to="loc_dei_LegalEntityAxis_390" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_393" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_390" xlink:to="loc_dei_EntityDomain_393" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_311943" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_391" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_311943" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_311944" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_311943" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_311944" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_392" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_391" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_392" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_394" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_392" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_394" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_395" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_392" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_395" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_396" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_392" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_396" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_397" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_392" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_397" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_398" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_392" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_398" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g667344g59z57.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g667344g59z57.jpg
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MP < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P <
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MZS\I^L:X\K$!P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < '
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M<^ES)Z P)V<Y](>KOZ//=#G\_P"T/O7C.N?2YD] 8$[.<^D/5W]'GNAS^?\
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MSFUTNKT_,LR'%--+)=2@1$.XEH4G"TI:DVNHB*QCE(R45R.Y=?.,M<V0)#@
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MC!)->,XD@W6X\A)*2IY!.N*(C<)";3.ZDH7<-CKL&N%9N$TJOU.A60\99DV
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M[..WR1X.9^W7[,.Z_,\"1OOCOL ]012/Q*6KY<"/NSCM\D>#F?MU^S#NOS/
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ME=H,,IU288;CF\A@E-R6G59QQ*U)+"@S.UD*N>HK<8W@Y9!BH< ' !P < '
M!P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' ")W.CUC8(B&
M!MPW)44/ME#O$2+B;/@=E9]97FN[(I)+MQLJ'(<P&N=4 F,PG'5P"6(.1Y6+
M.%RID*0 0C8&A=:;,.L6JS#C[-KAAX((=:*M>+O2+ *'#CS=EBMBRM.L(.5
M=[U1G,J1'6AXB.?F R2Y82?-'2 "!1^C+IIBU=BF,:QB8KL:T5FY,0G+#;GW
MT6"JZO"Z4A2LDY!]TJY&+:F!1J!<Q;LUP5L&M$+*/O4*Q(MUIR8";GUY?7R"
M0A>F'38.A776S8*P%ZQL7,#%U5:]A;#N-D/L"0P>O!X<JZ6FTE[BW!$!  H>
M-AQCK$>*EB1*2WD@3*RYP+GH/9JU#W".F720*S5*XBJ8J+8Z,^J35R'I':W\
M#'U8VUA2\Q)!QV#-\>-Y[1_HD(TI&/2;'B3_ /(M?[J!<^7\;=!#'0'H0Z7Z
MO*KDFO4,X(;K$>EPX0R)L_:R0)&#KOT+72X%GKZ[LL);X0&1KNF2XT:T0"[;
MTH+VLS$G!0TDD"Y];<?2/2CH)Z7&8:1L6B6""+S5X%'EBQ^U-LP1I:CPM>ZS
MU7)I9V#%N[4<[5+%0=-ZMKMR %VY@RZQZ0%DVN.8G)E2I(+GU(N;9YALW3*7
M6M?@&JQ4AV10-@E8"[4+,R=/RDA:; 4M)V1YR2DS):O/3IDE.[)3^68V)'FT
M1MB(RPPT$"4\ ' !P < ' #F7TR==EDV&,1.W147JZY9=2Z5VOK^/5-:[!AS
M#^=MM7E4JJBH#I*\)LHNLNU4.RUL_!"K B[UIA-$*[64HB/$@J45O5R>8MHN
ML?K;L5&HFLK]M$!7-A/;_K-!MFI=6].4,S:MKC47*A7[9Y 2="%RSD6U54!3
M:$3<@[@'O4\79#S$X.Y0JZTPP2E!%M?!:][ZM%ND6X7USW&VZKZK]@5"C@$3
M=)Z4L.T=<#[2FQ!<6 C'VEU6T&O"[U =2@N!9>@Z!K,XY%C,-%1TX^>B=DE4
M.(T@%O69<END1&+X4 0R3V&7)ZJL1*C577.B38$93Y84ILHU?;Y3-W7W;-90
M#,' 4,HUJN#JAVFD!E;44LP^] =@-60<*KU;*F 03A/SWMY-73UN+["\)56X
MD>\32FNKA9_1.A;?W!W51XM5A2(^H=0[MZB=:FK=.+7W8-8'2RF >G:Y-DU&
M"TV7P7LCCHC)L2@HJJ MJX^@C_'_ $$KMWA(==TP->2Y346XW54QY]^,)@(U
ME..W&NPBG4*(GV2I!HVR729*/%D],VQ9#@E<1@_&$RZR>*"Q@)VTDJD$83Z^
M;I+\-(DT+KUJ):P#ZL$U!MPH<MEIO=3UA%2YJV ULN9K*R;2KM[FB)A39<*)
M6QX/]D-L+-.7UVJ22P]0I J++(S<P606]1'P\-K>L0F/X2C7Z)18<C4N^;F\
M&1L^41*:[UJQ9 D%RF6K>P>NU51 /;3@^;9;1%T65A"),$HZ(-F;%45Q5CV#
M1:'5 FWDX-9^3I\WKW8TWM,-NG70'8X$>1$#S;Y^"H27?#O%A1*L60Q4S8TH
MD(4+Q(1& :!D(LX1*E,'0LEIT19A(&QPBH,<%(R=P < ' #"?41J$7O?4E@U
M8=>'- ;(7HTD^T7C*F#2(&LWZKVPV%F1TO1\J9/"P4L)E>7<)9R0P\M+B&U-
MK .=;W@X=CR\V$[-WK7KM=[YKH;3K;:K/7#B%3;B%@;/JU/WY!:"V1EY.TM0
MU*V4H;KJ2U+BX8>K1=YHS7C)<78P03?\.NF_EV7X!.CO@_;*N4?GA;Q4"J;.
M>*V*S5JYA+%*K-R.%+%U731]FMJ!)R)**6&E#NH*@2*O)7A669>DJR,'/5U$
M.E':$"Y]'%JU>8K"Q /!PRJ>S>S>-JA@5NDF!!NN[J&5_(?8@%O.Z]M[>V9<
M2Y=$Z/&1<;B#VK-I)8LW(S&F"0+<@JZL>4E!HH+GUZZMA< Q]J7HKE6[79.?
M6=YT"]E&%2 5:>S4X[E8KLITCHY=UCCJZ3 XJ0Z5L6GZUN+!2<YK$J.4G;IJ
M?90^UFYUU*[*!?;Y^/CX^7D+5ZP/0COFIUZ^-R+'%L9FFQ9\K5]SI*H8?9EU
MDP]'S*C1J<&09N=?I5.UU3=FE@.PH58+SQ(IJY:DK;B1\H*X&DA@:-'XZ2X/
M78[\1V'5K3=,*Z]UE3*E9#"#]OAB//[L?0N1EJQ7T[)>L%^L,1J4I3T:":N)
M8R4AP<>2P-BS8\".TQ&CLLH"!D[@!X=JWXT8[1'C<\K+>/+3XW/)QXU>1CQ_
MT_)Q_%7D^/Q8_CG@!Y\ ' !P < /GT\.I6V[5.Z3Q3MDK%53Y&^)/>MMGRAH
MGQLIT[C$;SF' (O><O>7XV6_-_)5A#GE.)\6/'G^0[IM(JRR:==TP"P,I)2]
M/9NFRE)*Q<.G8-Q;D[YQDY0N$Q(D?S2G-QD)<=TG4=]A4M!82MI/%HN6@<#_
M -B,/WW:*_-Q[[2YG79ROU&?]BW[8;>^-U>":Q]U:]Y#]B,/WW:*_-Q[[2X[
M.5^HS_L6_;!\;J\$UC[JU[R'[$8?ONT5^;CWVEQV<K]1G_8M^V#XW5X)K'W5
MKWD/V(P_?=HK\W'OM+CLY7ZC/^Q;]L'QNKP36/NK7O(?L1A^^[17YN/?:7'9
MROU&?]BW[8/C=7@FL?=6O>0_8C#]]VBOS<>^TN.SE?J,_P"Q;]L'QNKP36/N
MK7O(?L1A^^[17YN/?:7'9ROU&?\ 8M^V#XW5X)K'W5KWD/V(P_?=HK\W'OM+
MCLY7ZC/^Q;]L'QNKP36/NK7O(?L1A^^[17YN/?:7'9ROU&?]BW[8/C=7@FL?
M=6O>1U(\#O26:;UH(PS=J+<N\=+[$RK-*+SRN!WFAJB^+!+SX2+[#,OSG/FG
M9=OVGFTGR^S[-/:8SE<^;U&.[#[.&9'_ )="48KH?^;A6N]K:=5KEM& [I4L
MY63&F),BX*I"_P![:0WCQ,S/Y/"XY?#AWU[6Q)M>^CZL^:L'GT. #@ X . #
M@ X . #@ X . #@ X . #@ X . &E_6S^T'-3U$FC.WYD4O=$=.R7=>Q=XRR
M:*-C5&V51N]6>G%Z/N'(3.P4T-+BJJ^TVDHH5D[E5>[T;6$EP^3\2&!7MS]5
MP VBL4^AVES38NF:K;';0+Z5WC<+FT9)E-4#MJQG*M?+*O<5GS0JH;.VNME[
M.$EV"[&K(= D8KQ/I]LL':H.O7KSGHCXO>_6Y51M]8:U);;]:[,4UL;U+&.Z
MJNU>#$I).QMQ=L!C\AJP681IZNC:NL%/K0JWW!]84@2.M1CMT6"+^9!-BL1Z
MM!WT\G+PVYAZ=?7CK<.[0F1X2[,[5[QLJ6/;V/?-#;.IH.G4QK2FAGY+PG4-
MINPGN*.C8<#88V 1//2,R3ZCI*"]*%$),8D#>VX[:"\YZ]&RVP2GIFZNMY[)
MW".H.U  <58&]";'V)?M05>@F81NB72FO=-K=:KT/8)RY/5XV8M;&T[P\9IL
MJ/#+4LK!$5NQSA,H'.GV8(,BX#V>?7?1S"(F^HSJ[$VEP[0-9W^;KJW[?@FH
M<7:NF-I#R([512PZUHEC0A>(:)&O5T0>SL*^.!=D#]>0IL%N':*Y8+P.DRJV
MZ#1P[.#;I\O$0M%7ZKNMVQ5[2IX'K5ZTB;K8J"4,V%WIVVU4H!JE6 ?TWRKS
M&B0<E+.1J*JQ(V%NGT3-6N,'KEP#TB"5@7(BNHS(VU@';CYCV[/-SZ] WBZ6
M;=U#VBNR'.H8*-&'I-/U+;(BQ=*+4=@<9NM$AEKU178!6QV5R;*H5K;F"WIN
M9<67A,IN'/A(D1>V> 9<?"9<G#YQM5P(#@ X . #@ X . #@ X . #@ X .
M#@ X <D>G'K6Z/ZX+.V6O:IU1HBN'JG0+6;,:7'UZTO-D+<6[LI&NMJA]74@
M8;!;7DX,D2H:G.0;-AL(-O9M):(+KQ68Z$F1WX]/-L_ 30-NKP=!2$7%2M8:
MF@4O:NRJ2+%%&]",&*/N$_;:9K:]T2U&Y@?7\P'')EG-ZC!@+%\=A6#)0@8?
M9;;:>(.-@L?)RE8S]5O,,F >J3H<)+%5T7D*/>W- G#,U\GH>^5B3:*RS! [
M!G3;B&-ZY%OQ*-YCOD?<)!VXQ8=5PW?[&:?G)SBXR(0#(^O7BMYK#&)CJ9\'
MI>JM"FUVA4?<B#U\#0LUJ)T^%R#\8W;KO6LRKC;(QS7&&*F/65ZIG+<Y;;<@
M1"-SMF7%^$3EF#%M\D)L9<7\/]-'F&.]P[+\&QL2DH&[H%Q-?U<$>DQY<$7J
M^VPJV: EJW9=HCG91^N:]EUN6/+:MV4[MLH1 $6[+JV/N!3LBQ52R7N7DZ"Q
MZ]?K]=_)Y/*,G1^H;HKV&/O\?9^E!*(U"LMN;F#3G35=]@1DUJH;KW+I,+<S
M$B+IZ< !2+9L03O.77 621 LP#(76PSG(>"5R9@A%CY=GD(^#S>3RB[6CJ/Z
M"3%0JZI5%KU^UA<# 85&/_N[G"6I(L"XI1M,A8"5J.4%BBX""I9)NW7ER,0E
MRZY9)<N79HD R./NC 6/KKV:M8O>=N] UCLPX:0H%:=MBU2Z6\S9NEB\CBU5
MB;.* X9 1='[#J>([KT#?YV_ADHCFYNU\-9(FSB9B<N4.*V"9@%NMRYMOF&W
M^J7M<2M>56=J$:"%:T)#<E:=%K%>15JZZ(*R7R+9(*%:'"F61IEZ2\8B3(\%
MN*79G),17),>>W*>"/*,A< ' !P UZZJ-3%MY:+M^K KT2/-M1&BH<?G-B7X
M[(L/L*J6 X[YJ?#6$#.?;""B"X@\X",!B$O#$(H.EP7Y#*PDCL=_+ZASBF]!
MV_ZS/%#Z"=#1X58V]L>\#;6 /C=3O&O2YK5@W7UD>HVJZI3*A6<4(0&GLWVC
M5\4U4-D'J5,V3+!S+3L5X.-";\EBT>3KYK\6G+9#7/A SA\;:X-BBU:%%LTT
MH5U]+VXER&?!(U)HNIU,!DN/HAI(+NC==4V+N*S$AB'.^ZC/)ZXF#+*C8\UR
MFA&C^-O+IM?98N?@TV"A=.G6F0RA.SMBD55^%?:G,%5-O:-UDP9>OI]PZ;5;
M0"W.&7MFPI]GR7HP7J4&P 5GOUY#CG[O Q7Y ;+%5S3 FY;.#GTVV<6G1PZ[
MC)%ZZ7CE=O%.K&EUVJKU4G6(D"79@ME.AR-8%IZC- 6;;X)JV#<Y)5XEL'2X
M:V"ZK.%NCB:BXZY$TFX5RN1*PE0B^WKH,BY!A\'TX=:.ME[:D40NS()[)JUN
M"P92-MDX(D#936OZE5J%<XP4B.FC1$S7!*EFB!+T?%Q)EDDW\;->=(RX9J4+
M"=&C3JU%8M5^<7P#H[JYN-H('B>VT%J@2O!IL":K.V''3E2TP5ZD.G$^1T_
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MP2>BY_\ 5R?]AR1 ]N+S4U?PP:C9_P#0D?['D7+;UT=) />FXUI7]Z6CY_\
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MR7ANA2J>7;FW#9.SCN++9:.+H0NNG+:,)W28+LJ0R-:5%=?!G8I(!66X$F&
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MO=]7ZVFR$FP1:I6 8>K'"$V8]6%A03T9B3!&9%2@7ZV&T( $'JP(+6*\.BB
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MN*B/S'5JDO.6F..*FEV0,J:4T)JWIYK9.I:FKKE: &#TBRSX+A<P8PX7E0H
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MY.WAP4BN 546P3)%BM)69KP03U_6246&H0=M54L.TJ<#LR&)K0L9)DFY3I+
M^F7F76@6/26S7T^3KPD/1"Z]--H/P*S985QJANQ7M-$IXHM53\(P>(SHM7[A
MC2 9D6%,B+&7,VH?7I50=@RCM4(N1WKDS7Q\QF9P(%ML'753)E0'W/5 21?@
MEHI&PKI0"1))^HQ[FYJ6SU"K7FLPH9BM()0B[QJ\ J]4G),?*#]D8L0EJ,B<
M*"PK6$D5^O78-[N! < .;OA+O^*Z@?\ 3Y7_ &=+\\0_#F_0/([^]R_\FGC?
MOP??TCK?]B%_CXHXP\^8H]9AP < ' !P < ' !P < .E/@S_ /C(V+_T(B_]
M?0N>X?@,?IQEG_=1G_-X@\__  @_Y@H/]L.?X)X=E^?3<>3PX . #@ X . #
M@ X . #@ X . #@ X . #@ X . #@!R-\,/M(S2-!TRF"GUQ(VS+VF$?>;7E
M"I 2M#W#.1F?%XL]G+++$RG<XS_20/RPK"FGW$YTONX39+62\:G1U&E%3GI3
M*,C.ZX\5LW\S8OZ*W\RM6DM#6'22C&*96S5Q8+#2#MV4_@6>J[;:36:+\&)6
M#DMPV&F>9W1^WN@[71]&RT<]$[$ CL]_CUZ@C2A^HIME8V".D)?[=ZSS":8M
M?9JBE9#PRRW;"U,62>ACF=,5&F;G"LHID<J)>4=-J$-"%2FNUYIUK)Y^8BLM
M'B)2IZY!-140#/L5J0:IB'#?-IE/30]3$RU-(:WY-J18EI[%(RBFZ3Q'<^^&
M>%&;^9BWY&:C*V8C8.CPJQJAZLU"BO IS&BE6XRNNZS[%J 5A51=JE(M#=]E
M7.40?-R%Q#+,REPT-L2BZ'I.(\=,AZQ919.4%NG9+]@4+)YR$ZK(<JS*=I.3
M5DQ9":6JK.IJOQVY6'7W9:C:F-O49I!-.RTN.YELEN7E*D$B.:$HP&F,:U$3
M96)24&K?YTUF>([+(VTVTZ=&G/G0 ] QN7J$@"TL-C8#[L8>W$RG,5N"Q;"[
M$1N/E&5([!#"$)9RE64Y:PGR<YQ_'G=^## CP-TC=7:A-MM0D*-J(VR1$RW&
M;KD]+*&L.]S26B03=M& B(M N$1PE+>26I*M!<%L1V/K^(ZP<]OCO!P < '
M#!O4/LT]JG7<4[580>59K)L;4.K*_)LJ9CE8!F-P[3J&KH%EL4<?*'SB(NNR
M+:@OD##*!I5HF1(E8C'0+YELU  77KUL-7[%NGJ='[&C:B%; Z3Y-GK>O=][
M"NEGS3M@3@4M&KGNGB76*F?KT?<D.?HD\2"[O=GV-PO8=Q)BUV-5+S @YB6=
M5:'A5HUZ;:/QXM.KB$5Z:NO:U=1VW0^OF]>L:Q"3H[MN;-7D58F'+4"=TUI_
M8>-7T"3YQ#%G-IU.;MV&:V*6D.Q1(6J"V!U<JMK+/W<IK (,K%?C\]M5[<&G
M0)S^_,D%?[51;)K.QF6P>WR%'=LM/>KC(>N5%>S=7:C!';''LML@&291VV;2
M%2R,.L"YJ45T>8FQV.\8D 29"33J\A'S&?X>H8(QX2RW+U-K8](T^0#;9M>I
M-1;5>ITMBMDZ[< ^V*M,,!IM/.0]J1O1>,3)UFYPPXZYK=*1FXH/%EP$;(2I
M\0%M.O1<ROY-(F=Q\)+!I]M<BS]86=JOU)1M&WQ3[=:59*&FDTSKKL]LD@C$
M*]2P5[D$)/1PZ@ ,C004>$&+IFE#SYPRY6J:$6Z\G2-C-<=636P]T$=#_L@O
M];O%12=SLYXL5U]* :_4,K-!M@=M\D&N!&197+4'VC1GQ.*R/(IA*(DFK H.
M^'>:>!;KMUZN3AL-N^! < ' !P < ' #B#0M$]?>EZM5YU9RX]9S>F]1P+5*
MHDJN]^ACT6U"W]NP[\%V_M/9%&V-N:-"6-?J>U:U"$UDO5'MSCY-7'VAO6";
M"%9F1^2^B_-:Q7(MI>2W"92Z/ZRNK&!4]H#:%-FKMJ&X;'+M$]"RJW.$OT;I
MPJVZ8<ZG%"5I-U=H"@'MP\'@ZRNK<=5DQ+P'&72-/'SG@C1Y-!\MSMP>3S"I
MH5L\)2>KVCK6,AWHV,/RJR0L@W8HWICJ4Z<+L-,T+(-%[X2J#,]\%4:O9Y6Z
M"%?JM'J,:]6P*Q+%EKG6"<6A.6<!D6G3MV\?\--^46U$#PE-AI=4'[#C[4FK
M3<ZJ5,1:FQTLURRR5@+9TVGBPFXDH%F:@.:W\S@[Y;&2J"Y7[L3<B]RE<FA;
M]0FVT&]VEJ/;K._%P:.#G$DL=7\))5*I)=H-BL+Q.=:&'\U\= T#9&ATLMHF
MHW(X:A>GG<\\A5SW5#:=K K/!)WN$6%@*]1(%&CU"G=\VB8 L/#UT]&KCUCV
MP-=]=NN(VTLU0[M O'L.P[0:"1!Y/IF>*.O7[JDZDC!6\.3[M2#DF?Z.:*"]
M-XFL4^7-"!A=;MY0.W%B%P.54,&CBX-NPB]=S/R"TKB^$PL5+H4\XUL,1ML/
M.U[9;*!%3^FT5I.24:J-7B=QR)(B<_LDN!7<"A\AND8Z4EQ$,@32]7.JAM4=
M)H&]\VFVOG_#S7$E(VGK@H]<V3M"XVG8H:AZK +NE*JUX#=,#MZW)-#L:A(R
M]47-&M@94://7ZPL[=UQKE_7TFO2O^$-+FS)9<RS$P2"+<!<O7@MKT< Z3:P
M8O4?75);VA-B$-CJK(>1>WQS41D6W;94)J4?A!T08\5C(4:3>DC@SBFU2G1<
M6([.D2YJY$MX($[X . #@!0E!@XV,(AC$&*3$EX,L84&SF&Y,(@.GQW(LV#,
MC.I4U(BRXSKK$AAQ*FW6G%MK3E*LXX :_P CI)Z>I0H.!<UTP@"$UO#U%'!1
M;'<(04CKP:&LX 37K,)AV!@?<>Y1MTMV 9:V1C1P)/LIPP))0RY*7.=";GSW
M\XJ;?TIZ OA"T$[5KR*2D7AH@Q>&FSUJ&#KLP1@=W=A<A D[!$VM@4UER56&
M3\(BW4"\B6>JJ0QN9+(/!%^;4*<MTD]/)]L]&/:XBFQUD,D["2"F+!;2==9,
M&,71PE-!UN<?? UA4HAL*X6!3-:'"8[=L,JN#++=IA#2\,'7KR#W!NE/0U?O
M$;8PFE2HMNB64E<F9RKI?9,#TK+%=@&IMA>KTNT/UR27R1VKL9R--DB77Q[%
MS/08"XL"<Y&X$W/KYN@AD^V4(1;S6O[!->E1BNM[5+M0%^+ECR'W2=2LM)+B
MB;;S+OG8@B!M9++D5*V<H*Q@Y-*\NC&4*"!A^/T==-D,0/KH_5PX76QU&DZV
M161!NU":S.ILH=<!619VNC3T4+9)$6%L&[(&&K#!)G1#]H-3!1.'-FNR,A-S
MZ^;H(2F?TX:7)6V;>95*;392Q)!:P2X9VSCH5KFQEM/#57,&.-10-TC I;62
M59@6H88@58N_-,5V,,*$)TN0$"(0.C7IQ&1FXL"@3(Z(HP0+%.IONR%3:\D+
M,I)*(6JA%RWKGU&U2"FN*(6,W.LR1-NL1:J!2E@-DR$-$G@!X8Z,>FMJ0S*A
MZY6*?:35,+4#N>P *9SE#(-EJ/*+M!K5!:-SZ<6;45JQ$PB=/KY.41("9,28
M3(O2@FY^L^76)=0^G356K[(#.Z]K<2G#JM5[;5:K3J^V@=3ZY%OQBG&[O)#@
MV4^:CGK%.U[3I$F-!3&'LSH!8NS#P8M-CGD@@9SX . '-WPEW_%=0/\ I\K_
M +.E^>(?AS?H'D=_>Y?^33QOWX/OZ1UO^Q"_Q\4<8>?,4>LPX . #@ X . #
M@ X . '2GP9__&1L7_H1%_Z^A<]P_ 8_3C+/^ZC/^;Q!Y_\ A!_S!0?[8<_P
M3P[+\^FX\GAP < ' !P < ' !P < ' !P < ' !P < ' !P < ' #FOX4OIR
ML/4#TW.2*1 DEKQJP\W>@X>$C+LTX)1!ECK*(@LX_I/3LCY+9>&PUA<F8^&0
M/C-N/S4(SKK=-R>?K^3BCAMJ>FTUXIK+*2NM]HD*;DM(+A6;:LZ@BNI:FB;2
M1FNPQK*JFN5&F'F$FM^*X4AM!:5.)))I=0DN%1H/&DM:C022TJ'S1#]\OMFX
MR_10,P.&S#<B,&DI>SCSDI,0^AV:M&&<.O"D-(&04>;H3&#MMBU)6RWY:O*T
MZ<:W4N(@QS;9<D.)CK29[]Y>+$LR)-U-$1--[TB2RDFC(TEIURU5E)<TLH)*
M5.&EM1F976=[F>C2W\Q.]T-[S45QD@!N*7EU/:BA2XN>PPW%0A;*6,QY+\B.
MXPZWGQMO,I=:9:6I*T9;A1$O-.H:RWG Y\IU.+%$CK;(TV;)&#!@6M:%-FDS
MLM)&E)*-)D9--8DJ2@TB]1JD9F1X4X=&@M!$=U:B+49$>$O(7"5A]#'@W]2'
M*K0;5MBTA\@"FW"<<B#"Y:4QYA4(JI4L<^B,O&'8K).62E.PV7<84H9%'2<?
MT9*>>H?@^9$R*%2ZWE34(A09F5DIMZ)$)&;)BDL*>=C*2V>^;1(=E.J:2JQG
M':CN:ED,\I*%Y@WUI-!OGB0@]:6])EY"49F9?5L?".DO/1(NH< ' "A<(QVE
MJ;4W.RI&<ISEL62=1G./^2XU$6VO'^12%J3G_%G@!';0)I]XKQ>HW2L1+;5;
M!"='':U9:E(. 3(][Q=K"*""8J3 GQ7/$G*X\J.ZTK*4YRGQXQG !AB;TM])
MQ,77097IJTZ5#U+-C561A72=>)P0:[C/'%;<X-C3JO(:C.VHH'$D[*ZA.'#I
M 9 FE5RY,1AU 3<]I_Z:"YAE%=)UDY,BD7*  60@W+]HD*<JB8S,AW[T==J.
M;M%DY#=M'MF:H^_6%6%E:"JJ\^\&S+R.=<C*"!1NZZU(_-($GM9U9X@7G)*%
M9SNO&5RR1)!T/:$$)\E0/+TN:BRUT!8$RGUN/)-!!)/"\31\1YH%^@6 IH[I
M\-CHP@SI#7)85#J@:AQ!A/4PJ</C4BNPR0^OT]B'*KCL=JL!(!@M"$@4-X%C
MXA0A&B16F9DA#@+GM%.G0G3FF /%8T5K?(T5B/@=!7J84Y%B>:YO^6<M,KKJ
MD84E6U]HJ4K.,J=5LB^*=RM5N/Y( N>WKU(A(Z1K33^M.S_9WK&K4=3<:="0
MY5->M 'O-"<U@D1CJ>&!(SJV9Y"+%FS$+6I,F5&COO86XPTI !D7O2-[(C\'
M+?1< '>D;V1'X.6^BX .](WLB/P<M]%P =Z1O9$?@Y;Z+@ [TC>R(_!RWT7
M!WI&]D1^#EOHN #O2-[(C\'+?1< '>D;V1'X.6^BX .](WLB/P<M]%P =Z1O
M9$?@Y;Z+@ [TC>R(_!RWT7 !WI&]D1^#EOHN #O2-[(C\'+?1< '>D;V1'X.
M6^BX .](WLB/P<M]%P =Z1O9$?@Y;Z+@ [TC>R(_!RWT7 !WI&]D1^#EOHN
M#O2-[(C\'+?1< '>D;V1'X.6^BX .](WLB/P<M]%P =Z1O9$?@Y;Z+@ [TC>
MR(_!RWT7 !WI&]D1^#EOHN #O2-[(C\'+?1< '>D;V1'X.6^BX .](WLB/P<
MM]%P =Z1O9$?@Y;Z+@ [TC>R(_!RWT7 !WI&]D1^#EOHN #O2-[(C\'+?1<
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M"8)#IH-LUWBQF%*WBC391J3IO:^D9?[TC>R(_!RWT7-D#%@[TC>R(_!RWT7
M!WI&]D1^#EOHN #O2-[(C\'+?1< '>D;V1'X.6^BX .](WLB/P<M]%P =Z1O
M9$?@Y;Z+@ [TC>R(_!RWT7 !WI&]D1^#EOHN #O2-[(C\'+?1< '>D;V1'X.
M6^BX .](WLB/P<M]%P =Z1O9$?@Y;Z+@ [TC>R(_!RWT7 !WI&]D1^#EOHN
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MPQ7I,.G079N4"SHDJ?*J2<FHLE4JE(.9'C?&)N,SDM1G3F,:G[JZG[38]?\
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M@*+B*+9:CBTSY;X#;-J'1 &;>"W)ZNGS#:QS7W6+)=D2<]1>MQF9)W8A)L=
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MPAOTRI7]V8G^:U@?57X"_P#Y592__4&I?_CF2X[ \T*/:8< ' !P < ' !P
M< ' !P < ' !P < ' !P < ' !P YY^$JZB36@- 814I[XNY[+/-TH,5BKRU
M+##5091&Q%H;V,>4S,1 C(%Q'VE(D1))9J?&6EZ(E6-7[K>4DO)[)5Q-.<6Q
M4*J\5/9D-GA<C,J;6Y*?;5_1<)I.9;61DMM;Y.H,E-D96'**HG3X.\,TNR7"
M90I/SD),C4XLN,DEA(RTD:B,M)#E@GI)I8^]F!'[=0DT1%KAAZ,+[+RMD2=@
M#*!+O4JK3JYG_N<3''QLF'[FI60DF ]&&1WLGI#D>/Y<JFY%2%U66RK*F,<9
M,"8XTP3>*M.UF/2'JHJ Y#.Q(C);;[(<JAGV*XRI#"#[+<PIM+<1MMY39S4+
M3@59!_[P;R63>-M2/HDDL9O?---DEOSWLS(:/UO4H.N(SMFLDP_>L:H9QYO9
MM9O(ARMAC@A>7F14HQ>1>X$&!"(RVXDPB&:C.R$0%./J8G,K>P7*'<GR5@L9
M/LNSZL[/KKN2C)9BHY,J1'=R@;@R9"UTI$IRNQV([$A]#3[T)+2G4L&I1MO(
M-=U;2V@F2-:C6X3/])NW?$I49FC%G"(B5:ZDZ3L=[FDSW)\'S$:#[3WG767U
MR6:^V@.T^[A*77FQEE)P4/.)1_12MU+&%K2G^BE2LX3_  YG_P %"D)H>7VZ
MA3&UK=:I[+4!IY9));K<.LS6$.+).]):DMDI1)T$9G;1872,HC4X1'?">$_*
M1F6KU'PEJ/60ZO\ /=P[8< ' !P P?U&[+TUJ/4%AO/4"V.<U+#+T4%:,&*P
MY< Z'[K?ZO2:R^6!-CRF'1<:V6$%)(D7X3D(##:>/3W8L(8_*9[$65*A/MRH
M4F1$DM8C:D17G([[9J2I"C;>:4AQ&)"E(5A45TJ4D]!F0Z51I=.K,-^F5:GP
M:K3Y1(*3 J46/-A2":<0\V3\64AUATFW6VW4$XA6%Q"%ILM*3+"=JZA^BJ@W
M;:PJX.Z_J]ATW=:?:=GV(O18L"#7]A7*H=Y5.TOV5P,EHG:YE;))%HL(R1.*
M05$% Y4V,XY(C)[)U>K&T3!U2HFRF$=-2R<V2;14Y3J7E0";SN H1O(0Z<4B
MS!NI2X;>))&5O+)7)DI*IB<G*$4Q=63E J45(IY25UU$=R&BMJ?*/G55=$1U
MV*FI&KLQ,9QQDGB:6I)R9@1T)5:;8+Q%%])-<(:PLL!FU7!B%IT1-UY<7R"D
M"VK!8&VH[]2LKQ1I:8#9*6/*.$&E)CXS(1G&.\]E7E3(CN0Y&4M??B.M*8=B
MO5BHNQW6%)P*9<87)4VMI2-ZIM230:=Z96T"RQ-S+<W@3V*K!W/LB(54C24S
M(U2B9)T&-/CRT+SJ);$QF B0U)0YWQ+[;B74KWY*)6D5Y3:'1_O(#;$72QZ/
MN@34UBL,>XCMCR:5+;H!.J7 S0)ILV-M:U*K@R98@1* $L4UF&.L,/L9 N9-
M@S65N]"G5>JTAU;U)J4^F/.MFTZ[3YDB&XXV>DVUKCN-J6B^G"HS(E$2B*Y$
M8O=>R6R;RICLP\ILGJ+E#%CO%)CQJW2X5588D$FQ/,M36'T-NX#-)K025&A1
MH49I49'.YVPNG(^T.II*\:3-,Q ([8 FJSK+1234:L5N$.M0F[#@<B:\AD"
M'+$V,=9(T5(\5"4.,1IK#&8TC/ S-F1WG)+$N2Q(=0^VZ^R^ZV\XB2A3<E#C
MJ%I6M$AM:T/I4HR=0M27"42C(^Y+H])G0V($ZET^9 C.PWXT*7!C2(<=^G.M
MOT]YB.\TMEIV"\RT]#<;0E<9UIMQDT+0DRA0WJ0Z6+[/JUB&7W6-L/0;U+HF
MNYS4^M%+')L)HX.U^8EZX<=?<)D@TN47:&F+!5%OC9(IN=YQ)?B17T)AN5*9
M8D1F9,AJ-,)HI<=MYQ#$HF',ZP4AI*B;?)ETB<:)U*B;<+&BRM(Y)%,I\J7
MJ$JGPI,^EJD+IDY^(P]+IJIC)Q9:H$EQM3T-4N,:H\@XZVS?8,VG,;9X1D0%
MOG3]LLP:I4[8=5NI<XNX1XWH8;'6L?$G4-FO2+0+,$P,F?!#%QK%J!/*%$GX
MT]QJ<AQMA2<*SCKCN"VC>I#2!-/9IV35!Y1RR[)J4"MFS, );#9S4MUNNOKO
M&K]7*2(ITZV/M&O+A#BR14"4P3CA9,X>Y(B8[;@+'ZN?4(9GK/Z9\T6M[-C[
M9J<^@V; %+5K&EH) ,#D6*X:KHL2%;I<62ZBI3H-@W/0&K!%/^8NUJ$5>(GL
M#X<*0ZD)L>P2F7U/Z!'V:NU,AM:EPBEP DK34)#YT?@):*T%JKEW-V )8$2%
MA984/5&^_B!3,YN"R-4B4E];.<KP$<8FX+;FJ;1-KPRL[.U[8B5N#2K'5!X*
MZ5LO-L]>@R9,*:=KT0>2D/F@T.9#F1)10:W)@QY,62PZ^AUAU*0#(7 #\5Y6
M4J\G.,*\6?)RI.5)PKQ?PRI.%(RK&,_QRG"DYSC^&%8_NX .9+G65M'4,':I
MK=HRK;.#T&T[I@>+2^O2NOB FGZ U_!V->+43CW7<VQ56,B8%$XXRMU<(T-=
M0791B>54/GO30P3;21%PVYQZ;/X2P*!'Y91IJ]LVJ/YX(,!C,4T*9K]I(D+D
M"H#!3,VL128>N7$[3"*(YF\C:%.E#VBF*H&MAVM6D"$ 1<?7S</%?B%\KGA!
M'YC](C6+1]F'Q;+,KH@E8A-IK)07#)2]A:/U-9Y T4F0D^1'!K[U!4)H6A41
MF>;K\"ZD\,0IH6O"[B"QZCU_A:_7_6UJJ7A+JY<Q0,R*T;M&)!)U65LN>Y8$
M0ZPH;JQE.C),>T1F+$T+DGRC\'?=:7D*&9DBWI04_D1:# 1RO'SP+='KZ#$F
M9Z\9 _1>I-D&].6TC>MA5Z.>,U(!&-BZ8&C)TCM#?1!T'M2Y@ 5,N+K%.U49
M'9#U@D7+#+66"AK(T#B+GF((+>3J=O6?((\<\(:S/M9.I:[UK8S),58\,"FG
MABR7[2!(FT7:CV()4R'>E<KD*V.W*F2  V1"/W4:&G/NB[G# VH6;JPH%CM?
M\=NKKL$MI?A#]:;#V95*33:3?CE3M_<\@7M.*&FN4YT-:+-M>EU6R>>LPGH,
M0(5L^E+[&<=-E LW(G%>/@X-A&D#2ZV"W6_DZ1D;=G6)3](;+ Z\-4^YG&90
M.G6:TVT,,>56:<"V#=B&OJF1*'I##=:A1LV$22DV&39;#5H 6OQ>\HTTO/D1
M SX1UZ]?QMKQ%\(W,MRQ :DZ6L(ZQXV?4*9<5WF0Z&%54*<N'26/>F)'$8M>
MMA8L8KG5K3>XNQ!,!8Q<:=+8(GZO"!3;@$VV^;GZ!FR'UK #FC[%NRKZUO9R
M("N%,U\FJ1H;I"R2[I8H%)5:@;(FJP[4=GS-6V.W$:)?1U9!V6PC[I0[P%B
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M2L"4H)TWD)(L!I3E%*4;J7GM:5+PI496-5C,S,]FLKVX;Z- ZP<]8B[!P <
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M*L$@7+/29;,,>RW)D&Y0,+)+O/)6X2D!Q;TU3S@^(ID N3-+IT<7&"1ZG66
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M^4;4?%:%Z3?]T'FGY!=$_K'JO[NQ/S4/4@TS\05G_(0K[EX^4;4?%:%Z3?\
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MYP]'^K3WHZ(^3MV_6#CO>Q?*GH#?_5YP]'^K3WHZ(^3MV_6#CO>Q?*GH#?\
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MS::F,ER/,Q-H^,FNRR,Y/QD;_P 71DIP.M6.PU*Z=MY=2EFU)T[Z]UMN2'I
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M5&DC(L1%J5:Y<!BA3+:U$M3;:UD1H)2D)-1)5K22C*Y)5;25['PD,B!MR,K
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MTNG=M%S<3;"X>C2M.C"L]\6BQC*& @;#L!_ @7A\4N4X+>Q B=J-<G>/SUR
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MH+D!,>>Y!-EQ],@U&W'C2,X2TM-$1&4DDX<)F1H,[Z;%OKS"1F < ' !P <
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MM>8#A<<?&F.M(E.PH4 5#CQLS79<U26U+E39+JU.9"#.^DQF3@ X . #@ X
M<(Q/1EU,Z8I.M3D<O'8;Z5JM>+'IN+1GK/<[0U;MH:?M5CVH,*UFO5PD8NXP
MYU()J@P2&%0I<I.L25D&L)CLR'$8"HCX#U';F,OP&8IW3[UY6^P1,W>^C"U:
M-%-67<V&>L$K 0+'BR=<W6[ZTC0>^WQ$F15]P#[L;IAF)K^(;QKV/6*S(V[+
M',N41(+ES6T<.@ROQ:].G7P"S6OIQZX[IKLW2K98CE@#6/4)&EV.NN;L6Q*-
M=0Y*OA1Y_=[AU ]GR.GTVXS:(H[0Z<,0H3IF&38U[7,9C1*H$:/7R<_+P<>B
MTT"TKK@M!^J6T=<K*NM5/>Y^HB0MI)6>D-'M&4/8=?:K%WOU8FJHMI(72R5M
M&R@Q6PD6[?6;$/:J)AO4%P9L5?V#KT&@K^0N<O/JOS:RX<3T;2?7;8ZGJS94
M]ZTP;"O0(FLGP6P]EFIFUH-OO9[I+L^XC$6= .ZZ,5V#<6M87=J)KZ%L'6DN
MGR8LK$&=2Y=A;KHL),RU:_)JT7(OP/CX=-S.9A>GWKM,9K$/:]KD6J&*&=)1
MZSX'[:L@QLC>=0[$Z6+%L/T6>%V ) 7 ,0:%OPK,B'*8&*EC%G#22U_N$*P#
M*IIT%R\GSN<CMZ[=%M.=^G#3W4E3J=-IVV7EF"J-),4S!>/M:9!UE*+,4B@@
MJG7ZUKVM5YB?27*U*'7B):+O6)-7FRE3H9B'#N[QH6QJH!V/KIX=?4_+MUUU
MGH#J1TDNC4G7(N5K6O;"V36*;9QPT73)! 7K.-2TR-MWRQ6K16M*-J8?9 D&
MBU6FZ#O-EK=>V(:P?-Q[DLP9?!#Q(1H/K_'1>YF8K[OTP=:!_4)36YJ]638(
M^Z:#>K-H&2=S3QD_/4';-4URM6"YE+!+AX=GZ=&V.#=<$]6P,IK9-VX#B@>H
MLI&9\P";E?1MT:+Z+F?+JX?.)?<-%]<[(TTW2-GV5VX'*K,D5RSD]MS,UBD7
M"5:MP2+I&,U*1 7%.0K9KTKIBJZQ\T'$(>NK'5S-L:]%R/?$_801P<?^FKCT
M'<5-YZ?>M 0^]^S+;EJ+5R2?MZK(&M>S+2=.&:.W:]/E:0$JT_%MH1.N6%J-
M^VMX@6%; I)&>-("ZF1M306-4F:L#UW+KZN =$=4#;N&U=K<1LPLR?V.+H=1
M'7XY'6RZP9ND( /C6<HR[''B6'FYYMN;*0\P*%LNI=PXT-@-J3%:"!Z-M[%B
MZDUY9-DDA4LL"IS4 Q:4PGF67A%-9+0&[G;5]MC.'XE(JKIBXD(36,RR$ %)
M@P<9F26. &LUFZ[M65&1M]LR,LCV-;2B\"M0ZY7[;<+!LN568.V4VIT*"JM5
M+NBQ8&S:)W!5I9*;)>;8D4(F3(M#1I*M.G FW79Y1>Y77=TX"XUQ4;LEL'$M
M=U<=<+T&CZIVP;(@0!!QZ)DLPP$I$]T^'CDF%#5F*^V2&NR9 S,>0ZT:$.30
M6/KUZV/88CNQ.O'6=<DG:[0PY^^[ J9BN0[;2386X:LE5\'8)YL7BS22-XIL
M6/('P2 "?'>3%:=RYY+"VW?$1"I*@(K^3BT\UQD^S]4E!HRY;EV@6:NP0.LM
M>[*N3N:Y83A*JL[5-V,#1@LP!6PY<P[*E3J-?4GYRXT4?6/1^-DH\ELPTY%!
M;KY!&Y/71TV1X<PEZ4W.2+A4.D[.<+P=,[HFAG*'LA#CE%LK!F-K]P4\/M#4
M8@Z)RB9VS[0<ZOLDI!%\P@$1GU(1J[>$!Z?ZO0B6R <ZV7JKC:_9K,P4KNO=
MC8#6>#5=7V#:Q,;2+7,IS-+LUF:! \QI -%DA*&$79H\M+@% A4:P"QWMQV_
M 4-R\(%INHPVW,1[$6G-&=ICCV(]2V/'!4N'J\=U SYDN[6)_7^8U>*3E=.U
MRAJJ3L9^TM/Y:?%BSP]X/-. L?JX2X=7K%]L7A!^DRHPS$^T;** (X0LV(D=
M[ZSVK >G+<>VA'42 1I-);DV6OLOZ6VDT[8J^T2"8=I\MI,Y;A("DL"QZ./^
M!_B0V*U[LL+L5Z]Q12<)DZ_NF*<64S*9GP):B%/J.Q:V6%D(_DM3()RA7ZHF
M_&E&/,IA"6*RY)4/S+D!%K=>.WX#(_ !P < /G*_LDO_  9-!_Z=W?\ 5_:N
M;^^#Y^D5<_L5/^.C#1V[K_,-&_M=7^#?'QN<]9#S ' !P < ' !P < ' !P
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MPTL1F%-I+&I1"4ZTZIWL5(2TVKR494X%*B(CL77J0W(X%(< ' !P < ' !P
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M %4:;YY#^$!^E]+_ +MQ?\SJX]4;AOZ*U+^\$G_+J6/H+YHL;H#@ X . #@
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M+YHL;H#@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X
&. #@!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6948890912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-Based Compensation Expense for Stock Awards</a></td>
<td class="text"><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Total share-based compensation expense for all stock awards consists of the following, (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"><div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="padding: 0px;;width:82%;"></td><td style="padding: 0px;;vertical-align:bottom;;width:3%;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;;vertical-align:bottom;;width:3%;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended<br/>September&#160;30,</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2018</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Research and development</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">781</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">630</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">1,332</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">1,307</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total share-based compensation</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#160;2,113</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#160;1,937</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Summary of Stock Option Activity and Related Data</a></td>
<td class="text"><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Stock option activity for the three months ended September&#160;30, 2019 was as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"><div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"><tr style="font-size: 0px;"><td style="padding: 0px;;width:47%;"></td><td style="padding: 0px;;vertical-align:bottom;;width:8%;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;;vertical-align:bottom;;width:7%;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;;vertical-align:bottom;;width:8%;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;;vertical-align:bottom;;width:8%;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/>Options</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Weighted-<br/>Average<br/>Exercise&#160;Price</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Weighted-Average</div><br/>Remaining&#160;Contractual<br/>Term&#160;(in years)</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Aggregate<br/>Intrinsic&#160;Value</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Outstanding at June&#160;30, 2019</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">8,356,961</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#160;3.20</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">3,083,333</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">2.50</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Exercised</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(46,667</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1.54</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Forfeited / Cancelled</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">(49,186</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">1.81</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Expired</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(527,080</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">6.89</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at September&#160;30, 2019</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">10,817,361</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">2.83</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">8.5</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">501,818</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Vested and exercisable at September&#160;30, 2019</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">4,114,253</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2.52</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">7.3</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#160;428,455</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Fair Value of Stock Options Weighted-Average Assumptions Used</a></td>
<td class="text"><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following weighted-average assumptions were used to determine the fair value of options granted during the period: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"><div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="padding: 0px;;width:85%;"></td><td style="padding: 0px;;vertical-align:bottom;;width:5%;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;;vertical-align:bottom;;width:4%;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended<br/>September&#160;30,</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2018</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Risk-free interest rate</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1.8</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2.8</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Expected life (years)</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">6.0</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">6.0</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Expected volatility</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">73.6</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">86.0</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">0.0</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">%&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">0.0</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">%&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Weighted-average grant date fair value</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1.63</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">3.11</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6775269440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Changes in Estimated Fair Value of Warrant Liability (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_FairValueMeasurementsSignificantUnobservableInputsLineItems', window );"><strong>Fair value measurements Significant unobservable inputs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Beginning balance</a></td>
<td class="nump">$ 17,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss', window );">Change in estimated fair value of liability classified warrants</a></td>
<td class="nump">9,269<span></span>
</td>
<td class="num">$ (4,962)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Ending balance</a></td>
<td class="nump">8,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_FairValueMeasurementsSignificantUnobservableInputsLineItems', window );"><strong>Fair value measurements Significant unobservable inputs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Beginning balance</a></td>
<td class="nump">17,613<span></span>
</td>
<td class="nump">46,313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Reclassification of warrant liability to equity upon exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,068)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss', window );">Change in estimated fair value of liability classified warrants</a></td>
<td class="num">(9,269)<span></span>
</td>
<td class="nump">4,962<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Ending balance</a></td>
<td class="nump">$ 8,344<span></span>
</td>
<td class="nump">$ 50,207<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_FairValueMeasurementsSignificantUnobservableInputsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Measurements, Significant Unobservable Inputs [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_FairValueMeasurementsSignificantUnobservableInputsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3) and still held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6774897264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_ClinicalDevelopmentProgramsPolicyTextBlock', window );">Clinical Development Programs</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Clinical Development Programs </div></div></div></div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Our approach to building our pipeline is to license promising cancer agents and build value in programs through development, commercialization and strategic partnerships, as appropriate. Our drug candidate pipeline includes: </div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"><div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:13%;"><div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:left;;vertical-align:top;;width:4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:top;;width:2%;"><div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">ME-401,</div> an oral phosphatidylinositol <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">3-kinase</div> delta (&#8220;PI3K<div style="font-family: symbol; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">d</div>&#8221;) inhibitor; </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"><div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:13%;"><div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:left;;vertical-align:top;;width:4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:top;;width:2%;"><div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Voruciclib, an oral cyclin-dependent kinase (&#8220;CDK&#8221;) inhibitor; </div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"><div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:13%;"><div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:left;;vertical-align:top;;width:4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:top;;width:2%;"><div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">ME-344,</div> a mitochondrial inhibitor targeting the oxidative phosphorylation (&#8220;OXPHOS&#8221;) complex; and </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"><div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:13%;"><div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:left;;vertical-align:top;;width:4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:top;;width:2%;"><div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Pracinostat, an oral histone deacetylase (&#8220;HDAC&#8221;) inhibitor. </div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_LiquidityPolicyTextBlock', window );">Liquidity</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Liquidity </div></div></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">We have accumulated losses of $234.2&#160;million since inception and expect to incur operating losses and generate negative cash flows from operations for the foreseeable future.&#160;As of September&#160;30, 2019, we had $65.9&#160;million in cash and cash equivalents, short-term investments, and common stock proceeds receivable, which we believe will be sufficient to meet obligations and fund our liquidity and capital expenditure requirements for at least the next 12 months from the issuance of these financial statements.&#160;Our current business operations are focused on continuing the clinical development of our drug candidates.&#160;Changes to our research and development plans or other changes affecting our operating expenses may affect actual future use of existing cash resources.&#160;Our research and development expenses are expected to increase in the foreseeable future.&#160;We cannot determine with certainty costs associated with ongoing and future clinical trials or the regulatory approval process. The duration, costs and timing associated with the development of our product candidates will depend on a variety of factors, including uncertainties associated with the results of our clinical trials. </div></div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0);font-family: &quot;times new roman&quot;;font-size: 13.3333px;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: 0px;orphans: 2;text-align: start;text-indent: 9%;text-transform: none;white-space: normal;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;text-decoration-style: initial;text-decoration-color: initial;float: none;display: inline !important;top: 0px;;display:inline;">To date, we have obtained cash and funded our operations primarily through equity financings and license agreements.&#160;In order to continue the development of our drug candidates, we expect to pursue one or more capital transactions, whether through the sale of equity securities, debt financing, license agreements or entry into strategic partnerships. There can be no assurance that we will be able to continue to raise additional capital in the future.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Basis of Presentation </div></div></div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) for interim financial information and in accordance with the instructions to Form <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> and Article 10 of Regulation <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">S-X.</div> Accordingly, the accompanying financial statements do not include all of the information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying financial statements reflect all adjustments (consisting of normal recurring adjustments) that are necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. We have evaluated subsequent events through the date the financial statements were issued.</div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The accompanying unaudited financial statements should be read in conjunction with the audited financial statements and notes thereto as of and for the fiscal year ended June&#160;30, 2019, included in our Annual Report on Form <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> (&#8220;2019 Annual Report&#8221;) filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on August&#160;28, 2019. Interim results are not necessarily indicative of results for a full year.</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Use of Estimates </div></div></div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. We use estimates that affect the reported amounts (including assets, liabilities, revenues and expenses) and related disclosures. Actual results could materially differ from those estimates. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Revenue Recognition </div></div></div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">We recognize revenue when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. To determine revenue recognition, we perform the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. See Note <div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div> for further discussion. </div></div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Cost of revenue primarily includes external costs paid to third-party contractors to perform research, conduct clinical trials and develop and manufacture drug materials, and internal compensation and related personnel expenses to support our research and development performance obligations. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Research and Development Costs </div></div></div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Research and development costs are expensed as incurred and include costs paid to third-party contractors to perform research, conduct clinical trials and develop and manufacture drug materials. Clinical trial costs, including costs associated with third-party contractors, are a significant component of research and development expenses. We expense research and development costs based on work performed. In determining the amount to expense, management relies on estimates of total costs based on contract components completed, the enrollment of subjects, the completion of trials, and other events. Costs incurred related to the purchase or licensing of <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development for early-stage products or products that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred.</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Share-based Compensation</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Share-Based Compensation </div></div></div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation expense for employees and directors is recognized in the Condensed Statement of Operations based on estimated amounts, including the grant date fair value and the expected service period. For stock options, we estimate the grant date fair value using a Black-Scholes valuation model, which requires the use of multiple subjective inputs including estimated future volatility, expected forfeitures and the expected term of the awards. We estimate the expected future volatility based on the stock&#8217;s historical price volatility. The stock&#8217;s future volatility may differ from the estimated volatility at the grant date. For restricted stock unit (&#8220;RSU&#8221;) equity awards, we estimate the grant date fair value using our closing stock price on the date of grant. We recognize the effect of forfeitures in compensation expense when the forfeitures occur. The estimated forfeiture rates may differ from actual forfeiture rates which would affect the amount of expense recognized during the period. We recognize the value of the awards over the awards&#8217; requisite service or performance periods. The requisite service period is generally the time over which our share-based awards vest. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Income Taxes </div></div></div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Our income tax expense consists of current and deferred income tax expense or benefit. Current income tax expense or benefit is the amount of income taxes expected to be payable or refundable for the current year. A deferred income tax asset or liability is recognized for the future tax consequences attributable to tax credits and loss carryforwards and to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. As of September&#160;30, 2019 and June&#160;30, 2019, we have established a valuation allowance to fully reserve our net deferred tax assets. Changes in our ownership may limit the amount of net operating loss carry-forwards that can be utilized in the future to offset taxable income. </div></div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Financial Accounting Standards Board (&#8220;FASB&#8221;) Topic on Income Taxes prescribes a recognition threshold and measurement attribute criteria for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div> to be sustained upon examination by taxing authorities. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. There were no unrecognized tax benefits as of September&#160;30, 2019 or June&#160;30, 2019.</div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">There have been no material changes in our unrecognized tax benefits since June&#160;30, 2019, and, as such, the disclosures included in our 2019 Annual Report continue to be relevant for the three month period ended September&#160;30, 2019. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Recent Accounting Pronouncements </div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Adopted Accounting Standards </div></div></div></div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In February 2016, the FASB issued ASU <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-02,</div> Leases. The new standard establishes a <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> (&#8220;ROU&#8221;) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases are classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after July&#160;1, 2019, including interim periods within those fiscal years. See Note 8 for further discussion.</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_ClinicalDevelopmentProgramsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clinical development programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_ClinicalDevelopmentProgramsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_LiquidityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Disclosure In Its Entirety Pertaining to the Accounting Policy In Respect Of Liquid Resources Held By The Entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_LiquidityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32247-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32280-109318<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6943818688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.00000002<span></span>
</td>
<td class="nump">$ 0.00000002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">226,000<span></span>
</td>
<td class="nump">226,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">73,655<span></span>
</td>
<td class="nump">73,545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">73,655<span></span>
</td>
<td class="nump">73,545<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6639425888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BeiGene Collaboration<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">BeiGene Collaboration</a></td>
<td class="text"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><div style="display:inline;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note 4.&#160;&#160;&#160;&#160;BeiGene Collaboration</div></div></div></div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In October 2018, we entered into a clinical collaboration with BeiGene, Ltd. (&#8220;BeiGene&#8221;) to evaluate the safety and efficacy of <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">ME-401</div> in combination with BeiGene&#8217;s zanubrutinib, an investigational inhibitor of Bruton&#8217;s tyrosine kinase (&#8220;BTK&#8221;), for the treatment of patients with <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">B-cell</div> malignancies. Under the terms of the clinical collaboration agreement, we amended our ongoing Phase 1b trial to include evaluation of <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">ME-401</div> in combination with zanubrutinib in patients with <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">B-cell</div> malignancies. Study costs are being shared equally by the parties, and we agreed to supply <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">ME-401</div> and BeiGene agreed to supply zanubrutinib. We record the costs reimbursed by BeiGene as a reduction of our research and development expenses. We retained full commercial rights for <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">ME-401</div> and BeiGene retained full commercial rights for zanubrutinib.</div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6633010768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note 8.&#160;&#160;&#160;&#160;Leases&#160;</div></div></div></div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">As of July&#160;1, 2019, <div style="letter-spacing: 0px; top: 0px;;display:inline;">we&#160;</div>adopted ASU <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-02,</div> Leases, using a modified retrospective basis method under which prior comparative periods are not restated.</div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The new standard establishes an ROU model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. In addition, the FASB issued ASU <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2018-10,</div> Codification Improvements to Topic&#160;842, ASU <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2018-11,&#160;Targeted</div> Improvements,&#160;and ASU <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2018-20,&#160;Narrow-Scope</div> Improvements for Lessors, to clarify and amend the guidance in ASU <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-02.</div> <div style="letter-spacing: 0px; top: 0px;;display:inline;">We</div>&#160;elected the following as practical expedients from within these ASUs: 1) an entity need not reassess whether any expired or existing contracts are or contain leases, 2) an entity need not reassess the lease classification for any expired or existing leases, and 3) an entity need not reassess initial direct costs for any existing leases.</div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">As of July&#160;1, 2019, <div style="letter-spacing: 0px; top: 0px;;display:inline;">we</div>&#160;had an operating lease for our office located in San Diego, California. We have leased approximately 20,800 square feet of office space under a lease which expires in May 2020. </div></div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As of July&#160;1, 2019, <div style="letter-spacing: 0px; top: 0px;;display:inline;">our</div>&#160;remaining minimum lease payments were approximately $0.7&#160;million. Using a discount rate of 8% and a remaining lease term of <div style="letter-spacing: 0px; top: 0px;;display:inline;">ten</div> months, <div style="letter-spacing: 0px; top: 0px;;display:inline;">we</div>&#160;determined the ROU asset and corresponding lease liability at the date of adoption was $0.7&#160;million. There was no cumulative adjustment to our beginning accumulated deficit balance. As of September&#160;30, 2019, <div style="letter-spacing: 0px; top: 0px;;display:inline;">our</div>&#160;remaining minimum lease payments were approximately $0.5&#160;million, our lease liability was $0.5&#160;million, classified as &#8216;Accrued liabilities&#8217; on our <div style="letter-spacing: 0px; top: 0px;;display:inline;">Condensed&#160;B</div>alance <div style="letter-spacing: 0px; top: 0px;;display:inline;">S</div>heet, and our <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset was $0.4&#160;million, <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">classified as &#8216;Property and equipment, net&#8217; on our Condensed Balance Sheet.&#160;</div></div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6948954896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">The Company and Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note 1.</div></div><div style="background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; line-height: 107%; font-family: calibri, sans-serif; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></div><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">The Company and Summary of Significant Accounting Policies </div></div></div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">We are a late-stage pharmaceutical company focused on leveraging our extensive development and oncology expertise to identify and advance new therapies intended to meaningfully improve the treatment of cancer. Our portfolio of drug candidates contains four clinical-stage candidates, including one candidate in an ongoing Phase 3 global registration trial and another candidate in an ongoing Phase 2 clinical trial that we intend to submit to the U.S. Food and Drug Administration (&#8220;FDA&#8221;) to support accelerated approval of a marketing application. Our common stock is listed on the NASDAQ Capital Market under the symbol &#8220;MEIP&#8221;. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Clinical Development Programs </div></div></div></div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Our approach to building our pipeline is to license promising cancer agents and build value in programs through development, commercialization and strategic partnerships, as appropriate. Our drug candidate pipeline includes: </div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"><div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:13%;"><div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:left;;vertical-align:top;;width:4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:top;;width:2%;"><div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">ME-401,</div> an oral phosphatidylinositol <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">3-kinase</div> delta (&#8220;PI3K<div style="font-family: symbol; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">d</div>&#8221;) inhibitor; </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"><div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:13%;"><div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:left;;vertical-align:top;;width:4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:top;;width:2%;"><div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Voruciclib, an oral cyclin-dependent kinase (&#8220;CDK&#8221;) inhibitor; </div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"><div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:13%;"><div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:left;;vertical-align:top;;width:4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:top;;width:2%;"><div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">ME-344,</div> a mitochondrial inhibitor targeting the oxidative phosphorylation (&#8220;OXPHOS&#8221;) complex; and </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"><div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:13%;"><div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:left;;vertical-align:top;;width:4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:top;;width:2%;"><div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Pracinostat, an oral histone deacetylase (&#8220;HDAC&#8221;) inhibitor. </div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Liquidity </div></div></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">We have accumulated losses of $234.2&#160;million since inception and expect to incur operating losses and generate negative cash flows from operations for the foreseeable future.&#160;As of September&#160;30, 2019, we had $65.9&#160;million in cash and cash equivalents, short-term investments, and common stock proceeds receivable, which we believe will be sufficient to meet obligations and fund our liquidity and capital expenditure requirements for at least the next 12 months from the issuance of these financial statements.&#160;Our current business operations are focused on continuing the clinical development of our drug candidates.&#160;Changes to our research and development plans or other changes affecting our operating expenses may affect actual future use of existing cash resources.&#160;Our research and development expenses are expected to increase in the foreseeable future.&#160;We cannot determine with certainty costs associated with ongoing and future clinical trials or the regulatory approval process. The duration, costs and timing associated with the development of our product candidates will depend on a variety of factors, including uncertainties associated with the results of our clinical trials. </div></div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0);font-family: &quot;times new roman&quot;;font-size: 13.3333px;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: 0px;orphans: 2;text-align: start;text-indent: 9%;text-transform: none;white-space: normal;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;text-decoration-style: initial;text-decoration-color: initial;float: none;display: inline !important;top: 0px;;display:inline;">To date, we have obtained cash and funded our operations primarily through equity financings and license agreements.&#160;In order to continue the development of our drug candidates, we expect to pursue one or more capital transactions, whether through the sale of equity securities, debt financing, license agreements or entry into strategic partnerships. There can be no assurance that we will be able to continue to raise additional capital in the future.</div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Basis of Presentation </div></div></div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) for interim financial information and in accordance with the instructions to Form <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> and Article 10 of Regulation <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">S-X.</div> Accordingly, the accompanying financial statements do not include all of the information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying financial statements reflect all adjustments (consisting of normal recurring adjustments) that are necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. We have evaluated subsequent events through the date the financial statements were issued.</div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The accompanying unaudited financial statements should be read in conjunction with the audited financial statements and notes thereto as of and for the fiscal year ended June&#160;30, 2019, included in our Annual Report on Form <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> (&#8220;2019 Annual Report&#8221;) filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on August&#160;28, 2019. Interim results are not necessarily indicative of results for a full year.</div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Use of Estimates </div></div></div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. We use estimates that affect the reported amounts (including assets, liabilities, revenues and expenses) and related disclosures. Actual results could materially differ from those estimates. </div></div><div style="font-size: 1px; margin-top: 18px; margin-bottom: 0px; background: none;"><div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Revenue Recognition </div></div></div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">We recognize revenue when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. To determine revenue recognition, we perform the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. See Note <div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div> for further discussion. </div></div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Cost of revenue primarily includes external costs paid to third-party contractors to perform research, conduct clinical trials and develop and manufacture drug materials, and internal compensation and related personnel expenses to support our research and development performance obligations. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Research and Development Costs </div></div></div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Research and development costs are expensed as incurred and include costs paid to third-party contractors to perform research, conduct clinical trials and develop and manufacture drug materials. Clinical trial costs, including costs associated with third-party contractors, are a significant component of research and development expenses. We expense research and development costs based on work performed. In determining the amount to expense, management relies on estimates of total costs based on contract components completed, the enrollment of subjects, the completion of trials, and other events. Costs incurred related to the purchase or licensing of <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development for early-stage products or products that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred.</div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Share-Based Compensation </div></div></div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation expense for employees and directors is recognized in the Condensed Statement of Operations based on estimated amounts, including the grant date fair value and the expected service period. For stock options, we estimate the grant date fair value using a Black-Scholes valuation model, which requires the use of multiple subjective inputs including estimated future volatility, expected forfeitures and the expected term of the awards. We estimate the expected future volatility based on the stock&#8217;s historical price volatility. The stock&#8217;s future volatility may differ from the estimated volatility at the grant date. For restricted stock unit (&#8220;RSU&#8221;) equity awards, we estimate the grant date fair value using our closing stock price on the date of grant. We recognize the effect of forfeitures in compensation expense when the forfeitures occur. The estimated forfeiture rates may differ from actual forfeiture rates which would affect the amount of expense recognized during the period. We recognize the value of the awards over the awards&#8217; requisite service or performance periods. The requisite service period is generally the time over which our share-based awards vest. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Income Taxes </div></div></div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Our income tax expense consists of current and deferred income tax expense or benefit. Current income tax expense or benefit is the amount of income taxes expected to be payable or refundable for the current year. A deferred income tax asset or liability is recognized for the future tax consequences attributable to tax credits and loss carryforwards and to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. As of September&#160;30, 2019 and June&#160;30, 2019, we have established a valuation allowance to fully reserve our net deferred tax assets. Changes in our ownership may limit the amount of net operating loss carry-forwards that can be utilized in the future to offset taxable income. </div></div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Financial Accounting Standards Board (&#8220;FASB&#8221;) Topic on Income Taxes prescribes a recognition threshold and measurement attribute criteria for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div> to be sustained upon examination by taxing authorities. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. There were no unrecognized tax benefits as of September&#160;30, 2019 or June&#160;30, 2019.</div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">There have been no material changes in our unrecognized tax benefits since June&#160;30, 2019, and, as such, the disclosures included in our 2019 Annual Report continue to be relevant for the three month period ended September&#160;30, 2019. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Recent Accounting Pronouncements </div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Adopted Accounting Standards </div></div></div></div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In February 2016, the FASB issued ASU <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-02,</div> Leases. The new standard establishes a <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> (&#8220;ROU&#8221;) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases are classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after July&#160;1, 2019, including interim periods within those fiscal years. See Note 8 for further discussion.</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>85</ContextCount>
  <ElementCount>274</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>38</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="meip-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>1001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="meip-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1002 - Statement - CONDENSED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/CondensedBalanceSheets</Role>
      <ShortName>CONDENSED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="meip-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/CondensedBalanceSheetsParenthetical</Role>
      <ShortName>CONDENSED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="meip-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1004 - Statement - CONDENSED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/CondensedStatementsOfOperations</Role>
      <ShortName>CONDENSED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="meip-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/CondensedStatementsOfStockholdersEquity</Role>
      <ShortName>CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="meip-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/CondensedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="meip-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1007 - Disclosure - The Company and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/TheCompanyAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>The Company and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="meip-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1008 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="meip-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1009 - Disclosure - License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/LicenseAgreements</Role>
      <ShortName>License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="meip-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1010 - Disclosure - BeiGene Collaboration</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/BeigeneCollaboration</Role>
      <ShortName>BeiGene Collaboration</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="meip-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1011 - Disclosure - Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/RevenueRecognition</Role>
      <ShortName>Revenue Recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="meip-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1012 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="meip-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1013 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="meip-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1014 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="meip-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1015 - Disclosure - Short-Term Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/ShortTermInvestments</Role>
      <ShortName>Short-Term Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="meip-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>1016 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="meip-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>1017 - Disclosure - Share-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="meip-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>1018 - Disclosure - The Company and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/TheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>The Company and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.meipharma.com/role/TheCompanyAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="meip-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>1019 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.meipharma.com/role/FairValueMeasurements</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="meip-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>1020 - Disclosure - Revenue Recognition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/RevenueRecognitionTables</Role>
      <ShortName>Revenue Recognition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.meipharma.com/role/RevenueRecognition</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="meip-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>1021 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.meipharma.com/role/NetLossPerShare</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="meip-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>1022 - Disclosure - Share-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.meipharma.com/role/ShareBasedCompensation</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="meip-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>1023 - Disclosure - The Company and Summary of Significant Accounting Policies  - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/TheCompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>The Company and Summary of Significant Accounting Policies  - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="meip-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>1024 - Disclosure - Schedule of Financial Instruments Measured at Fair Value on Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/ScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetail</Role>
      <ShortName>Schedule of Financial Instruments Measured at Fair Value on Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="meip-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>1025 - Disclosure - Schedule of Assumptions Used to Calculate Fair Value of Warrant Liability (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/ScheduleOfAssumptionsUsedToCalculateFairValueOfWarrantLiabilityDetail</Role>
      <ShortName>Schedule of Assumptions Used to Calculate Fair Value of Warrant Liability (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="meip-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>1026 - Disclosure - Schedule of Changes in Estimated Fair Value of Warrant Liability (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/ScheduleOfChangesInEstimatedFairValueOfWarrantLiabilityDetail</Role>
      <ShortName>Schedule of Changes in Estimated Fair Value of Warrant Liability (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="meip-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>1027 - Disclosure - License Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/LicenseAgreementsAdditionalInformationDetail</Role>
      <ShortName>License Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="meip-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>1028 - Disclosure - Revenue Recognition - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/RevenueRecognitionAdditionalInformationDetail</Role>
      <ShortName>Revenue Recognition - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="meip-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>1029 - Disclosure - Revenue Recognition - Revenue Associated With The Following license agreements (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/RevenueRecognitionRevenueAssociatedWithTheFollowingLicenseAgreementsDetail</Role>
      <ShortName>Revenue Recognition - Revenue Associated With The Following license agreements (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="meip-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>1030 - Disclosure - Revenue Recognition - Schedule of Changes in Contract Assets and Contract Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/RevenueRecognitionScheduleOfChangesInContractAssetsAndContractLiabilitiesDetail</Role>
      <ShortName>Revenue Recognition - Schedule of Changes in Contract Assets and Contract Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="meip-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>1031 - Disclosure - Net Loss Per Share - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/NetLossPerShareAdditionalInformationDetail</Role>
      <ShortName>Net Loss Per Share - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="meip-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>1032 - Disclosure - Antidilutive Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/AntidilutiveSecuritiesDetail</Role>
      <ShortName>Antidilutive Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="meip-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>1033 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/CommitmentsAndContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="meip-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>1034 - Disclosure - Leases - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/LeasesAdditionalInformationDetail</Role>
      <ShortName>Leases - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="meip-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>1035 - Disclosure - Short-Term Investments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/ShortTermInvestmentsAdditionalInformationDetail</Role>
      <ShortName>Short-Term Investments - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="meip-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>1036 - Disclosure - Stockholders' Equity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/StockholdersEquityAdditionalInformationDetail</Role>
      <ShortName>Stockholders' Equity - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="meip-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>1037 - Disclosure - Share-based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/ShareBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Share-based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="meip-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>1038 - Disclosure - Share-Based Compensation Expense for Stock Awards (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/ShareBasedCompensationExpenseForStockAwardsDetail</Role>
      <ShortName>Share-Based Compensation Expense for Stock Awards (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="meip-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>1039 - Disclosure - Summary of Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/SummaryOfStockOptionActivityDetail</Role>
      <ShortName>Summary of Stock Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="meip-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>1040 - Disclosure - Fair Value of Stock Options Weighted-Average Assumptions Used (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com/role/FairValueOfStockOptionsWeightedAverageAssumptionsUsedDetail</Role>
      <ShortName>Fair Value of Stock Options Weighted-Average Assumptions Used (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>meip-20190930.xml</File>
    <File>meip-20190930.xsd</File>
    <File>meip-20190930_cal.xml</File>
    <File>meip-20190930_def.xml</File>
    <File>meip-20190930_lab.xml</File>
    <File>meip-20190930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6778662256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense related to unvested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected weighted average period for recognition of compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Stock option vested percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based compensation arrangement by share-based payment award, award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based compensation arrangement by share-based payment award, expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSUs granted</a></td>
<td class="nump">332,193<span></span>
</td>
<td class="nump">364,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_NumberOfSharesToBeReceived', window );">Number of common stock to be received for each RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">RSUs grant date fair value per unit</a></td>
<td class="nump">$ 245,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares withheld to satisfy tax withholding obligations</a></td>
<td class="nump">86,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=meip_TwoThousandAndEightOmnibusPlanMember', window );">2008 Omnibus Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,089,794<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,979,777<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based compensation arrangement by share-based payment award, award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based compensation arrangement by share-based payment award, award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_NumberOfSharesToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares to be received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_NumberOfSharesToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=meip_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=meip_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=meip_TwoThousandAndEightOmnibusPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=meip_TwoThousandAndEightOmnibusPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6767063008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems', window );"><strong>Purchase Commitment, Excluding Long-term Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_MilestonePaymentsMaximumAmount', window );">Future aggregate milestone payments</a></td>
<td class="nump">$ 74,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_PercentageOfPurchasesFromMajorSuppliers', window );">Percentage of Purchase Requirement</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=meip_SbioPurchaseAgreementMember', window );">S*Bio Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems', window );"><strong>Purchase Commitment, Excluding Long-term Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_AccruedMilestonePayments', window );">Accrued payment for potential future payments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=meip_CydexLicenseAgreementMember', window );">CyDex License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems', window );"><strong>Purchase Commitment, Excluding Long-term Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_AccruedMilestonePayments', window );">Accrued payment for potential future payments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=meip_PresageLicenseAgreementMember', window );">Presage License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems', window );"><strong>Purchase Commitment, Excluding Long-term Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_AccruedMilestonePayments', window );">Accrued payment for potential future payments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_AccruedMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_AccruedMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_MilestonePaymentsMaximumAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments, maximum amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_MilestonePaymentsMaximumAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_PercentageOfPurchasesFromMajorSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of purchases from major suppliers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_PercentageOfPurchasesFromMajorSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=meip_SbioPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=meip_SbioPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=meip_CydexLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=meip_CydexLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=meip_PresageLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=meip_PresageLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6777768400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 5,984<span></span>
</td>
<td class="nump">$ 9,590<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">59,932<span></span>
</td>
<td class="nump">64,899<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Total cash, cash equivalents and short-term investments</a></td>
<td class="nump">65,916<span></span>
</td>
<td class="nump">74,489<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable', window );">Common stock proceeds receivable (Note 10)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,274<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,135<span></span>
</td>
<td class="nump">2,435<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">68,051<span></span>
</td>
<td class="nump">82,198<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">253<span></span>
</td>
<td class="nump">261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">619<span></span>
</td>
<td class="nump">204<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">68,923<span></span>
</td>
<td class="nump">82,663<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,098<span></span>
</td>
<td class="nump">4,787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">3,295<span></span>
</td>
<td class="nump">4,559<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">3,675<span></span>
</td>
<td class="nump">4,955<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">10,068<span></span>
</td>
<td class="nump">14,301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, long-term</a></td>
<td class="nump">3,231<span></span>
</td>
<td class="nump">2,819<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Warrant liability</a></td>
<td class="nump">8,344<span></span>
</td>
<td class="nump">17,613<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">21,643<span></span>
</td>
<td class="nump">34,733<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.01 par value; 100 shares authorized; none outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.00000002 par value; 226,000 shares authorized; 73,655 and 73,545 shares issued and outstanding at September 30, 2019 and June 30, 2019, respectively</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in-capital</a></td>
<td class="nump">281,492<span></span>
</td>
<td class="nump">279,148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(234,212)<span></span>
</td>
<td class="num">(231,218)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">47,280<span></span>
</td>
<td class="nump">47,930<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 68,923<span></span>
</td>
<td class="nump">$ 82,663<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of subscription receivable from investors who have been allocated common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6607776000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note <div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div>.</div></div><div style="font-size: 10pt; line-height: 107%; font-family: &quot;times new roman&quot;, serif; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Revenue Recognition </div></div></div><div style="text-indent: 9%; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Payments received under commercial arrangements, such as licensing technology rights, may include <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> fees at the inception of the arrangements, milestone payments for specific achievements designated in the agreements, and royalties on the sale of products. At the inception of arrangements that include milestone payments, we use judgment to evaluate whether the milestones are probable of being achieved and we estimate the amount to include in the transaction price using the most likely method. If it is probable that a significant revenue reversal will not occur, the estimated amount is included in the transaction price. Milestone payments that are not within our or the licensee&#8217;s control, such as regulatory approvals, are not included in the transaction price until those approvals are received. At the end of each reporting period, we <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">re-evaluate</div> the probability of achievement of development milestones and any related constraint and, as necessary, we adjust our estimate of the overall transaction price. Any adjustments are recorded on a cumulative <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> basis, which would affect revenues and earnings in the period of adjustment. To date, we have not recognized any material cumulative <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> adjustments from changes in our estimate of the transaction price.</div><div style="text-indent: 9%; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">We develop estimates of the stand-alone selling price for each distinct performance obligation and allocate the overall transaction price to each accounting unit based on a relative stand-alone selling price approach. We develop assumptions that require judgment to determine the stand-alone selling price for license-related performance obligations, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical, regulatory and commercial success. We estimate stand-alone selling price for research and development performance obligations by forecasting the expected costs of satisfying a performance obligation plus an appropriate margin. </div></div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In the case of a license that is a distinct performance obligation, we recognize revenue from <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">non-refundable,</div> <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">up-front</div> fees at the point in time when the license is transferred to the licensee and the licensee can use and benefit from the license. For licenses that are bundled with other obligations, we use judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. If the performance obligation is satisfied over time, we evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.</div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The selection of the method to measure progress towards completion requires judgment and is based on the nature of the products or services to be provided. Revenue is recorded proportionally as costs are incurred. We generally use the <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">cost-to-cost</div></div> measure of progress because it best depicts the transfer of control to the customer which occurs as we incur costs. Under the <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">cost-to-cost</div></div> measure of progress, the extent of progress towards completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation (an &#8220;input method&#8221; under ASC 606). We use judgment to estimate the total cost expected to complete the research and development performance obligations, which include subcontractors&#8217; costs, labor, materials, other direct costs and an allocation of indirect costs. We evaluate these cost estimates and the progress each reporting period and, as necessary, we adjust the measure of progress and related revenue recognition. To date, we have not recognized any material cumulative <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> adjustments from changes in our estimate of the measure of progress.</div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">For arrangements that include sales-based or usage-based royalties, we recognize revenue at the later of (i)&#160;when the related sales occur or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, we have not recognized any sales-based royalty revenue from license agreements. </div></div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">We recognized revenue associated with the following license agreements (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"><div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="padding: 0px; width: 84%;"></td><td style="padding: 0px; width: 4%;;vertical-align:bottom;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px; width: 4%;;vertical-align:bottom;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;&#160;</td><td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended<br/>September&#160;30,</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;&#160;</td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;&#160;</td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">2018</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 84%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">KKC License Agreement</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">797</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; width: 84%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Helsinn License Agreement</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 4%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">360</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 4%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">488</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 84%;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 4%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 4%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 84%;;vertical-align:top;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,157</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">488</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 84%;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 4%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 4%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Revenue for the three months ended September&#160;30, 2019 included revenue related to the KKC License Agreement (Note <div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div>). The KKC License Agreement included distinct performance obligations that will be satisfied over time, and accordingly we recognized $0.8&#160;million related to our progress toward satisfying those obligations during the three months ended September&#160;30, 2019. </div></div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Revenue for the three months ended September&#160;30, 2019 and 2018 included revenue related to the Helsinn License Agreement (Note <div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div>). The Helsinn License Agreement included distinct performance obligations that will be satisfied over time, and accordingly we recognized $0.4&#160;million and $0.5&#160;million related to our progress toward satisfying those obligations during the three months ended September&#160;30, 2019 and 2018, respectively. </div></div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">As of September&#160;30, 2019, we had $6.9&#160;million of deferred revenue associated with our remaining performance obligations under the KKC and Helsinn License Agreements. We expect to recognize approximately $3.7&#160;million of deferred revenue in the next 12 months, and an additional $3.2&#160;million thereafter. </div><div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 9%; line-height: 12pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Contract Balances </div></div></div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following table presents changes in contract assets and contract liabilities during the three months ended September&#160;30, 2019 (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"><div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:84%;"><tr style="font-size: 0px;"><td style="padding: 0px; width: 60%;"></td><td style="padding: 0px; width: 9%;;vertical-align:bottom;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px; width: 9%;;vertical-align:bottom;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px; width: 9%;;vertical-align:bottom;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;&#160;<div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;<div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div></div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;<div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div></div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div></td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;June&#160;30,<br/>2019</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div></td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">Net&#160;Change</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;September&#160;30,<br/>2019</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 60%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Receivables</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 9%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 9%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">326</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 9%;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">326</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; width: 60%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Contract Assets</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 9%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">686</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 9%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">(217</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 9%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">469</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 60%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Contract Liabilities</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 9%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">7,774</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 9%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(868</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 9%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">6,906</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The timing of revenue recognition, invoicing and cash collections results in billed accounts receivable and unbilled receivables (contract assets), which are classified as &#8220;prepaid expenses and other current assets&#8221; on our Condensed Balance Sheet, and deferred revenue (contract liabilities). We invoice our customers in accordance with agreed-upon contractual terms, typically at periodic intervals or upon achievement of contractual milestones. Invoicing may occur subsequent to revenue recognition, resulting in contract assets. We may receive advance payments from our customers before revenue is recognized, resulting in contract liabilities. The contract assets and liabilities reported on the Condensed Balance Sheet relate to the KKC and Helsinn License Agreements. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6768097920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Term Investments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Short-Term Investments</a></td>
<td class="text"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><div style="display:inline;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note 9.&#160;&#160;&#160;&#160;Short-Term Investments</div></div></div></div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">As of September&#160;30, 2019 and June&#160;30, 2019, our short-term investments consisted of $59.9&#160;million and $64.9&#160;million, respectively, in U.S. government securities. The short-term investments held as of September&#160;30, 2019 and June&#160;30, 2019 had maturity dates of less than one year, are considered to be &#8220;held to maturity&#8221; and are carried at amortized cost. As of September&#160;30, 2019 and June&#160;30, 2019, the gross holding gains and losses were immaterial. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6778715312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (2,994)<span></span>
</td>
<td class="num">$ (14,542)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss', window );">Change in fair value of warrant liability</a></td>
<td class="num">(9,269)<span></span>
</td>
<td class="nump">4,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">2,113<span></span>
</td>
<td class="nump">1,937<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">300<span></span>
</td>
<td class="num">(2,085)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable</a></td>
<td class="num">(1,689)<span></span>
</td>
<td class="num">(2,088)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="num">(1,702)<span></span>
</td>
<td class="num">(965)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(868)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(14,078)<span></span>
</td>
<td class="num">(12,816)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of short-term investments</a></td>
<td class="num">(19,979)<span></span>
</td>
<td class="num">(4,937)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments', window );">Proceeds from maturity of short-term investments</a></td>
<td class="nump">24,946<span></span>
</td>
<td class="nump">9,725<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">4,967<span></span>
</td>
<td class="nump">4,788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">72<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,118<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_ProceedsFromPreviouslyIssuedCommonStock', window );">Collection of common stock proceeds receivable</a></td>
<td class="nump">5,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payment of RSU tax withholdings in exchange for common shares surrendered by RSU holders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(324)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">5,505<span></span>
</td>
<td class="nump">837<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(3,606)<span></span>
</td>
<td class="num">(7,191)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of the period</a></td>
<td class="nump">9,590<span></span>
</td>
<td class="nump">13,309<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of the period</a></td>
<td class="nump">5,984<span></span>
</td>
<td class="nump">6,118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes paid</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_ChangeInFairValueOfWarrantsExercised', window );">Change in fair value of warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,068<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_ChangeInFairValueOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents Change in fair value of warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_ChangeInFairValueOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_ProceedsFromPreviouslyIssuedCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Previously Issued Common Stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_ProceedsFromPreviouslyIssuedCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3) and still held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>26
<FILENAME>0001193125-19-287262-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-19-287262-xbrl.zip
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MN6VA!74,Q+("^."QQ+*/>P=C-BXW*Z\I^PEV,=B8+@%AZ%X#0N+;FW[^6,1
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M6HSJ!3R[5<'.-B9?J*-*/,]5H.\(/R(:G<5+[@%&897'H@!%MS\8#RJ48!G
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MO5@5[TU!W,4BJVMU%[6%W'Z5896+](V65<NIOH).$\1=[)+="HBV K[Z$C4
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M:>G<^O\RW3.#/BC,79CD]Q<3>*<YT6;47+Q1_DN;S<_^\FSWS*4SH .+/"K
MG9H5_7"F\#<8D-8;16W/W3-EIN&Y>M.UYV^4^!=WMNO:,_\[0"!I3KF' ^]U
MX*L7_W7OGJ6@,2B;F]KB#;7P^=Q'=-NTG3>*<W_WLMU0\'^O8'3B@E769'--
M!U3CE$]GB@_0T]E9B6'YJAX%?'>V:>2^\]5VB=)K<6S\W^J@?;;\TSM",5U:
MB>VK;>&\KV'B (8RGV-PX@8WJ05F)^!Q_*N_'<$&IK9MQ68-"C:+K_63I5SJ
MKHTU1%!2-I1'HA!N^X*4M5Q;T13=YPH@O-@"E4?J3A5_[0WELVNTE)<"*:-.
M)\1*^(UZ]@JV2B'8:ABOO8!EJ#!M0MR% FRDD,D$YM 7BCU14KAXG%*7\$V'
MY5GVHZ/-SY2JZ./+AV:OK<9W I8-H\_NJ)5=9[ :=7C&E']KEG?G>&#6TKL&
M+ )>1+N'WO/W4"I94WI'7=O!1;V#)VTK,8"[<&R\O*'\A+G *D^@[_;/..H:
ML,4.QYD+#B&WK7#0.4S%[3X.Y#[Q]JZI$]-,X TD);VWP#(!O[:E\!Z& F(P
M"1E"BW\4$),6)()S M3@DP$$:'N .B%7\:87H$B] P2@Q =2HA9/5 I("H>I
M)_'$"04?J/&NW;B>L8#I&$"'1T]W!''/0UO HW]YFFDNE+L%W\JYYF (H\'Y
M%W>-][#$G6'8JW1QZ*U L +9G($MOB<MY3M1T)1R#$&C?/D.H;,[ST%S$Q8<
M#@1X@9\,3P\(#HG4\2N@\#F-J :*0H2_R_PI1&MM9>*9R "S&9J20,P.OZ+,
M6;Q&."L#;@*-B9'P#Y=?K (F!U& AV+AJJCA3M^H[38H-OY,$T"S/??-A#X1
MXPQ,'*!2?R7\/?Q[KAF&_W>@,%TG_&2$"C7^T8D^XC3X5_Q$KK0=EAMYC)YC
M2PRVLK=H:VVP'=P:2[VXP=2=.'6V2IIA=YK^\]ZQ/<M [H.ASDJ!G+?,^,XD
MD=X>INT[T(_TSJ$-,) LUF3$H9,"KL\ J'#+T4!AQC50\/4FFU72_BV)RT/2
M$/*L(@K3Q[(_F%)GRWQ[DM_1!G!D/H@J_PRTW80K"5",J#N)?SE8F?-:>^Y4
M<Y5'VS-!B7(=*]K=H^H @UECC( =ZX I0;ERQAO[; )VHP8\(@Y)%LI+>)(\
M45<,^0HM*&Y^.&  TCGH(QA@!BI;T8P'C?=/MSV&:/T)@P=F<SA5-"Z, R-S
MY00& 9]:$UK]CKB/A%C!&-S0P:F09&PQ^RPB(P5# "U.7L+H<XD^M>A?>'O"
M8\+J\!]7)A'N9AZ /,..XD =?$QXF!L4=\#Q_IUDS$]B7"MC%:[TDYZ5>;:E
MW$X3TTPI<= T ;,-BVH)^,$8@IT',X7;Y>+-!GX$>P.L&)QB0AV SWVTN1T(
M*HQ1@WN%L2D1+GS6U.#1.# -L?$S;8';O@0)0$ :6A*F:3^R-YOP8YS!.J75
M7D9NYC',3H5K"=[<DW OC_/0VDK;=2G[+&._56?4B$F;W'N<,_@Z^!3^E,2"
MV'SX [@]^+\&GOC9&<<E=W[>F&0"DPFK=*S^>A8S,'/(#,>-GC"")_SU^_,^
M$)09FNG/@+L1SA";(&:M;C"26ME(XW;^4#$3.H6+\AIO#A*Y>><0[6>3<BGR
M1M$>;&HL06(3=\2'.O@JI.?PFXBC"Q97E1X- C&#\C91^.DSBMGH3S7]S*BC
M=K)\MV0S=XB;K,"IRFRLQ_HV6,UE1ADS#_U\IJ"$ KW&C1+&C0D='4G?:!#N
M,=X;X) )^X/%#1",MRS!2S'G^;P5MQ-WA<0SWTD9Y2J-Q":"' :\6GA5[;"P
M2)%5L<CJ2)%U5"+KDY!3-MZ]03O<4OB&*JHPRM&<CUOJA/('#0K>F0N.$(HM
M*_BKD1)W90[R<E'HBTD4B@S\&%-S\D7B65:N!@(UA-ZR75_8GN';8J&^=,Y9
M(CZC:^C5@9!R')N'_$14-_:0[^N!+Z<)*+T[O(KI4A[RYAX1AD'Q,",XRY R
M7<KT(Y7I72G3CTJF?\M&>B)1AT=:MN.+-)!"KI!YEAT(-2XLJ7_2'KT&0%(\
M=;=<'GM+QHTJD''1H4LZVF$2S7D##KL[10_]*8R%)USKHCBR?#GY\I)@UKKQ
M[-YV\>Q$ .YX MK?PW"N8 (>C<1S[PGE!^/\*@=S'4\<&@#[Q/G$X@?"_N5]
M#++23! VN/W 2,&0C\0AL4"H\I+'N&V/ <.R5W6+B]8T6'F0J.1H@Z#DF<"\
MPO]:'HWD9^05A"/%:,J@OU[$T'^M\^O964JY":I99["#/RI7(U<C5_-L5K.=
MSSC:F\M8@%-? :QVTO<\?YEP@1HI5U__!1.J<U=AMDF-E/6P.?0QQ:GSB\OE
M%I1C+*VZ1')#YBZO6AISHP%\O+ZU6\?RR"CDN='%W[W@8OB1D(24C >3C)U3
M9(#,$7=]25]2Q:&HHB.I0E)%ABJZDBHD+4B](26$U!N2*DY$;QSJLL**T^GH
M@*89.\#IM'O@KW9'\*]^_U7BH""-A*+C[,0)8E,EL]09X@ZSU_SOQ/[RF1.I
M59;MS#2SJK/#<AC,/V$4Q4.BY),,^>[N5L):^[XJQEM*$FT-<F[6:SGL+P'^
MEWI!&I.=/*&V!.+%)9UCWH.=@BPI75)Z;?9 4OH&(.^;J'= OR]'C6ZO=S1D
M^NKPF[X^G1X+<J4</OP>'"-]'Q^6):4??@\DI3]3BT,=-@9J]VCHM-CD6)T?
MM>RJZR8++(YV[<_TJ!'/K+K?%PN@E;M.+@+0(CE@_I0;?<Z+V%5Z#WUWU3$D
M[D\$]Y++):5)+C]UW$LNEY0FN?S4<5]#+I?T=4+T)7$O>5MJ\%.G-(E[R>62
MRT^=TB3NZ\KE-;U$>\378[L[OAZ;2UBWMJN9^Z.I6@GVW..S.ARB'^/QN#R>
MDQ0E*6JO!M .B*?&5RD/=TGR\.%$*5>D7)$4)2FJSA15;TVUURMX\G+=R5'P
MML&F[OQ),6P/"Z#*:)-$?LV0+_E<DIKD\]-'ON1S26J2ST\?^37D<TE@IT1@
M$OF2NZ46/WU2D\B7?"[Y_/1)32*_MGPN^_75[>7$A<'Q'COR57;I;TH477.<
M!;R@:#-@&9=WP,OO?1<T&-8U-E7(7QY]T$S\H:&PJ>VX3=YQEUH/A+E^_SW+
M4#1=%\/.M05O^Z;-YX[]1&>:*YKX.<3D37[C3?@,CP2-+F-#PRN>P]M:1EWZ
M8O"UE._$GUZQ/4<A3SIA/K34*NKG-Z6X* ?AT S8-T6W+2X#1?].@ ('B+HK
MST"@+()VG1.0,6*9WUHW+>7>AC<M'%AAV&=0M.!4+C+X>ISR-H+SN0FBEO=V
MQC&*L B/ZJ;&&)U0P!/ D"['C=\9!!8H&HNF^H-.*7$T1Y\N6DN[$YX277^R
ME"_:0NFTU1$@&_:1,0]P\RB*N_)>U;#-%M&QW2$8/^Z44\S<@2T"LH3Q=,*W
M$>B,36$#.,7I]@QV'V"U]9\MY<ISF!?KR(K[%A!F.!.?'1C -+"IM8-$X  @
M\ HCO/MK_&$.ED^M^#WLL@!!LX"-X%5&.;S^'!?V;*Y9O%5L RD FULRSW0;
MR4$%;4<3WX4]-(U4@TRD08?X#6KY@&$5W "D"QNI@L'O[S03V(DH-U-"W%9$
MC-]Q-AVUOE'0J#:$S)O#8G!K^$ >0R&$#[P#]/]LWNA3VP3$X[N\+26PGD%,
M(512:W*(F"&Y<%<A&C"M6!(.;N#F\MU&O.E3S;H7C<MC0(; (Z*!)J(5W[CP
M>D 5EW,BFF7Z+40C*-.KI QI#2^U([ @,(B39N!N\%(>U\:%H47$>CW&^_UZ
MLSD'(=B="(BP=3 JMA7]@WUJX"M#Y'JQ#L:QC?6;U7M,@& 0)'C@. 4$%9?F
M1O%>QUL2 ["ZZ1EBLY:]RU%E<M7$60XW-+E*W,]&:IQXV_>("QW*?C8G#N$B
M'38"5 2VEH=?R-,<Q "\"&((]BB0YWS0X*<'&U24X(,"V 01Q/'LY?2!YKCS
M]ZI@ Y;@C;>>Y0B(P,%%1/ N14)+^8-80%.FN6C@'H"^8S#J2X/X'U_E@%:X
M%3!E:KI'+N6$",*1-,"H(R0LS@G( ?6A.0H%J:6OH$.!3L&@A5!%I,G92>EF
ML+9 YG/(Q!3;F)%A!1P-"LT1(GV*% ,RWYTR!4@#7REN+9=5K^L[*OONQ%ND
M]#/MI;?/?2DT!)+N'W]LMXDNH&1-W3,# W2UU%HT4NVFX[*7LR5R]O+FS[&5
MR(;/>VGXK,8#$#OH^#P<5-GP>3C<J.'S^+A:O:Y8S>BX5B/;,^YD_B60G';K
MG'SC D>Z<U[C S5O5UJ#^4^;0#(-;(^'-FJ:)KY6M634T<>63%[C7DO7^4[Y
M_LY;UMO]5:;6D=3*K@%T:V7LJ*W!+@Z\=U(P^]?#([>L*7UP0&L.W9HT.CP!
M&JVIBI;*=[V0S(<@;&W2"5%>+HCFL%=[5*IU4I<'NY.\EOCH[DW%'3J]\X!:
MZ5A(851G4JBIBI!>W.&\N _94U+IP4GK. 9O?] :GX!Y+%VX$R?2?6E>Z<-)
MU;O"AWOO7T92%I28AG3>:FRQMUOM&ECLNU5;AU=(DA:JH(6::@?IOAW.?4M>
MMOZ(=^'^@7?AI ^W4_/X2#K6MEO]SM%8Q8??\1HHRF=#FFI+W9>RW2%IRJ3.
MNKU\],EOMXFKZN+J-2,N3VO U">%>3, B>>RQ'*@EJ7C8")4)F<IFVVQ6=X$
M3R;!5#WE)0?#]AA\PU[)^_3R/OT6]^F[&]VGSW$NZGP#?<5J!L>U&GF??B?S
ME[DN/3C%Z]+HS4:K%VYM^*<]B24M^SF2T3??,!LY^O,FRNQ$0/PKU]_B.9Y^
M?NQ+/QDQ>^/F5.YB2SZ3>2M)/JMYZD$-YC_Y_1_5>/]/(NK=E5'O"J/>FU!Y
M4/%$<Y6_>^8B5G^GL3187I/ ^2K/1@;.*XU.[K/-S"F%SE>YK)),JR33WJ#1
M/04RK:F*/V+E?9 FQ-<D*'2GA\6T4E-M,*H?J$XHXY"0HNBU:_,B??")%R8C
M3\31*>/Q[Z"&TAYU>ZVT=KU2262SP$I(JQ::]CCN=;U4&^U!'1)S-FD:*)W<
M8]:36SBY%V']O*)SW4CYQ0K,'D#9/4='M@;0K2<#QXW.X'CR>';;"?PYNK0U
M@&X]W[8Q'IS Y<5#=0/.4\;[-E%K(>IWV1(#-B_WU$=VQ)"X/S3NI2,J*4UR
M^:GC7L;53^M0?!?'W<5U:0]PZ'TLIN$.3@#7\W]&C6ZO5X.8I30AZD -_7:C
MT]Y7E4+IZ)Z:--O6#).]'R7RZXM\J:<DJ4D^/WWDRUSL(W@YD]SJCR1$J-IN
M_WHFLIJ;0%*VY[Z9T"=BG&637E-)L9%Q&5%4#IGE4L%OKSW6O->T^1O,*>.9
M9.\ITTT;.]:Q6S#$WYFV_O/M?_[';S-"8T]=3OS<LL_!4?MYU#OL%H</7U:H
M\?N+CYKN4N/'<#P:#0;#%]@Z$LW\:S+Y_<55>_BCK?[ ;)M;NSW^T6WSSR_>
M+@MUR$YNLI-;A?)89IZO3B&7G=QD)S>9$?NL,V)E)S>9,BL[N=7XIK$L(BD[
MN<D+F5M#)SNY[9Y:C[J89 V@DYW<ZJ*BI?*5G=QV<FY2FT1!V<E-]@*0G=RD
M%W>47ISLY":M8]G)3;IP]8-.=G*KC8*6JE=V<CM1B[WNW;ND]R9IH>;:0;IO
MLI/;,_/ACJ32I^SD]OP\MR,A3=G)C0-<LVOX1_IR/;,'-DX*"#,*0*\3PS/A
M75'6CWVREHRW*K-@5$%F@>R-)WOCR0R%H\Q0D+WQ9&\\F:$@>^.%JY>]\22?
M'9S/3C+1H^;)'#68_^3W7_;&DVT#CN@<81,JE[WQ9+RW?+Q7]L9[UHT$CH1,
M96\\6<,W7WG+WGBR-UY-DW-D;[Q*2*L6FO8X;LK)WGC2R3V0GI2]\4[4D:T!
M=+(WGG1I3Y=@96^\[3P/V3*@A(F:U.^R<Y/$_<G@7CJBDM(DEY\Z[F5<_;0.
MQ65OO)HHC8-W0Y.]\20U1 #(WGC2T3V@&2;;-DGDUQ?Y4D])4I-\?OK(E]GM
M1_!RC;/;MTE0QRSWH,%>D&_VU79O@', 1?#D)^M"8].<WGO9U/9Q*K7]G%U:
M[8&?TC[Z$8XA<M)X1EKW"_?@/88 A ^\6X0?_T:)HSGZ=,$?/W^B+!KG"]$0
MD!D!F*^)[CD.X+1@P-BS'QWRET<L?8&CO5 \BPIXO\&'']]NWK]0#*)3$$;L
M]Q?-[HNWO4%7[;;;[:@3X7J(BJ,X#_;OU)W&<_8$>F!!MJ7#CO$KA^'RWFF,
MLG OQ>P< 9GM&+:+*@V,8I4&CG=;U/9@E-B5W>$VOH/7L&#+(Q\=>W8!V'4
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M[P7Z!6"T>X<$0V%9%L=>:*9+87I;/, TD]\<G#NVX>DN:RGG.7#%88)? ?0
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ML9T)H:@$6GA_RT%8X%^6731QB9&$[[E^&U?$'5XF;BGOBS%(683 1)29>;/
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MM-Z$PM\Z=71OQER<EF7$9S4Z1!V5.AX8_[IWK<(_OZ$NR&4]_=+9RB?XL%=
M]EA$Y3/5B07$=AZ00:W%SXYP?,X4^%KW&-(DT#[7RJFY\M[KQG'24!X)9W:4
M=@LNZT"S"NR&3"9X+$"^H&H0>R!]X.69ME#NP'DD?WF4\[0-7_T$)O-<SXEQ
MES>W+<[HFCZEP'Q\8.#7@'5C0JP!H]UC81O;60B!!JJ'.#H(,P5V!]@2U#%K
M@%@& $P3_QN6U0GF=>R%9G+Y+9B63X\5<I@& [04P!Y,GE^)0$'#CF.&RQW+
M=E$N.![R/@@S;08BTQ7"+3-OL-[66D5U)*]G\TS_GW?45JY\,_]YL_KW#(\:
M9 (ZGA^P@G$"9!WX0VFNY6ALX,_, P,'WPY95]-]G@UXD _%N%7@4.0:8!$*
M+I!I@M?E 9&#!IT3!(*;242?6K#"^P5J=/#:45GR4R5N$\P=7" H?,T5BAP!
MB^1#,&?(T)&H@$?$[@O672XW F,G(S1"9O?5=H'D2,.C!V8MF ^:8]E@[&0
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ML46N+P#*0-DKG49'[34&_5$@2\650APE9_E<^/[2S[U&HDU@UQ28TQ/7[NT
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M/(YN>PR(@;UZLU:0TL=/)XV?XB8*%;9"V$F]Z26+S_B:*9\QXU-6=WCL]YX
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MK'G-HV&'AT#.*W?Z.<Q;3R-/1IKW'FF>4T?&F4_4^UO/*.UWAHWVZ'ANB,I
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M<5!AJD$;%9_)@[ N A233872'8H^4V,GV(Z88(, 94 !1FR@/B!N,@X164N
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MDAXV89 !BR5.;Q K"$@Y4TL+CE@E56W?P! <%(O6H,,1] =P))E7 MRK;^3
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M_<O^9?^RQ]P><WO,O0>HS6/N79Z]_<#<#P6OORA\-M-YF%<)ZXG4.<A"$ N
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M$/ %\8Y,"YNMCNQ>.V>7%G:=+>VT<OL\FX3I6- .,7P0!2%4$<^6VQ (-E
M0P>]%D"F>2T<C4 H[9:S2B2)>RB4TW!N'@(5R L@CR4L@%$@=>(:@@7>C0:B
M =U#.Y%8Y,I*LLI^D#>L(< <UA$E,/  \;M1QG]'-4G3+(>V411Q$]J5S"<
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M$J"R3QH=+!*>H'62O _8Y!L'\A_ J$W)S;89ECP2W]".,&YA+X3A=9/NL\%
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M2T[B]'L&[PUW<,KI3A2+0YM\G0'KR2:L(259D>X9HN>,3YB F</SZ$@&[DP
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M!5FRS@X<Q5QN4B&R4CC$Z<P%C;F8!&UXP@A?8]ES<,U/LQ>F'*Z;PJ:*7N5
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MV%20/@%$4TBC&%11K[;]2)" B\<$8L1[7SE3O)^/^X&W]%]2#?SYW.-,+?'
M26H>D-0.1E%-=IB;$T#"_XUYY 6TJ*_C9\IJ. PIIDA=O?EQ#AU&F%!$,X-X
M4V9])P5,PV XYU([G$%E#:Y>@UY#GOCR0_ 3\S078G.N;ZX]6Q2H,*D$ +U>
MB[8H4+Y%X1XA3,3VHP.P>7_D\4FP'S;#RT7-C*@B>M0V4ZX^MHA]-HU!PY@I
MH IU::;A176IK?&?/WU^O?Z;([Q*W[6 _7N)4HG,"PWN0M>C9K/P-+4'5X..
MN^S&[2*^R7VYFO2LL $>9H= *1<^^'(0G=A3E=BARJ*ISE)&F5UZ12$Y39J_
MK$(5=G&"G(LQ!_V.F7,V >_)YOCS@COR#00/!36IR^-.%=<3[M?0Z@TU:@LR
MHO#,6UPFDF3T?8.ZNG8F::Z'5]"I4B<'J8F]SSHV?@I9.$-X;9Y=@O<M?>$S
M?U:;'[^]E=M4J*VM%PN7O;R>'YLKOL+%DA&7T?[7*[0F5WR%C7,&:Q,+_X G
MC%EF/_Q"O:-?N$O?T!9Z05VJ[ 78+],6]QZU6[=XXFZW<6'F;G)#8+L6Y=L6
MW8=<W9"\DJKQJZK;M:AK28RNCMC/_+4= NY0GK.!]-Q'X8*W5>-!R?99M(PZ
M]=W<IGAG+!0IW CRVIM?9#XJIDI]39\R;QR_![7\(ZKV,D0C-M^J0VT>KX%P
M\9:J7YE!G%]AN=FF0?GY:O@LAU/I:W 2<0[$M ']F> C7^.\V%S+BNE1_7I=
M,"1P*@@"A<V;\]J6_ZZST;KP"DO+;.[)!6ORLDA"9 4'+3TG$,Y+$UOO?+&J
M$OJ^-A%,>LZ,I0<21?8^]= /:7!7LO$6%0&]'7S!]</_ %!+ P04    " !9
M@&=/9A@R;B8(  !G80  %0   &UE:7 M,C Q.3 Y,S!?8V%L+GAM;.U<6V\:
M.11^7VG_PRQ]GD#*=MM$32L*2864!$32B[1:56;F$*SUV*SM(:2K_>]KFX%P
MF8LG21D3]2$*##Z>\YWOV#X^OKQ]/XN(-P4N,*,GM<.#1LT#&K 0TYN36BQ'
M_IO:^W>__O+V-]__"!0XDA!ZPSNO<]:]]+Y^&)Q[72HDH@%X'1;$$5#I^=Y8
MRLEQO7Y[>WL0CC 5C,12O4 <!"RJJ]\_SU_H#9H'#?55?6J\]B_9%*(A</]E
MX_#(^[/1/&Z^.G[5_,O[MW_QG^]K+0BF?P^1 $]I3<5);>4]LR$G!XS?U%\V
M&LWZHF!M7O)X)O!:Z=OFHNQA_>O%^54PA@CY.(&RE-+5I,D='AT=U<VOJJC
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MU- NPTTUU!+]28(3'Z^U#94-0]C^1/KO$GXZF60+&L02OK'6/WD8R8+*]"8
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M8WF:1E_#_ ]2TJWVXL\%Z.'WM%-050TYC<Y(7L(*H'TF:/DO5H3<S'CEZI7
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MP!R4&&L[0E5X5"QPQEUU6'/P(K]<F^D 98<M<EU(O3UZB_XQ3">PZZRZ8\3
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MVU,V93[_2S-!^ -T\QD>>]5R4D,F&U(50NI+<Y[A"590OI!UNQS>I;@O/7F
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M:$A.!YJS1'&_98I]QG4AW XRR;6$?![G9 +S2>].FP\%HWVTFE^-/J-=@?$
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MQYJ.D -8C;(5 8>[/7D/L'JM"EFWR^%=BGO3#/L O=UJ"SZK- 1OS-K&1FE
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M%Q//R?P8):R:NMXZ-'1.;VFI)1 O:/'V#% -"EB[&"5%4%/ 7F4RP))XB\D
M2.[LH;Q,56[?&ZQ@Y20.K4#!MY#Q7%Y,K Z3YES!&N9S6O!_@W,4)5E&'ZKE
MVWZ@:U@=8KJ U\$%#NNG7A;ZU [#:)\K3XJTE(#(%Z70&\ *,2H^)7 ZF&G
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M2]:9E4H:<6+UN\;$#IM..ACJ8FKI8)Q#+*;6<1X&8;2G;TW4A2LNWOQH'^"
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M=%.F\254?XK=1JT_ANJO0?J3X]4:F"^;SQQ;7G#AMFCD/QVC:]= E]=&5]!
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M3?'P$^39K2'6NF>VAD #S_SK5%<8=L.WMQ/X;,!^V=2)= N\\SM C 6F_2F
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MP/]&R#QZ;LR8 KOTS[Y^C^F&4Q@_]^I&N8UI1.]T9]-,(HDYTE<,"DJ)):Y
M_,Q8\<[Q!J<I@5SI=M99EO@A R]S.SJQ87=1+5 J;JQ:0-2=Y9TE,8L(J/+/
M]EF>;'':R]H#^=]L$^+@*B:QZVN8[#/IK<LI.W=HLY/H0CQ$YIWR]TO*;E>R
MX*'J&H4Q*CN?Z\ZGX<GY+'HIX@TF]"TMR]9V#)!V/IU-=)W = 8QIK1($#"U
MT\)"U1C0(FE\!(H!D$7OIM3.RHR82B-$5!4ALL2BDQU7 +G<U1ZQ0F"[ HE[
M^)G5(1DZ7(\O95HM#>Z]JIOH0&+R79+2R"@H!RY)T3[&7AJ3GXN(G4?VGUD(
MWQ/0HV#/GL+*7P;7-I&XD9_^^)/=CJ^"P-EC)0J>A2= _OB3RUU>HZ=+ELN^
M?G?"BOF?SI9X=*2%?/M5%AW>1^V^E;9>[NQ5ZR@:6Q"G<IE$4?*9F'Z7ATRQ
MISMAW^YV\";1A"0\_5O_4I7%\M1S5WV+<,V =Y GQTEG8VTZD #9@?*=]@DZ
M/@8+D#W^-@G\@9\RGPP;DP%_JI?AQO!PK7OD>Z+.CP']U\KJI1-8P/4"GK^>
M%"R3F8* %'=;GH_AEG!TNV&)VV1A=;OYD"3!;?J TU?"IN:"@1&UPTU+,VF$
M52>CHBO.DH[^3"GI&K.@E5PU<+D59S%6W;TVBX%:#/:T^?J&],O!GS1)WA"!
M"TB>MQHS2Q3:I]C/=^Q#O#>F]82J9ZL-DG\L^P$^S%%):'INP_I@99*J7A:2
M*C1H3$U.*+0#.B*4-?J><J5FTX.KH-1**C/D]0,/XJ'Q)4CH+'JVQV<K1 8"
MI]&1Q81#Z)=#Z%5#&)4]3'7>8,2N=G5KV\NB/(9JO6IC4XIEZ5)<AP-1E^5#
MU$MM0-A.YTO,QU3E3Q ;TI#V,Y5K6?L^/8!ME-VYP?DI?@YCFJEUZD4T.4.:
M$&%&["P?PE 6(6V@H&L6NB"4J")%!>WD'H,?2S_D7IJK,R(&2E:WS_32N,N!
ML,%<.P7".>#,,B#& J]19RS&-$FY'*HG3CNKM5_$P4!3[U""VGE7"E,CYW0S
M6SCYB+U]ZR1J&K=:"EC+[L67WJSG ]=PFS8&6<>@,1^>H=8\\\87$>Q,^[R2
M$?42-KE:TEAM;:VH0UBA@AIBLI](.-;48,:?W[M-*Q"\EQM@2\;;C*(AP?J&
M:O%BZ14:=,#^H"F!J2>H:)9F_T;"E(U"DX ?UORMY5FV]0O68F+W@JFXL_BK
MV$^QE^%SS/][%4L=D\+^K7IQZ WLI.O"KZ1&7Y?TW] [2<K@ >8RXC@YZ?KG
M[(7\!M2:!B"Q:UL#8 AI:8V5FY5MM>A K:DM@:']-(B68BUJ.99J'SWXT5M$
M#WC<V<"#_X*#?81O-^LX#X,PVN?A*W[ _CYED_O%FQ_M QS0BKRT]O ^+ZIW
M7'@I#6'H%<"'%R_%LO/PN3[DT,HFUU$7SN4':+91\Q.H_@8J/\*K6#<^0XG*
M#]%+N8A]"N88_DO4F$N/,H\U=EW0/*8XQ8LMT>%<X.9VGV>YQY88PGED=S-\
M0$?.WW*QD%'ZRD9T0.<]B&]T WV@OB1QW;\%8XOC_H=A0$!L]TH,\.BZBY/^
MA.F;"CA8O^+4>\8W>WII\G;#W&!&'Z=,XH<\\7]]V#_]%?LY?7F^?+/N-CVC
M^R)1I*L8-.$W'$9'4VJFBY&R;U1TCGCO= +G_:\0_P)BGT#%-VC-J?HK-'>[
M^1V8D&A.-14ZR)@.LEH':4L'FR3=X##?IZ"+ILD-J1O=3&Y%[IS,R'#L]-#?
M@>;VT*Q?=>B(YM6><*(L675 /H6R9 VX]#$.[*CK=1P8$;0?NO&V^LM@>E)P
MC]"2PQ#4*T2I@!]Z<28.O*V*6#,S.!%H[JSF8KN+D@/&++JXW5%#EQ8?,J!Q
M:"<JSKN(*ML6$3=O#5:": ()DAW<HF"TXB$M5XOWKLEJP>ZRN&^6IZ%/E@F,
MF4]QF&?W#Y^T]JJA<UK,5RV!F)1:MB\ Q"C0UX0F^P:H!M<LLL!6XS6 E5B%
MUP!3#G>ZO)2^(ZHUA4X[ESM.'0Z%72/^=V!0&W()^DQK[U@+&RI] PV]&#%>
M64G??9BX?_!EC;U&3!?TE@>ILU6!-XP%YU+/8Y)[$2*6$)Y46LK8KN+RUD\#
MS6/B78VV;3A\Z;S8SZ6[O6%.3[,XR_1$*HF?B?O>UG_2):X,Z<SE>^A#9!7.
MXLIC@KKI"E7](-K1">VI\7?8!).E2>W2XH>C6WAN?3"TW=GR-4V26],(Y)E5
M:7LD']0<:,A)'-JE@N\N#EE3U&B[0K0UZ%'";.R[M!0==KKVH ,.+.JU>^\J
M(F#D2S>HI> !W6F?501H"U#OJ^M!M- X[EJ1'#BVPZ7&<]>J_*HAT<TU5-+@
MXL5?;(0GX'Y4E"> ?EQ1BW2/@X]AA+,\B?&==V!U=GL,5-/>80$+&<<]%05H
M4U2U165C@&S; 7SO>!.:%89V92HFVNQI?ECY1Y"-#2/H=*M4S(\;T]H4MN.P
MK?!3*GVJFC("%Q^]MW"[WZI?PM51N3)%+?==A8J&N$(%#=SSM]927'(#+!]*
MQCWX #-*,T"U3-,AFHP,= 2J=A6JM@6J^!-9D]62/ 3XS>[U*B6)LRJ12KZ%
M5.7#.7Y;UB-0DP@ 5\A1#YMVU49'F#$KT3B%ZJ<RP(>G,"EC94,#5)*X,D U
MW\+-R=,P0=7B:!$&:"G _^J7 ,P"#7#3LD!7H#&R0$O=HW[= Q5.N\U?<%JO
M7747'?J;.]S;D?#;U3)KUMB76$)*O4K5W0T'E9[AP*'=/I<1  )$NN?< Y$%
M[#:K5:Z#"=0N\S7.,HQO=S@EGC)^9AO@CSC=WF[*6C7*,Q<]L=.S%P-9Q ,,
M2K1"%1EB="M$*6F.3TD+=1@S2"8Z0=%FL,<OIM 2CV%,<>704+PXJ&Y-?DC)
MXC=@?"G/XN4T+LU"P;F '%K9O7&1F#?G)@%4'LF&_76*/?JP>DN,QX3S#VH+
M.O0()J"#CL-8HF6'&=^D^QC&=!NHW$DZWV-]L5[;CES&'K8R"C%)>_K(5JC8
MS"PZJ?9E$>F&EO1](\#\C*-7TH+XM!<@XYI:;G2/:1Q#_[TM!.>_EYT/.8W0
M!@%9B-P&H1@VHCL/,U8"_-[+5=F>>E+@:*XCAW$L5](A2KB<0$XC3M>VE%)
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M4WN8RX050$MB%B;(CACU=*X.& TDD,XCMXU9DE A3L9#/("BHP-$J=C'!6W
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MLY7M0>OKSBN#2YLSP%+7?@R !&X+VEJ]&CIX>Y#N4BK0!%K9=WXY%F 7ZCK
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M^=H*$<+<:2MU:N@%8[/&A-ITIOL*;X"L2AN918U0V8H\PERI%<#Z9E/Q(&^
MK!L;,5 I SQTMH*44/?GLCYB?N._T1N@AKK,'>#M(5M/%:P2[.5B++9BE)!Y
MF\%E?Y,T<O;RQWA8,4M-.2R!8RMZ"9/)9_.)SLO5J3G,'^!AV[EJL5>"11#6
M86S"<NM(-CJ*O3UWCF!]G@IP"/AI;I)"5+;7Q/4Z30+3Y?H^!JZ(NT?8#FH+
M2I8:H(#UQA8M7&OTO$1O?IT6=Z0H8D)5CLN$M4U9E# [B_(@3FG19HE$F+W(
M&R*EMUD4D1J(!3)C;!W#E9D*[?1V?F\/V<)I]];%X A8:6X&0_9N"MN>2)V7
M@E'>'K*9TP*C5? $C.]4'%HMBYJ,FMW?S17H!%SOE"WM9C%3AE45G\9YVMM#
MC_Z5,DGH7N8"$;#4V%"&>QA7(BN4$8=KCWI[Z'DM-=C)12'@I;%A#)>7[^6F
M;_PHI*KD<P3:006QS$:F'.SM(6_3M?BMB4L@ 9VRFMW2^L\)"<_]+ &E(Q\%
MP6S*&L>$<!^-@DAV/*L'>_O(:G@M_FOB$N3F=,JRQNMS9Z".>?O(VG<M_@IP
M"/C9*<N:2BUMX+[V]I!#$^Q>J<48!7+0/' ,,Z%[M3]U#[.[]X<8NV>][.Y]
M9'^$-D%%^^<&FH^2W;WO5G;W_H;W2#3I_F=W[R.6;>)1?),O&]/]F=WM[;L2
M"R=:4(JY]R"[>]5:!8K".&-@0V;L>.^:KFFW$[W VT>W_7 YJ&/"DV+J09;X
M*MJR8M5H5CRE6?2O=^U3R?KU@=X^NOFG-LNY6'J01,Y#*2_0ICG2PZK.9HW9
MZV!ZD"]>L5G6V-@U1GL'Z!8@ Z[K NI#9OEZ!4*M_5PRRCMPKYJ+%J>Y0&QE
MBKO$X4N6TVS"W7*$=X </=>,LQ40MO*UG6*KWNDLK3AZX(K9HA:#UY&TEI6]
M90/MDBKY^''\3#+VB:V7WKQ,8&9D.1<->ZQ@A'=PT!T3["'REB>CH9;5]5"\
MW3ELU*MG=3UPQ7+P3GJUU?7 7M=5AZVNF$U6>1176%TM=E7MLM7UT!557K2@
M%'/O@=5UGN8A8]SB$>_(%7_A*A?X+%N9M27;*'; 8\XBL^?E@G0*H8J&> ?H
M\:P&K)2BZ($ME.(;/WY-TY"%@Y#L)0I(?I?&\DNT:)!WB.S,DO)+S&()FAZ8
M0&^!%4!&6B/T#+:F.&6U9>8DDNZ^DG'>(?*67(/5:D ],'M^)0E<I&/ . JG
M4<):$=.F'6I^*T9ZA\@[=PV.ZT#JA2%TE3(&Y[)WB'RUK+EE;V"P9OE$#%Z=
MV\"226D<N4JY/1$E3WM8'61K:5<B -;,FXBLO$Z3=!7>HM:F6G=6CO4.W?,T
MB]FL!\=:M4K$?7B9@UX)L_Y&?)J+'HZ36]JR, ,BG/AYE)^RMH67R?<D(WY,
MW7)?_2A1+'D['_".D*T?>A+!ER:+)+!5.!/W<OY> KPD)6O4!K^A6F[T$H4D
MD5WF-$9[1\BN@B;BHHNO#R4V60WG*K'4.K]H"&VE>HA=U+H)WY7 &M?L/"X9
MGI )#:'!4C-(H:4KKCSG'2&;:9HP=A.)M9J;F.IB%96.BLA[WCMP+]I4HA8*
M(=@JIUGW7*8A"XQ1.\?#'<8F^INU";_X44Q]-_=I)5QCGDM'E8^ G3#QK. &
M)#5[(=O$]K%/92'_5OEM"6H?ZG N\JD7H98:"UTTQ#OJTEJ7HK!5?!-7#5^'
MJ-X#-$>R%8 59:#%0#V>BV#UH3[G'R2:/ &H$<B@/R'7L^D#R<:/&]%[&@O>
M]%7>H7NAC>*-H!8Z6Q4_D<L^2J!7D.OO&_5>R-;=$7+.0BTQ,)<H#2K8*BGJ
M4B@MI^H%7KV#FG7O-,9[>SO'.\MJU1T(N67S=26228NR_"4G@&4I&#=V. Z7
M074E@&F5^JNLDDW>4DSN=OAD&H[+0#K4YGY!]$WV<*=M*32W%F\L;HSE=@*7
M^^<TH6>28(EIC2MIX\IM5[;HS.!8"N%%8O4:-.$"E3[/:(%?(4^'6X([KA25
MI=A?) Y73'/?"%6JI5%%:\^6-$"^9<BYP^>H&$D/PGT%=3V5[)6.*PF$'%%0
MA]5ZJ'H1 +Q:SE/);_Z DB3(7H<ZC%; Z4'0+VWC'861G[W=^3&97^U42I=H
M#&O^C<UG,X5+"<52D"^67OV.ZMJ?PH_WF9_D<%$'.$K-2SVXI!*V&5G)0P'O
M]>'9"A%&D@+J.EWIC7'R=NT7LPPPO_]:9,TP?TE)-E?,53K;0 ULMD*-G1")
M.5KECB 951(&V<)5@X\Z L$':BON&-OD<E4O$9HI0=A;?RWCRB8&6_&\:*QL
M5HJ>D<&]_(\%=T3L%.*P%9+[3+(HI0ZRK' AND\[2I/1P16[IRX_^1 :!]LZ
MX<%GLEH6VSJ;T22#&R99+!OAFOQ@?Y%OOQKC&<T<K#2GL8RUH=F*V'57'&Y)
M7F114,S+:XY^^%D(2V/\>)%FCR2B>DA=2=%Y-:7T8+=K>X<UU(X&$+.91PQ?
MR/"5)],+Q9?3O_V8MS<EKR0+HEP<.6S^)DJ;W2-77-<JB6@*TE:PL+L;#/O;
MF"',SR7B4OM=Y6;MRLW QA8BA]F/*.11^(]9F>Z6WZ<"!P<+C7OP 3PUHY,D
M9UR]):!]YU%!YB502L+=DB"=).PMJE:';7^ZY%37[C=;HXJM,&H'MKR&=^!#
M]PIRU[H#'XK#4XWMD^71>9ZLY"DBAJBRCNUQ^F/KQ5XK\8_+.9@%I&X,\XX[
M%(.ZN^.*8T]$2879KP+CHU1_/7;ET*O0?I5+HEGWO_SK[B[2:2,B^29C-N?[
MLP L"+$K)C;AHE+-O@<U8*])00^!FRREI3C"D[?OH"=<)LO"4*.@B%[*;J5:
M.?&&+P,ZNJ<K,MX*C>NU$/:B05?Z&!4*_\G[0][N #FLN"ZO^)Q?1V8I&-4A
M8P6]V"9!%),5#])]:F]_:.-SWC%VC1RK8M8:B2Q%T>+*:U?*N^WN()MM6Q,C
MOM3:)%O38& GJD(MZBVL&A1E"C)W % $N5#4E@5)1H8>E D^(S#7(&*@X.>8
M,&XFX6B:9D7T+Y60Z P'6B$?B%L6&7VB]*$U&] 0MLV<G)'ROQ6JS7T9>MVS
M-%_B'2,[K.UJ5X; 6^ORABHP-QEY]J/P;(Y@4?@O"5G%QE&>DT*F(M5[(7 %
M69(,>:\K0/K@&\<Y.Z'9;%)@% 3I##;[&_^-E93+_%#F#M%[ 9 ,V>;>DKR(
MP=H*GG9KMP&\V0QF_GXQ,)6-M>% +.2PNO8D@PNU#X61-]'2K!!*HC^BXND4
M]$70#+,%=%G(@>&;O-U=9#-D2]*B@=I6S'<W_!-6_!+>[@#9'V%7X35%WI-*
MSCS,91UZ2RXMR<N ':[44VGBTE(BM!7BC>K3\M\6@8'!/V=11NZ>TJRX)]GT
MO6N!U-VE,QXV8S<OT4H6"SQA^J ;1X$[<>4!N@6$A/D%$/8;S6!EI&(7OY(2
M<-L[]>.8%GZDI"CTY:?9FX'(R)<DRY)E@QRVPL@=U'HX9+5R= 'AD*]4=N7(
M%+FU MCN:3T74>(G@26M1_(R[]B]7#=SI4<%T%8P.'(<SW*3-<UA4HZ%]83=
MV:P>9]4'D@1O:R6LD<3BCS*M;X%25X-9'P;$P>^0THXP\*$*Y*!3%MPJ2IK&
M!X1B55^611DUA8$[EA9]/QKT=8>00Q8(QY;,N(*$Z.KT0<]^B=)9'K^5Z9MR
MGIL,+VG@9IR>&=MKH19POE-VV,6E_Y;$]"9^G][[K]3T3)/F@'@7:68<\E3W
ME;#7(D?7V=U!&I%!(%OZ!ELG+"SZ!+5R:0'28?=?M"E!IL %,F-NN46\[E+
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M;&_C)+\U.0Y._9Q60:;_H?U\7_R8JK7Y4YH5]R2;7B8O9*X(TZ?2Z31-&'E
M#0X("?-;$A 8Q?==6?Y"2<NN[AQM$4,@6)T)7G^OB;5H_769P $Z8U18E,(:
M%>^5<-:J8IGZI=TM8;J[/]S^/K^<T<G;B1\# \C=$R'%URR=/0.)56YIG>$
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M?HXC^)Z0D7K#@0#(X3'UN6J"4,#B+5FB!"Q>BB%M_! EC/+7:0$R*M>F5.,
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M#WD41G[V=N<OMPY521?1&-AFL,.,S/9 340]Z"17P46;L(T?*^5YE3D>ZL%
M)VQ#B9R% KYK G.Q\=RHN'\BW_SL3U)0&)H5I>6C8%O#5F(T.;+*3VUH/6@%
M=TMBOR#AC9\5;]4:VR=OU;\HMG#]E[!ZO=AMGFINZS50NI4[W4@XE-OZYL,E
M&9 -GS6XIF;_&CZW\JF-V6RGG0\C!G;,:+V5+0=D*],:*S43K7,/(Z ;E4X$
MK.6+0UV<'4_87@91E09OVHLT38BZ\)5T'(N7PN[@5/<>IP6LXYG;:]B4QSSW
M^9(8V,J^%KOXK):C0LO9ML/B>GW?&7CD<"(Y6_BLY*/H>))VM:#LE490"O=Y
M;X!=]+KF1BQ!8RMC&_,./I?8_#HM[DA1Q(32XS(Y]?.G"S_*?O?C&7GO/ZQ>
MP)HO HHC+V\)7Z5KVP@@;E*WJ+/B$XD?;\DDHD$%=&K+PXMA$-G;%,.\(7:E
M26V.ZL/I0ZXVH\=EGL](>#;+:-E-DD5I>/<$1,VOR0_V)[F.K?,"$'CD"[CQ
MBC8!UH=L[#F!YAO9.&.9BM<SJJL V4@ -*!%@T[].";AR=MBPYL_J''DUWTS
MD!A9.3"6'2N(<9.\6Q2J\U>2!5%.;K(H(,L_+M%+,P?KO _(B7S-MR- >CBQ
M$\A%>D7I\&*[YR@)%Y/_3M/8EBXLH7:A,Q@.962+OJ&.H0\*-SM<P-'E?E8B
MH#,.[],3<I?&H1Y;]=\ 9.B*_E +&6YNN(#!B_WF?:NY2%FC4ZH. QE$;%6-
M \C(011FS-3#TX?\[9LL#4!265N[.=8%>&E+5\DP( YRE+SQX:N&8RO%&K=(
MB^"&PVZX#:Y^J^.9#VH/V0!OZ_(G@"80ATZ9^BK[&3NT:)Q9D$4/<#^9%=^3
MB-%B_DN&-+\E 8E>%/DS35[+Z+O?%9W.*F*!1#7J5[*M\@V ^<3/24B=(R3)
M2X:YD[3V;H6E=3;?ISB/HCE-\R)G(!XHB$7)#8TDMV8O]H:#780CX-WMP>=;
M)>#@Y.W]F?GL1S_\+#1(H6OV#2 1LB'(!HL%!XY=(J&G\[6=A33$:IG1$L-6
MI8*#U:F6JRVD*\')=X 5E,TAMX ?:Y/M7LM4\WPEAA4[E6R-[IO<X<^Y>WU3
MS?MS4JP#)'N* 7^X<W:J?ZJYM23V$YJ\H8A"K#X&FXL[@<CVSRTQY!ZD$"Y
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MRH*S;FR3'K<C@2.K9D$7](5C-!%@('8D>;_63@WJ?XA6$2JZ<4S'6 O(<"K
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M+LMYO7;K+?K5C1N_'_<@>+>%-="$G+9*7^FY'K]0X%0A^X__#U!+ 0(4 Q0
M   ( %F 9T^UZ$*0N)8  )]]"  1              "  0    !M96EP+3(P
M,3DP.3,P+GAM;%!+ 0(4 Q0    ( %F 9T_0CFCG=0X   "(   1
M      "  >>6  !M96EP+3(P,3DP.3,P+GAS9%!+ 0(4 Q0    ( %F 9T]F
M&#)N)@@  &=A   5              "  8NE  !M96EP+3(P,3DP.3,P7V-A
M;"YX;6Q02P$"% ,4    " !9@&=/QDC.XX(]  #H^0, %0
M@ 'DK0  ;65I<"TR,#$Y,#DS,%]D968N>&UL4$L! A0#%     @ 68!G3ZKG
M\^E]4   D;D$ !4              ( !F>L  &UE:7 M,C Q.3 Y,S!?;&%B
M+GAM;%!+ 0(4 Q0    ( %F 9T\JLNJ+&T$  -)?!  5              "
M 4D\ 0!M96EP+3(P,3DP.3,P7W!R92YX;6Q02P4&      8 !@"* 0  EWT!
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6948884288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Financial Instruments Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">We measure the following financial instruments at fair value on a recurring basis. The fair values of these financial instruments were as follows (in thousands): </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"><div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:100%;"><tr style="font-size: 0px;"><td style="padding: 0px; width: 65%;"></td><td style="padding: 0px; width: 2%;;vertical-align:bottom;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px; width: 2%;;vertical-align:bottom;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px; width: 2%;;vertical-align:bottom;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px; width: 2%;;vertical-align:bottom;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px; width: 2%;;vertical-align:bottom;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px; width: 2%;;vertical-align:bottom;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;&#160;</td><td colspan="10" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">September&#160;30, 2019</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td><td colspan="10" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">June&#160;30, 2019</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;&#160;</td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;&#160;</td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;&#160;</td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;&#160;</td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;&#160;</td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 65%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Warrant liability</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(8,344</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 2%;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(17,613</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td></tr><tr style="font-size: 1px;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 65%;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; width: 65%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">(8,344</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">(17,613</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">)&#160;</td></tr><tr style="font-size: 1px;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 65%;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_FairValueOfWarrantLiabilityAssumptionsTableTextBlock', window );">Schedule of Assumptions Used to Calculate Fair Value of Warrant Liability</a></td>
<td class="text"><div style="text-indent: 4%; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">To calculate the fair value of the warrant liability, the following assumptions were used: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"><div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="padding: 0px; width: 77%;"></td><td style="padding: 0px; width: 9%;;vertical-align:bottom;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px; width: 8%;;vertical-align:bottom;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;&#160;</td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">September&#160;30,<br/>2019</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2019</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 77%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Risk-free interest rate</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 9%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1.6</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 8%;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1.7</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; width: 77%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Expected life (years)</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 9%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">3.6</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 8%;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">3.8</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 77%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Expected volatility</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 9%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">56.9</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 8%;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">56.8</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; width: 77%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 9%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">0.0</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">%&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 8%;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">0.0</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">%&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 77%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Black-Scholes Fair Value</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 9%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">0.52</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 8%;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1.10</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_ScheduleOfChangesInFairValueOfWarrantLiabilityTableTextBlock', window );">Schedule of Changes in Estimated Fair Value of Warrant Liability</a></td>
<td class="text"><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth a summary of changes in the estimated fair value of our Level&#160;3 warrant liability for the three months ended September&#160;30, 2019 and 2018 (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"><div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="padding: 0px; width: 73%;"></td><td style="padding: 0px; width: 7%;;vertical-align:bottom;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px; width: 6%;;vertical-align:bottom;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;&#160;</td><td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">Fair&#160;Value&#160;of&#160;Warrants&#160;Using&#160;Significant<br/>Unobservable Inputs (Level 3)</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;&#160;</td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">2018</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 73%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-weight:bold;display:inline;">Balance at July&#160;1,</div></div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 7%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">17,613</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">46,313</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; width: 73%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Reclassification of <div style="letter-spacing: 0px; top: 0px;;display:inline;">warrant</div>&#160;liability to equity upon exercise of warrants</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 7%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 6%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">(1,068</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">)&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 73%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Change in estimated fair value of liability classified warrants</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 7%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(9,269</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">4,962</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 73%;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 7%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 6%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; width: 73%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance at September&#160;30,</div></div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 7%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">8,344</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 6%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">50,207</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 73%;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 7%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 6%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_FairValueOfWarrantLiabilityAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value of Warrant Liability Assumptions [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_FairValueOfWarrantLiabilityAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_ScheduleOfChangesInFairValueOfWarrantLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Changes In Fair Value Of Warrant Liability [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_ScheduleOfChangesInFairValueOfWarrantLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6778811728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Nov. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Fair value of warrants</a></td>
<td class="nump">$ 8,344,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,613,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_ShelfRegistrationStatementValue', window );">Aggregate value of securities available under shelf registration statement</a></td>
<td class="nump">144,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_ExerciseOfWarrantsForCommonStock', window );">Warrants exercised for common stock</a></td>
<td class="nump">440,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,118,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock Value Issued</a></td>
<td class="nump">$ 159,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable', window );">Common Stock, Share Subscribed but Unissued, Subscriptions Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,274,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants outstanding</a></td>
<td class="nump">16,061,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="nump">$ 2.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=meip_AtTheMarketSaleAgreementMember', window );">ATM Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock share issued</a></td>
<td class="nump">63,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,214,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock Value Issued</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_SaleOfSharesAndWarrantsUnderAgreement', window );">Sale of shares and warrants under agreement</a></td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | ATM Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_NumberOfSharesAgreedToBeSoldUnderAgreement', window );">Sale of shares under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_ExerciseOfWarrantsForCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise Of Warrants For Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_ExerciseOfWarrantsForCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_NumberOfSharesAgreedToBeSoldUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Shares Agreed to be Sold Under Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_NumberOfSharesAgreedToBeSoldUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_SaleOfSharesAndWarrantsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of shares and warrants under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_SaleOfSharesAndWarrantsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_ShelfRegistrationStatementValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents Shelf registration statement value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_ShelfRegistrationStatementValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of subscription receivable from investors who have been allocated common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=meip_AtTheMarketSaleAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=meip_AtTheMarketSaleAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6777914032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Antidilutive Securities (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_PotentiallyDilutiveSecuritiesOutstandingLineItems', window );"><strong>Potentially Dilutive Securities Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive shares</a></td>
<td class="nump">26,992<span></span>
</td>
<td class="nump">24,090<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_PotentiallyDilutiveSecuritiesOutstandingLineItems', window );"><strong>Potentially Dilutive Securities Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive shares</a></td>
<td class="nump">10,930<span></span>
</td>
<td class="nump">7,774<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_PotentiallyDilutiveSecuritiesOutstandingLineItems', window );"><strong>Potentially Dilutive Securities Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_PotentiallyDilutiveSecuritiesOutstandingLineItems', window );"><strong>Potentially Dilutive Securities Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive shares</a></td>
<td class="nump">16,062<span></span>
</td>
<td class="nump">16,186<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_PotentiallyDilutiveSecuritiesOutstandingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potentially Dilutive Securities Outstanding [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_PotentiallyDilutiveSecuritiesOutstandingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6775263632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company and Summary of Significant Accounting Policies  - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>ClinicalTrials</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TargetedOrTrackingStockStockLineItems', window );"><strong>Targeted or Tracking Stock, Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_NumberOfClinicalStageCandidates', window );">Number of clinical stage candidates | ClinicalTrials</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_NumberOfCandidateInAnOngoingGlobalRegistrationTrial', window );">Number of candidate in an ongoing global registration trial | ClinicalTrials</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated Losses Since Inception</a></td>
<td class="num">$ (234,212,000)<span></span>
</td>
<td class="num">$ (231,218,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_CashAndCashEquivalentsshortTermInvestmentsAndCommonStockProceedsReceivable', window );">Cash And Cash Equivalents,Short Term Investments And Common Stock Proceeds Receivable</a></td>
<td class="nump">$ 65,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_CashAndCashEquivalentsshortTermInvestmentsAndCommonStockProceedsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents Cash And Cash Equivalents,Short Term Investments And Proceeds Receivable From The Sale Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_CashAndCashEquivalentsshortTermInvestmentsAndCommonStockProceedsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_NumberOfCandidateInAnOngoingGlobalRegistrationTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of candidate in an ongoing global registration trial.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_NumberOfCandidateInAnOngoingGlobalRegistrationTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_NumberOfClinicalStageCandidates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of clinical stage candidates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_NumberOfClinicalStageCandidates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TargetedOrTrackingStockStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TargetedOrTrackingStockStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=SL37586934-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6778524496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2016</div></th>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_PercentageOfPurchasesFromMajorSuppliers', window );">Percentage of Purchase Requirement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_AgreementTerminationNoticePeriod', window );">License and supply agreement notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=meip_PotentialRegulatoryAndSalesbasedMilestonePaymentMember', window );">Potential Regulatory and Sales-Based Milestone Payment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_PotentialMilestonePaymentsReceivable', window );">Milestone payment receivable amount</a></td>
<td class="nump">$ 444,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=meip_KyowaKirinCoMember', window );">Kyowa Kirin Co</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_UpFrontPayment', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_LicenseAgreementExpiryPeriod', window );">License agreement expiry period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=meip_KyowaKirinCoMember', window );">Kyowa Kirin Co | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_PaymentRelatedToDevelopmentAndCommercialMilestonePayments', window );">Development and commercialization milestones payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=meip_HelsinnLicenseAgreementMember', window );">Helsinn License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Compensation Receivable For Grant Of Rights</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=meip_PresageLicenseAgreementMember', window );">Presage License Agreement | Presage Biosciences, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Compensation payable for grant of rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_PaymentForLicenseAgreement', window );">Payment for license</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=meip_PresageLicenseAgreementMember', window );">Presage License Agreement | Presage Biosciences, Inc. | Incremental Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Compensation payable for grant of rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=meip_PresageLicenseAgreementMember', window );">Presage License Agreement | Presage Biosciences, Inc. | Potential Payments on Achievement of Development Regulatory and Commercial Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_PotentialMilestonePaymentsPayable', window );">Milestone payments payable amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 179,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_AgreementTerminationNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement termination notice period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_AgreementTerminationNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_LicenseAgreementExpiryPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement expiry period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_LicenseAgreementExpiryPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_PaymentForLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment for license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_PaymentForLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_PaymentRelatedToDevelopmentAndCommercialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment Related to Development and Commercial Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_PaymentRelatedToDevelopmentAndCommercialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_PercentageOfPurchasesFromMajorSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of purchases from major suppliers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_PercentageOfPurchasesFromMajorSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_PotentialMilestonePaymentsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential milestone payments payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_PotentialMilestonePaymentsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_PotentialMilestonePaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential milestone payments receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_PotentialMilestonePaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_UpFrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Up Front Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_UpFrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLicenseFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from licensees for license fees during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLicenseFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=meip_PotentialRegulatoryAndSalesbasedMilestonePaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=meip_PotentialRegulatoryAndSalesbasedMilestonePaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=meip_KyowaKirinCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=meip_KyowaKirinCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=meip_HelsinnLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=meip_HelsinnLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=meip_PresageLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=meip_PresageLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=meip_PresageBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=meip_PresageBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=meip_IncrementalPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=meip_IncrementalPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=meip_PotentialPaymentsOnAchievementOfDevelopmentRegulatoryAndCommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=meip_PotentialPaymentsOnAchievementOfDevelopmentRegulatoryAndCommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6777927424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Detail) - Accounting Standards Update 2016-02 [Member]<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 01, 2019 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">Operating Lease Remaining minimum Lease Payments</a></td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Operating Lease Discount Rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating Lease Remaining Lease Term</a></td>
<td class="text">10 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right Of Use Assets</a></td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease Liabilities</a></td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1', window );">Cumulative Adjustment To Retained Earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear', window );">Operating lease Minimum Lease Payments Remaining</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accrued Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Property Plant and Equipment Net [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right Of Use Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">CA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Area Of Land Subject To Lease | ft&#178;</a></td>
<td class="nump">20,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease Term</a></td>
<td class="text">0 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee Operating Lease Remaining Lease Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cumulative effect on retained earnings net of related income tax effect.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LandSubjectToGroundLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of land subject to a ground lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LandSubjectToGroundLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=meip_PropertyPlantAndEquipmentNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=meip_PropertyPlantAndEquipmentNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_CentralAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_CentralAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6944107456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Schedule of Changes in Contract Assets and Contract Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_ContractWithCustomerAssetAndLiabilityLineItems', window );"><strong>Contract with Customer Asset and Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_AccountsReceivableNetBeginningBalance', window );">Receivables Beginning Balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Net Change</a></td>
<td class="nump">326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_AccountsReceivableNetEndingBalance', window );">Receivables Ending Balance</a></td>
<td class="nump">326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract Assets Beginning Balance</a></td>
<td class="nump">686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset', window );">Net Change</a></td>
<td class="num">(217)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract Assets Ending Balance</a></td>
<td class="nump">469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract Liabilities Beginning Balance</a></td>
<td class="nump">7,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Net Change</a></td>
<td class="num">(868)<span></span>
</td>
<td class="num">$ (48)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract Liabilities Ending Balance</a></td>
<td class="nump">$ 6,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_AccountsReceivableNetBeginningBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts receivable net beginning balance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_AccountsReceivableNetBeginningBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_AccountsReceivableNetEndingBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts receivable net ending balance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_AccountsReceivableNetEndingBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_ContractWithCustomerAssetAndLiabilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with customer asset and liability Line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_ContractWithCustomerAssetAndLiabilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6632994256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation Expense for Stock Awards (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">$ 2,113<span></span>
</td>
<td class="nump">$ 1,937<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">781<span></span>
</td>
<td class="nump">630<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">$ 1,332<span></span>
</td>
<td class="nump">$ 1,307<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>36
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MA]]5V _6[=T_-KX(JA9^W87Z E!+ P04    " !9@&=/F5R<(Q &  "<)P
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M2@7(C-Y*)BOEVS(:!,Y"31,Y9_T-VQN"ML/C@<87+/\'4$L#!!0    ( %F
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M;#=MR>0$[.<'()976/P&4$L#!!0    ( %F 9T^E^&SAJ $  )$#   8
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M_(^)XVL0'7@IFRN_ 9U_'[,CH7'!_.1M,VW)Y#CLTP-@\RLL_P)02P,$%
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MUP2!;:#I,'3 !@0=MCXK-FT+U<65Y+C[^U&RZQJ;L1>+I X/#VDJ&ZQ[\2U
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MWR&\]">''ENRU%*#\=(:XJ IZ'UV..XC/@%>)8Q^99/8R=G:M^A\K0NZBX)
M015B!H''!1Y J9@(9?R<<]*E9"2N[8_LGU/OV,M9>'BPZH>L0U?0.TIJ:,2@
MPK,=O\#<SPTE<_-/< &%\*@$:U16^?0EU>"#U7,6E*+%^W1*D\YQNN'93-LF
M\)G %\)=JL.F0DGYHPBBS)T=B9MFWXOXB[,#Q]E4,9A&D>Y0O,?HI<QNLIQ=
M8J(9<YPP?(U9$ RS+R7X5HDC_X?.M^G[387[1+_^K\(MS-]%V&HD&ER;EL&3
MR@XF+>(JNNS;/4\C_0.?EO6;<*TTGIQMP!^3QM=8&P"E[*YP SI\'XNCH G1
MO$7;35LR.<'V\P-@RRLL?P-02P,$%     @ 68!G3]7-+*&H 0  D0,  !D
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M^#77I(MD(*[W;]4_QMZQEXMP\&343UGY-J<'2BJHQ:#\LQD_P=S/.TKFYK_
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M2ML%@6V@Z3"LP 8$';8^*S9M"]7%E>2X^_M1LNNZG5\LDCJ'/*2I;+#NV;<
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M'451$*2H(VWOE[F9V_(R9T=)VQZVW!/'KB/\SQHH&PL_],\3+^VAD7H"E?E
M#O =Y(]AR]4(S2I5VT$O6M9['.K"_QBNGC.--X"?+8SBHN]I)SO&7O7@2U7X
M@2X(*.RE5B"J.<$&*-5"JHS?5M.?E]3$R_Y9_9/QKKSLB( -H[_:2C:%_^A[
M%=3D2.4+&S^#]9/XGC7_%4Y %5Q7HM;8,RK,K[<_"LDZJZ)*Z<C;U+:]:4>K
M?Z:Y"9$E1#,AQ/\EQ)80WTO EH#O)226D%P1T.3=A/E$)"ESSD:/3\=A(/K4
MA:M$;==>3YK=,=]4GD+-GLHHB'-TTD(6LYXPT25FB=C<(G"PA#S=0K)L"7EV
MK!/@&8.4C]E,Y#03&8%X(9"X!6*G0&P$\(5 <E7D>H*D!M(;R(?'&..K0!RH
M,$O#V%T,=A:#;XJ)@M0MD#@%DOOC2)T"Z?MQ3)#DG3@<J&4<TQE);U-+@BBX
M/B<.&$[C?X6;.:UECG"OO65W;;4#Y=IJ='$C]1O\C?!#VPMOQZ2ZW.8*UHQ)
M4)+!@TJJ4<_^/*!02]W-5)]/C]\TD&RP[SJ:_US*OU!+ P04    " !9@&=/
M/%%F D<"  !1"   &0   'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6R55MN.
MFS 4_!7$!\286TA$D+JI5JW42M%6;9^=Q EH#69M)VS_OK8AB,#)BGV)+\P9
M9B8Y=M*&BU>94ZJ<]Y)5<N/F2M5KA.0AIR61"U[32C\Y<5$2I9?BC&0M*#G:
MHI(AW_-B5)*B<K/4[NU$EO*+8D5%=\*1E[(DXM\39;S9N-B];;P4YUR9#92E
M-3G37U3]KG="KU#/<BQ*6LF"5XZ@IXW[!:^W.#8%%O&GH(T<S!UC9<_YJUE\
M/VY<SRBBC!Z4H2!ZN-(M9<PP:1UO':G;O],4#N<W]F=K7IO9$TFWG/TMCBK?
MN(GK'.F)7)AZX<TWVAF*7*=S_X->*=-PHT2_X\"9M)_.X2(5+SL6+:4D[^U8
M5'9L.OY;&5S@=P5^7X###PN"KB 8%:!6F;7ZE2B2I8(WCFB_K9J8'P5>!SK,
M@]FTV=EGVJW4N]?,]Y(470U1AWEJ,?X0<X_83A&AUT.0%M"K\$$5OJT/[U2L
M8(( ) @L03 DP \4A"!!.%6 \2B'%I-83&4Q>!&/DH P2UA(! J) "$^3!"#
M!/'\*)8@P7)&%,N)S6 2!81)8"$)*"0!A 0PP0HD6,V/ GMP>W@SPNA 0Z=1
MO%B->P1$/0@$/^A6#,@)'U# K8;]3X0"-QL.YH32@J*!76^<R$>0>R%PTV*H
M:Z,'%'"[X>@3<< -A^,Y<;2@U=#K(IJ<HU,47N"1&C0XV\UE^Y.(<U%)9\^5
MOB;L87[B7%%-J%_A.KF^W_L%HR=EIDL]%^TEURX4K[L+'/7_(K+_4$L#!!0
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M%5A&Z3_+<I5RM X;@D]"+1.Y9OU\Z3>"MF9V>L, S_\!4$L#!!0    ( %F
M9T_.FCMXU (  *0,   9    >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;)57
MT6Z;,!3]%<0'%&P,)%42:6U7;=(F59VZ/;N)DZ "9N DW=_/-@0%.* D#P&;
M<\^]Y^(#9G&2Y4>U%T(YGUF:5TMWKU1Q[WG5>B\R7MW)0N3ZRE:6&5=Z6.Z\
MJB@%W]B@+/6H[T=>QI/<72WLW$NY6LB#2I-<O)1.=<@R7OY[$*D\+5WBGB=>
MD]U>F0EOM2CX3OP2ZJUX*?7(:UDV22;R*I&Y4XKMTOU"[I]I; (LXG<B3M7%
MN6.DO$OY80;?-TO7-Q6)5*R5H>#Z<!2/(DT-DZ[C;T/JMCE-X.7YF?W9BM=B
MWGDE'F7Z)]FH_=*=N<Y&;/DA5:_R]$TT@D+7:=3_$$>1:KBI1.=8R[2R_\[Z
M4"F9-2RZE(Q_UL<DM\=3PW\.PP&T":!M &&3 4$3$%P;P)H =FU V 2$UP9$
M34#4"_#J9MGN/W'%5XM2GIRR7D %-^N4W$?Z_J[-I+V=]IJ^ 96>/:XH#1;>
MT1 UF(<:0SL8UL4\(DS8Q3PA3-3%? 68+N(9L<0MQM-J6\D42J:6(.@0S#!!
M  D"2\ Z!/.>#H )_)Z2:4RG$ 8+88" ])(@#,5)0I@D! 0!)H@@071]OV-(
M$(,*>NOOH<9$%I-;#&/,MS^<:@93S4"J$!/,(<'\>K'$QX[T00U1WV[^0"_Q
MI^22$?L3D"SN)T.@,5'8<X0"BOD(!78="6YH+?8+ 69@?E\M&[1V%H=3K<6^
M(< XC(Q08.>0&ZQ#L'<(, ^C_0?\T#UT>C5A]Q!@'S;RK"#8/^0& U%L( H,
MQ'K/BR<Z-!";3RBFV#\46(/UWWL-*+QL[V2ND?<6\!"+1BBPA^@-'J+80Q1Y
M:-!=-E0\M9XHMA!%%AI[UV,+T1LL1+&%*++0K*]X:"$2SZ%F[V)O9O;O/WFY
M2_+*>9=*;_/L9FPKI1*:UK_3'=CK3X9VD(JM,J>Q/B_K?7,]4+)HO@F\]L-D
M]1]02P,$%     @ 68!G3Z1'LK<@ @  .@8  !D   !X;"]W;W)K<VAE971S
M+W-H965T,C@N>&ULC57K;ILP%'X5Q /$7 -$!*E)-6W2)D6=UOUVR$E M3&S
MG="]_7RAE!%OZI_8/OXNYSCVH1P8?Q$-@/1>*>G$UF^D[#<(B;H!BL6*]="I
MG3/C%$NUY!<D>@[X9$B4H"@(UHCBMO.KTL0.O"K959*V@P/WQ)52S'_O@+!A
MZX?^6^"IO312!U!5]O@"WT'^Z ]<K="D<FHI=*)EG<?AO/4?PLV^T'@#>&YA
M$+.YIRLY,O:B%U].6S_0"0&!6FH%K(8;[($0+:32^#5J^I.E)L[G;^J?3.VJ
MEB,6L&?D9WN2S=;/?>\$9WPE\HD-GV&L)_6]L?BO< .BX#H3Y5$S(LRO5U^%
M9'144:E0_&K'MC/C8'>R?*2Y"=%(B":"\OX?(1X)\3LA,<7;S$RICUCBJN1L
M\+C]LWJL[T2XB=5AUCIHSL[LJ6J%BMZJ*"E*=--"(V9G,=$,$TX(I-0GB\AE
ML8ONZ-'?!OM[1):Y'6)G$;'A)W.'-%@483%A8$"= :U7A=LE<;HD#I=PX6(Q
M^<PD7OVCE-1IDCI,%L>U2QTFD=MD[319.TQBMT#F%,@< LDBR^PNRV"5NTUR
MITGN,$G= H53H/A EL7]M0A6"]#>"5JF@F9/C@*_F.XDO)I=.ZDO]RPZ-<"'
M2#_917RG&J/M8^\RMJM^P_S2=L([,JD:@GFV9\8DJ!Q5/K[7J$8^+0B<I9YF
M:LYM.[,+R?JQ4Z/I<U'] 5!+ P04    " !9@&=/F2[I[R$"  !:!@  &0
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M4YZ$9,W(HE)IR.NPUJU9^^$F2D8WNX,_.OB3@XK]-X=@= C>'4(C?LC,2/U
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M[6+O@!WG"C2A_Z 3K_1GP3A@L%.FF^J^Z._&?J!X-]S[WOCQ4?P!4$L#!!0
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M/JWUW7--,UJ2<Q!*F,<)DR\P^7O$[B.BR&8(\09F%_E-%WGDTW<NBML"]*8
MC0+%TL!UB@FRCA 5(?>;#;U.\A&U+AXVFRLO9'&\X;I_9^;(E44'[?R?BN?9
M:>W *V9W_@[U_H7-A8#.A>DG/S?3/9L*IX?TA,C\CNM_4$L#!!0    ( %F
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MZ1SC.[T6!]WPCX.:[92YS?6]Z+O>?J!X-W3TT?BW8OD?4$L#!!0    ( %F
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M]7#+S'T_#HSC0LO.#</)-)%O_P%02P,$%     @ 68!G3_0(Y'<K @  B 8
M !D   !X;"]W;W)K<VAE971S+W-H965T-# N>&UL?571CILP$/P5Q ?$ 9)
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MLU4Z2ZN\>&6/=G!X&.N_KXH$B!]HNDEEQEC!%N,I6 @@#-7#VN[_I_/)F3M
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M;%,QYY/I)U"D^_2V-QC%49'>KJI>ONS5;NC=&Q1%?B:V^L$@QVY9::2MCZ)
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MY'OH#2)TK8A>YRZ&$[H]8G2A^[09;.A8#7R?[!:$:+YZ69;5#_\?4$L#!!0
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M4')O<',O87!P+GAM;%!+ 0(4 Q0    ( %F 9T_=4P)7[@   "L"   1
M          "  9D!  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( %F
M9T^97)PC$ 8  )PG   3              "  ;8"  !X;"]T:&5M92]T:&5M
M93$N>&UL4$L! A0#%     @ 68!G3U&RERBY @  / L  !@
M ( !]P@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( %F
M9T^PHF);FP,  %80   8              "  >8+  !X;"]W;W)K<VAE971S
M+W-H965T,BYX;6Q02P$"% ,4    " !9@&=/YL1N+2("  #-!@  &
M        @ &W#P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%
M  @ 68!G3WQX<@P, P  !PP  !@              ( !#Q(  'AL+W=O<FMS
M:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( %F 9T\_:ED#0 ,  *4-   8
M              "  5$5  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"
M% ,4    " !9@&=/S\5K<]L#  !P$0  &               @ ''&   >&PO
M=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ 68!G3[LUOP*H 0
MD0,  !@              ( !V!P  'AL+W=O<FMS:&5E=',O<VAE970W+GAM
M;%!+ 0(4 Q0    ( %F 9T^):D'!J $  )$#   8              "  ;8>
M  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " !9@&=/I?AL
MX:@!  "1 P  &               @ &4(   >&PO=V]R:W-H965T<R]S:&5E
M=#DN>&UL4$L! A0#%     @ 68!G3P_2K-FH 0  D0,  !D
M ( !<B(  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " !9
M@&=/I#&$8J8!  "1 P  &0              @ %1)   >&PO=V]R:W-H965T
M<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( %F 9T_W\C&FJ $  )$#   9
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M970Q-BYX;6Q02P$"% ,4    " !9@&=/U<TLH:@!  "1 P  &0
M    @ &'+P  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    (
M %F 9T^9.[I5& (  , &   9              "  68Q  !X;"]W;W)K<VAE
M971S+W-H965T,3@N>&UL4$L! A0#%     @ 68!G3UI1L]S& 0  6P0  !D
M             ( !M3,  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"
M% ,4    " !9@&=/<6 (JKD!  #V P  &0              @ &R-0  >&PO
M=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( %F 9T\'K8XHJP$
M )$#   9              "  :(W  !X;"]W;W)K<VAE971S+W-H965T,C$N
M>&UL4$L! A0#%     @ 68!G3]B9L+'( 0  6P0  !D              ( !
MA#D  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " !9@&=/
M->?V,QD"  #N!0  &0              @ &#.P  >&PO=V]R:W-H965T<R]S
M:&5E=#(S+GAM;%!+ 0(4 Q0    ( %F 9T^"W%$A$0(  &@&   9
M      "  =,]  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%
M  @ 68!G3SQ19@)' @  40@  !D              ( !&T   'AL+W=O<FMS
M:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " !9@&=/.=!F^&8"  #,!P
M&0              @ &90@  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+
M 0(4 Q0    ( %F 9T_.FCMXU (  *0,   9              "  39%  !X
M;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ 68!G3Z1'LK<@
M @  .@8  !D              ( !04@  'AL+W=O<FMS:&5E=',O<VAE970R
M."YX;6Q02P$"% ,4    " !9@&=/F2[I[R$"  !:!@  &0
M@ &82@  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( %F
M9T]994T86P(  )<'   9              "  ?!,  !X;"]W;W)K<VAE971S
M+W-H965T,S N>&UL4$L! A0#%     @ 68!G3[IB8139 0  7@0  !D
M         ( !@D\  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4
M    " !9@&=/GF"*ITD"  !V!P  &0              @ &240  >&PO=V]R
M:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( %F 9T^/99>U10(  )4'
M   9              "  1)4  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL
M4$L! A0#%     @ 68!G3U$KY'!4 @  B @  !D              ( !CE8
M 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " !9@&=/HF%-
MX;(!  #3 P  &0              @ $960  >&PO=V]R:W-H965T<R]S:&5E
M=#,U+GAM;%!+ 0(4 Q0    ( %F 9T_^9]#F% ,  #8,   9
M  "  0);  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @
M68!G3_RL&F;_ @  8@P  !D              ( !35X  'AL+W=O<FMS:&5E
M=',O<VAE970S-RYX;6Q02P$"% ,4    " !9@&=/)N3P\"H"  !_!@  &0
M            @ &#80  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4
M Q0    ( %F 9T_#JW7]^P(  )T+   9              "  >1C  !X;"]W
M;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ 68!G3_0(Y'<K @
MB 8  !D              ( !%F<  'AL+W=O<FMS:&5E=',O<VAE970T,"YX
M;6Q02P$"% ,4    " !9@&=/(>42L+0Q  "3WP  %               @ %X
M:0  >&PO<VAA<F5D4W1R:6YG<RYX;6Q02P$"% ,4    " !9@&=/Z.V=#4T"
M  !:"P  #0              @ %>FP  >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0
M   ( %F 9T\M=GR"^P,   P;   /              "  =:=  !X;"]W;W)K
M8F]O:RYX;6Q02P$"% ,4    " !9@&=/_O=.0Z0!  #=&   &@
M    @ '^H0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M" !9@&=/<<K.T:@!   N&0  $P              @ ':HP  6T-O;G1E;G1?
@5'EP97-=+GAM;%!+!08     ,0 Q $D-  "SI0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6768082224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note 7.</div></div><div style="background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; line-height: 107%; font-family: calibri, sans-serif; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></div><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Commitments and Contingencies </div></div></div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We have contracted with various consultants and third parties to assist us in <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> research and development and clinical trials work for our leading drug compounds. The contracts are terminable at any time, but obligate us to reimburse the providers for any time or costs incurred through the date of termination. We also have employment agreements with certain of our current employees that provide for severance payments and accelerated vesting for share-based awards if their employment is terminated under specified circumstances.</div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 9%;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Presage License Agreement </div></div></div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">As discussed in Note <div style="display:inline;">3</div>, we are party to a license agreement with Presage under which we may be required to make future payments upon the achievement of certain development, regulatory and commercial milestones, as well as potential future royalties based upon net sales. As of September&#160;30, 2019, we have not accrued any amounts for potential future payments. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 9%;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">S*Bio Purchase Agreement </div></div></div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">We are party to a definitive asset purchase agreement with S*Bio, pursuant to which we acquired certain assets comprised of intellectual property and technology including rights to pracinostat. We agreed to make certain milestone payments to S*Bio based on the achievement of certain clinical, regulatory and net sales-based milestones, as well as to make certain contingent earnout payments to S*Bio. Milestone payments will be made to S*Bio up to an aggregate amount of $74.5&#160;million if certain U.S., E.U. and Japanese regulatory approvals are obtained and if certain net sales thresholds are met in North America, the E.U. and Japan. As of September&#160;30, 2019, we have not accrued any amounts for potential future payments. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 9%;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">CyDex License Agreement </div></div></div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">As discussed in Note <div style="display:inline;">3</div>, we are party to a license agreement with CyDex under which we may be required to make future payments upon the achievement of certain milestones, as well as potential future royalties based upon net sales. Contemporaneously with the license agreement, CyDex entered into a commercial supply agreement with us, pursuant to which we agreed to purchase 100% of our requirements for Captisol from CyDex. As of September&#160;30, 2019, we have not accrued any amounts for potential future payments. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6644686304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Compensation</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note 11. Share-based Compensation </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">We use equity-based compensation programs to provide long-term performance incentives for our employees. These incentives consist primarily of stock options and RSUs. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our 2008 Stock Omnibus Equity Compensation Plan (the &#8220;2008 Plan&#8221;) provides for the grant of options and/or other share-based or share-denominated awards to our <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> directors, officers, employees and advisors. The 2008 Plan was initially adopted in 2008 and was amended and restated in 2011, 2013, 2014, 2015, 2016 and 2018. There are 19,089,794 shares of common stock authorized for issuance under the 2008 Plan. As of September&#160;30, 2019, there were 6,979,777 shares available for future grant under the 2008 Plan.</div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Total share-based compensation expense for all stock awards consists of the following, (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"><div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="padding: 0px;;width:82%;"></td><td style="padding: 0px;;vertical-align:bottom;;width:3%;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;;vertical-align:bottom;;width:3%;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended<br/>September&#160;30,</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2018</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Research and development</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">781</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">630</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">1,332</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">1,307</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total share-based compensation</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#160;2,113</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#160;1,937</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Stock Options </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Stock option activity for the three months ended September&#160;30, 2019 was as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"><div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"><tr style="font-size: 0px;"><td style="padding: 0px;;width:47%;"></td><td style="padding: 0px;;vertical-align:bottom;;width:8%;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;;vertical-align:bottom;;width:7%;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;;vertical-align:bottom;;width:8%;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;;vertical-align:bottom;;width:8%;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/>Options</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Weighted-<br/>Average<br/>Exercise&#160;Price</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Weighted-Average</div><br/>Remaining&#160;Contractual<br/>Term&#160;(in years)</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Aggregate<br/>Intrinsic&#160;Value</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Outstanding at June&#160;30, 2019</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">8,356,961</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#160;3.20</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">3,083,333</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">2.50</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Exercised</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(46,667</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1.54</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Forfeited / Cancelled</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">(49,186</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">1.81</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Expired</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(527,080</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">6.89</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at September&#160;30, 2019</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">10,817,361</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">2.83</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">8.5</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">501,818</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Vested and exercisable at September&#160;30, 2019</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">4,114,253</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2.52</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">7.3</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#160;428,455</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 1px; margin-top: 12px; margin-bottom: 0px; background: none;"><div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The fair value of each stock option granted during the three months ended September&#160;30, 2019 is estimated on the grant date under the fair value method using a Black-Scholes valuation model. Stock options granted to employees during the three months ended September&#160;30, 2019 vest 25% one year from the date of grant and ratably each month thereafter for a period of 36 months and expire ten years from the date of grant. Stock options granted to directors during the three months ended September&#160;30, 2019 vest ratably each month for a period of 12 or 36 months from the date of grant and expire ten years from the date of grant. The estimated fair values of the stock options, including the effect of estimated forfeitures, are expensed over the service period. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following weighted-average assumptions were used to determine the fair value of options granted during the period: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"><div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="padding: 0px;;width:85%;"></td><td style="padding: 0px;;vertical-align:bottom;;width:5%;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;;vertical-align:bottom;;width:4%;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended<br/>September&#160;30,</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2018</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Risk-free interest rate</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1.8</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2.8</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Expected life (years)</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">6.0</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">6.0</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Expected volatility</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">73.6</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">86.0</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">0.0</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">%&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">0.0</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">%&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Weighted-average grant date fair value</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1.63</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">3.11</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">As of September&#160;30, 2019, there was $8.5&#160;million of unrecognized compensation expense related to the unvested portion of stock options. Such compensation expense is expected to be recognized over a weighted-average period of 1.8 years. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Restricted Stock Units </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In June 2016, we granted 364,726 RSUs to employees. Each RSU represented the contingent right to receive one share of our common stock. The RSUs vested in August 2018, and we released 332,193 RSU shares. We issued 245,782 shares of common stock to RSU holders; 86,411 shares were surrendered to us by RSU holders as payment for the employee portion of the required withholding of associated payroll taxes. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6777526784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 1,157<span></span>
</td>
<td class="nump">$ 488<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenue</a></td>
<td class="nump">688<span></span>
</td>
<td class="nump">989<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">8,962<span></span>
</td>
<td class="nump">6,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">4,130<span></span>
</td>
<td class="nump">3,401<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">13,780<span></span>
</td>
<td class="nump">10,521<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(12,623)<span></span>
</td>
<td class="num">(10,033)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss', window );">Change in fair value of warrant liability</a></td>
<td class="nump">9,269<span></span>
</td>
<td class="num">(4,962)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterestAndDividend', window );">Interest and dividend income</a></td>
<td class="nump">374<span></span>
</td>
<td class="nump">454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Other expense</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(2,994)<span></span>
</td>
<td class="num">(14,542)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Net loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="num">$ (2,994)<span></span>
</td>
<td class="num">$ (14,542)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Shares used in computing net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="nump">73,628<span></span>
</td>
<td class="nump">70,885<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net income loss available to common stockholders basic and diluted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3) and still held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterestAndDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterestAndDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6948939904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note <div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div>.</div></div><div style="background: none;;font-weight:bold;display:inline;"><div style="font-size: 10pt; line-height: 107%; font-family: calibri, sans-serif; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div></div><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurements </div></div></div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value is as follows: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"><div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; margin: 0in 0in 0in auto;;text-align:left;;width:91%;"><tr style="font-size: 0px;"><td style="padding: 0px; vertical-align: top;;width:9%;"></td><td style="padding: 0px; vertical-align: top;;width:1%;"></td><td style="padding: 0px; vertical-align: top;;width:90%;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#160;&#160;&#160;&#160;&#160;Level&#160;1&#160;&#8212;</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: top;"><div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Observable inputs such as quoted prices in active markets for identical assets or liabilities.</div></td></tr><tr style="font-size: 1pt;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: top;;height:8;">&#160;</td><td colspan="2" style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: top;;height:8;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#160;&#160;&#160;&#160;&#160;Level&#160;2&#160;&#8212;</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: top;"><div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted<div style="display:inline;">&#160;</div>prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</div></td></tr><tr style="font-size: 1pt;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: top;;height:8;">&#160;</td><td colspan="2" style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: top;;height:8;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#160;&#160;&#160;&#160;&#160;Level&#160;3&#160;&#8212;</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: top;"><div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">We measure the following financial instruments at fair value on a recurring basis. The fair values of these financial instruments were as follows (in thousands): </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"><div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:100%;"><tr style="font-size: 0px;"><td style="padding: 0px; width: 65%;"></td><td style="padding: 0px; width: 2%;;vertical-align:bottom;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px; width: 2%;;vertical-align:bottom;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px; width: 2%;;vertical-align:bottom;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px; width: 2%;;vertical-align:bottom;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px; width: 2%;;vertical-align:bottom;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px; width: 2%;;vertical-align:bottom;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;&#160;</td><td colspan="10" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">September&#160;30, 2019</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td><td colspan="10" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">June&#160;30, 2019</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;&#160;</td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;&#160;</td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;&#160;</td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;&#160;</td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;&#160;</td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 65%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Warrant liability</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(8,344</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 2%;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(17,613</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td></tr><tr style="font-size: 1px;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 65%;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; width: 65%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">(8,344</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">(17,613</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">)&#160;</td></tr><tr style="font-size: 1px;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 65%;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The carrying amounts of financial instruments such as cash equivalents, short-term investments and accounts payable approximate the related fair values due to the short-term maturities of these instruments. We invest our excess cash in financial instruments which are readily convertible into cash, such as money market funds and U.S. government securities. Cash equivalents, where applicable, and short-term investments are classified as Level&#160;1 as defined by the fair value hierarchy. </div></div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In May 2018, we issued warrants in connection with our private placement of shares of common stock. Pursuant to the terms of the warrants, we could be required to settle the warrants in cash in the event of an acquisition of the Company and, as a result, the warrants are required to be measured at fair value and reported as a liability in the Condensed Balance Sheet.&#160;We recorded the fair value of the warrants upon issuance using the Black-Scholes valuation model and are required to revalue the warrants at each reporting date with any changes in fair value recorded on our Condensed Statement of Operations. The valuation of the warrants is considered under Level&#160;3 of the fair value hierarchy due to the need to use assumptions in the valuation that are both significant to the fair value measurement and unobservable.&#160;Inputs used to determine estimated fair value of the warrant liabilities include the estimated fair value of the underlying stock at the valuation date, the estimated term of the warrants, risk-free interest rates, expected dividends and the expected volatility of the underlying stock. The significant unobservable inputs used in the fair value measurement of the warrant liabilities were the volatility rate and the estimated term of the warrants. Generally, increases (decreases) in the fair value of the underlying stock and estimated term would result in a directionally similar impact to the fair value measurement. The change in the fair value of the&#160;Level 3 warrant liability is reflected in the Condensed Statement of Operations for the three months ended September&#160;30, 2019. </div><div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-indent: 4%; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">To calculate the fair value of the warrant liability, the following assumptions were used: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"><div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="padding: 0px; width: 77%;"></td><td style="padding: 0px; width: 9%;;vertical-align:bottom;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px; width: 8%;;vertical-align:bottom;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;&#160;</td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">September&#160;30,<br/>2019</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/>2019</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 77%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Risk-free interest rate</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 9%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1.6</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 8%;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1.7</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; width: 77%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Expected life (years)</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 9%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">3.6</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 8%;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">3.8</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 77%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Expected volatility</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 9%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">56.9</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 8%;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">56.8</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; width: 77%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 9%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">0.0</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">%&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 8%;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">0.0</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">%&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 77%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Black-Scholes Fair Value</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 9%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">0.52</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 8%;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1.10</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth a summary of changes in the estimated fair value of our Level&#160;3 warrant liability for the three months ended September&#160;30, 2019 and 2018 (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"><div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="padding: 0px; width: 73%;"></td><td style="padding: 0px; width: 7%;;vertical-align:bottom;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px; width: 6%;;vertical-align:bottom;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;&#160;</td><td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">Fair&#160;Value&#160;of&#160;Warrants&#160;Using&#160;Significant<br/>Unobservable Inputs (Level 3)</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;&#160;</td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">2018</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 73%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-weight:bold;display:inline;">Balance at July&#160;1,</div></div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 7%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">17,613</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">46,313</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; width: 73%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Reclassification of <div style="letter-spacing: 0px; top: 0px;;display:inline;">warrant</div>&#160;liability to equity upon exercise of warrants</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 7%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 6%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">(1,068</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">)&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 73%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Change in estimated fair value of liability classified warrants</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 7%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(9,269</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">4,962</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 73%;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 7%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 6%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; width: 73%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance at September&#160;30,</div></div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 7%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">8,344</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 6%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">50,207</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 73%;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 7%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 6%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6639346368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Revenue Associated With The Following license agreements (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsLineItems', window );"><strong>Recognized Revenue Associated with The Following License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 1,157<span></span>
</td>
<td class="nump">$ 488<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=meip_KHKLicenseAgreementMember', window );">KKC License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsLineItems', window );"><strong>Recognized Revenue Associated with The Following License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=meip_HelsinnLicenseAgreementMember', window );">Helsinn License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsLineItems', window );"><strong>Recognized Revenue Associated with The Following License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 360<span></span>
</td>
<td class="nump">$ 488<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_RecognizedRevenueAssociatedWithTheFollowingLicenseAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=meip_KHKLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=meip_KHKLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=meip_HelsinnLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=meip_HelsinnLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6640430512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Antidilutive Securities</a></td>
<td class="text"><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following table presents weighted-average potentially dilutive shares (in thousands) that have been excluded from the calculation of net loss per share because of their anti-dilutive effect: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"><div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="padding: 0px; width: 82%;"></td><td style="padding: 0px; width: 2%;;vertical-align:bottom;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px; width: 2%;;vertical-align:bottom;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;&#160;</td><td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended<br/>September&#160;30,</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;&#160;</td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;&#160;</td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">2018</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 82%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Stock <div style="display:inline;">o</div>ptions</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">10,930</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">7,774</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; width: 82%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Restricted stock units</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">130</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 82%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Warrants</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">16,062</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">16,186</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 82%;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; width: 82%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Total anti-dilutive shares</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">26,992</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">24,090</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 82%;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6779061232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Assumptions Used to Calculate Fair Value of Warrant Liability (Detail) - ClinicalTrials<br></strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk Free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected life years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="nump">3.6<span></span>
</td>
<td class="nump">3.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="nump">56.9<span></span>
</td>
<td class="nump">56.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember', window );">Black-Scholes Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="nump">0.52<span></span>
</td>
<td class="nump">1.10<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6929147520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Stock Options Weighted-Average Assumptions Used (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">73.60%<span></span>
</td>
<td class="nump">86.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value</a></td>
<td class="nump">$ 1.63<span></span>
</td>
<td class="nump">$ 3.11<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6638586064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_ScheduleOfRevenueAssociatedWithLicenseAgreementTableTextBlock', window );">Schedule Of Revenue Associated With License Agreement</a></td>
<td class="text"><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">We recognized revenue associated with the following license agreements (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"><div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="padding: 0px; width: 84%;"></td><td style="padding: 0px; width: 4%;;vertical-align:bottom;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px; width: 4%;;vertical-align:bottom;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;&#160;</td><td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended<br/>September&#160;30,</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;&#160;</td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;&#160;</td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">2018</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 84%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">KKC License Agreement</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">797</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; width: 84%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Helsinn License Agreement</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 4%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">360</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 4%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">488</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 84%;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 4%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 4%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 84%;;vertical-align:top;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,157</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">488</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 84%;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 4%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 4%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Changes in Contract Assets and Contract Liabilities</a></td>
<td class="text"><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following table presents changes in contract assets and contract liabilities during the three months ended September&#160;30, 2019 (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"><div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:84%;"><tr style="font-size: 0px;"><td style="padding: 0px; width: 60%;"></td><td style="padding: 0px; width: 9%;;vertical-align:bottom;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px; width: 9%;;vertical-align:bottom;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px; width: 9%;;vertical-align:bottom;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;&#160;<div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;<div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div></div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;<div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div></div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div></td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;June&#160;30,<br/>2019</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;"><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div></td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">Net&#160;Change</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;September&#160;30,<br/>2019</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 60%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Receivables</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 9%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 9%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">326</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 9%;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">326</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; width: 60%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Contract Assets</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 9%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">686</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 9%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">(217</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 9%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">469</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 60%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Contract Liabilities</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 9%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">7,774</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 9%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(868</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 9%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">6,906</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_ScheduleOfRevenueAssociatedWithLicenseAgreementTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Revenue Associated With License Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_ScheduleOfRevenueAssociatedWithLicenseAgreementTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contract balances and changes in contract balances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6775010880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Financial Instruments Measured at Fair Value on Recurring Basis (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Warrant liability</a></td>
<td class="num">$ (8,344)<span></span>
</td>
<td class="num">$ (17,613)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Fair Value, Measurements, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Warrant liability</a></td>
<td class="num">(8,344)<span></span>
</td>
<td class="num">(17,613)<span></span>
</td>
<td class="num">$ (50,207)<span></span>
</td>
<td class="num">$ (46,313)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liability</a></td>
<td class="num">$ (8,344)<span></span>
</td>
<td class="num">$ (17,613)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6778598304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Deferred Revenue Associated With Remaining Performance Obligation</a></td>
<td class="nump">$ 6.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Recognition Of Deferred Revenue</a></td>
<td class="nump">3.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_AdditionalRecognitionOfDeferredRevenue', window );">Additional Recognition Of Deferred Revenue</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=meip_KHKLicenseAgreementMember', window );">KHK License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_RevenuePerformanceObligationAmount', window );">Revenue Recognised With Performance Obligation</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=meip_HelsinnLicenseAgreementMember', window );">Helsinn License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_RevenuePerformanceObligationAmount', window );">Revenue Recognised With Performance Obligation</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_AdditionalRecognitionOfDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additionally reported deferred or unearned revenue that was recognized as revenue during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_AdditionalRecognitionOfDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_RevenuePerformanceObligationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_RevenuePerformanceObligationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12A<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL108322424-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=meip_KHKLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=meip_KHKLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=meip_HelsinnLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=meip_HelsinnLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6767311696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Stock Option Activity (Detail)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning Balance | shares</a></td>
<td class="nump">8,356,961<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted | shares</a></td>
<td class="nump">3,083,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised | shares</a></td>
<td class="num">(46,667)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited / Cancelled | shares</a></td>
<td class="num">(49,186)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired | shares</a></td>
<td class="num">(527,080)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance | shares</a></td>
<td class="nump">10,817,361<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Vested and exercisable at end of period | shares</a></td>
<td class="nump">4,114,253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning Balance | $ / shares</a></td>
<td class="nump">$ 3.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted | $ / shares</a></td>
<td class="nump">2.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised | $ / shares</a></td>
<td class="nump">1.54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited / Cancelled | $ / shares</a></td>
<td class="nump">1.81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired | $ / shares</a></td>
<td class="nump">6.89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance | $ / shares</a></td>
<td class="nump">2.83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Vested and exercisable at end of period | $ / shares</a></td>
<td class="nump">$ 2.52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Remaining Contractual Term (in years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding at end of period</a></td>
<td class="text">8 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Vested and exercisable at end of period</a></td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at end of period | $</a></td>
<td class="nump">$ 501,818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Vested and exercisable at end of period | $</a></td>
<td class="nump">$ 428,455<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, options, weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6635217280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Short-Term Investments - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">$ 59,932<span></span>
</td>
<td class="nump">$ 64,899<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6635605232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Additional Information (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_PotentiallyDilutiveSecuritiesOutstandingLineItems', window );"><strong>Potentially Dilutive Securities Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation', window );">Common stock subject to repurchase or forfeiture</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_PotentiallyDilutiveSecuritiesOutstandingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potentially Dilutive Securities Outstanding [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_PotentiallyDilutiveSecuritiesOutstandingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e2646-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6948954896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">License Agreements</a></td>
<td class="text"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note <div style="display:inline;">3</div>.</div></div><div style="font-size: 10pt; line-height: 107%; font-family: &quot;times new roman&quot;, serif; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">License Agreements </div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">KKC License Agreement </div></div></div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In October 2018, we entered into a license agreement with Kyowa Kirin Company (formerly &#8220;Kyowa Hakko Kirin Co., Ltd.&#8221;) (&#8220;KKC&#8221;), a Japanese life sciences company, for <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">ME-401</div> (the &#8220;KKC License Agreement&#8221;). Under the terms of the KKC License Agreement, KKC was granted the exclusive right to develop and commercialize <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">ME-401</div> in Japan. We also granted KKC the right to purchase supply of <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">ME-401</div> for commercial requirements at cost plus a <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">pre-negotiated</div> percentage, as well as manufacturing rights in Japan. In return, we received an upfront payment of $10.0&#160;million and are also eligible to receive up to $87.5&#160;million in additional development and commercialization milestones, as well as royalties on net sales of <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">ME-401</div> in Japan extending into the <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">mid-teens.</div> The KKC License Agreement expires at the end of the royalty term, that is, upon the last to occur of (a)&#160;expiration of our patents in Japan, (b)&#160;expiration of regulatory exclusivity for <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">ME-401</div> in Japan or (c) 10 years from the first commercial sale of <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">ME-401</div> in Japan.</div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We assessed the KKC License Agreement in accordance with ASC 606 and determined that our performance obligations comprise the license, research and development obligations, and our obligation to provide clinical trial materials to KKC. We determined that the transaction price amounts to the upfront payment of $10.0&#160;million. Future milestone payments are fully contingent as the risk of significant revenue reversal will only be resolved depending on future research and development and/or regulatory approval outcomes. We will <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">re-evaluate</div> the likelihood of achieving future milestones at the end of each reporting period.</div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">We determined that control of the license was transferred to KKC during the year ended June&#160;30, 2019. Revenue allocated to the research and development obligations is recognized based on the proportional performance of these research and development activities, which we expect to recognize through fiscal year 2022. Revenue allocated to providing clinical trial materials is recognized upon delivery.</div></div><div style="text-indent: 9%; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Helsinn License Agreement </div></div></div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In August 2016, we entered into an exclusive worldwide license, development, manufacturing and commercialization agreement with Helsinn Healthcare SA, a Swiss pharmaceutical corporation (&#8220;Helsinn&#8221;) for pracinostat in acute myeloid leukemia (&#8220;AML&#8221;), myelodysplastic syndrome (&#8220;MDS&#8221;) and other potential indications (the &#8220;Helsinn License Agreement&#8221;). Under the terms of the agreement, Helsinn was granted a worldwide exclusive license to develop, manufacture and commercialize pracinostat, and is primarily responsible for funding its global development and commercialization. As compensation for such grant of rights, we received payments of $20.0&#160;million. In addition, we are eligible to receive up to $444&#160;million in potential regulatory and sales-based milestones, along with royalty payments on the net sales of pracinostat, which, in the U.S., are tiered and begin in the <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">mid-teens.</div></div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">We determined that the agreement contains multiple performance obligations for purposes of revenue recognition. Revenue related to the research and development elements of the arrangement is recognized based on the extent of progress toward completion of each performance obligation. Revenue is recognized on a gross basis as we are the primary obligor and have discretion in supplier selection. During the three months ended September&#160;30, 2019, our only remaining performance obligation under the agreement is the conduct of a Phase 2 dose-optimization study of pracinostat in combination with azacitidine in patients with high and very high risk MDS who are previously untreated with hypomethylating agents (the &#8220;POC study&#8221;), for which Helsinn has agreed to share third-party expenses. </div><div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 9%; line-height: 12pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Presage License Agreement </div></div></div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In September 2017, we entered into a license agreement with Presage Biosciences, Inc. (&#8220;Presage&#8221;). Under the terms of such license agreement (the &#8220;Presage License Agreement&#8221;), Presage granted to us exclusive worldwide rights to develop, manufacture and commercialize voruciclib, a clinical-stage, oral and selective CDK inhibitor, and related compounds. In exchange, we paid $2.9&#160;million. With respect to the first indication, an incremental $2.0&#160;million payment, due upon dosing of the first subject in the first registration trial, will be owed to Presage, for total payments of $4.9&#160;million prior to receipt of marketing approval of the first indication in the U.S., E.U. or Japan. Additional potential payments of up to $179&#160;million will be due upon the achievement of certain development, regulatory and commercial milestones. We will also pay <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">mid-single-digit</div> tiered royalties on the net sales of any product successfully developed. As an alternative to milestone and royalty payments related to countries in which we sublicense product rights, we will pay to Presage a tiered percent (which decreases as product development progresses) of amounts received from such sublicensees.</div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 9%;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">CyDex License Agreement </div></div></div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We are party to a license agreement with CyDex Pharmaceuticals, Inc. (&#8220;CyDex&#8221;). Under the license agreement, CyDex granted to us an exclusive, nontransferable license to intellectual property rights relating to Captisol<div style="font-size: 7.4pt; vertical-align: top;;vertical-align: super;font-size: smaller;display:inline;">&#174;</div> for use with our isoflavone-based drug compounds (currently <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">ME-344).</div> We agreed to pay to CyDex a <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> license issuance fee, future milestone payments, and royalties at a low, single-digit percentage rate on future sales of our approved drugs utilizing Captisol. Contemporaneously with the license agreement, CyDex entered into a commercial supply agreement with us, pursuant to which we agreed to purchase 100% of our requirements for Captisol from CyDex. We may terminate both the license agreement and the supply agreement at any time upon 90 days&#8217; prior written notice.</div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6775285728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Nov. 04, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1 <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MEIP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MEI Pharma, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001262104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--06-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,654,927<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6632110672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note 6.&#160;&#160;&#160;&#160;Net Loss Per Share</div></div></div></div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per share are computed using the weighted-average number of shares of common stock outstanding during the period, less any shares subject to repurchase or forfeiture. There were no shares of common stock subject to repurchase or forfeiture for the three months ended September&#160;30, 2019 and 2018. Diluted net loss per share is computed based on the sum of the weighted average number of common shares and potentially dilutive common shares outstanding during the period. Our potentially dilutive shares, which include outstanding stock options, restricted stock units, and warrants, are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. </div></div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following table presents weighted-average potentially dilutive shares (in thousands) that have been excluded from the calculation of net loss per share because of their anti-dilutive effect: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"><div style="color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="padding: 0px; width: 82%;"></td><td style="padding: 0px; width: 2%;;vertical-align:bottom;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px; width: 2%;;vertical-align:bottom;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;&#160;</td><td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended<br/>September&#160;30,</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;&#160;</td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;&#160;</td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">2018</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;;width:;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 82%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Stock <div style="display:inline;">o</div>ptions</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">10,930</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">7,774</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; width: 82%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Restricted stock units</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">130</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 82%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Warrants</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">16,062</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255); width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">16,186</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 82%;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; width: 82%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Total anti-dilutive shares</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">26,992</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">24,090</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 82%;;vertical-align:bottom;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; width: 2%;;vertical-align:bottom;">&#160;&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6633010768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Equity Transactions </div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Warrants </div></div></div><div style="text-indent: 9%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">As of September&#160;30, 2019, we have outstanding warrants to purchase 16,061,602 shares of our common stock. The warrants are fully vested, exercisable at a price of $2.54 per share and expire in May 2023. In the event of a sale of the Company, the terms of the warrants require us to use our best efforts to ensure the holders of such warrants will have a continuing right to purchase shares of the acquirer and, if our efforts are unsuccessful, to make a payment to such warrant holders based on a Black-Scholes valuation (using variables as specified in the warrants). Therefore, we are required to account for the warrants as liabilities and record them at fair value. The warrants were revalued as of June&#160;30, 2019 at $17.6&#160;million and as of September&#160;30, 2019 at $8.3&#160;million; the changes in fair value were recorded in our <div style="letter-spacing: 0px; top: 0px;;display:inline;">Condensed&#160;</div>Statement of Operations. No warrants were exercised during the three months ended September&#160;30, 2019. During the three months ended September&#160;30, 2018, warrants were exercised for 440,043 shares of common stock, and we received proceeds of $1.1&#160;million. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 9%;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Shelf Registration Statement </div></div></div><div style="text-indent: 9%; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 12pt; line-height: 12pt;">We have a shelf registration statement that permits us to sell, from time to time, up to $150.0&#160;million of common stock, preferred stock and warrants. In November 2017, we entered into an <div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">At-The-Market</div></div> Equity Offering Sales Agreement (the &#8220;ATM Sales Agreement&#8221;), pursuant to which we may sell an aggregate of up to $30.0&#160;million of our common stock pursuant to the shelf registration statement. During the year ended June&#160;30, 2019, we sold 2,214,658 shares under the ATM Sales Agreement for $5.4&#160;million, after deducting offering costs; $5.2&#160;million of these proceeds were received on July&#160;2, 2019 and were recorded as common stock proceeds receivable as of June&#160;30, 2019. During the three months ended September&#160;30, 2019, we sold 63,684 shares under the ATM Sales Agreement for $0.2&#160;million, after deducting offering costs. As of September&#160;30, 2019, there is $144.3&#160;million aggregate value of securities available under the shelf registration statement.</div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6777644144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Shares</div></th>
<th class="th"><div>Additional paid in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Jun. 30, 2018</a></td>
<td class="nump">$ 50,459<span></span>
</td>
<td class="nump">$ 70,406<span></span>
</td>
<td class="nump">$ 264,858<span></span>
</td>
<td class="num">$ (214,399)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(14,542)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,542)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock for vested restricted stock units</a></td>
<td class="num">(324)<span></span>
</td>
<td class="nump">246<span></span>
</td>
<td class="num">(324)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_meip_Stockissuedduringperiodvaluestockwarrantsexercised', window );">Exercise of warrants</a></td>
<td class="nump">2,186<span></span>
</td>
<td class="nump">440<span></span>
</td>
<td class="nump">2,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">1,937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Sep. 30, 2018</a></td>
<td class="nump">39,759<span></span>
</td>
<td class="nump">71,115<span></span>
</td>
<td class="nump">268,700<span></span>
</td>
<td class="num">(228,941)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Jun. 30, 2018</a></td>
<td class="nump">50,459<span></span>
</td>
<td class="nump">70,406<span></span>
</td>
<td class="nump">264,858<span></span>
</td>
<td class="num">(214,399)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Jun. 30, 2019</a></td>
<td class="nump">47,930<span></span>
</td>
<td class="nump">73,545<span></span>
</td>
<td class="nump">279,148<span></span>
</td>
<td class="num">(231,218)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(2,994)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,994)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">159<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="nump">159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">72<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">2,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Sep. 30, 2019</a></td>
<td class="nump">$ 47,280<span></span>
</td>
<td class="nump">$ 73,655<span></span>
</td>
<td class="nump">$ 281,492<span></span>
</td>
<td class="num">$ (234,212)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meip_Stockissuedduringperiodvaluestockwarrantsexercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meip_Stockissuedduringperiodvaluestockwarrantsexercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
